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\ m i - G n
SUMMARY
Human herpesvirus 8 (HHV-8), also called Kaposi’s sarcoma-associated 
herpesvirus (KSHV), is associated with all forms of Kaposi’s sarcoma (KS), and 
is considered to be the infectious cause of this disease. Classical KS, which 
affects mainly elderly men in the Mediterranean region, usually presents as 
benign paranodular skin lesions, but endemic KS of human immunodeficiency 
virus- (HIV-) negative individuals in equatorial (East and Central) Africa and KS 
associated with HIV infection or post-transplantation immunosuppression can be 
clinically aggressive, affecting internal organs. HHV-8 is also associated with 
primary effusion lymphomas (PEL) and multicentric Castleman’s disease.
KS is a prominent disease in Uganda accounting for approximately 50% of 
reported cancer cases. Epidemic (HIV-associated) and endemic KS occur in 
Uganda, each afflicting both adults and children.
The highest seroprevalence of HHV-8, with estimates ranging from 11-77%, has 
been reported for sub-Saharan Africa, followed by the Mediterranean countries 
(2-28%) and then Northern Europe, Southeast Asia and the Caribbean countries 
(2-4%). Estimates o f seroprevalence in the USA range from 0-20%. The mode by 
which HHV-8 is transmitted is not known, but transmission most probably 
occurs via sexual means in countries where KS is non-endemic, and via non- 
sexual means in countries where KS is endemic, such as Uganda and Zambia.
The HHV-8 genome consists of a unique region o f approximately 140.5 kbp 
flanked by multiple 801 bp terminal repeats. Two almost complete genome 
sequences are available, one from an AIDS TOL cell line, BC-1 and one from an 
AIDS KS lesion. The great majority of the genome is highly conserved, but 
genes at both ends of the unique region exhibit striking variation. The K1 gene,
at the left end of the genome, encodes a highly variable type 1 membrane protein. 
Five HHV-8 K1 subtypes, generally called A, B, C, D and E have been 
identified. Subtype B appears to predominate in Africa, together with a variant 
(A5) of the A subtype, while subtypes A and C predominate elsewhere in the 
world. The K15 gene, at the right end of the genome, occurs as two highly 
diverged alleles, P (predominant) and M (minor), showing only 30% amino acid 
sequence identity. The P allele is more frequent among HHV-8 genomes, and the 
M allele is rarer. Evidence for recombination has been observed in 20-30% of 
HHV-8 strains with almost half of the African strains displaying mosaic 
genomes.
Although KS is a prominent disease in Uganda, little is known about the 
prevalence of HHV-8 in the Ugandan population and the characteristics of HHV- 
8 strains present in this country. The aims of this project were to determine the 
prevalence of HHV-8 in Ugandan blood donors and to characterise the genomes 
of HHV-8 strains in Ugandan KS patients. During the course of this work, one 
report on HHV-8 seroprevalence in Ugandan blood donors and three on K1 
subtypes in samples from various parts of the world, including some from 
Uganda, were published.
Using a combination of two serological tests, ELISA (against lytic (ORF65) and 
latent (ORF73/LANA) antigens) and LANA IF test, antibodies were detected in a 
high percentage (74%) of 114 HIV-negative blood donors, confirming previous 
results. Attempts to detect HHV-8 DNA by PCR in peripheral white blood cells 
of the blood donors were largely unsuccessful.
PCR, sequence and phylogenetic analysis of the K1 gene in tumour samples from 
17 KS patients indicated that the majority (11) were infected by the B subtype of 
HHV-8. Five patients were infected by the A5 subtype. A variant of the C
subtype, showing characteristics o f both A and C subtypes in addition to unique 
characteristics, was detected in a single patient. PCR and sequence analysis of 
other genome loci implied that at least five of nine (55%) HHV-8 strains are 
recombinants between subtypes. Three of the five strains with a K1 A5 gene 
were analysed and all were found to be subtype B in the rest of the genome. The 
single K1 subtype C strain was also a recombinant between subtypes C and B.
PCR analysis for the K15 gene in tumour samples from 30 KS patients 
confirmed previous results that the P allele predominates. For the first time, a 
single strain bearing the M allele was identified in East African samples. 
Sequence analysis o f the entire K15 gene in selected samples indicated that the P 
and M alleles occur in two distinct forms. Divergence between the M allele 
found in the Ugandan strain and that in the previously sequenced BC-1 strain is 
at least as great as that between representatives of the P allele. This indicates that 
introduction of the M allele into extant HHV-8 subtypes did not occur by a 
single, relatively recent recombination event as was concluded from a previous 
study in which very limited variation in the M allele was reported.
The study increases our understanding of the characteristics of HHV-8 strains 
involved in KS in Uganda and provides new insights into the evolution of 
HHV-8.
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The study reported here involved two principal areas: determination of the 
seroprevalence of human herpesvirus 8 (HHV-8) in Ugandan blood donors and 
characterization of the genomes of HHV-8 strains in Ugandan Kaposi’s sarcoma 
(KS) patients. This chapter gives an overview of the family Herpesviridae, the 




The family Herpesviridae is a diverse collection of over 120 large DNA viruses 
infecting all vertebrates, including humans (Minson et al., 2000), and at least one 
documented invertebrate, the oyster (Comps and Cochennec, 1993). 
Herpesviruses have a characteristic morphology consisting o f both symmetric 
and nonsymmetric components (Homa and Brown, 1997; Steven and Spear,
1997). The virion (e.g. o f herpes simplex virus type 1 [HSV-1]) is spherical, 
comprising a core, capsid, tegument and envelope (Fig. 1.1). The core consists of 
the viral genome packed in a liquid crystalline array that fills the entire volume 
of the preformed icosahedral capsid. The mature capsid is 125 nm in diameter 
and is composed of 162 capsomeres. The capsid is enclosed within a 
proteinaceous matrix, the tegument, which in turn is intimately associated with 
the lipid bilayer, the envelope. The envelope contains a number of different 
integral glycoproteins (Fig. 1.1). The virions range in diameter between 160 nm 




Fig. 1.1. Herpesvirus morphology.
A. Schematic representation of a herpesvirus virion with diameters in nm. E, 
envelope; T, tegument, C, capsid; G, genome. B. Electron micrograph image 
of a HSV-1 strain 17+ virion. (Courtesy of F. Rixon).
2Herpesvirus replication involves two stages, lytic and latent. Lytic infection 
follows viral adsorption to the cell, penetration of the nucleocapsid and migration 
to the nucleus, where gene expression occurs from the viral genome in a 
sequentially ordered cascade involving three main phases: immediate early, early 
and late. Transcription, viral DNA replication, capsid assembly, DNA packaging 
and at least one stage of envelopment take place in the nucleus. New viral 
progeny are released from the cell by exocytosis.
Following primary infection, all herpesviruses have the ability to persist in an 
inapparent (or latent) form for the lifetime of the host, with only a subset of viral 
genes being expressed (Kieff and Liebowitz, 1990; Rock, 1993). Reactivation 
(due to poorly defined stimuli) occasionally occurs leading to lytic viral 
production.
Herpesvirus genomes consist of single molecules o f linear double-stranded 
DNA. Those sequenced show a wide range in size: the smallest 125 kbp (SVV; 
virus names are listed in Table 1.1) and the largest 245 kbp (HCMV, clinical 
isolates) (McGeoch and Davison, 1999a). The viruses also exhibit an 
impressively wide range of base compositions ranging from 32-75% in G+C 
content (Minson et al., 2000). Characteristically, herpesvirus genomes contain 
terminal or internal repeated sequences, in direct or inverse orientation. The 
layouts of these repeat elements in relation to unique sequences define at least six 
genome types (Fig. 1.2). The genomes encode approximately 70 (e.g. HSV-1) to 
200 (e.g. HCMV) genes. About 40 of these genes have counterparts in all three 
subfamilies {Alpha-, Beta-, and Gammaherpesvirinae; see below) and are 
referred to as core or conserved genes (McGeoch and Davison, 1999a). Most of 
these genes are involved in vital aspects of the viral life cycle, such as entry into 
the cell, viral DNA replication, packaging of the genome and virion assembly. 
Nine genes (of which all but one are involved in DNA metabolism and
Table 1.1. Herpesvirus classification and accession numbers for sequenced 
genomes




Herpes simplex virus type 1/(HSV-1) Human herpesvirus 7/HHV-l X14112
Herpes simplex virus type 2/HSV-2 Human herpesvirus 2/HHV-2 Z86099
Bovine mamillitis virus/BHV-2 Bovine herpesvirus 2/BoHV-2 Not available
Varicellovirus (a2)
Varicella-zoster virus/(VZV) Human herpesvirus 5/HHV-3 X04370
Simian varicella virus/SVV Cercopithecine herpesvirus P/CeHV-9 AF275348
Infectious bovine rhinotracheitis Bovine herpesvirus 7/BoHV-l AJ004801
virus/BHV-1
Pseudorabies virus/PRV Suid herpesvirus //SuHV-1 Not available
Feline rhinotracheitis virus/FHV-1 Felid herpesvirus 7/FeHV-l Not available
Equine abortion virus/EHV-1 Equid herpesvirus 7/EHV-l M86664
Equine rhinopneumonitis virus/EHV-4 Equid herpesvirus 4/EHV-4 AF030027
“Marek’s disease-like virus” (a3)
Marek’s disease virus 1/(MDV-1) Gallid herpesvirus 2/GaHV-2 AF243438
Marek’s disease virus 2/MDV-2 Gallid herpesvirus 5/GaHV-3 AB049735
Herpesvirus of turkeys/HVT Meleagrid herpesvirus 7/MeHV-l AF291866
“Infectious laryngotracheitis-like
viruses” (a4)




Human cytomegalovirus/(HCMV) Human herpesvirus 5/HHV-5 X I7403
Chimpanzee cytomegalovirus/CCMV None!None Not available
Rhesus cytomegalovirus/RHCM Cercopithecine herpesvirus <S/CeHV-8 Not available
Muromegalovirus (pt)
Mouse cytomegalovirus/(MCMV) Mur id herpesvirus 7/MuHV-l U68299
Rat cytomegalovirus/RCMV Mur id herpesvirus 2/MuHV-2 AF232689
Roseolovirus (P2)
Human herpesvirus 6/(HHV-6) Human herpesvirus 5/HHV-6 X83413, AB021506,
AF157706
Human herpesvirus 7/HHV-7 Human herpesvirus 7/HHV-7 U43400, AF037218
Unassigned member
Guinea pig cytomegalovirus/GCMV Caviid herpesvirus 2/CavHV-2 Not available
GAMMAHERPES VIRINAE
Lymphocryptovirus (yO
Epstein-Barr virus/(EBV) Human herpesvirus 4/HHV-4 M35547, V01555,
Rhadinovirus (y2) M80517
Herpesvirus saimiri/(HVS) Saimiriine herpesvirus 2/SaHV-2 X64346
Herpesvirus ateles/HVA Ateline herpesvirus 2/AtHV-2 AF083424
Kaposi’s sarcoma-associated Human herpesvirus 5/HHV-8 U75698, U93872
herpesvirus/KSHV
Rhesus rhadinovirus/RRV Cercopithecine herpesvirus 77/CeHV-17 AF083501, AF210726
Mouse herpesvirus 68/MHV68 Mur id herpesvirus 4/MuHV-4 U97553, AF105037
Equine herpesvirus 2/EHV-2 Equid herpesvirus 2/EHV-2 U20824
Malignant catarrhal fever virus/AHV-1 Alcelaphine herpesvirus!AWN -1 AF005370
Bovine herpesvirus 4/BHV-4 Bovine herpesvirus 4/BoHV-4 AF318573
UNDEFINED SUBFAMILY
“Ictalurid herpes-like virus”
Channel catfish virus/(CCV) Ictalurid herpesvirus 7/IcHV-l M75136
Footnotes overleaf.
Footnotes for Table 1.1
a Genera names and synonyms (lowercase bold) are given for each subfamily 
(uppercase bold). Type species are enclosed in parentheses. 
b ICTV, International Committee on Taxonomy of Viruses (Minson et al., 2000). 
Adapted from Davison (2001).
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Figure 1.2. Types of herpesvirus genome structure.
Unique sequences and repeat elements are represented by single lines and rectangles, 
respectively (not drawn to scale). Relative orientation for large repeats are indicated 
by arrowheads. The number of terminal repeats in types B and C, and the number of 
internal repeats in type C, are variable. Adapted from McGeoch & Davison (1999a).
3replication) are clearly related by similarities in encoded amino acid sequences to 
cellular genes (McGeoch and Davison, 1999a), and probably originated from the 
cellular genome. Viral structural genes, on the other hand, do not appear to have 
any obvious cellular homologues. Most genes involved in control of the life 
cycle, latency and cell-virus interactions are not conserved in the three 
subfamilies (Davison, 2001).
The gene complements o f herpesviruses have diverged by acquisition of cellular 
genes and by other recombination processes, including gene duplication and 
rearrangement, and possibly by genes arising de novo (e.g. US11 gene of HSV-1; 
Rixon and McGeoch, 1984). The genes have also evolved via extensive 
nucleotide mutations (substitutions, insertions and deletions).
1.1.2. Classification and phylogeny of herpesviruses
The herpesviruses that infect mammals and birds are grouped into three 
subfamilies, the a-herpesviruses (formally known as the Alphaherpesvirinae), 
the P-herpesviruses (Betaherpesvirinae) and the y-herpesviruses 
(Gammaherpesvirinae), based on biological characteristics (Roizman et al., 
1992, 1995). The a-herpesviruses exhibit rapid cytolytic growth in vitro and 
establish latency in the nervous system. The P-herpesviruses have a long 
productive cycle, usually associated with the formation of enlarged 
(cytomegalic) cells, and have a restricted host range in vitro. The y-herpesviruses 
establish latent infection in lymphocytes and are often associated with 
lymphoproliferative disease.
Extensive sequence data on herpesviruses have allowed a more objective 
subdivision of the family based on genomic attributes o f the viruses, which 
correlates well in general with that established previously (McGeoch and Cook,
41994; McGeoch et al., 1995, 2000). Table 1.1 gives an outline of the current 
herpesvirus classification and the accession numbers for the sequenced genomes. 
Limited sequence data o f herpesviruses isolated from turtles (Quackenbush et al.,
1998) suggest that these viruses belong to the a-herpesviruses. However, 
herpesviruses of fish (Davison, 1992, 1998), amphibians (Davison et al., 1999) 
and one invertebrate (the oyster) (A.J. Davison, unpublished data) are only 
remotely related to the mammalian/avian group.
An in-depth phylogenetic analysis of mammalian and avian herpesviruses based 
on a set of eight conserved genes has recently been accomplished by McGeoch et 
al. (2000) (Fig. 1.3 A). This analysis, which included more virus species and used 
more rigorous tests than previous studies (McGeoch and Cook, 1994; McGeoch 
et al., 1995), confirmed the presence o f an overall high level o f congruence 
between virus hosts’ lineages and the herpesvirus phylogenetic tree. This 
supports the inference made previously that many herpesviruses have evolved 
with their hosts (cospeciation). Based on this hypothesis and using the 
divergence times of the host lineages (Benton, 1990; Kumar and Hedges, 1998), 
it is estimated that the three herpesvirus subfamilies arose approximately 180- 
220 million years ago, that the genera diverged 80-60 million years ago 
(probably before the mammalian radiation) and that the species arose within the 
last 80 million years.
The study by McGeoch et al. (2000) revealed complex features about the 
phylogeny of the y-herpesviruses compared with the a -  and P-herpesviruses. 
MHV4 (MHV68) has a uniquely long terminal branch (probably indicating that 
this lineage has been evolving at a higher rate than other species) and its exact 
phylogenetic locus could not be resolved (Fig. 1.3B). It appears in various tree 
locations with different genes. A cospeciational history was also not indicated for 
this species. The EBV lineage, on the other hand, has an unusually short terminal
Fig. 1.3. Herpesvirus phylogenetic trees.
(A) A maximum likelihood tree based on amino acid sequences o f the UL27- 
plus-UL30 (HSV-1 homologues) gene set o f 28 herpesvirus species. (B) A 
maximum likelihood tree showing y-herpesviruses; the a -  and P-herpesviruses 
branches are each represented as compressed to a single heavy line in (i). i, the 
top scoring tree; ii, the second top scoring tree; iii, representation o f the uncertain 
branching order of MHV4 (MHV68) as a heavy bar. See Table 1.1 for full names 
o f the viruses; MHV4 is MHV68. (A) and (B) adapted from McGeoch et al. 




























































5branch, indicating that it may have a lower evolutionary rate. Next, whereas 
cospeciation is powerfully evident in the tree for the a -  and P-herpesviruses, it is 
discernible but less obvious in the y-herpesvirus tree. The branching of Old 
(HHV-8, RRV) from New (HVA, HVS) World primate viruses (Fig. 1.3) is 
consistent with cospeciation, but the magnitude of divergence between these two 
groups implies a rate o f change about twice that seen for the a -  and P- 
herpesviruses, another indication of more rapid evolution in the y2-herpesviruses. 
Finally, unlike the ungulate viruses in the a-herpesviruses (EHV1, EHV4), 
ungulate viruses in the y-herpesvirus group (AHV1, EHV2) do not form a clade 
as might have been expected. It was not clear whether this finding is genuine or 
an artifact of tree inference associated with aberrant substitution rates McGeoch 
et al., 2000).
1.1.3. Human herpesviruses
Presently, eight herpesviruses, representing all the major mammalian lineages 
( a b a 2, pb p2, yb y2; Table 1.1), are known to infect the human species. These 
viruses cause a wide variety of diseases and possess varied molecular properties 
(shown in Table 1.2). The infections range from inapparent to severe, disabling 
or fatal infections in the foetus, the very young or the immunosuppressed. Most 
of these viruses occur at high prevalence levels in human populations, although 
HSV-2 is characteristically sexually transmitted and HHV-8 occurs at high 
prevalence only in some populations (discussed in section 1.8 below). The 
viruses establish a life long infection in their host, utilizing varied mechanisms of 
latency; HSV-1, HSV-2 and VZV are neurotropic, HHV-6, HHV-7 and EBV are 
lymphotropic, while HCMV establishes latency in the monocytic lineage. The 
situation with HHV-8 will be discussed below. EBV and HHV-8 have 
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61.2. DISCOVERY AND CLASSIFICATION OF HHV-8
For a long time, the distribution of KS in the human population suggested 
involvement of an infectious agent (Beral, 1991, Beral et al., 1990; Oettle, 1962). 
The eighth, and most recently discovered, human herpesvirus (HHV-8), also 
referred to as Kaposi’s sarcoma-associated herpesvirus (KSHV), is proposed to 
be this agent (Chang et al., 1994; Ganem, 1996). Employing a PCR-based 
method (representational difference analysis, RDA), HHV-8 was identified as 
two DNA fragments (330 and 631 bp in length) in AIDS-KS lesions. These 
fragments showed high sequence homology to capsid and tegument protein 
genes, respectively, of two known y-herpesviruses, HVS and EBV. Subsequent 
characterization of a larger genomic region containing blocks o f structural genes 
found in all herpesviruses indicated that HHV-8 is a y2-herpesvirus (Table 1.1).
HHV-8 is the first human y2-herpesvirus to be identified and was originally 
found to be most closely related to HVS (Moore et al., 1996b). However, it is 
now known to be more closely related to RRV (Fig. 1.3A), a virus recently 
isolated from rhesus monkeys (Desrosiers et al., 1997). Several other new HHV- 
8-related y2-herpesviruses (for which only the sequence of a DNA polymerase 
gene fragment is available) have also been detected in lower and higher Old 
World primates (Fig. 1.4). The presence of HHV-8-like viruses in primates, 
especially in the great apes, raises the possibility that these animals could serve 
as reservoirs of new y2-herpesviruses for humans (Lacoste et al., 2000c). It is 
evident from Fig. 1.4 that two distinct HHV-8-related viruses (the RRV and 
HHV-8 lineages) are found in the lower primates, while only the HHV-8 lineage 
has thus far been found in the higher primates (chimpanzees, gorillas and 
humans). If viruses belonging to the RRV lineage are also present in the higher 
















Fig. 1.4. HHV-8-related rhadinoviruses.
A neighbour joining tree based on a 150 amino acid segment of the DNA 
polymerase gene. The figure illustrates the two lineages of the Old World 
rhadinoviruses (HHV-8/KSHV/RV-1 and RRV/RV-2). PtRV-1, PANRHVIa 
and PANRHVIb are from chimpanzees); GORRHVl is from gorillas; ChRV- 
1 and ChRV-2, Chlorocebus rhadinovirus 1 and 2, respectively, of African 
Green monkeys {Chlorocebus aethiops); RFHVMm and RFHVMn, 
retroperitoneal fibromatosis-associated herpesviruses of rhesus {Macaca 
mulatto) and pigtail {Macaca nemestrina) macaques; MneRV, was also 
detected in M. nemestrina. RRV infects rhesus macaques. Reproduced from 
Greensill & Schulz (2000).
71.3. ASSOCIATION OF HHV-8 WITH DISEASE
HHV-8 is associated with three tumour conditions, Kaposi’s sarcoma (KS), 
primary effusion lymphoma (PEL), also known as body cavity-based B-cell 
lymphomas (BCBL) and multicentric Castleman’s disease (MCD) (reviewed by 
Sarid et al., 1999; Schulz, 1998).
1.3.1. Kaposi’s sarcoma
Kaposi’s sarcoma (KS) is the leading disorder in AIDS patients, but it also 
occurs at a lower frequency in HIV-negative individuals (Beral, 1991). It is a 
vascular disorder involving the skin and mucosal surfaces, and in aggressive 
cases may involve visceral organs and lymph nodes. The lesion contains spindle 
cells, activated endothelial cells, fibroblasts, smooth muscle cells, infiltrating 
inflammatory and lymphoid cells, and an extensive and aberrant 
neovascularisation (Beckstead et al., 1985; Moses et al., 1999; Roth et al., 1992; 
Rutgers et al., 1988). Microscopically, KS appears as a disorganised collection of 
blood-filled vascular slits composed of spindle cells (Fig. 1.5; Sarid et al., 1999). 
The spindle cells, which possibly originate from the lymphatic or precursor 
endothelium as opposed to vascular endothelium (Dupin et al., 1999), are 
thought to play a key role in KS pathogenesis. Whether KS is a true cancer is still 
debatable. Clonality studies provide evidence for both a monoclonal (neoplasia) 
and a polyclonal (hyperplasia) origin (Delabesse et al., 1997; Diaz-Cano and 
Wolfe, 1997; Dupin et al., 1999; Kaaya et al., 1995; Rabkin et al., 1995, 1997). 
Although KS cells are disseminated, it is not clear whether this represents a 
multicentric or metastatic process (Rabkin et al., 1997). The lesion generally 
lacks the nuclear pleomorphism characteristic o f many aggressive cancers.
Fig. 1.5. Lung KS lesion (x25 magnification).
Haematoxylin and eosin stain showing the highly vascularized 
tissue and slit-like cells surrounding the aberrant vessels (slide 
provided by David Blackbourn).
8KS appears to be primarily a growth factor disorder (Ganem, 1996; Levy and 
Ziegler, 1983). Direct assay of AIDS-KS cells reveals expression of a wide array 
o f cytokines and growth factors, including IL-1, IL-6, basic fibroblast growth 
factor (bFGF), platelet-derived growth factor (PDGF) and transforming growth 
factor (TGF)-beta. Some of these factors can stimulate spindle cell growth 
(Ensoli et al., 1989; Ganem, 1996; Miles et al., 1990). Basic FGF is a particularly 
powerful angiogenic factor and has been proposed to be an important 
determinant of the new vascular tissue formation seen in KS (Ensoli et al., 1994). 
Thus, the following paradigm can be envisaged for the genesis o f KS. Spindle 
cells or their precursors are triggered to proliferate by exogenous factors, such as 
infectious agents, and HHV-8 could be such a factor. Once activated they 
produce angiogenic and other factors that induce the vascular and inflammatory 
components characteristic o f the tumour (Ganem, 1996). It is becoming 
increasingly clear that human immunodeficiency virus type 1 (HIV-1) plays an 
enhancing role in the pathogenesis o f KS, and not a direct etiologic role (Ganem,
1996). HIV-1 appears to increase the risk o f KS beyond that expected to arise 
from immunodeficiency per se (Beral et al., 1990). HIV-1 tat protein is known to 
be a strong angiogenic factor, and can act in synergy with bFGF in the induction 
of KS (Ensoli et al., 1994).
KS occurs in four forms, based on clinical and epidemiological differences 
(reviewed by Tappero et al., 1993): classic, African endemic, AIDS/HIV- 
associated (epidemic) and transplantation-associated. HHV-8 is associated with 
all four forms (Boshoff et al., 1995b; Buonaguro et al., 1996; Chang et al, 1994, 
1996a; Chuck et al., 1996; Dictor et al., 1996; Dupin et al., 1995; Gaidano et al., 
1996b; Luppi et al., 1996b; Moore and Chang, 1995; Noel et al., 1996; Schalling 
et al., 1995; Su et al., 1995).
91.3.1.1. Classic KS
Classic KS, which was first described by Mortiz Kaposi in 1872, occurs 
predominantly in elderly men of Mediterranean descent. The disease occurs as a 
benign tumour affecting mainly the skin of the distal extremities (reviewed by 
Sarid et al., 1999). Classic KS is more common in men than in women probably 
due to hormonal differences (Fotsis et al., 1994) or differences in other risk 
factors for HHV-8 infection. HIV-negative gay men may also be affected by 
classic KS, and they appear to be at a higher risk compared to HIV-negative 
heterosexual men (Fenoglio et al., 1982; Friedman-Kien et al., 1990; Hjalgrim et 
al., 1996).
1.3.1.2. African endemic KS
African endemic KS occurs in Central and East African countries, including the 
Democratic Republic of Congo, Uganda and Zambia, with a particularly high 
incidence. The disease was already common prior to the AIDS epidemic (Beral, 
1991; Taylor et al., 1971). Like classic KS, African endemic KS occurs more 
commonly in men than in women and, in adults, has a clinical presentation 
similar to that o f classic KS (Fig. 1.6A). African endemic KS patients have no 
apparent immunosuppression (Kestens et al., 1985), although one study in 
Tanzania reported some decreased reactivity on antigen skin testing and low 
CD4+ lymphocyte levels in patients compared to controls (Urassa et al., 1998). 
Endemic KS also affects children at a median age of 4 years (Ziegler and 
Katongole-Mbidde, 1996).
1.3.1.3. AIDS/HIV-associated KS
AID S/HIV-associated (epidemic) KS is the most recently described form o f KS 
and is associated with HIV-1 infection. It was first recognised in the United 
States in the early 1980s, but is now widely prevalent. The presence of HIV in 





Fig. 1.6. Ugandan KS cases.
A. Endemic KS in an elderly man showing nodular lesions. B. Childhood KS of 
the oro-facial dominant type (left eye blinded). C. Epidemic (AIDS-associated) 
KS showing patches. The whole body surface of this patient was affected. Slides 
A and B were provided by Edward Katongole-Mbidde; slide C was produced with 
the help of Naomi Byabazaire.
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(Athale et al., 1995; Bouquety et al., 1989; Wabinga et al., 1993; Ziegler and 
Katongole-Mbidde, 1996). For example, childhood KS increased more than 40- 
fold in Uganda (Ziegler and Katongole-Mbidde, 1996) and approximately 80% 
of the cases are HIV-associated (E. Katongole-Mbidde, personal 
communication). KS in children is characterised by a rapidly progressive 
lymphadenopathy that is generally fatal within 1 year o f onset (Ziegler and 
Katongole-Mbidde, 1996). In addition to the lymphadenopathy, muco-cutaneous 
lesions are present and the distribution of the tumours shows two major patterns: 
oro-facial dominant (in the majority of cases; Fig. 1.6B) and inguinal-genital 
dominant (in the minority of cases). KS has been seen in infants as young as 1 
year o f age in Uganda (Ziegler and Katongole-Mbidde, 1996), and 7 months of 
age in Zambia (Athale et al., 1995). Childhood KS is extremely rare outside 
Africa. Adult AIDS-KS is the most clinically aggressive form o f adult KS, most 
likely as a result of immunodeficiency and the HHV-8 enhancing effect o f HIV-1 
infection. Internal organs, as well as the whole body surface, are often affected 
(Fig. 1.6C) (Beral, 1991).
1.3.1.4. Transplantation-associated KS
The occurrence of posttransplantation KS is highly related to iatrogenically 
induced immunosuppression. It also tends to be clinically aggressive; however, 
remission has been reported following discontinuation of the immunosuppressive 
therapy (Besnard et al., 1996; Harwood et al., 1979; Penn, 1983).
1.3.2. Primary effusion/body cavity-based B-cell lymphoma
HHV-8 is also consistently found in all forms of primary effusion/body cavity- 
based B-cell lymphoma (PEL/BCBL) (Ansari et al., 1996; Carbone et al., 1996; 
Cesarman et al., 1995a; Gaidano et al., 1996b; Gessain et al., 1997; Komanduri 
et al., 1996; Nador et al., 1996; Otsuki et al., 1996; Pastore et al., 1995). This is a
11
rare form of B-cell lymphoma that occurs most frequently in AIDS patients. 
HHV-8 is also found in a few non-AIDS-related PEL cases (Carbone et al., 1996; 
Hermine et al., 1996; Nador et al., 1995; Strauchen et al., 1996). PEL is a truly 
neoplastic disorder characterised by malignant effusions (as opposed to solid 
growths) of B cells in the pleural or abdominal cavity, immunoglobulin gene 
rearrangement, lack of most cell surface markers and, unlike Burkitt’s 
lymphoma, a lack of c-myc rearrangements (Dupin et al., 1999; reviewed by 
Jaffe, 1996). The majority of cases of PEL are persistently coinfected with EBV 
and HHV-8 (Cesarman et al., 1995a,b; Gessain et al., 1997), but occasional cases 
restricted to HHV-8 infection have also been reported (Carbone et al., 1996; 
Cesarman et al., 1996a; Renne et al., 1996b; Strauchen et al., 1996). The HHV-8 
genome occurs as multiple (approximately 50-100) copies o f circular DNA 
(episomes) in all PEL lymphoma cells (Cesarman et al., 1995a,b; Dupin et al., 
1999). Several HHV-8 persistently (latently) infected B-cell lymphoma cell lines 
have been established from PEL tumours and these have been invaluable in the 
study of HHV-8 (Arvanitakis et al., 1996; Cesarman et al., 1995b; Gaidano et al., 
1996a; Gao et al., 1996b; Renne et al., 1996b; Said et al., 1996). Like the parent 
tumours, most of these cell lines are coinfected with HHV-8 and EBV (e.g. BC- 
1), although a few infected with HHV-8 alone (e.g. BCBL-1 and BCP-1) have 
also been established.
1.3.3. Multicentric Castleman’s disease
HHV-8 is frequently detected in lymph nodes o f AIDS patients with multicentric 
Castleman’s disease (MCD), a complex lymphoproliferative disorder 
characterised by fever, adenopathy, splenomegaly and elevated levels of IL-6 in 
circulation. MCD occurs in two histological forms, the hyaline-vascular and the 
plasma cell variant (Peterson and Frizzera, 1993). Patients with the plasma cell 
variant are at increased risk for KS (Corbellino et al., 1996b). HHV-8 is found
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much less frequently in HIV-negative MCD patients (Barozzi et al., 1996; 
Gessain et al., 1996; Soulier et al., 1995), indicating that HHV-8 is less strongly 
associated with MCD than with KS and PEL.
1.3.4. Other conditions
HHV-8 has been associated with a number of other conditions, including 
angioimmunoblastic lymphadenopathy, squamous cell skin carcinoma of 
transplant recipients, angiosarcoma, cutaneous T-cell lymphoma, bone marrow 
stromal cells of patients with multiple myeloma and benign monoclonal 
gammopathy (Gyulai et al., 1996a,b; Luppi et al., 1996a; McDonagh et al., 1996; 
Rady et al., 1995; Rettig et al., 1997; Sander et al., 1996). However, these 
findings have not been confirmed by others (Boshoff et al., 1995b, 1996; Chang 
et al., 1994; Dictor et al., 1996; Jin et al., 1996; MacKenzie et al., 1997; Marcelin 
et al., 1997; Masood et al., 1997; Olsen et al., 1998c, Parravicini et al., 1997a; 
Pawson et al., 1996; Tomita et al., 1996; Uthman et al., 1996; Whitby et al.,
1997). Recently, HHV-8 infection has also been associated with a non-neoplastic 
condition, bone marrow failure following organ transplantation (Luppi et al., 
2000).
1.4. GENERAL CHARACTERISTICS OF HHV-8
As with other tumour viruses (e.g. papillomaviruses in cervical cancer and EBV 
in nasopharyngeal carcinoma), the study of HHV-8 has met with certain 
obstacles. First, the virus cannot be propagated in vitro from KS lesions. 
However, it can be cultured to high copy numbers in several latently-infected 
PEL cell lines, and these are the primary tools for HHV-8 isolation, 
characterization and seroepidemiologic studies. Second, it has been difficult to 
transmit HHV-8 in vitro. Finally, no animal model is readily available to study
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HHV-8 infection. Thus, most work in HHV-8 has employed molecular biological 
techniques rather than the methods of traditional virology.
A number of cell types (including cells o f B-cell, endothelial, epithelial and 
fibroblastic origin) have been tested for culture o f HHV-8. Most support 
replication either poorly or not at all, and infection is generally only detectable 
by PCR-based assays (Blackboum et al., 1997; Foreman et al., 1997; Ganem, 
1996; Renne et al., 1998). The adenovirus-transformed human embryonal kidney 
epithelial 293 cell line was used to culture HHV-8 transiently from KS lesions 
(Foreman et al., 1997), thus confirming the presence of HHV-8 virions in KS 
tumour samples. This cell line was also used to isolate HHV-8 from saliva 
(Vieira et al., 1997).
Latently infected PEL cell lines contain a small proportion of cells undergoing 
lytic virus production (Orenstein et al., 1997). Lytic replication can be induced in 
other cells by treatment with sodium butyrate or phorbol esters, such as 12-0- 
tetradecanoylphorbol-13-acetate (TPA) (Lennette et al., 1996; Miller et al., 1996,
1997). Unfortunately, in most cases the supernatants produced by induced cell 
lines are not highly infectious (Sarid et al., 1999; Schulz, 1998). Recently, a new 
PEL cell line (JSC-1) that yields a highly infectious HHV-8-containing 
supernatant has been reported (Cannon et al., 2000). Analysis o f virions 
produced from induced PEL cell lines showed that HHV-8 has characteristics of 
other herpesviruses (Minson et al., 2000). The HHV-8 capsid is 110 nm in 
diameter (Sarid et al., 1999) and its three dimensional structure has recently been 
determined using electron cryomicroscopy and computer reconstruction (Wu et 
al., 2000). Virions containing DNA are 120-150 nm in diameter (Sarid et al., 
1999). Similar particles have also been observed in KS lesions in a few 
productively infected spindle cells (Ioachim, 1995; Orenstein et al., 1997; Walter 
et al., 1984). Like other herpesviruses, HHV-8 replicates in the cell nucleus and
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undergoes latency, a stage at which its genome is present in the form of circular 
episomes (Sarid et al., 1999).
The effect o f herpesvirus DNA polymerase inhibitors on lytic HHV-8 replication 
in TPA-induced PEL cell lines provides indirect experimental evidence for the 
role that HHV-8 may play in KS and PEL pathogenesis. Phosphonoacetic acid 
(foscamet), ganciclovir and cidofivir, but not acyclovir, inhibit HHV-8 
replication at pharmacological concentrations (Kedes and Ganem, 1997). A 
number of studies also suggest that foscamet reduces the rate o f KS in AIDS 
patients (Glesby et al., 1996; Jones et al., 1995a; Mocroft et al., 1996), and, in 
one small study, it induced the regression of existing lesions (Morfeld and 
Torssander, 1994). However, neither foscamet nor ganciclovir eliminates PCR- 
detectable HHV-8 from the PBMC of infected individuals (Humphrey et al., 
1996), indicating that DNA polymerase inhibitors do not eliminate latent 
infections.
1.5. HHV-8 GENOME AND TUMORIGENESIS
The first published almost complete sequence of the HHV-8 genome (lacking an 
unclonable G+A-rich repeat segment between the right end of the unique region 
and the terminal repeat [TR] region) was from the PEL-derived cell line, BC-1 
(Russo et al., 1996). Subsequently, another almost complete sequence from an 
AIDS-KS lesion (lacking part of the coding sequences at the right end of the 
unique region) was obtained (Neipel et al., 1997a). The size o f circular HHV-8 
genome in BC-1 cells is 270 kbp on pulse field gel electrophoresis (PFGE) 
analysis (Moore et al., 1996). In contrast, that of encapsidated linear viral DNA 
from another cell line (BCBL-1) is 160-170 kbp on PFGE analysis (Renne et al., 
1996a; Zhong et al., 1996), a size similar to that of HVS and just smaller than 
that o f EBV. The BC-1 HHV-8 genome is bigger largely due to the presence of a
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duplicated part of the unique region of the genome within the TR (Russo et al., 
1996). This rearrangement most likely occurred in the parental tumour since it is 
also found in another cell line (HBL-6) independently derived from the same 
tumour (Gaidano et al., 1996a).
The organisation of the HHV-8 genome (Fig. 1.7) is very similar to that of other 
y2-herpesviruses, in particular RRV, HVS and MHV68 (Albrecht et al., 1992; 
Alexander et al., 2000; Neipel et al., 1997a; Nicholas et al., 1997a; Russo et al., 
1996; Searles et al., 1999; Virgin et al., 1997; Table 1.1). It consists of a single 
unique region, about 140.5 kbp in length, flanked by multiple G+C-rich 801 bp 
tandem repeats (TR), which may be involved in DNA packaging. The total 
length of the TR region (in circularized DNA) is estimated to vary between 25 
and 35 kbp (i.e. 35 to 45 tandem repeat units; Lagunoff and Ganem, 1997). The 
unique region has a G+C content of 53.5%, and contains all the known protein- 
coding regions of the HHV-8 genome. At least 81 open reading frames (ORFs) 
encoding proteins, including 66 homologous to HVS ORFs, were predicted by 
Russo et al. (1996). It is currently estimated that HHV-8 possesses at least 86 
genes (McGeoch and Davison, 1999b). HVS gene nomenclature forms the basis 
for HHV-8 gene nomenclature (Albrecht et al., 1992; Russo et al., 1996). The 
ORFs homologous to HVS ORFs (ORF2-75) are assigned the corresponding 
HVS ORF number, even if their relative position in the HHV-8 genome is 
different from that in HVS (as is the case with dihydrofolate reductase [ORF2] 
and thymidylate synthase [ORF70] genes). ORFs categorised as unique to HHV- 
8 (before the RRV sequence became available) are numbered in consecutive 
order with a K prefix, i.e., K1 to K15, with newly identified ORFs being 
assigned a decimal notation (e.g. K4.1). All these genes are now known to have 
homologues in RRV, except K3, K5, K7 (nut-1) and K12 (kaposin). The K3 and 
K5 genes (which possibly play a role in immune evasion by downregulation of 
MHC class 1; Coscoy and Ganem, 2000; Ishido et al., 2000) are homologous to
Fig. 1.7. HHV-8 genome in comparison with HVS and RRV.
Open reading frames are represented by boxes with the arrow ends indicating the 
direction of transcription. Colour shading: blue, core herpesvirus genes; orange, 
genes found in y2-herpesviruses only; pink, genes found in y-herpesviruses only; 
black, genes found in a -  and y-herpesviruses; brown, genes found in P- and y- 
herpesviruses; red, genes found in HHV-8 and RRV only; green, genes unique to 
a particular virus. Adapted from Greensill & Schulz (2000) and amended on the 
basis o f data in Alexander et al. (2000).
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each other as well as to HVS 0RF12 (McGeoch and Davison, 1999b). ORF12 is 
not present in RRV.
The HHV-8 genome contains blocks of genes that are conserved between 
herpesvirus subfamilies (Fig. 1.7). The core genes are currently estimated to be 
42 in number (McGeoch and Davison, 1999b). Between the conserved gene 
blocks are clusters of nonconserved genes. A number o f these genes have 
homologues in the cellular genome (Neipel et al., 1997a,b,c; Nicholas et al., 
1997a,b, 1998; Russo et al., 1996), and possibly play a role in averting cellular 
antiviral responses. Examples of these genes include a complement binding 
protein (ORF4), three CC chemokines (vMIPs-K4, K4.1 and K6), four viral 
interferon regulatory factors (vIRFs-K9, K10, K10.5 and K ll) , and three 
potential cellular growth regulators (vIL6 [K2], vcyclin D [ORF72] and viral G- 
protein-coupled receptor [vGCR or IL8R-like gene; ORF74]). Viral IL6, the 
vIRFs, and two other cellular homologues, vbcl2 (ORF16) and vFLIP 
(K13/ORF71) may be involved in inhibiting apoptosis (Chang et al., 1996a; 
Djerbi et al., 1999; Moore et al., 1996a; Rivas et al., 2001; Thome et al., 1997). 
The vcyclin D gene is expressed in KS lesions (Chang et al., 1996a; Cesarman et 
al., 1996b) and can substitute for human cyclin D in phosphorylating (i.e. 
inactivating) the retinoblastoma protein (pRB) (Chang et al., 1996a), and thus 
may play a significant role in KS pathogenesis. Although the vIL6 gene is 
functional (Chang et al., 1996a; Moore et al., 1996a), it is expressed in only a 
small number of cells in the KS lesion, and thus it is questionable whether it 
plays a significant role in the prominent angiogenesis seen in KS (Moore et al., 
1996a). The vbcl-2 is also functional (Sarid et al., 1997). There is a striking 
parallel between the cellular homologues encoded by HHV-8 and the cellular 
genes known to be induced by EBV infection (Russo et al., 1996; Sarid et al.,
1999). Cellular cyclin D, CD21/CR2, bcl-2, an IL8 receptor-like protein (EB11), 
IL-6, M IP-la, M IP-lb, RANTES and adhesion molecules are upregulated by
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EBV infection (Birkenbach et al., 1993; Finke et al., 1992, 1994; Jones et al., 
1995b; Palmero et al., 1993). Thus, by introducing exogenous genes, HHV-8 
appears to modify the same signalling and regulation pathways as EBV.
Although the genome of HHV-8 (BC-1 strain) does not contain sequence homologues 
of the major transforming proteins of HVS (STP and Tip; Jung and Desrosiers, 1991; 
Jung et al, 1991) or of EBV (EBNA1, EBNA2, EBNA3, LMP1, LMP2 or gp350/220; 
Kieff and Liebowitz, 1990; Sarid et al, 1999), dysregulation of the cell cycle by the 
identified HHV-8-encoded proto-oncogenes and cytokines may contribute to 
tumorigenesis. HHV-8 from induced cell lines has been reported to be able to change 
the morphology and prolong the survival of some cells, including primary human 
keratinocytes and endothelial cells (Cerimele et al, 2001; Flore et a l, 1998; Moses et 
al, 1999). A number of HHV-8 genes have been shown to be oncogenic in vitro, 
including K1 (Lee et al, 1998b; see below), vGCR (Arvanitakis et a l, 1997; Bais et al, 
1998; Cesarman et al, 1996b; Guo et al, 1997), K12 (kaposin; Muralidhar et al, 1998), 
and K9 (Gao et al, 1997; Li et al, 1998; Zimring et al, 1998). However, the role of 
these genes in natural infection is not clear since expression of their proteins has not 
been demonstrated in HHV-8 latently infected KS or PEL tumours (Katano et al, 
2000b; Kirshner et al, 1999; Parravicini et a l, 2000; Sarid et a l, 1997). Presently, only 
one protein, the latency-associated nuclear antigen (LANA/LANA 1 also referred to as 
latent nuclear antigen [LNA/LNA1]), encoded by ORF73 (Kellam et a l, 1997; 
Rainbow et a l, 1997), has been shown by immunohistochemistry to be expressed in all 
HHV-8-infected cells (Dupin et al, 1999; Katano et al, 2000b; Parravicini et a l, 2000). 
LANA appears to have a multifunctional role in HHV-8 infection. It is involved in 
maintenance of latency (by tethering the viral genome to host chromatin during 
mitosis), inhibition of apoptosis (by targeting p53 and pRB) and regulation of viral and 
cellular transcription (Ballestas et al, 1999; Friborg et al, 1999; Krithivas et al, 2000; 
Renne et al, 2001; Schwam et al, 2000). A recent study has also implicated LANA in 
tumorigenesis. In cooperation with the cellular oncogene Hras (Harvey rat sarcoma
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viral oncogene), LANA transforms primary rat embryo fibroblasts and renders them 
tumorigenic in nude mice (Radkov et al., 2000).
1.6. HHV-8 GENE EXPRESSION AND TROPISM
1.6.1. Gene expression
Initial screening for HHV-8 transcripts was performed by Zhong et al. (1996) 
using hybridisation of viral genomic segments with radiolabeled cDNA probes 
derived from KS tissue and the BCBL-1 cell line. Two highly abundant 
transcripts, T0.7 (spanning K12) and T l.l  (also referred to as polyadenylated 
nuclear (PAN) RNA or nut-1) were identified in this study. T l.l  contains 
features of both mRNAs and small nuclear RNAs (snRNAs). Although it is 
polyadenylated and is transcribed by RNA polymerase II, it lacks a 
trimethylguanosine cap and appears to be a non-coding transcript (Sun et al., 
1996; Zhong et al., 1996). It can associate with small ribonuclear proteins and 
contains regions that are homologous or complementary to U1 and U12 snRNAs 
(Hall and Padgett, 1996; Tam and Steitz, 1996), suggesting that it might be 
involved in RNA processing (Sun et al., 1996; Zhong and Ganem, 1997). T l.l  is 
expressed in a few tumour cells undergoing lytic replication in the KS tumour 
and its expression is enhanced by chemical induction of PEL cell lines (Sarid et 
al., 1998; Zhong et al., 1996). Thus, it differs from non-coding nuclear RNAs 
encoded by EBV (EBERs), HVS (HSURs), and HSV (LATs), which are 
expressed as latent transcripts.
T0.7 spans the K12 gene (absent from RRV, see above) which encodes a small 
hydrophobic protein (kaposin) of 60 amino acid residues (Neipel et al., 1997a; 
Russo et al., 1996). This protein has been shown to have oncogenic potential in 
vitro (Zhong et al., 1996). T0.7 is expressed abundantly in KS spindle cells and
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in persistently infected PEL cells (Renne et al., 1996b; Staskus et al., 1997; 
Stiirzl et al., 1997a; Zhong et al., 1996). Its expression is also induced by 
chemicals in PEL cell lines (Sarid et al., 1998).
Sarid et al. (1998) used Northern blot analysis and DNA probes spanning the 
entire genome to map HHV-8 transcripts in induced and uninduced BC-1 cells. 
In this study, HHV-8 gene transcription was categorised into three broad classes. 
Class I genes (the noninduced or “ latency” genes) are transcribed constitutively 
and are not enhanced by chemical induction. This class comprises o f three genes, 
vcyclin (ORF72), vFLIP (ORF71) and LANA (ORF73). Class II genes (the 
enhanced genes) are transcribed to higher levels in induced cells. These genes are 
primarily clustered in nonconserved regions of the genome and include T l.l  and 
TO.7 as well as most of the virus-encoded cytokines and signal transduction 
genes (e.g. vMIPs, vIL6, vIRF-1 and vIRF-2). It is not clear whether the recently 
identified vIRE-3 (also known as LANA2) encoded by K10.5/K10.6 (Lubyova 
and Pitha, 2000; Rivas et al., 2001) is a Class I or Class II gene. One group 
reported an increase in its expression on TPA treatment (Lubyova and Pitha,
2000), while the other observed no such increase (Rivas et al., 2001). Class III 
genes (the inducible or “ lytic” genes) are transcribed only in induced cells and 
cluster primarily in the conserved regions o f the genome. A small population of 
cells in KS tissue expresses inducible genes and these are believed to correspond 
to lytically infected cells (Staskus et al., 1997; Stiirzl et al., 1997a,b; Sun et al., 
1999). Thus, the lytic cycle of HHV-8 may also directly contribute to tumour 
pathogenesis.
As in other herpesviruses, HHV-8 gene transcription can be classified into four 
distinct kinetic stages: latent, immediate early, early and late (Sun et al., 1999). 
Latent gene expression (e.g. of LANA and vFLIP) is constitutive and unaffected 
by chemical induction. Immediate early genes (e.g. the transactivator gene, Rta,
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encoded by ORF50) are induced within 4 h of chemical treatment and are not 
inhibited by cycloheximide. Two sets of HHV-8 early genes were described by 
Sun et al. (1999), those expressed within 8 to 13 h after chemical induction (e.g. 
K3, K5 and vIL6), and those that are slightly delayed (e.g. vGCR, K12 and 
vbcl2). Late genes (e.g. the structural gene, ORF25) do not appear until after 30 
h after induction and their expression is abrogated by phosphonoacetic acid, an 
inhibitor of HHV-8 DNA replication.
HHV-8 Rta (a homologue of EBV rta, also called BRLF1 or R) is an immediate 
early gene that is conserved among all y-herpesviruses (Liu et al., 2000; Manet et 
al., 1989; van Santen, 1993; Whitehouse et al., 1997; Wu et al., 2000). It plays a 
central role in the switch of the viral life cycle from latency to lytic replication. 
Rta has been shown to be necessary and sufficient to activate lytic gene 
expression in latently infected cells (Lukac et al., 1998, 1999; Sun et al., 1998).
HHV-8 gene expression in PEL induced and uninduced cells has also been 
studied using DNA arrays (Jenner et al., 2001). This method allowed the 
simultaneous measurement of the expression level of almost every known HHV- 
8 ORF. Cluster analysis was used to group together genes that share similar 
patterns of expression. Genes that may be involved in a common process and 
genes in the same kinetic stage of herpesvirus replication group together. Overall 
the expression patterns determined by HHV-8 DNA array analysis were 
consistent with those described by Sarid et al. (1998) and Sun et al. (1999). In 
addition, the study allowed categorization of genes whose expression had 
hitherto not been analysed (e.g. ORF11 and ORF58), as well as the prediction of 
possible roles for genes that have yet to be characterized (e.g. K10.7, another 
homologue of IRFs).
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There is evidence to suggest that gene expression may be tissue-specific for the 
various HHV-8-related disorders. For example, vIL6 is expressed in PEL cells 
and HHV-8-infected B-cells in lymphatic tissue, but not in KS spindle cells 
(Moore et al., 1996a; Staskus et al., 1999). Also, LANA2 is expressed in B cells 
but not in KS spindle cells (Rivas et al., 2001). Moreover, Friborg et al. (1998) 
showed that HHV-8 isolates in PEL cell lines may be biologically distinct from 
those in primary KS lesions. The virus derived from KS lesions could be 
propagated in 293 cells, while propagation of virus derived from PEL cell lines 
was not observed in these cultures.
1.6.2. Tropism
HHV-8 has been detected in a wide range of cells in infected individuals, 
including endothelial and spindle cells of KS lesions, haematopoeitic cells (B 
cells, CD8+ cells and macrophages), and epithelial cells (keratinocytes, 
oropharyngeal, duodenal and rectal mucosa, and prostatic glandular cells) 
(Ambroziak et al., 1995; Boshoff et al., 1995a; Corbellino, 1996c; Harrington et 
al., 1996; Li et al., 1996; Mesri et al., 1996; Pauk et al., 2000; Sirianni et al., 
1997; Staskus et al., 1997; Stiirzl et al., 1997 a,b; Thomas et al., 1996). LANA 
immunohistochemistry (Dupin et al., 1999; Rainbow et al., 1997) and in situ 
hybridisation (Staskus et al., 1997; Stiirzl et al., 1997a,b) confirm HHV-8 gene 
expression in the majority (>90%) of nodular KS spindle cells and in <10% of 
cells forming the walls o f the aberrant vessels in early KS lesions (Dupin et al., 
1999). Lytic replication of HHV-8 occurs in monocytes/macrophages (Stiirzl et 
al., 1997a) and there is presence of linear viral genomes in PBMCs, suggesting 
productive infection (Decker et al., 1996).
1.7. VARIATION AND EVOLUTION OF HHV-8 STRAINS
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The genome is well conserved within most coding regions between differing 
HHV-8 strains (Neipel et al., 1997a; Poole et al., 1999; Russo et al., 1996). 
However, genes (K1 and K15) at both ends of the unique region display striking 
variability. The K1 gene, located at the left end of the genome, shows high 
diversity (up to 17.5% nucleotide variation) among strains (Kasolo et al., 1998, 
Cook et al, 1999; Lacoste et al., 2000a; Meng et al., 1999; Zong et al., 1999). K1 
occupies a position equivalent to STP of HVS, LMP1 of EBV and R1 of RRV 
(Damania et al., 1999; Hayward, 1999). However, no sequence homology is 
apparent between these genes. Expression of K1 is significantly increased during 
the early phase of lytic replication, indicating that this gene most likely plays a 
key role at this stage of the virus life cycle (Lagunoff and Ganem, 1997). K1 
encodes a type 1 membrane protein with structural resemblance to R1 but not to 
STP or LMP1. Transfection experiments showed that this protein is highly 
glycosylated and is principally associated with the plasma and cytoplasmic 
membranes (Lee et al., 1998b). K1 has been shown to transform rodent 
fibroblasts and to possess in vivo tumorigenic potential when inserted into an 
STP-negative (non-transforming) HVS strain (Lee et al., 1998b). However, its 
tumorigenic potential in natural infection is still unclear. K1 contains a highly 
conserved region in its cytoplasmic domain with a sequence similar to that of 
immunoreceptor tyrosine-based activation motifs (ITAMs) (Lee et al., 1998a). 
Using a chimera containing the N-terminus of CD8 fused to the C-terminus of 
K l, Lee et al. (1998a) showed that the putative K1 IT AM is functional and that it 
can transduce signals to induce cellular activation. The full length K l protein 
was also shown to be a constitutive signal transducer in B cells (Lagunoff et al., 
1999). Recently, Lee et al. (2000) reported that K l downregulates BCR surface 
expression in stably transfected B cells.
The amino acid sequence of the K l protein shows up to 44% variation, with 
variability concentrated in two extracellular domains, VR1 and VR2 (Cook et al.,
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1999; Lacoste et al., 2000a; Meng et al., 1999; Zong et al., 1999). Variability is 
driven by positive selection (Cook et al., 1999), an evolutionary phenomenon in 
which non-synonymous nucleotide changes outnumber synonymous changes, 
with striking alterations in amino acid sequence. The biological forces behind 
this phenomenon are not known.
HHV-8 subtypes were originally defined on the basis of limited variability within 
highly conserved genes, such as ORF25, ORF26 and ORF75 (Kasolo et al., 
1998; Luppi et al., 1997; Zong et al., 1997). This method did not always allow 
clear genotypic or epidemiological discrimination between strains. The extensive 
polymorphism in K l, on the other hand, has proven to be more phylogenetically 
robust, allowing the performance of molecular epidemiological studies. Five 
main HHV-8 K l subtypes, named A (I), B (IV), C (II), D (III) and E (Table 1.3), 
have been defined (Biggar et al., 2000; Cook et al., 1999; Meng et al., 1999; 
Nicholas et al., 1998; Zong et al., 1999). Subtype B appears to predominate in 
Africa together with a variant (A5) of the A subtype so far seen only in African 
samples (Cook et al., 1999; Kasolo et al., 1998; Lacoste et al., 2000a; Meng et 
al., 1999). Subtypes A and C occur in Europe and the USA, subtype C in 
northern Asia, and subtype D in southern Asia, Australia and New Zealand. 
Subtype E has thus far been found in Brazilian Amerindians. There is variation 
within the main K l subtypes (up to 5%) and this has been used to define 
subgroups (Table 1.3; Cook et al., 1999; Meng et al., 1999; Poole et al., 1999).
A possible link between specific HHV-8 subtypes and diseases (such as KS, 
MCD, PEL) has been proposed by some authors implying that some subtypes 
may have different biological properties,. Boralevi et al. (1998) suggested that 
subtype A may be responsible for more aggressive KS tumours in France. In 
addition, studies by Luppi et al. (1997) suggested that subtype A strains 
predominate in Italian classic KS, whereas subtype C strains may be more
Table 1.3. Nomenclature of HHV-8 Kl subtypes8
First (highest) 
level





Subgroups A1-A5, C1-C5, 
D1 and D2
Subgroups Al, A3, A5, large 
subgroup A’, C’ and C” 
Subtypes IA-IF
Clades C3’ andA l’ Zong et al. (1999)
Cook et al. (1999)
Meng et al. (1999) 
Biggar et al. (2000)
a Modified slightly from Meng et al. (2001).
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prevalent in Italian non-malignant lymphoproliferations. These data, however, 
were based on a small fragment of the ORF26 gene, recently shown to be 
ambiguous for distinguishing between strains (Poole et al., 1999). In contrast, 
most studies on K1 variability have not found a correlation between HHV-8 K1 
subtypes and the various diseases or even with the different clinical and 
epidemiological forms of KS (Cook et al., 1999; Kasolo et al., 1998; Lacoste et 
al., 2000a; Meng et al., 1999; Zong et al., 1999). HHV-8 subtypes, however, 
show an apparent geographic and ethnic restriction (Cook et al., 1999; Meng et 
al., 1999; Zong et al., 1999). This led Hayward (1999) to propose that HHV-8 
branched into its various K1 subtypes within the last 105 years, in correlation 
with the migratory patterns of humans out o f Africa (Cavalli-Sforza and Cavalli- 
Sforza, 1995). It has been proposed that subtype B is older than subtypes A and 
C, which could have diverged more recently (in the order o f 104 years ago) 
(Cook et al., 1999; Zong et al., 1999).
The K15 gene, located at the right end of the genome, is at a position equivalent 
to the gene encoding LMP2A of EBV. It is a class II gene that occurs as two 
highly diverged alleles, P (predominant or prototype) and M (minor) with only 
29% amino acid identity (Choi et al., 2000; Glenn et al., 1999; Poole et al., 
1999). The K15 divergence resembles that seen in EBNA-2, EBNA-3A, EBNA- 
3B and EBNA-3C genes of EBV, each of which also occurs in two main forms 
but with relatively less divergence (Dambaugh et al., 1984; Sample et al., 1990). 
Thus EBV occurs as two main types, types 1 and 2. Each K15 allele comprises 
eight exons specifying a protein with 12 membrane-spanning domains and a C- 
terminal cytoplasmic domain. This structure resembles that o f EBV LMP2A, 
except that LMP2A possesses an N-terminal, rather than a C-terminal, 
cytoplasmic domain (Sample et al., 1989). The cytoplasmic domain of K15 
contains several YXXI/L motifs (reminiscent o f LMP2A) and a putative TRAF 
binding site (as in LMP1). Transfection experiments showed that the K15 protein
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(P allele) primarily localizes to plasma and cytoplasmic membranes (Choi et al., 
2000; Glenn et al., 1999), and a CD8-K15 chimera stimulated with an anti-CD8 
antibody significantly inhibited BCR signalling (Choi et al., 2000). Thus, K15 
proteins possibly play a role in regulation of signal transduction (Poole et al., 
1999).
PCR analysis of HHV-8 strains from various parts o f the world indicates that the 
P allele is present in the great majority of HHV-8 genomes and is found in 
association with A, B, C and D K1 subtypes from all parts o f the world (Lacoste 
et al., 2000a,b, Meng et al., 2001; Poole et al., 1999). The M allele, on the other 
hand, is rare and has thus far been found in association with the A, B and C 
subtypes from various parts of the world, including parts o f Africa but not from 
East Africa (Lacoste et al., 2000a,b; Meng et al., 2001; Poole et al., 1999). The 
K15 allele linked to subtype E is unknown.
The origin o f the K15 divergence is not clear, but one o f the two K15 alleles may 
have resulted from a recombination event with a closely related y2-herpesvirus 
(Glenn et al., 1999; Poole et al., 1999).
The patterns o f sequence variation observed in the internal (conserved) gene loci 
of various HHV-8 strains generally correlate with the K1 patterns (Poole et al., 
1999). However, the K15 alleles appear to be essentially unlinked to the K1 
patterns. Evidence for recombination (based on lack of co-segregation of strains 
at various loci) was reported in 20-30% of the HHV-8 strains analysed by Poole 
et al. (1999). Almost half (5 o f 12) o f the African strains analysed in this study 
displayed mosaic genomes that probably reflect a history of recombination 
within and among the major subtypes.
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1.8. EPIDEMIOLOGY OF HHV-8
Detection of HHV-8 by both serology and PCR-based methods has been used to 
study the epidemiology and transmission of HHV-8. Accurate seroprevalence 
rates of HHV-8 remain unclear owing to the use o f different tests and target 
antigens (Rabkin et al., 1998). However, the results point to the same conclusion. 
Unlike most herpesviruses, HHV-8 does not appear to be ubiquitous in most 
populations. The highest seroprevalence rates (>50%) have been reported for 
central and southern Africa, followed by the Mediterranean and eastern European 
countries (5-20%). The lowest prevalence (0-5%) occurs in North America, 
Northern Europe, most of Asia and the Caribbean countries (Table 1.4; reviewed 
by Chatlynne and Ablashi, 1999; Moore, 2000; Schulz, 1998). This pattern of 
infection matches the geographic distribution of KS (Table 1.4; Moore, 2000). 
The rates of AIDS-associated KS are highly dependent on local rates o f infection 
with HIV-1, but not HIV-2 (Ariyoshi et al., 1998). The combined effects of 
widespread HIV-1 and HHV-8 infection have made KS the most common 
tumour in several sub-Saharan countries, including Uganda.
1.8.1. Seroprevalence of HHV-8
Serological assays have been developed that detect antibodies to both lytic and 
latent HHV-8 antigens, including the immunofluorescent (IF) test, Western blot 
(WB) analysis, radioimmunoprecipitation assay (RIPA) and ELISA (Table 1.5). 
The predominant latent antigen in PEL cell lines is LANA, which can be 
detected by WB (as a 224-236 kDa protein) or IF of untreated PEL cell lines 
(Gao et al., 1996b; Kedes et al., 1996; Simpson et al., 1996). By IF, LANA- 
positive cells show a characteristic nuclear stippling or speckled pattern. 
Antibodies to LANA are detected in 80-85% of patients with AIDS-KS, >90% of 
those with classic KS and only 0-3% of USA or UK blood donors (Gao et al.,
Table 1.4. Patterns of HHV-8 infection and KS among HIV-negative individuals
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1996a,b; Kedes et al., 1996; Lennette et al., 1996; Simpson et al., 1996). LANA 
has no homologue in EBV (Russo et al., 1996), thus eliminating the possibility of 
antigenic crossreactivity with this highly prevalent y-herpesvirus.
To address the possibility that LANA assays may underestimate HHV-8 
prevalence, several groups have developed assays based on lytic (structural) viral 
proteins. The minor capsid protein encoded by ORF65 and the K8.1 glycoprotein 
have been identified as potent and useful antigens for serological analysis 
(Chandran et al., 1998a,b; Li et al., 1999; Lin et al., 1997; Pau et al., 1998; Raab 
et al., 1998). Antibodies to these and other proteins have been detected by IF test, 
WB and RIPA in chemically induced PEL cell lines (Table 1.5). Whole HHV-8 
virions purified from induced PEL cell lines have also been used successfully in 
ELISA. However, the specificity o f the assays based on lytic proteins is 
debatable due to the high homology of certain HHV-8 structural proteins with 
their EBV counterparts (Andre et al., 1997; Moore et al., 1996b). Recently, a 
mixed-antigen ELISA containing four proteins (K8.1, ORF59, ORF65 and 
ORF73) detected 100% HHV-8 seropositivity in sera from Japanese KS patients 
and only 1.4-1.9% in control groups (Table 1.5). No cross-reactivity with HCMV 
or EBV was detected in this assay, indicating that it is specific. ORF65 ELISA 
detects antibodies in 75-80% of AIDS-KS, 85-90% of classic KS, 1-3% of UK 
blood donors and 5-10% of USA blood donors. The assay therefore has 
sensitivity and specificity comparable to that of LANA IF and WB tests. 
Recombinant K8.1 has also been shown to have high sensitivity and specificity 
(Table 1.5). However, ORF26 (major capsid protein)-based assays detect 
antibodies in approximately 40-60% of KS sera and 20% of blood donor sera 
(Andre et al., 1997; Davis et al., 1997). Antibodies to ORF26 protein cross-react 
with EBV (Andre et al., 1997).
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Among UK and USA blood donors, serological reactivity to LANA, ORF65 and 
unidentified structural antigens ranges from 0-3%, 1-5%, and 0-25%, 
respectively (Table 1.5). In Italy and Greece, reactivity in blood donors ranges 
from 4-25%. The relatively high HHV-8 prevalence in Italy is broadly in 
agreement with the higher incidence of classic KS in this region. In Africa, 
antibodies to LANA have been found (with considerable regional variation) in a 
relatively higher proportion (6-53%) of blood donors (Ariyoshi et al., 1998; Gao 
et al., 1996b; Lennette et al., 1996; Simpson et al., 1996). While HHV-8 appears 
to be widespread in Africa, endemic KS is restricted to East and Central Africa 
(Beral, 1991; Gompels and Kasolo, 1996), suggesting differences in HHV-8 
strain pathogenicity or involvement of other co-factors. For example, in The 
Gambia (West Africa) where HHV-8 seroprevalence is approximately 60% in 
antenatal HIV-negative mothers, endemic KS is rare and AIDS-KS is virtually 
limited to individuals infected with HIV-1 but not with HIV-2 (Ariyoshi et al.,
1998). This supports a co-factor role for HIV-1 (Ensoli et al., 1994; Albini et al., 
1996).
Among HIV-infected individuals from the USA and Northern Europe, HHV-8 
antibodies are found significantly more frequently in HIV-positive homosexual 
men (30-35%) than in other HIV risk groups, such as haemophiliacs and 
intravenous drug users (Gao et al., 1996b; Kedes et al., 1996; Lennette et al., 
1996; Simpson et al., 1996). This suggests sexual transmission of the etiologic 
agent. Furthermore, the distribution of HHV-8 in HIV risk groups correlates with 
the reported high incidence of KS in HIV-infected homosexual men and the 
rarity o f KS in HIV-infected patients with haemophilia or intravenous drug users 
(Beral, 1991; Beral et al., 1990; Peterman et al., 1993), thus providing an 
argument for HHV-8 being the cause of KS. The seroprevalence of HHV-8 
among HIV-infected women (4%) in the USA is much lower than that in HIV- 
infected homosexual men (30-35%) (Gao et al., 1996a,b; Kedes et al., 1996;
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Simpson et al., 1996). This, again, is consistent with the reported lower incidence 
of KS among women than in HIV-infected men, further extending the argument 
for the causative role of HHV-8. Longitudinal serologic studies o f HIV-positive 
men show that seroconversion precedes KS development (Gao et al., 1996a,b). 
Thus, in contrast to HHV-8 endemic areas, presence of HHV-8 antibodies in 
individuals in non-endemic areas (USA and Northern Europe) is strongly 
associated with KS. HHV-8 seroprevalence among HIV-infected individuals in 
endemic areas ranges from 36-91%, with higher prevalence rates in individuals 
with KS (reviewed by Chatlynne and Ablashi, 1999).
1.8.2. Molecular epidemiology
PCR-based methods have been used to detect HHV-8 DNA in KS lesions, 
PBMCs, lymphoid tissue, saliva, and semen of KS patients and healthy 
individuals. The HHV-8 genome has been detected in virtually all KS lesions 
(Boshoff et al., 1995b; Buonaguro et al., 1996; Chang et al, 1994, 1996b; Chuck 
et al., 1996; Dictor et al., 1996; Dupin et al., 1995; Gaidano et al., 1996b; Luppi 
et al., 1996b; Moore and Chang, 1995; Noel et al., 1996; Schalling et al., 1995; 
Su et al., 1995). HHV-8 DNA was also detected in 14% (3/22) o f non-KS 
tumour lesions from Ugandan control cancer patients (Chang et al., 1996b). 
HHV-8 DNA can be detected in 50-60% of PBMC samples from KS patients 
(Whitby et al., 1995). Thus, this method underestimates HHV-8 prevalence. 
HHV-8 is not, or only infrequently, detected in PBMCs from HIV-negative 
individuals (Bigoni et al., 1996; Brambilla et al., 1996; Humphrey et al., 1996; 
Lefrere et al., 1996; Moore et al., 1996c; Whitby et al., 1995). It has been 
detected in 10% of PBMCs from HIV-negative individuals in The Gambia 
(Ariyoshi et al., 1998) and in 0% (0/21) o f PBMCs from KS-negative individuals 
in Uganda (Purvis et al., 1997). Detection of HHV-8 DNA in PBMCs occurs at a 
relatively higher frequency in HIV-infected individuals and its presence predicts
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progression to KS (Whitby et al., 1995). The HHV-8  genome has been detected 
in the lymphoid tissue of about 10% of healthy Italian subjects (Bigoni et al., 
1996; Viviano et al., 1997).
Using quantitative PCR analysis in a longitudinal study involving HHV-8 - 
positive, KS-negative men from the USA who have sex with men, Pauk et al. 
(2000) detected HHV-8  in 30% of oropharyngeal samples, as compared to 1% of 
anal and genital samples. HHV-8  was detected in saliva in 39% of these men on 
more than 35% of the consecutive days on which samples were obtained. HHV-8 
has also been detected in the saliva of KS patients by some studies (Boldough et 
al., 1996; Koelle et al., 1997) but not by others (Ambroziak et al., 1995; Whitby 
et al., 1995), and in the semen of KS patients (Corbellino et al., 1996a,c; Gupta et 
al., 1996; Howard et al., 1997; Monini et al., 1996a,b). Although the virus is 
generally not detected in the semen of healthy men (Corbellino et al., 1996a,c; 
Gupta et al., 1996; Howard et al., 1997; Lebbe et al., 1997; Lefrere et al., 1996; 
Moore et al., 1996c; Whitby et al., 1995), it has been detected in 13-23% of 
semen samples from healthy Italian donors from areas where classic KS appears 
more frequently (Blackboum and Levy, 1997; Monini et al., 1996a,b; Staskus et 
al., 1997; Viviano et al., 1997).
1.8.3. Transmission of HHV-8
Little is known about the precise way in which HHV-8  is transmitted. There is 
evidence from several studies to suggest that it can be sexually transmitted, and 
this may be the major route o f transmission in non-endemic areas. HHV-8 
antibodies are more frequently found in sexually transmitted diseases (STD) 
clinic attendees (Kedes et al., 1996, 1997; Simpson et al., 1996; Lennette et al., 
1996). In the USA, HHV-8  seroprevalence among homosexual men is strongly 
associated with promiscuity and a history of STDs (Martin et al., 1998). Also
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among Danish homosexual men, HHV-8  seropositivity and seroconversion are 
associated with promiscuity, duration of homosexual activity, receptive anal 
intercourse and, in the early 1980s, sexual contact with homosexual men from 
the USA (Melbye et al., 1998). These behavioural risk factors have been shown 
previously to increase the risk o f KS developing in homosexual men (Beral et a l, 
1990), thus supporting the notion that HHV-8  plays a causative role in the 
development of KS. Additional evidence that HHV-8  may be primarily sexually 
transmitted in non-endemic countries comes from data indicating that HHV-8 
infection is rare in infants and children, but occurs mainly after puberty in these 
areas (Blauvelt et al., 1997; Lennette et al., 1996; Raab et al., 1998; Regamey et 
al., 1998). Evidence for possible heterosexual transmission has also been 
documented. Sitas et al. (1999) reported a statistically significant association 
between the number of heterosexual partners and HHV-8  seropositivity among 
black cancer patients in South Africa. Furthermore, a large study by Davidovici 
et al. (2001) of HHV-8  seroprevalence among Jewish families in Israel indicated 
that HHV-8  can be transmitted between heterosexual married couples. Semen 
could be a source of infection in sexual transmission. However, the study by 
Pauk et al. (2000) suggests that saliva rather than semen or anal secretions may 
play a more significant role in the transmission of HHV-8  in men who have sex 
with men. Indeed, one study has showed that HHV-8  from saliva of men with KS 
could be transiently propagated in 293 cells, indicating that it was infectious 
(Vieira et al., 1997).
Factors favouring HHV-8  transmission in endemic African countries (where 
HHV-8  infection is widespread in both men and women) appear to be different 
from those in non-endemic countries. Antibodies, steadily increasing with age, 
have been detected to HHV-8  LANA and ORF65 proteins in young children 
(aged 2-12 years) in East Africa and Italy (Calabro et al., 1998; Mayama et al.,
1998). These results suggest that horizontal, non-sexual, routes o f transmission
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may be more important in areas where KS is more common. HHV-8  has also 
been detected by PCR in PBMCs of 8% of young children in Zambia (Kasolo et 
al., 1997). In the study by Mayama et al. (1998), which involved Ugandan 
children and adolescents, the presence of HHV-8  antibodies was independently 
associated with hepatitis B virus (HBV) infection. This finding implies that both 
HHV-8  and HBV are transmitted via similar routes in this population or that 
factors associated with HBV infection also favour HHV-8  transmission.
The mode of transmission in children is not known, but saliva, through some 
form of casual contact, may be responsible for spreading HHV-8  in endemic 
areas. One study of a Sardinian population (where KS is highly endemic) found 
clustering of HHV-8  seropositivity among family members, suggesting possible 
vertical or, more likely, horizontal transmission within a family (Angeloni et al., 
1998). The study by Mayama et al. (1998) showed that o f 9 children younger 
than 2 years, only 1 infant (6  months old) had antibodies to HHV-8 . This finding 
does not exclude vertical transmission from mother to child, but overall results of 
this study suggested that this might not be the predominant mode of HHV-8 
infection among young children in this cohort. Among Jewish families in Israel, 
Davidovici et al. (2001) found that for a child to test positive, the most important 
risk factor was maternal seropositivity, suggesting that mother to child 
transmission was important. All the children in this study were older than 2 
years; thus a positive test indicated exposure to the virus since transplacental 
(passive) maternal antibodies would not be expected to be present at this age. 
Transmission of HHV-8  from sibling to sibling (in addition to from mother to 
child) has also been shown to be important in an African population living in 
French Guiana (Plancoulaine et al., 2000).
Iatrogenic transmission of HHV-8  is also o f concern. Transmission through solid 
organ allografts has been documented (Luppi et al., 2000; Parravicini et al.,
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1997b). However, it is apparent that most transplantation-associated KS is due to 
HHV-8  reactivation (Parravicini et al., 1997b). Blood transfusion does not appear 
to present a particular risk in HHV-8  transmission (Beral et al., 1990; Calabro et 
al., 1998; Whitby et al., 1998), although a single case of infectious HHV-8  from 
a healthy blood donor has been documented (Blackboum et al., 1997).
1.9. CONCLUDING REMARKS
Since the discovery of HHV-8  in 1994, a strong case has developed for its 
causative role in KS. Epidemiologically, HHV-8  is found in all forms of the 
disease, irrespective of HIV status, and infection tracks closely with known risk 
groups for KS in non-endemic areas. Furthermore, infection precedes the 
development of the tumour and is predictive of increased probability of KS 
development in HIV-infected individuals. In countries, and regions within 
countries, where KS occurs more frequently, HHV-8  is also more common; 
however, the converse is not always true. Thus, although HHV-8  appears to be 
required for development of KS, it is evident that other factors (e.g. other 
infectious agents, like HIV-1, immunosuppression or environmental factors) are 
necessary. Biologically, HHV-8 is closely related to other oncogenic 
rhadinoviruses and encodes several proteins that have been shown (in vitro) to 
have signalling properties and to control cellular growth. Furthermore, HHV-8 
infection is targeted to the cell type (spindle cell) thought to play a key role in the 
pathogenesis of KS. Finally, some herpesvirus DNA polymerase inhibitors have 
been shown to reduce the appearance of KS lesions in AIDS patients. Taken 
together, these data strongly suggest that HHV-8  is a cause o f KS.
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1.10. JUSTIFICATION AND OBJECTIVES OF THE STUDY
1.10.1. Justification of the study
KS is a prominent disease in Uganda accounting for half the reported cancer 
cases (Wabinga et al., 1993). It occurs in epidemic and endemic forms affecting 
both children and adults. At the time this study was initiated, little was known 
about the prevalence of HHV-8  in the Ugandan population or the strains present 
in this country. I performed a study to determine the prevalence of HHV-8  in 
Ugandan blood donors and to characterise the HHV-8  strains in Ugandan KS 
patients.
1.10.2. Specific objectives of the study
1. Determination of HHV-8  prevalence in HIV-negative blood donors.
2. Characterization of the HHV-8  K1 gene in tumour DNA from KS patients.
3. Characterization of the HHV-8  K15 gene in tumour DNA from KS patients.







One hundred and sixteen blood donors visiting Nakasero blood bank (NBB) in 
Kampala, the capital city of Uganda, during April-August 1998 were recruited 
into the study. NBB is the only blood bank facility serving the central Uganda 
region.
2.1.2 Kaposi’s sarcoma patients
Twenty eight unrelated, adult Ugandan KS patients attending the Uganda Cancer 
Institute (UCI) clinic at Mulago Hospital, Kampala, during April-July 1998 were 
recruited to the study. Samples had also been collected from two other patients 
(Ugdl and 2) in August 1997 bringing the total number of KS patients to 30. The 
patients were at various stages o f anticancer chemotherapeutic treatment. Mulago 
Hospital is the major national referral hospital, and UCI receives KS referrals 
from across the country. UCI has a 40-bed unit for admitted patients.
Skin biopsy punches (6  mm in diameter) used to collect skin biopsies from KS 
patients were obtained from Rocialle Medical Limited, Sawston, Cambridge, 
UK.
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2.1.3 DNA extraction and Polymerase Chain Reaction (PCR)
Nucleon BACC 2/3 for cell pellet DNA 
extraction
Taq DNA polymerase, 10X PCR buffer 
with magnesium chloride
Primers
dNTPs mixture (each 12.5 mM)
Mineral oil
Aerosol resistant tips (ART)
2.1.4 Electrophoresis
High and low melting point agarose 
and ethidium bromide (10  mg/ml 
aqueous solution)
DNA markers (lambda DNA Hind. Ill 




Initially synthesized at the Institute of 








2.1.5 Purification, cloning and sequencing of DNA fragments
Hybaid DNA purification kit Hybaid
pGEM-T Vector System II (including Promega 
JM 109 competent cells)
Restriction endonucleases and other 
enzymes and buffers
ABI PRISM Termination Ready 
Reaction Mix
Internal gene primers for sequencing
M13 Universal Sequencing Primers
2.1.6 Chemicals
All chemicals were obtained from BDH, Boehringer-Mannheim or Sigma.
2.1.7 Solutions and buffers
Boehringer-Mannheim, BRL or New 
England Biolabs
Perkin-Elmer
Synthesized at the Institute of Virology 
and later supplied by MWG-Biotech 
AG
Pharmacia Biotech








10 mM Tris-HCl, pH 7.5 
5 mM EDTA 
0.5% SDS
0.5 mg/ml proteinase or 100 pg/ml 
proteinase K
109 g/1 Tris 
55 g/1 boric acid 
9.3 g/1 EDTA
37.2 g/1 EDTA 
100 g/1 Ficoll 400 
5X TBE
1% (w/v) bromophenol blue
250 mM Tris-HCl, pH 7.5 
50 mM MgCl2 
5 mM DTT 
25% (w/v) PEG 6000
40 mg/ml 5-bromo-4-chloro-3-indoyl 
P-D-galactoside in N,N’-dimethyl
formamide





2.1.8 Bacterial growth media
20% (w/v) PEG 6000
2.5 M NaCl






85 mM NaCl 
1% (w/v) bactopeptone 
1% (w/v) yeast extract
177 mM NaCl 
1% (w/v) bactopeptone
1.5% (w/v) agar in L-broth
0 .6 % (w/v) bacto-agar in water
Published sequences used in this study were obtained from the following 
references: Alagiozoglou et al. (2000); Cook et al. (1999); Glenn et al. (1999); 
Lacoste et al. (2000a); Nicholas et al. (1998); Poole et al. (1999); Russo et al. 
(1996); Zong et al (1999). The sources o f some are listed in Table 2.1.
Table 2.1. Sources of some of the published sequences used in this study
Strain K1 subtype K15 allele Source Country Reference (GenBank 
accession)
BC-1 A2 M AIDS-PEL cell line USA Russo et al. (1996) 
(U75689)
BCBL-R Al P AIDS-PEL tumour cells USA Nicholas et al. (1998) 
(U85269)
ASM72 Cl M Autopsy: AIDS 
disseminated KS
USA Zong et al. (1999)
BC2 C3 P AIDS-PEL cell line USA Zong et al. (1999
GK18 C P Classical KS biopsy Greece Glenn etal. (1999) 
(AF148805)
Kl-43/Ber Undefined M HIV positive, PEL 
ascitic fluid
France Lacoste et al. (2000a) 
(AF178810)
ST1 B Unknown AIDS-KS biopsy Uganda Zong et al. (1999)
ST2 B Unknown AIDS-KS biopsy Uganda Zong et al. (1999)
Ug374 A5 Unknown HIV positive, no KS, 
PBMC
Uganda Cook et al. (1999) 
(AF 130289)
431KAP B P Endemic KS biopsy Zaire Zong etal. (1999)
OKS3 A5 P AIDS-KS biopsy Tanzania Zong et al. (1999)
OKS4 B P AIDS-KS biopsy Tanzania Zong et al. (1999)
Kl-8/Dem Undefined No product AIDS-KS biopsy Central African 
Republic
Lacoste et al. (2000a) 
(AF 178780)
DS814ZA Unknown Unknown HIV positive, no KS, 
PBMC
South Africa Alagiozoglou et al. 
(2000) (AF243803)
KS70ZA Unknown Unknown AIDS-KS, PBMC South Africa Alagiozoglou et al., 
(2000) (AF243831)
KS84ZA Unknown Unknown AIDS-KS, PBMC South Africa Alagiozoglou et al. 
(2000) (AF243823)
KS91ZA Unknown Unknown AIDS-KS, PBMC South Africa Alagiozoglou et al. 
(2000) (AF243823)




Individuals donating blood during the times I was at NBB were sampled. As well 
as collection of blood samples, demographic data, including age, gender, place of 
residence and birth were recorded. Blood samples were collected in 7 ml EDTA- 
tubes. Plasma was harvested and stored at -70 °C at the Makerere University- 
Johns Hopkins University (MU-JHU) collaborative laboratory, Mulago Hospital, 
until shipped on dry ice to the UK. A cell pellet (containing all white blood cells) 
was prepared from the rest of the sample by staff at the MU-JHU laboratory 
using the method involving lysis of red blood cells.
All samples were tested for HIV-1 antibodies using two commercially available 
ELISA kits (Burroughs Wellcome and Welcozyme).
2.2.2 Kaposi’s sarcoma patients
The HHV-8-positive DNA samples used for genome characterization were 
derived from skin biopsies of KS patients. Ethical approval for this study was 
obtained from the Uganda AIDS Research Committee and the Uganda National 
Council for Science and Technology. Informed consent was obtained from each 
patient before samples were taken. Samples were taken from randomly selected 
in-patients meeting the following inclusion criteria: >18 years old (except one 
patient, Ugdl9, who was 16 years old), having clinically typical KS with 
haematological indices acceptable for therapy (Hb>10 g/dl, WBC >3.0 X 109/1 
with absolute neutrophil count o f >1.5 X 109/1 and platelets >100 X 109/1) and a 
signed consent form. Patients with a bleeding tendency or with small lesions, and 
pregnant women in the first trimester were excluded. All patients, except Ugd30,
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were clinically and histologically diagnosed by Dr. Edward Katongole-Mbidde 
(UCI). Ugd30 became unavailable after preliminary clinical diagnosis. The 
patients were tested for HIV-1 antibodies at the MU-JHU collaborative 
laboratory using two commercial ELISA kits (Burroughs Wellcome and 
Welcozyme). Samples that reacted non-specifically were confirmed by Western 
blot (WB) analysis.
The biopsies were collected by Sister Naomi Byabazaire. She immediately 
dropped them into absolute ethanol kept on liquid nitrogen to minimize DNA 
degradation. The ethanol was removed following overnight incubation at -80 °C, 
and the biopsies were stored at 4° C until extracted. Matching blood samples 
were collected in EDTA-tubes for HIV-1 testing, HHV-8  serology and for 
preparation of cell pellets as described above.
2.2.3 Serological tests
Serological tests were performed on all blood donor samples and some (19) KS 
patient plasma samples by Julie Sheldon in the laboratory of Professor Thomas 
Schulz (Department of Medical Microbiology and Genitourinary Medicine, 
University of Liverpool, Liverpool, UK). Diluted (1:100) plasma were screened 
for antibodies to HHV-8  ORF65 and ORF73 recombinant proteins by ELISA, as 
described previously (Simpson et al., 1996). The antigens were diluted 1:60 
(ORF65 and control) or 1:50 (ORF73) in 100 mM N aH C03 (pH 8.5). The plates 
were coated at room temperature overnight. The cut-off values for the ELISA 
scores, (+), 1+, 2+ and 3+, were, respectively, 3, 5, 7 and 10 standard deviations 
above the average value for 10 negative control sera. An immunofluorescence 
(IF) test for LANA (Rainbow et al., 1997) was then performed on all samples on 
paraformaldehyde-fixed BCP-1 cells (Boshoff et al., 1998) at a plasma dilution 
of 1:50, as described previously (Simpson et al., 1996). WB analysis against
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ORF65 protein was performed for all samples that were positive in the ELISA 
(one or both antigens) but negative or non-specific in the IF test. The results of 
the IF test and the WB analysis were scored arbitrarily on the basis of the 
intensity of the signal. Overall, samples were interpreted as being positive if they 
were positive in both the IF test and the ELISA (one or both antigens), or in the 
IF test alone or in the ELISA alone followed by a positive WB result.
2.2.4 DNA extraction
Tumour DNA was extracted from biopsies and cell pellet samples at the MU- 
JHU laboratory. Biopsies were extracted as described previously for fresh frozen 
biopsy samples (Cook et al., 1999). Briefly, ethanol-treated tissue was cut into 
small pieces with a scalpel and incubated overnight at 55 °C in extraction buffer. 
Proteinase K was inactivated by incubating at 95 °C for 15 min. DNA was 
extracted using phenol and chloroform-isoamyl alcohol, and precipitated with
2.5 volumes of 100% ethanol and 0.1 volumes of 3M sodium acetate (pH 5.5) at 
room temperature for 5 min. The pellet was then rinsed twice with 70% ethanol. 
Cell pellet DNA was extracted using a commercial kit (BACC 2/3; Nucleon 
Biosciences) as instructed in the manufacturer’s manual. Precipitated DNA was 
resuspended in 100-300 pi TE and stored at 4 °C until shipped at ambient 
temperature to the Institute of Virology, Glasgow, UK.
2.2.5 PCR and DNA sequencing
Tumour DNA was amplified by PCR for seven loci o f the HHV-8  genome: K1 
(1277 bp), K3 (635 bp), ORF26 (160, 233, 571 bp), K9 (594 bp), T0.7/K12 (648 
bp), ORF75 (749 bp for genomes with the K15 P allele and 1487 bp for the 
genome (UgdlO) with the K15 M allele), K15 P (285 bp to identify the allele and 
2494 bp to sequence it completely) and K15 M (298 bp to identify the allele and
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two overlapping regions of 1374 and 1483 bp to sequence it completely). The 
locations of the ORF and the PCR products are shown in Table 2.2. The sizes of 
the PCR products and corresponding primer pairs are listed in Table 2.3. Primary 
PCR products (i.e. not nested) were obtained, except for the K1 locus in three 
samples (Ugd4, Ugdl2 and Ugd24) which was obtained as a 874 bp product by 
nested PCR and for ORF26 in the detection of HHV-8  DNA in cell pellet 
samples. As a control the human P-globin gene was amplified using primers 
shown in Table 2.3.
PCR was performed using Taq polymerase in a total volume of 50 pi containing 
20-200 ng of template DNA. Stringent measures were undertaken to prevent 
PCR contamination: all original DNA samples were extracted in a laboratory in 
Uganda; separate rooms were used for pre-PCR, PCR and post-PCR steps; 
aerosol resistant tips were used and the premix was UV-irradiated. Each 
experiment involved a sizeable batch of reactions, and incorporated appropriate 
negative (water and uninfected cellular DNA) and positive controls. The 
conditions used to amplify the products are shown in Table 2.3.
PCR products were purified directly from solution or from 1% low melting point 
agarose gels stained with ethidium bromide using a commercial kit (Hybaid). K l, 
K15 and ORF75 (linked to K15 M allele) products were cloned into pGEM-T. 
Plasmid (template) DNA for sequencing was prepared by the alkaline lysis 
method followed by PEG/NaCl precipitation. Sequencing was performed using 
universal and gene-specific primers except for some samples (K15 gene of Ugd2 
and initial clones of ORF75 and K15 products of UgdlO), where the shotgun 
M l3 sequencing technique was employed. The K15 product o f Ugd2 was 
sequenced by Andrew Davison and Charles Cunningham. The initial, almost 
complete, sequence of the ORF75 and K15 products o f UgdlO was used to 
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clones were sequenced for each product to exclude PCR-induced errors. All 
other products were sequenced directly using the appropriate PCR primers. The 
sequencing reactions were performed with the ABI-PRISM Big Dye Terminator 
cycle sequencing ready reaction kit and the sequences were determined on an 
ABI PRISM 377 DNA sequencer. Data were derived from both DNA strands for 
all products.
2.2.6 DNA sequence analysis
DNA sequences were assembled and edited using SAP or Pregap4/Gap4 (Staden, 
1987; Staden et al., 1998) and aligned using Pileup and Pretty (GCG, Madison, 
Wisconsin). K1 sequences were analysed phylogenetically together with 
published sequences (Cook et al., 1999; Lacoste et al., 2000a; Zong et al., 1999) 
by the neighbour joining method, using Seqboot, Dnadist, Neighbor and 
Consense from the PHYLIP package version 3.572 (University o f Washington, 
Seattle). Phylogenetic analysis was performed with the help of Duncan McGeoch 
(MRC Virology Unit, Institute of Virology, Glasgow, UK). DNA sequences 
were translated into amino acid sequences using Translate (GCG), and 
divergence values between pairs of amino acid sequences were determined using 
Protdist (PHYLIP).
Network analysis (Bandelt et al., 1995) o f DNA sequence data was used to 
determine genotypes at all other loci with extensive assistance from Rory 
Bowden (Department of Statistics, University o f Oxford, Oxford, UK). Networks 
provide an objective summary of sequence data and an effective way to infer a 
likely history of a set o f closely related sequences. They offer an advantage over 
phylogenetic trees in studying variation between very similar sequences, and 
facilitate identification of potential sequencing errors.
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CHAPTER 3 
RESULTS AND DISCUSSION-I 
PREVALENCE OF HHV-8 IN UGANDAN BLOOD DONORS
3.1 INTRODUCTION
It is now evident from the literature that HHV-8  infection is not found uniformly 
throughout the world’s population. Several studies have shown that HHV-8 
seroprevalence in African populations is significantly higher than elsewhere in 
the world, and is not limited to adults or HIV-infected individuals (Calabro et al., 
1998; Gao et al., 1996; Mayama et al., 1998; Sarid et al., 1999; Simpson et al., 
1996; Schulz, 1998). Several studies have determined the prevalence of HHV-8 
antibodies among different groups of the Ugandan population using various 
serological tests. The results o f these studies (summarized in Table 3.1) show 
that HHV-8 prevalence in individuals who are not patients and do not have KS or 
HIV ranges from 11-77%. The prevalence of HHV-8  in blood donors has been 
reported by one study which employed the whole virus ELISA method as being 
38% (Chatlynne and Ablashi, 1999). The prevalence in HIV-infected individuals, 
with or without KS, ranges from 46-89%, and that in KS patients ranges from 
78-100%. HHV-8  prevalence in children and adolescents in Uganda was found 
to be 43% and 33% by ORF65 ELISA (confirmed by Western blot) and LANA 
IF, respectively, and 52% by both tests combined.
Several groups have failed to detect HHV-8  by PCR in the peripheral blood of 
healthy donors (Ambroziak et al., 1995; Whitby et al., 1995), while others have 
reported detection in 9% of PBMC and lymphoid tissue o f HIV-uninfected 
individuals (Bigoni et al., 1996). PCR and Southern blot analysis of PBMC from 
KS-negative, HIV-positive Ugandan blood donors indicated that 0 o f 10 samples
Table 3.1. HHV-8 seroprevalence among different groups of the Ugandan 
population





HIV-negative without KS 51/47 BCP-laIF Gao et al., 1996
HIV-negative without KS 62/47 LANA WB Gao et al., 1996
HIV-negative without KS 35/17 ORF65 ELISA Simpson et al., 1996
HIV-negative without KS 53/17 Latent IF Simpson et al., 1996
Blood donors 38/58 Whole virus ELISA Chatlynne & Ablashi, 1999
General population 77/82 Lytic BCBL-1 IF Lennette et al., 1996
General population 11/82 Latent BCBL-1 IF Lennette et al., 1996
HTV and/or KS patients
HIV-negative with KS 100/21 Lytic BCBL-la IF Lennette et al., 1996
HIV-negative with KS 100/21 Latent BCBL-1 IF Lennette et al., 1996
AIDS-KS 78/18 BCP-1 IF Gao et al., 1996
AIDS-KS 89/18 LANA WB Gao et al., 1996
AIDS-KS 82/17 ORF65 ELISA Simpson et al., 1996
HIV-positive without KS 51/35 BCP-1 IF Gao et al., 1996
HIV-positive without KS 71/35 LANA WB Gao et al., 1996
HIV-positive without KS 46/35 Whole virus ELISA Chatlynne & Ablashi, 1999
HIV-positive without KS 47/34 ORF65 ELISA Simpson et al., 1996
HIV-positive without KS 53/34 Latent IF Simpson et al., 1996
Children and adolescent 43/212 ORF65 ELISA Mayama et al., 1998
patients 33/212 LANA IF Mayama et al., 1998
a BCP-1 and BCBL-1 are HHV-8-infected, EBV-negative PEL cell lines.
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contained detectable HHV-8 DNA, and 0 of 11 samples from KS-negative, HIV- 
negative controls contained detectable HHV-8  DNA (Purvis et al., 1997).
The objectives of the current study were to determine the prevalence of HHV-8 
in HIV-negative blood donors, using more sensitive serological tests and PCR, 
and to determine HHV-8  subtypes in this population by sequencing and analysis 
of the K1 gene.
3.2 BLOOD DONORS
Blood was collected from 116 blood donors, 98 male and 18 female. A summary 
of the demographic data is given in Table 3.2. The median age of the donors was 
27 years (range, 18-54 years). The majority of the donors were residents of the 
greater Kampala area, although most o f them were bom in other areas of Uganda 
(Table 3.2). Two donors were HIV-positive, and their samples were excluded 
from further analysis.
3.3 HHV-8 SEROPREVALENCE IN BLOOD DONORS
Two serological tests, ELISA and IF test, were used to analyse plasma from 114 
HIV-negative blood donors for antibodies against HHV-8  ORF73 and ORF65 
antigens. The raw data are shown in Table 3.3 and are summarized in Table 3.4. 
The 71 samples that were positive in ORF73 ELISA were also positive in 
ORF65 ELISA. O f the 51 samples that gave a positive result in the IF test, 43 
reacted in the ORF65 ELISA as well and eight in only the IF test. Thus, 97 
(85%) samples reacted in at least one of the assays (before confirmation with 
WB), and 54 (47%) in only one assay. The 46 samples that reacted only in the 
ELISA (36 with both antigens and 10 with only the ORF65 antigen) were tested 
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ELISA*
Plasma Gender' ORF 65 ORF 73 Control" ORF 65 ORF 73 Control IF* WB Results
1-596 0.246 0.209 0.154 3+ 3+ 3+ ns/+ [+] +
1-597 0.271 0.107 0.047 3+ 2+ (+) ns/+ [+] +
1-598 0.093 0.147 0.023 3+ 3+ + +
1-599 0.051 0.058 0.021 <+)H - - -
1-600 F 0.214 0.129 0.078 3+ 2+ 3+ 3+ +
1-601 0.064 0.146 0.025 2+ 3+ - - -
1-602 F 0.045 0.033 0.02 (+)H - - -
1-603 0.198 0.143 0.112 3+ 3+ 3+ - + +
1-604 0.108 0.124 0.024 3+ 2+ - -
1-605 0.203 0.41 0.049 3+ 3+ (+) - + +
1-607 0.052 0.082 0.028 1+ (+) 3+ +
1-608 0.386 0.475 0.219 3+ 3+ 3+ - + +
1-609 0.075 0.079 0.028 2+ <+) - ns/+ [ns] + +
1-610 0.234 0.102 0.043 3+ 1+ (+) ns + +
117580-S 0.284 0.187 0.098 3+ 3+ 3+ ns/- [ns] + +
117581-U 0.055 0.088 0.038 1 + 1+ ns + +
117582-D 0.471 0.085 0.028 3+ 1 + - + +
117583-Y 0.035 0.03 0.021 - - -
117584-W 0.063 0.07 0.026 2+ (+) - + +
117585-U 0.528 0.038 0.024 3+ ns/- [ns] + +
117586-C 0.068 0.055 0.039 2+ - - + +
117587-W 0.083 0.086 0.082 3+ 1+ 3+ 3+ +
117588-G 0.161 0.176 0.046 3+ 3+ <+) - + +
117589-0 0.055 0.096 0.042 1+ 1+ (+) 3+ +
117590-T 0.028 0.044 0.025 - - 3+ +
117746-G 0.053 0.047 0.029 1 + - - - -
117747-D 0.034 0.033 0.023 - - - 3+ +
117748-M 0.082 0.072 0.055 3+ (+) 1+ - + ♦
117749-1 0.283 0.199 0.029 3+ 3+ - 3+ +
117750-U 0.602 0.342 0.188 3+ 3+ 3+ 3+ +
117751-N 0.116 0.113 0.1 3+ 2+ 3+ 3+ +
117752-R 0.043 0.073 0.035 (+)H (+)H - ns
117753-C 0.143 0.068 0.022 3+ (+) - - -
117754-V F 0.132 0.04 0.021 3+ - - 3+ +
117755-K 0.103 0.267 0.078 2+ 2+ - - + +
11775Q-J 0.278 0.249 0.162 3+ 2+ 2+ 3+ +
117757-K 0.147 0.257 0.112 3+ 2+ (+) 3+ +
117849-C 0.119 0.163 0.052 3+ 3+ 1+ - - -
117850-T 0.028 0.03 0.023 - - - - -
117851-H 0.033 0.029 0.02 - - - - -
117852-X 0.336 0.147 0.055 3+ 3+ 1+ - + +
117853-D 0.127 0.089 0.09 3+ 1+ 3+ 2+ +
117854-J 0.074 0.137 0.047 2+ 3+ <+) 2+ +
117855-T 0.272 0.056 0.045 3+ - ns I * ) +
117856-W 0.015 0.015 0.021 - - - ns -
117857-R F 0.055 0.086 0.045 (♦> - - - (♦> +
117858-F 0.029 0.135 0.036 (+)H - - -
118021-1 0.226 0.048 0.035 3+ - 3+ +
118022-X 0.204 0.128 0.201 3+ - 3+ 3+ +
118023-N 0.295 0.096 0.09 3+ - (+) 3+ +
118024-G 0.066 0.065 0.144 (+) H - 2+ - -
118025-V F 0.063 0.081 0.061 (+>H - - - -
118026-C 0.035 0.04 0.016 - - - -
118157-W 0.125 0.079 0.025 3+ (+) - - + +
118158-F 0.053 0.058 0.019 1 + - - - - -
118159-N 0.214 0.198 0.075 3+ 3+ 2+ - - -
118160-Y F 0.193 0.334 0.08 3+ 3+ - ns + +
118161-R F 0.144 0.196 0.064 3+ 1+ - - + +
118162-G 0.354 0.478 0.427 3+ 3+ 3+ 2+ +
118163-V 0.106 0.116 0.052 3+ - - + +
118164-0 0.039 0.067 0.039 - - - + +
118165-V 0.036 0.065 0.038 - - - 3+ +
118166-1 0.132 0.117 0.064 3+ 2+ 2+ 2+ +
118167-Q 0.141 0.102 0.5 3+ 1+ (+) + +
118168-G 0.139 0.092 0.036 3+ 1+ - + +
118169-P 0.041 0.047 0.033 (+) H - - -
118170-T 0.282 0.103 0.028 3+ 1 + - - + +
118171-H 0.115 0.313 0.045 3+ 3+ <+> 3+ +
118172-V 0.295 0.365 0.133 3+ 3+ 3+ 3+ +
118173-0 0.217 0.072 0.028 3+ (+> - 3+ +
118174-J F 0.234 0.047 0.059 3+ 1 + 3+ +
118175-C 0.55 0.03 0.025 3+ - - - + +
118176-V 0.148 0.085 0.03 3+ 1+ - - -
118177-P F 0.09 0.105 0.036 3+ 2+ - 2+ +
118178-E 0.381 0.101 0.042 3+ 1 + (+) + +
118179-A 0.152 0.111 0.05 3+ 2+ 1+ - -
118244-W 0.075 0.067 0.028 2+ (+) - 2+ +
118245-R 0.526 0.105 0.058 3+ 2+ 1+ 2+ +
118246-M F 0.062 0.056 0.022 1+ - - 3+ +
118357-L 0.35 0.249 0.09 3+ 2+ 3+ - + +
118358-E 0.092 0.047 0.038 3+ - - ns/+ [+] +
118359-U 0.115 0.094 0.022 3+ 1+ - - + +
118360-T F 0.112 0.06 0.03 3+ - - - + +
118361-D 0.278 0.306 0.03 3+ 3+ - 3+ +
118362-W 0.033 0.038 0.017 - - - + +
118364-G 0.106 0.093 0.024 3+ 1+ - - -
118365-C F 0.088 0.057 0.026 3+ - - - ns
118494-Y 0.252 0.336 0.047 3+ 3+ (+) - + +
118495-W F 0.058 0.066 0.035 1 + (+) 2+ +
118496-K 0.132 0.187 0.033 3+ 3+ - + +
118497-G 0.375 0.132 0.053 3+ 2+ 1 + 3+ +
118498-M F 0.081 0.123 0.04 3+ 2+ (+) 3+ +
118631-H F 0.041 0.038 0.024 (+) - - + +
118632-Y 0.437 0.331 0.085 3+ 3+ 3+ ns ns -
118633-F 0.033 0.036 0.018 - - - -
118634-R 0.04 0.057 0.02 - - - -
118635-M F 0.058 0.611 0.031 1+ 3+ 3+ +
118636-G 0.216 0.621 0.034 3+ 3+ 3+ +
118637-K 0.044 0.038 0.025 (+>H - -
118638-S 0.244 0.174 0.067 3+ 3+ 2+ ns + +
126164-Q 0.12 0.108 0.103 3+ 2+ 3+ - <+> +
126165-V 0.141 0.066 0.036 3+ (♦) - - + +
126166-N 0.675 0.444 0.104 3+ 3+ 3+ - + +
126167-T 0.248 0.235 0.101 3+ 3+ 3+ 3+ +
126168-Q F 0.033 0.046 0.026 - - - 3+ +
126169-S 0.163 0.07 0.062 3+ <+) 2+ - ns
126170-T 0.035 0.041 0.037 - - - 3+ +
126171-V 0.09 0.07 0.022 3+ <+) - - + ♦
126172-N 0.042 0.064 0.027 (+)H - ns/- [ns]
126173-W 0.64 0.188 0.056 3+ 3+ 2+ ... fiL +
126174-A 0.032 0.053 0.033 - - - 3+ +
126175-N F 0.046 0.043 0.045 (+)H - (+) -
126729-B 0.099 0.074 0.051 3+ <+) 1+ 3+ +
126730-J 0.085 0.09 0.035 3+ 1+ - - + +
F ootn otes overleaf.
Footnotes for Table 3.3
a Results were scored as explained in the Methods section. 
b Nine (ORF65) and two (ORF73) samples scored as (+), which were negative in
the IF test but a WB was not done, were interpreted as being negative ([-]).
c Only females are indicated. 
d Average value for 10 negative control sera.
e All 4 samples scored as ns/+ were positive in the ELISA, 3 were counted as
being positive ([+]) because a WB was not done while 1 was counted as being 
non-specific (ns) because a WB was not done. All samples scored as ns/- were 
counted as being non-specific; interpreted scores are shown in square brackets, 
ns, non-specific or indeterminant result.












114 89a 25 0 79
ORF73
ELISA
114 71a 43 0 61
IFb 114 51 51 12 45
WB 46 33 10 3 72
a Excludes positive samples (9 for ORF65 and 2 for ORF73) that did not react in the IF 
test but where a WB analysis was not performed. These were counted as being 
negative (see Table 3.3).
b Samples that were positive in the ELISA and scored ns/+ in the IF test were 
interpreted as being non-specific (ns) if a WB analysis was performed or as being 
positive if a WB was not done; samples scored ns/-, were counted among the non­
specific samples (Table 3.3).
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positive, 10 were not confirmed and three were indeterminant. As shown in Fig. 
3.1, 76 (67%) and 61 (54%) samples had antibodies in the ELISA (confirmed by 
WB analysis) to the ORF65 and ORF73 recombinant proteins, respectively. All 
the 51 positive reactions in the IF test were considered to be specific, indicating 
that 45% of the samples had antibodies to LANA in the IF test (Fig. 3.1). The 
overall HHV-8 antibody prevalence (including all samples positive in the IF test 
plus samples confirmed by WB analysis) was 74% (84/114 HIV-negative blood 
donors) (Fig. 3.1).
3.3.1 Seroprevalence among male and female donors
To assess whether the predominance of males affected the results, the prevalence 
rates among the females and males were calculated. These were 73% and 77%, 
respectively, indicating no difference in the prevalence of antibodies among the 
two groups (Table 3.5A).
3.3.2 Seroprevalence among different age groups
To assess whether there was a correlation between age and prevalence, the 
prevalence rates by age were calculated. The donors were divided into five 
groups as follows: 18-23 (n=26); 24-29 (n=46); 30-35 (n=26); 36-41 (n=12); >42 
(n=4). The prevalence rates for each group are shown in Table 3.5B. The results 
show that the prevalence of antibodies is similar in all five age groups.
3.3.3 Conclusion
The serological results indicate that HHV-8 antibodies are highly prevalent in 
male and female HIV-1-negative blood donors in Kampala, and all age groups 
show a similar level of antibody prevalence.
% H H V -8 40  
positive
ORF65 ORF73 ORF73 IF Overall
ELISA ELISA
Fig. 3.1. HHV-8 seroprevalence in HIV-1 negative Ugandan 
blood donors.
The chart shows the seroprevalence rate by test, and the overall 
seroprevalence, which included all samples positive in the IF test 
plus samples positive in the WB analysis.
Table 3.5.
A. HHV-8 seroprevalence among male and female blood donors





Male 96 70 26 73
Female 18 14 4 77
B. HHV-8 seroprevalence among different age groups





18-23 26 18 8 69
24-29 46 34 12 74
30-35 26 20 6 77
36-41 12 9 3 75
>42 4 3 1 75
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3.4 FREQUENCY OF HHV-8 DNA IN THE BLOOD DONORS
The objective o f this study was to determine the frequency of HHV-8 DNA in 
PBMC from HIV-negative blood donors by amplification of the ORF26 gene. 
DNA was extracted from cell pellets consisting of white blood cells. All the 
samples were initially reacted with ORF26-specific primers (KS1/KS2), and 
none yielded a product. Then, the samples were amplified by nested PCR with 
ORF26-specific primers, KS1/KS2 (first round) and NS1/NS2 (second round). 
The results of these experiments were inconclusive in that the negative controls 
also had bands of the expected size (data not shown). Finally, the samples were 
amplified by nested PCR with ORF26-specific primers, KS4/KS5 (first round) 
and KS1/KS2 (second round). Only 2 (58 and 86) o f 114 samples yielded a 
specific product in these experiments (Fig. 3.2). Both samples came from the 
same area, Kawempe.
3.5 HHV-8 SUBTYPES IN THE BLOOD DONORS
The aim of this project was to determine the HHV-8 subtypes present in blood 
donors by K1 PCR and sequence analysis. Initially, attempts were made to 
amplify the K1 gene of the two HHV-8-positive DNA samples (discussed above) 
using nested PCR (first round primers, PMC20/PMC21 and second round 
primers, 01/02). However, no product was obtained. Attempts to amplify the K1 
products of other samples were not made.
Fig. 3.2. Detection of HHV-8 DNA in blood donors.
EtBr-stained 2% (w/v) agarose gel showing 233 bp products 
generated by nested PCR from cell pellet DNA samples of blood 
donors using KS4/KS5 (outer primers) and KS1/KS2 (inner 
primers). The two samples (58 and 86) that gave products are 
indicated. P, positive control; M, 123 bp DNA ladder.
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3.6 DISCUSSION
3.6.1 HHV-8 seroprevalence in blood donors
ORF65 ELISA detected antibodies in 67% of the blood donors while LANA IF 
detected antibodies in a lower proportion of individuals (45%). The results of 
these two tests are not in absolute agreement, as has also been found in other 
seroprevalence studies involving African samples (Table 3.1; Lennette et al., 
1996; Mayama et al., 1998). The two tests seem to complement each other; 
ORF65 ELISA detected HHV-8 antibodies in 33 individuals that did not react in 
the LANA IF test, while LANA IF test detected antibodies in eight individuals 
that did not react in the ORF65 ELISA. Combined, the two tests detected 
antibodies in a high percentage of blood donors (74%), indicating that HHV-8 
infection is widespread in Kampala, and probably in Uganda as a whole. This 
result falls within the range of seroprevalence rates reported by other studies for 
the general Ugandan population (Table 3.1). However, it was higher than the rate 
reported for blood donors (Table 3.1; Chatlynne and Ablashi, 1999). This could 
be explained by the fact that the combined tests used in the current study are 
more sensitive than the single test (whole virus ELISA) that was used in the 
previous study. Mayama et al. (1998) reported that HHV-8 transmission occurs 
during early childhood in Uganda and reaches adult levels (in approx. 50% of the 
children) before the age of puberty. The high prevalence of antibodies in the 
adult blood donor population studied here may be a reflection of a lifetime 
presence of HHV-8 infection in the majority o f the Ugandan population.
Although the blood donor population in this study was predominantly male, the 
results show that HHV-8 antibodies are distributed in virtually equal proportions 
among men and women. A study of HHV-8 distribution in blood donors in Italy 
reported similar findings (Calabro et al., 1998), whereas other studies have
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reported that men are twice as likely to be seropositive than women (Luppi et al., 
1998; Manns et al., 1998). This disparity may be explained by differences in 
HHV-8 seroprevalence in the different areas, whereby HHV-8 antibodies tend to 
be equally distributed among men and women in areas o f high seroprevalence.
3.6.2 Frequency of HHV-8 DNA in blood donors
Previous studies have reported that HHV-8 is not, or only infrequently, detected 
by PCR in the peripheral blood of healthy donors (Ambroziak et al., 1995; 
Bigoni et al., 1996; Brambilla et al., 1996; Humphrey et al., 1996; Lefrere et al., 
1996; Moore et al., 1996; Whitby et al., 1995). Consistent with these results, 
HHV-8 was detected in only 1.7% of cell pellet DNA samples of the blood 
donors in this study. However, this finding was surprising in view of the high 
seroprevalence detected in this population. HHV-8 DNA has been detected in 
10% of PBMCs from HIV-negative individuals in The Gambia, an area of high 
HHV-8 seroprevalence (89%) like Uganda. Thus it is possible that, with further 




RESULTS AND DISCUSSION-II 
CHARACTERIZATION OF THE K1 GENE
4.1 INTRODUCTION
HHV-8 strains from various parts o f the world fall into five groups (A/I, B/IV, 
C/II, D/III, E) (Biggar et al., 2000; Cook et al., 1999; Kasolo et al., 1998; Lacoste 
et al., 2000a,b; Meng et al., 1999, 2001; Zong et al., 1999). The majority of 
HHV-8 subtypes from the USA and Europe (A and C) are relatively closely 
related, whereas the B, D and E strains identified from Africa, Pacific Islands and 
Brazilian Amerindians, respectively, are phylogenetically more distant from 
these subtypes. Thus far, 13 HHV-8 strains from Uganda have been published 
(Table 4.1); two (Ugdl and Ugd2) are part of this study. Apart from Ugd2, all 
other samples (with the exception of UgRl whose source is not clear) came from 
HIV-positive individuals. The strains belong to three main HHV-8 subtypes, A 
(2/13), A5 (3/13), B (7/13) and C (1/13), subtype B being predominant. Kasolo 
et al. (1998) found that 15 of 15 HHV-8-positive children in Zambia (with or 
without KS) had subtype A5 K1 genomes in their peripheral lymphocytes. All 
five strains from Zambian AIDS patients that Zong et al. (1999) characterised 
were subtype B. Recently, Lacoste et al. (2000a) published a large study 
including 32 strains of African origin; 21 from West and Central Africa. The 
majority of these strains were either subtype B (13 cases) or variant A5 (11 
cases), the rest were subtype A or C. One strain from Central African Republic 
(Kl-8/Dem) had a K1 sequence with characteristics of both subtypes A and C, 
and another one (Kl-43/Ber) belonged to the A/C lineage but also had 
characteristics o f neither the C nor the A subtype. All these studies noted no 
obvious correlation between K1 subtypes and the different forms of KS (clinical 
and epidemiological).
Table 4.1. Published HHV-8 strains from Uganda
Strain Gender Source K1
subtype
Reference
ST1 F AIDS KS biopsy B Zong et al., 1999
ST2 F AIDS KS biopsy B Zong et al., 1999
Ugdl M AIDS KS biopsy B Cook et al., 1999
Ugd2 M Endemic KS biopsy B Cook et al., 1999
Ug52 M HIV positive, no KS 
PBMC
B Cook et al., 1999
Ug81 M AIDS KS PBMC B Cook et al., 1999
Ugl F AIDS KS PBMC B Meng et al., 1999
Ugl l l M AIDS KS PBMC A Cook et al., 1999
Ug4 M AIDS KS PBMC A Meng et al, 1999
Ug374 M HIV positive, no KS, 
PBMC
A5 Cook et al., 1999
Ug2 M HIV positive PBMC A5 Meng et al., 1999
Ug3 M HIV positive PBMC A5 Meng et al., 1999
UgRl unknown PBMC C Cook et al., 1999
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Virtually all the Ugandan strains whose K1 gene has been determined came from 
HIV-positive individuals. The objectives of this study were to characterise the 
K1 gene in samples from both HIV-positive and HIV-negative KS patients from 
Uganda and to evaluate the correlation between K1 subtypes and the type of KS, 
ethnicity and place of residence of the patients.
4.2 KS PATIENTS
Thirty KS patients (25 male, 5 female) accessed at UCI were the source of the 
HHV-8-positive DNA samples used in this study and in the studies reported in 
chapters five and six below. A summary of the demographic and clinical data is 
shown in Table 4.2. The median age was 38 years (range, 16-70 years). All 
patients came from the southern part of the country and represent 12 tribes. 
Almost half (14) of the patients belong to the Ganda tribe, which is the 
predominant tribe in the Kampala area. Twenty patients were HIV-1 positive and 
10 were negative. The majority had nodular KS lesions involving the lower, 
upper or both extremities. Several of the HIV-positive patients had lesions 
covering the whole body surface, and some also had generalised KS with 
lymphadenopathy. Patient U gdl2 had clinically aggressive non-AIDS-associated 
(endemic) KS. This patient was tested several times for HIV antibodies by 
Western blot analysis but was found to be negative in all instances.
Plasma from 19 patients tested for HHV-8 antibodies (as described in the 
previous section) were all positive with both the ELISA and the IF test. The 11 
plasma samples that were not tested had been inadvertently left in Uganda.












Type o f lesion Location o f lesion
Ugdl B 65 M Ganda Mukono + patches/plaques upper extremities
Ugd2 B 53 M Nyori Iganga - nodules lower/
upper extremities
Ugd3 B 31 M Nyarwanda Kampala/then
Rwanda
+ nodules right foot
Ugd4 AS 42 M Nyankole Ntungamo - nodules lower/
upper extremities
Ugd7 B 47 M Nyarwanda Mubende + nodules/plaques lower extremities/ 
oral cavity




Ugdl 2 A5 54 F Ganda Mpigi aggressive/plaques/
lymphadenopathy
whole body
Ugdl 3 B 29 M Ganda Kampala + plaques lower extremities
Ugdl 5 B 38 M Lugbara Mbarara + nodules/plaques extremities/trunk
Ugdl 6 A5 35 M Ganda Mpigi + nodules lower extremities
Ugdl 8 A5 65 M Ganda Masaka - nodules lower/
upper extremities
Ugdl 9 B 16 M Jopadhola Tororo - nodules lower/
upper extremities
Ugd21 B 30 M Sarnia Mukono + nodules/plaques whole body
Ugd23 C 43 M Mfumbira Jinja + nodules lower extremities
Ugd24 A5 52 M Konjo Kasese - nodules lower extremities
Ugd26 B 61 M Ganda Mukono - nodules lower extremities
Ugd29 B 67 M Ganda Mpigi - nodules nodules
Ugd5 38 F Ganda Mpigi + plaques whole body/ 
oral cavity
Ugd6 32 F Luo Kampala + nodules trunk/forearm/ 
hard palate
Ugd8 33 M Ganda Mpigi + nodules lower extremities/ 
oral cavity
Ugd9 29 M Nyoro Kampala + nodules/plaques whole body/ 
oral cavity
U gdll 28 M Nyankole Bushenyi + nodules head/extremities
Ugdl 4 66 M Ganda Kampala - nodules lower/
upper extremities
Ugdl 7 45 M Ganda Mpigi + plaques/
lymphadenopathy
generalised
Ugd20 29 M Ganda Kampala + nodules/plaques whole body
Ugd22 43 M Ganda Mpigi + plaques/patches lower extremities
Ugd25 30 F Jopadhola Kampala + plaques chest
Ugd27 37 M Ganda Mpigi + nodules/plaques/
lymphadenopathy
generalised KS
Ugd28 31 M Langi Luwero + nodules/plaques generalised KS
Ugd30 20 F Nyarwanda Mubende + records not available records not 
available
a Samples whose K1 subtypes are known are listed first.
bM, male; F, female.
c+, HIV-1 positive; HIV-1 negative.
d Clinically aggressive, non-AIDS-associated KS.
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4.3 IDENTIFICATION OF HHV-8-POSITIVE DNA SAMPLES
To identify HHV-8-positive samples, all tumour DNA samples were amplified 
by PCR with HHV-8 ORF26-specific primers, initially KS1/KS2 primers and 
later KS4/KS5 primers. All samples yielded a product o f the expected sizes with 
both primer sets, except Ugdl4, which did not yield a product with KS1/KS2 
(Fig. 4.1 A). This sample yielded a relatively faint product with KS4/KS5 (Fig. 
4 .IB). Ugd5 also yielded a very faint band on amplification with KS1/KS2. As a 
control for DNA extraction, the p-globin gene was amplified for samples Ugdl- 
U gdl6 using primers PC 03 and P64 (Fig. 4.2). This also allowed rough 
estimation of DNA concentration in the samples. Ugd5 yielded a faint band 
compared to other samples, indicating that the DNA concentration in this sample 
was relatively low. This could explain the faint band observed on amplification 
with KS1/KS2 (Fig. 4.1 A). Ugdl4, on the other hand, had a P-globin-specific 
band of similar intensity to that o f other samples (with the exception of Ugd5), 
indicating similar levels o f DNA concentration. Ugdl7-Ugd30 were not 
amplified for p-globin because it was judged that they contain similar 
concentrations o f DNA as the tested samples (with the exception of Ugd5), 
inasmuch as they yielded signals of similar intensity in the ORF26 PCR analysis.
Cell pellet DNA samples from 15 KS patients (Ugd3-Ugdl7) were subjected to 
PCR with ORF26-specific primers (KS1/KS2). None yielded a product. 
However, three of these samples (Ugd7, Ugdl 1 and Ugdl6) yielded a product in 
nested PCR with KS4/KS5 as outer primers and KS1/KS2 as inner primers (Fig. 
4.3).
The level of detection of HHV-8 DNA by PCR in PBMC of KS patients has 
been reported to be 50-60% (Whitby et al., 1995). Another study involving 
Ugandan KS patients reported a higher level o f detection (84%) in PBMC using
Fig. 4.1. Detection of HHV-8 DNA in KS skin tumour DNA samples.
EtBr-stained 2% (A) and 1% (B) (w/v) agarose gels showing, respectively, 233 and 571 
bp products of samples amplified with ORF26-specific primers, KS1/KS2 (A) and 
KS4/KS5 (B). Representative PCR products are shown. The numbers at the top of the 
lanes denote sample names without the Ugd-prefix, e.g. 3 stands for Ugd3. H, negative 
(water) control; M, lambda DNA-Hind III digest markers; Ml and M2 are 123 bp and 1 
kbp DNA ladders, respectively. The markers to the right of panel A and to the left of 
panel B are in bp and kbp, respectively.














Fig. 4.2. P-globin gene products.
EtBr-stained 1% (w/v) agarose gel showing 110 bp products generated 
from KS skin tumour DNA samples using PCO3/P6 4 . The numbers at the 
top of the lanes denote sample names without the Ugd-prefix, e.g. 3 stands 
for Ugd3. P, positive control; M l and M2 are 100 bp and 123 bp DNA 
ladders, respectively.
M P Ugd7 U g d ll U gdl6
Fig. 4.3. Detection of HHV-8 DNA in KS cell pellet DNA samples.
EtBr-stained 1.5% (w/v) agarose gel showing 233 bp products generated by 
nested PCR with KS4/KS5 (outer primers) and KS1/KS2 (inner primers). 
The samples that gave products are indicated at the top o f the respective 
lanes. P, positive control; M, 123 bp DNA ladder.
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a combination of PCR and Southern hybridization (Purvis et al., 1997). 
Therefore, the low frequency of HHV-8 DNA detected in the white blood cells 
o f the patients in this probably indicates suboptimal experimental conditions 
rather than absolute prevalence.
4.4 PCR AMPLIFICATION OF THE K1 GENE
The entire K1 gene was amplified as a 1277 bp or 874 bp product. PCR and 
cloning were successful for 17 (of 30) samples; representative PCR products are 
shown in Fig. 4.4. Ugdl and Ugd2 (Fig. 4.4A) gave stronger signals compared to 
samples that were collected subsequently (Fig. 4.4B). Since both sets o f samples 
had similar DNA concentrations as revealed by P-globin analysis (Fig. 4.2), the 
discrepancy in signals is most likely due to presence of higher HHV-8 copy 
numbers in Ugdl/2 than in other samples. The PCR products o f Ugd4/12/24 
were obtained by nested PCR (874 bp; Fig. 4.4C). The band of U gdl2 migrated 
slightly faster than bands of expected size. The PCR products were cloned before 
sequencing. Insufficient amounts of purified PCR products were obtained for 
some of the samples shown in Fig. 4.4B, so they were not cloned.
4.5 PHYLOGENETIC ANALYSIS OF THE K1 GENE
The 17 DNA (and amino acid) sequences obtained in this study together with 35 
sequences from previous studies (Cook et al., 1999; Lacoste et al., 2000a; Zong 
et al., 1999) were aligned as shown in Fig. 4.5A. The translated amino acid 
sequences were also aligned (Fig. 4.5B). TKS10 (Table 2.1) has a 39-bp (13-aa) 
duplication of sequences immediately upstream of the insertion (Fig. 4.5A,B). 
Phylogenetic analysis of the DNA sequences is presented in Fig. 4.6.
Fig. 4.4. PCR amplification of the entire K1 gene.
EtBr-stained 1% (w/v) agarose gels showing representative PCR products amplified 
from KS skin tumour DNA samples with K1 -specific primers, (A, B; 1277bp) 
PMC20/21 and (C; 874 bp), nested PCR with PMC20/21 (outer primers) and 01/02 
(inner primers). Numbers at the top of the lanes in (B) and (C) represent sample names 
without the Ugd-prefix; P, positive control (Ugd2). Samples in (B) were done in 











Fig. 4.5. Alignments of K1 DNA and amino acid sequences of 52 HHV-8 
strains.
The alignments include almost complete K1 DNA (A) or amino acid (B) 
sequences, 17 from this study and 35 from previous studies (Cook et al., 1999; 
Zong et al., 1999; Lacoste et al., 2000a). Prefixes on sequence names denote K1 
subtypes. The alignments run in the orientation o f the genomic sequence; 
nucleotides 1 and 879 are equivalent to 120 and 959, respectively, in the BC-1 
genome. Fifteen base pairs were omitted at each end o f the DNA sequences, 
while 5 and 4 amino acids were omitted at the N-terminus and C-terminus, 
respectively, of the protein sequences.
Ad l - t k s l O
1
GTCTGCAGTC TGGCGGTTTG CTTTCCAGGA CTATTGAGCC TTCATCTGTC
60
AGTGTCTCCA
d 2 - z k s 3 GTCTGCAATC TGGCGGTTTG CTTTCCAGGA CTATTGAGCC TTCATCTGCC AGCGTTTCCA
b - u g d l CTCTGCTGTT TGGTGGTTTG GTTTCCAAAA CTATTGAGCC TTCATCTGCC ATCGTTTCCA
b -u g d 2 6 CTCTGCAGTT TGGTGGTTTG GTTTCCAAAA CTATTGAGCC TTCATCTGCC ATCGTTTCCA
b - u g d l 9 CTCTGCAGTT TGGTGGTTTG GTTTCCAAAA CTATTGAGCC TTCATCTGCC ATCGTTTCCA
b - u g d 7 CTCTGCAGTT TGGTGGTTTG CTTTCCAAAA CTATTGAGCC TTCATCTGCC ATCGTTTCCA
b - u g d 2 CTCTGCAGTT TGGTGGTTTG GTTTCCAAAA CTATTGAGCC TTCATCTGCC ATCGTTTCCA
b -u g d 2 1 CTCTGCAGTT TGGTGGTTTG GTTTCCACAA CTATTGAGCC TTCATCTGCC ATCGTTTCCA
b -u g d lO GTCTGCAGTT TGCTGGTTTG CTTTCCAAAA CTATTGAGCC TTCATCTGCC ATCGTTTCCA
b -u k m a 2 4 CTCTACGGTT TTCTGGTTTG CTTTCCAAAA CTATTGAGCC TTCATCTGCC ATCGTTTCCA
b -u g d 2 9 GTCTCCAGTT TGCTGGTTTG CTTTCCAAAA CTATTGAGCC TTCATCTGCC ATCGTTTCCA
b -u g 5 2 GTCTGCAGTC TGGCGGTTTG CTTTCCAAAA CTATTGAGCC TTCATCTGCC ATCGTTTCCA
b -g 4 1 3 GTCTGCAGTC TGGCGGTTTG CTTTCCAAAA CTATTGAGCC TTCATCTGCC ATCGTTTCCA
b -g 4 8 2 GTCTGCAGTC TGGCGGTTTG CTTTCCAAAA CTATTGAGCC TTCATCTGCC ATCGTTTCCA
b - u g d l 3 GTCTGCAGTT TGCTGGTTTG CTTTCCAAAA CTATTGAGCC TTCATCTGCC ATCGTTTCCA
b -u g d 3 GTCTGCAGTT TGCTGGTTTG CTTTCCAAAA CTATTGAGCC TTCATCTGCC ATCGTTTCCA
b - u g d l 5 GTCTGCAGTT TGCTGGTTTG CTTTCCAAAA CTATTGAGCC TTCATCTGCC ATCGTTTCCA
b - g 7 1 GTCTGCAGTT TGCTGGTTTG CTTTCCACAA CTATTGAGCT TTAATCTGCC ATCGTTTCCA
b - g 9 1 CTCTGCAATT TGGTGGTTTG CTTTCCAAAA CTATTGAGCC TTCATCTGCC ATCGTTTCCA
c - g k l 7 GTCTGCAGTC TGGCGGTTTG CTTTCGAGGA CTATTAAGCC TTTATCTGCA ATCGTCTCCA
c - i a p 3 GTCTGCAGTC TGGCGGTTTG CTTTCGAGGA CTATTAAGCC TTTATCTGCA ATCGTCTCCA
c - e r l a GTTTGCAGTC TGGCGGTTTG CTTTCGAGGA CTATTAAGCC TTTCTCTGCA ATCGTCTCCA
c - i c a m l GTTTGCAGTC TGGCGGTTTG CTTTCGAGGA CTATTAAGCC TTTCTCTGCA ATCGTCTCCA
c - u k m a l GTTTGCAGTC TGGCGGTTTG CTTTCGAGGA CTATTAAGCC TTTCTCTGCA ATCGTCTCCA
c - i a p 2 GTTTGCAGTC TGGCGGTTTG CTTTCGAGGA CTATTAAGCC TTTCTCTGCA ATCGTCTCCA
c - b b g l GTCTGCAGTC TGGCGGTTTG CTTTCGAGGA CTATTAAGCC TTTCTCTGCA ATCGTCTCCA
c -u k m a 8 GTTTGCAGTC TGGCGGTTTG CTTTCGAGGA CTATTAAGCC TTTCTCTGCA ATCGTCTCCA
c - b c 2 GTTTGCAGTC TGGCGGTTTG CTTTCGAGGA CTATTAAGCC TTTCTCTGCA ATCGTCTCCA
c -u k m a 3 GTTTGCAGTC TGGCGGTTTG CTTTCGAGGA CTATTAAGCC TTTCTCTGCA ATCGTCTCCA
c - i v e l GTAGGCAGTC TGGCGGTTTG CTTTCAAGGA CTATTAAGCC TTTCTCTGCA ATCGTCTCCA
c -u k b 2 2 GTTTGCAGTC TGGCGGTTTG CTTTCGAGGA CTATTAAGCC TTTCTCTGCA ATCGTCTCCA
c - g k l 8 GTTTGCAGTC TGGCGGTTTG CTTTCGAGGA CTATTAAGCC TTTCTCTGCA ATCGTCTCCA
c - k l - 8 - d e m GTCTGCAGTC TGGCGGTTTG CTTTCGAGGA CTATTAAGCC TTTATGTGCA ATCGTCTCCA
c - u g d 2 3 GTCTGCAGTC TGGCGGTTTG CTTTCGAGGA CTATTAAGCC TTTATGTGCA ATCGTCTCCA
a - u g d l 6 GTCTGCAGTC TGGCGGTTTG CTTTCAAGGA CTATTAAGCC TTTATCTGCA ATCGTCTCCA
a - u g d l 8 GTCTGCAGTC TGGCGGTTTG CTTTCAAGGA CTATTAAGCC TTTATCTGCA ATCGTCTCCA
a - u g d 2 4 GTCTGCAGTC TGGCGGTTTG CTTTCAAGGA CTATTAAGCC TTTATCTGCA ATCGTCTCCA
a - u g 3 7 4 GTCTGCAGTC TGGCGGTTTG CTTTCGAGGA CTATTAAGCC TTTATCTGCA ATCGTCTCCA
a - u g d 4 GTCTGCAGTC TGGCGGTTTG CTTTCGAGGA CTATTAAGCC TTTATCTGCA ATCGTCTCCA
a - b c b l l GTCTGCAGTC TGGCGGTTTG CTTTCGAGGA CTATTAAGCC TTTATGTGCT ATCGTCTCCA
a - u k a l 3 GTCTGCAGTC TGGCGGTTTG CTTTCGAGGA CTATTAAGCC TTTCTCTGCT ATCGTCTCCA
a - u k a 2 1 GTCTGCAGTC TGGCGGTTTG CTTTCGAGGA CTATTAAGCC TTTCTCTGCT ATCGTCTCCA
a -u k m a 4 GTCTGCAGTC TGGCGGTTTG CTTTCGAGGA CTATTAAGCC TTTCTCTGCT ATCGTCTCCA
a - b c l GTCTGCAGTC TGGCGGTTTG CTTTCGAGGA CTATTAAGCC TTTCTCTGCT ATCGTCTCCA
a -e m a 7 GTCTGCAGTC TGGCGGTTTG CTTTCGAGGA CTATTAAGCC TTTCTCTGCT ATCGTCTCCA
a - b c b l r GTCTGCAGTC TGGCGGTTTG CTTTCGAGGA CTATTAAGCC TTTCTCTGCT ATCGTCTCCA
a - u k b l 2 GTCTGCAGTC TGGCGGTTTG CTTTCGAGGA CTATTAAGCC TTTCTCTGCT ATCGTCTCCA
a - u g l l l GTCTGCAGTC TGGCGGTTTG CTTTCGAGGA CTATTAAGCC TTTCTCTGCT ATCGTCTCCA
a - i a p l GTCTGCAGTC TGGCGGTTTG CTTTCGAGGA CTATTAAGCC TTTCTCTGCT ATCGTCTCCA
a - u k c l 2 GTCTGCAGTC TGGCGGTTTG CTTTCGAGGA CTATTAAGCC TTTCTCTGCT ATCGTCTCCA
c - k l - 4 3 - b e r GTCTGCAGTC TGGCGGTTTG CTTTCCAGGA CTATTAAGCC TTTATGTGCA ATCGTCTCCA
a - u g d l 2 GTCTGCAGTC TGGCGGTTTG CTTTCGAGGA CTATTAAGCC TTTATCTGCA ATCGTCTCCA
C o n s e n s u s - T -----C - -T - T -----GGTTTG -T T T C -A --A CTATT-AGC- T T - -T -T G - - A --G T-TCCA
d l - t k s l O
61
CAATTCTGCC CTGCAGTGCT TTCTACGTCT TACACGTTGA CCTGTCTCTC
120
TGATGCATCC
d 2 - z k s 3 CCATTGTGCC CTGGAGTGCT TTCTACGAAT TACACGTTGA CCTGTCTCTC TGATGCATCC
b - u g d l CATTTGTGCC CTGGAGTGCT TTTCACGCCT TACACGTTGA CTTGTCCGTC TAACAGATCC
b -u g d 2 6 CATTTGTGCC CTGGAGTGCT TTTCACGCCT TACACGTTGA CTTGTCCGTC TAACAGATCC
b - u g d l 9 CATTTGTGCC CTGGAGTGCT TTTCACGCCT TACACGTTGA CTTGTCCGTC TAACAGATCC
b - u g d 7 CATTTGTGCC CTGGAGTGCT TTTCACGCCT TACACGTTGA CTTGTCCGTC TAACAGATCC
b - u g d 2 CATTTGTGCC CTGGAGTGCA TTTCACGCCT TACACGTTGA CTTGTCCGTC TAACAGATCC
b - u g d 2 1 CATTTGTGCC CTGGAGTGCA TTTCACGTCT TACACGTTGA CTTGTCCGTC TAACAGATCC
b -u g d lO CATTTGTGCC CTGGAGTGAT TTCCACGCCT TACACGTTGA CCTGTCCGTC TAACAGATCC
b -u k m a 2 4 CATTTGTGCC CTGGAGTGAT TTCCACGCCT TACACGTTGA CCTGTCCGTC TAACAGATCC
b - u g d 2 9 CCTTTGTGCC CTGGAGTGAT TTCCACGCCT TACACGTTGA CCTGTCCGTC TAACAGATTC
b -u g 5 2 CATTTGTGCC CTGGAGTGAT TTCCACGCCT TACACGTTGA CCTGTCCGTC TACCAGATCC
b -g 4 1 3 CATTTGTGCC CTGGAGTGAT TTCCACGCCT TACACGTTGA CCTGTCCGTC TAACAGATCC
b -g 4 8 2 CATTTGTGCC CTGGAGTGCT TTCCACGCCT TACACGTTGA CCTGTCCGTC TAACAGATCC
b - u g d l 3 CATTTGTGCC CTGGAGTGGT TTCCACGCCT TACACGTTGA CCTGTCCGTC TAACAGATCC
b -u g d 3 CATTTGTGCC CTGGAGTGGT TTCCACGCCT TACACGTTGA CCTGTCCGTC TAACAGATCC
b - u g d l 5 CATTTGTGCC CTGGAGTGGT TTCCACGCCT TACACGTTGA CCTGTCCGTC TAACAGATCC
b - g 7 1 CATTTGTGCC CTGGAGTGAT TTCCACGCCT TACACGTTGA CCTGTCCGTC TAACAGATCC
b - g 9 1 CATTTGTGCC CTGGAGTGAT TTCCACGCCT TACACGTTGA CCTGTCCGTC TAACAGATCC
c - g k l 7 AATATGTGCC CTGGAGTGAT TTCAACGCCT TACACGTTGA CCTGTCCGTC TGGTACATCC
c - i a p 3 AATATGTGCC CTGGAGTGAT TTCAACGCCT TACACGTTGA CCTGTCCGTC TAATACATCC
c - e r l a AATTTGTGCC CTGGAGTGAT TTCAACGCCT TACACGTTGA CCTGTCCGTC TAATACATCC
c - i c a m l AATTTGTGCC CTGGAGTGAT TTCAACGCCT TACACGTTGA CCTGTCCGTC TAATACATCC
c - u k m a l AATTTGTGCC CTGGAGTGAT TTCAACGCCT TACACGTTGA CCTGTCCGTC TAATACATCC
c - i a p 2 AATTTGTGCC CTGGAGTGAT TTCAACGACT TACACGTTGA CCTGTCCGTC TAATACATCC
c - b b g l AATTTGTGCC CTGGAGTGAT TTCAACGCCT TACACGTTGA CCTGTCCGTC TAATACATCC
c -u k m a 8 AATTTGTGCC CTGGAGTGAT TTCAACGCCT TACACGTTGA CCTGTCCGTC TAATACATCC
c - b c 2 AATTTGTGCC CTGGAGTGAT TTCAACGCCT TACACGTTGA CCTGTCCGTC TAATACATCC
c -u k m a 3 AATTTGTGCC CTGGAGTGAT TTCAACGCCT TACACGTTGA CCTGTCCGTC TAATACATCC
c - i v e l AATTTATGCC CTGGAGTGAT TTTAACGCCT TACACGTTGA CCTGTCCGTC TAATACATCC
c -u k b 2 2 AATTTGTGCC CTCGAGTGAT TTCAACGCCT TACACGTTGA CCTGTCCGTC TAATACATCC
c - g k l 8 AATCTCTGCC CTGGAGTGAT TTCAACGCCT TACACGTTGA CCTGTCCGTC TAATACATCC
c - k l - 8 - d e r a AATTTGTGCC CTGGAGTGAT TTCAACGCCT TACACGTTGA CCTGTCCGTC TGATGCAACC
c - u g d 2 3 AATTTGTGCC CTGGAGTGAT TTCAACGCCT TACACGTTGA CCTGTCCGTC TGATGCAACC
a - u g d l 6 AATTTGTGCC CTGGAGTGAT TTCAACGCCT TACACGTTGA CCTGTCTGTC TGATGCATCC
a - u g d l 8 AATTTGTGCC CTGGAGTGAT TTCAACGCCT TACACGTTGA CCTGTCTGTC TGATGCATCC
a -u g d 2 4 AATTTGTGCC CTGGAGTGAT TTCAACGCCT TACACGTTGA CCTGTCTGTC TGATGCATCC
a - u g 3 7 4 AATTTGTGCC CTGGAGTGAT TTCAACGCCT TACACGTTGA CCTGTCTGTC TGATGCATCC
a - u g d 4 AATTTGTGCC CTGGAGTGAT TTCAACGCCT TACACGTTGA CCTGTCTGTC TGATGCATCC
a - b c b l l AATTTGTGCC CTGGAGTGAT TTCAACGCCT TACACGTTGA CCTGTCTGTC GGATTCATCC
a - u k a l 3 AATTTGTGCC CTGGAGTGAT TTCAACGCCT TACAATTTGA CCTGTCTGTC TAATGCATCC
a - u k a 2 1 AATTTGTGCC CTGGAGTGAT TTCAACGCCT TACAATTTGA CCTGTCTGTC TAATGCATCC
a -u k m a 4 AATTTGTGCC CTGGAGTGAT TTCAACGCCT TACAATTTGA CCTGTCTGTC TAATGCATCC
a - b c l AATTTGTGCC CTGGAGTGAT TTCAACGCCT TACACGTTGA CCTGTCTGTC TAATGCATCC
a -e m a 7 AATTTGTGCC CTGGAGTGAT TTCAACGCCT TACAACTTGA CCTGTCTGTC TAATGCATCC
a - b c b l r AATTTGTGCC CTGGAGTGAT TTCAACGCCT TACAAGTTGA CCTGTCTGTC TAATGCATCC
a - u k b l 2 AATTTGTGCC CTGGAGTGAT TTCAACGCCT TACACGTTGA CCTGTCTGTC TAATGCATCC
a - u g l l l AATTTGTGCC CTGGAGTGAT TTCAACGCCT TACAATTTGA CCTGTCTGTC TAATGCATCC
a - i a p l AATTTGTGCC CTGGAGTGAT TTCAACGCCT TACACGTTGA CCTGTCTGTC TGATACATCC
a - u k c l 2 AATTTGTGCC CTGGAGTGAT TTCAACGCCT TACAAGTTGA CCTGTCTGTC TAATGCATCC
c - k l - 4 3 - b e r CATTTGTGCC CTGGAGTGAT TTCAACGCCT TACACGTTGA CCTGTCCGTC TGATGCATCC
a - u g d l 2 AATTTGTGCC CTGGAGTGAT TTCAACGCCT TACACGTTGA CCTGTCTGTC TGATGCATCC
C o n s e n s u s -------T-TGCC C T--A G T G -- T T --A C G --T TACA--TTGA C -T G T C --T C -----------A --C
d l - t k s l O
121
TTGCCAATAT CCTGGTATTG CAACGGAACT CGGCTTCTTC GAATTACTGG
180
GGCAACACTG
d 2 - z k s 3 TTGCCAATAT CCTGGTATTG CAACGGAACT TTGCTTATGC GATATCACAG GACCACACTA
b - u g d l TTGCCAACAT CCTGGTATTG CAACGGGACT CAGCTTCGGC GAATACGGGG GTCTAACCTA
b -u g d 2 6 TTGCCAATAT CCTGGTATTG CAACGGGACT CAGCTTCGGC GAATAAGGGA GTCTACCCTA
b - u g d l 9 TTGCCAATAT CCTGGTATTG CAACGGGACT CGGCTTTGGC GAATAAGGGA GTCTAACCTA
b -u g d 7 TTGCCAATAT CCTGGTATTG CAACGGGACT CAGCTTTGGC GAATAACGGA CTCTACCCTA
b -u g d 2 TTGCCAATAT CCTGGTATTG CAACGGGACT CAGCTTTCGC GAATAAGGGC GTCTACCCTA
b -u g d 2 1 TTGCCAATAT CCTGGTATTG CAACGGGACT CAGCTTTGGC GAATAAGGGA GAATACCCTA
b -u g d lO TTGCCAATAT CCTGGTATTG CAACGGGACT CAGCTTCACC GAATAACGGC GTCTAACCTA
b -u k m a 2 4 TTGCCAATAT CCTGGTATTG CAACGGGACT CGGCTTCACC GACTAACGGC GTCTAACCTA
b -u g d 2 9 TTGCCAATAT CCTGGTATTG CAACGGGACT CGGCTTCACC GAATAACGGC GTCTAACCTA
b -u g 5 2 TTGTCAATAT CCTGGTATTG CAACGGGACT CGGCTTCACC GAATAACGGC GTCTAACCTA
b -g 4 1 3 TTGCCAATAT CCTGGTATTG CAACGGGACT CGGCTTTTGC GAATAACGGC GTCTAACCCA
b -g 4 8 2 TTGCCAATAT CCTGGTATTG CAACGGGACT CGGCTTTGGC GAATAACGGC GTCTAACCTA
b - u g d l 3 TTGCCAATAT CCTGGTATTG CAACGGGACT CGGCTTTGGC GAATAACGGC GTCTAACCTA
b -u g d 3 TTGCCAATAT CCTGGTATTG CAACGGGACT CGGCTTTGGC GAATAACGGC GTCTAACCTA
b - u g d l 5 TTGCCAATAT CCTGGTATTG CAACGGGACT CGGCTTTGGC GAATAACGGC GTCTAACCTA
b - g 7 1 TTGCCAATAT CCTGGTATTG CAACGGGACT CGGCTTTGGC GAATAACGGC GTCTAACCTA
b - g 9 1 TTGCCAATAT CCTGGTATTG CAACGGGACT CAGCTTTTGC GAATAACGGC GTCTAACCTA
c - g k l 7 TTGCCAACAT CCTGGTATTG CAACGATACT CGGCTTTTCC GACTGACGCA GGACACATTC
c - i a p 3 TTGCCAACAT CCTGGTATTG CAACGATACT CGGCTTTTCC GACTGACGCA GGACACATTC
c - e r l a TTGCCAACAT CCTGGTATTG CAACGATACT CGGCTTCTCC GACTGACGCA GCAAACATTC
c - i c a m l TTGCCAACAT CCTGGTATTG CAACGATACT CGGCTTCTCC GACTGACGCA GCAAACATTC
c - u k m a l TTGCCAACAT CCTGGTATTG CAACGATACT CGGCTTTTCC GACTGACGCA GCAAACATGG
c - i a p 2 TTGCCAACAT CCTGGTATTG CAACGATACT CGGCTTTTCC GACTGACGCA GCAAACATTT
c - b b g l TTGCCAACAT CCTGGTATTG CAACGATACT CGGCTTCTCC GACTGACGCA GCAAACATTC
c -u k m a 8 TTGCCAACAT CCTGGTATTG CAACGATACT CGGCTTCTCC GACTGACGCA GCAAACATTC
c - b c 2 TTGCCAACAT CCTGGTATTG CAACGATACT CGGCTTCTCC GACTGACGCA GCAAACATTC
c -u k m a 3 TTGCCAACAT CCTGGTATTG CAACGATACT CGGCTTCTCC GACTGACGCA GCAAACAATC
c - i v e l TTGCCAACAT CCTGGTATTG CAACGATACT CGGCTTTTCC GACTGACGCA GCAAACATTA
c - u k b 2 2 TTGCCAACAT CCTGGTATTG CAACGATACT CGGCTTTTCC GACTGACGCA GCAAACATTG
c - g k l 8 TTGCCAACAT CCTGGTATTG CAACGATACT CGGCTTTTAC GAGTGACGCA GGGAACATTG
c - k l - 8 - d e m TTGCCAATAT CCTGGTATTG CAACGATACT CGGCTTTTCC GACTGACGCA GCAAACACTC
c - u g d 2 3 TTGCCAATAT CCTGGTATTG CAACGATACT CGGCTTCTCC GACTGACGCA GCAAACATTC
a - u g d l 6 TTGCCAATAT CCTGGTATTG CAACGATACT CGGCTTTTGC GACTGACGGA CCAATCATTC
a - u g d l 8 TTGCCAATAT CCTGGTATTG CAACGATACT CGGCTTTTGC GACTGACGGA CCAATCATTC
a -u g d 2 4 TTGCCAATAT CCTGGTATTG CAACGATACT CGGCTTTTGC GACTGACGGA CCAATCATTC
a - u g 3 7 4 TTGCCAATAT CCTGGTATTG CAACGATACT CGGCTTTGGC GACTGACGGA CCAATCATTC
a - u g d 4 TTGCCAATAT CCTGGTATTG CAACGATACT CGGCTTTGGC GACTGACGGA CCAATCATTC
a - b c b l l TTGCCAATAT CCTGGTATTG CAACGATACT CGGCTTTGGC GACTGACGAA GCCAACACTC
a - u k a l 3 TTGCCAATCT CCTGGTATTG CAACAATACT CGGCTTTTCC GACTGACGGA GAGAACATTG
a - u k a 2 1 TTGCCAATCT CCTGGTATTG CAACAATACT CGGCTTTTCC GACTGACGGA GAGAACATTG
a -u k m a 4 TTGCCAATCT CCTGGTATTG CAACAATACT CGGCTTTTAC GACTGACGGA GAGAACATTG
a - b c l TTGCCAATAT CCTGGTATTG CAACAATACT CGGCTTTTGC GACTGACGGA GAGAAGAGTC
a -e m a 7 TTGCCAATAT CCTGGTATTG CAACAATACT CGGCTTTTGC GACTGACGGA GAGAAGAGTC
a - b c b l r TTGCCAATAT CCTGGTATTG CAACAATACT CGGCTTTTCC GACCGACGGA GACAACACTT
a - u k b l 2 TTGCCAATAT TCTGGTATTG CAACAATACT CGGCTCTTCC GACTGACGAA GACAATATTT
a - u g l l l TTGCCAATAT CCTGGTATTG CAACAATACT CGGCTTTTCC GACTGACGGA GAAAACACTC
a - i a p l TTGCCAATAT CCTGGTATTG CAACAATACT CGGCTTTTGC GACTGACGAC GAAAACACT C
a - u k c l 2 TTGCCAATAT CCTGGTATTG CAACGATACT CGGCTTTTCC GACTGACGGA GAGAACACTT
c - k l - 4 3 - b e r TTGCCAATAT CCTGGTATTG CAACGGAACT CAGCTTCTTC GACTGACGCA GCGATCAGTA
a - u g d l 2 TTGCCAATAT CCTGGTATTG CAACGATACT CGGCTTTGGC GACTGACGGA CCAATCATTC
C o n s e n s u s TTG -CA A--T -CTGGTATTG CAAC-----ACT --G C T -------C GA---------------
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ACTATTCCTT CCCTTACCGG CAATTTTACT TGTGTGGATC ACTCTGGCCT
240
TTCACACAGC
d 2 - z k s 3 ACTCTTATGA ACCTTGCCGC CAATTGGACT TGTGTGAATC AATCTGGAAT TTCACACAGC
b - u g d l ACTGTTTCTT TGCTCACCTG CAATTTTACT TGTATGACAG CATCTGGGCC TACACACAGC
b -u g d 2 6 ACTGTTTCTT TCCTCACCTG CAATTTTACT TGTATGACAG CATCTGGGCC TACACACAGC
b - u g d l 9 ACTGTTGCTT CGCTCACCGG CAATTTTACT TGTATGACAG CATCTGGGCC TACACACAGC
b - u g d 7 ACTGTTTCTT CGCTCACCGG CAATTTTACT TGTATGACAG CATCTGGGCC TACACACAGC
b -u g d 2 ATTGTTTCTT CGCTCACCGG CAATTTTACT TGTATGACAG CATCTGGGCC TACACACAGC
b -u g d 2 1 ACTGTTTCTT CGCTCACCGG CAATTTTACT TGTATGACAG CATCTGGGCC TACATACAGC
b - u g d l 0 ACTGTTTCTT CGCTCACCTG CAATTTTACT TGTATGACAA CATCTGGGCC TACACACAGC
b -u k m a 2 4 ACTGTTTCTT CGCTCACCTG CAATTTTACT TGTATGACAA CATCTGGGCC TACACACAGC
b - u g d 2  9 ACTGTTTCTT CGCTCACCTG CAATTTTACT TGTATGACAA CATCTGGGCC TACACACAGC
b -u g 5 2 ACTGTTTCTT CGCTCACCTG CAATTTTACT TGTATGACAA CATCTGGGCC TACACACAGC
b -g 4 1 3 ACTGTTTGTT CGTTAACCTG CAATTTTACT TGTATGACAG CATCTGGGCC TACACACAGC
b - g 4 8 2 ACTGTTTCTC GGTTAACCTG CAATTTTACT TGTATGACAA GATCTGGGCC TACACACAGC
b - u g d l 3 ACTGTTTTGT CGGTGACCTG CAATTTTACT TGTATGACAA CATCTGGGCC TACACACAGC
b -u g d 3 ACTGTTTTGT CGGTGACCTG CAATTTTACT TGTATGACAA CATCTGGGCC TACACACAGC
b - u g d l 5 ACTGTTTTGT CGGTGACCTG CAATTTTACT TGTATGACAA CATCTGGGCC TACACACAGC
b - g 7 1 ACTGTTTCTT CGCTCAGCTG CAATTTTACT TGTATGACAA CATCTGGGCC TACACACAGC
b - g 9 1 ACTGTTTCTG CGATGACCTG CAATTTTACT TGTATGACAA CATCTGGGCC TACACACAGC
c - g k l 7 ACTGTTGTCA ACTTTATGTG CAATTTTTCT TGTGTGGGAC AATCTGGGCA TCGACACAGC
c - i a p 3 ACTGTTGTCA ACCTTATGTG CAATTTTTCT TGTGTGGGAC AATCTGGGCA TCGACACAGC
c - e r l a ACTGTTGACA CCCTTATCTG CAATTTTAGT TGTGTGGGAC AATCTGGGCA TCGACACAGC
c - i c a m l ACTGTTGTCG CCCTTATCTG CAATTTTAGT TGTGTGGGAC AATCTGGGCA TCGACACAGC
c - u k m a l ACTGTTCACA CCCTTATCTG CAATTTTAGT TGTGTGGGAC AATCTGGGCA TCGACACAGC
c - i a p 2 ACTGTTAACA CCCTTATCTG CAATTTTACT TGTGTGGGAC AATCTGGGCA TCGACACAGC
c - b b g l ACTGTTGTCA CCCTTATCTG CAATTTTAGT TGTGTGGAAC AATCTGGGCA TCGACACAGC
c -u k m a 8 ACTGTTGTCA CCCTTATCTG CAATTTTAGT TGTGTGGGAC AATCTGGGCA TCGACACAGC
c - b c 2 ACTGTTGTCG CCCTTATCTG CAATTTTAGT TGTGTGGGAC AATCTGGGCA TCGACACAGC
c -u k m a 3 ACTGTTGTCA CCCTTATCTG CAATTTTAGT TGTGTGGGAC AATCTGGGCA TCGACACAGC
c - i v e l ACTGTTGTCA CCCTTATCTG CAATTTTAGT TGTGTGGGAC AATCTGGGCA TCGACACAGC
c -u k b 2 2 ACTGTTGTTG ACCTTATCTG CAATTTTAGT TGTGTGGGAC AATCTGGGCA TCGACACAGC
c - g k l 8 ACTGTTGACA CCCTTATCTG CAATTTTAGT TGTGTGGGAC AATCTGGGCA TCGATACAGC
c - k l - 8 - d e m ACTTTTACCA ACCTTACCTG CAATTTTACT TGTGTGGGAC AATCTGGGCA TCGACACAGC
c - u g d 2 3 ACTTTTGCCA ACCTTACCTG CAATTTTACT TGTGTGGGAC AATCTGGGTA TCGACACAGC
a - u g d l 6 ACTGTTGCCA CCATTACCTG CAATTTTACT TGTGTGGAAC AATCTGGGCA TCGACAGAGC
a - u g d l 8 ACTGTTGCCA CCATTACCTG CAATTTTACT TGTGTGGAAC AATCTGGGCA TCGACAGAGC
a - u g d 2 4 ACTGTTGCCA CCATTACCTG CAATTTTACT TGTGTGGAAC AATCTGGGCA TCGACAGAGC
a - u g 3 7 4 ACTGTTGCCA CCATTACCTG CAATTTTACT TGTGTGGAAC AATCTGGGCA TCGACAGAGC
a - u g d 4 ACTGTTGCCA CCATTACCTG CAATTTTACT TGTGTGGAAC AATCTGGGCA TCGACAGAGC
a - b c b l l ACTATTGACA TCATTACCTG CAATTTTACT TGTGTGGAAC AATCTGGGCA TCGACAGAGC
a - u k a l 3 TTTTCTGTCA CCATTGCCTG CAATTTTACT TGTGTGGAAC AATCTGGGCA TCGACAGAGC
a - u k a 2 1 TTTTCTGTCA CCATTGCCTG CAATTTTACT TGTGTGGAAC AATCTGGGCA TCGACAGAGC
a -u k m a 4 TTTTCTGTCA CCATTGCCTG CAATTTTACT TGTGTGGAAC AATCTGGGCA TCGACAGAGC
a - b c l ATTCTTGACA CCATTGCCTG CAATTTTACT TGTGTGGAAC AATCTGGGCA TCGACAGAGC
a -e m a 7 ATCCTTGTCA CCATTGCCTG CAATTTTACT TGTGTGGAAC AATCTGGGCA TCGACAGAGC
a - b c b l r TTTCCTGTCA CCATTGCCTG CAATTTTACT TGTGTGGAAC AATCTGGGCA TCGACAGAGC
a - u k b l 2 TCTACTGTCA CCATTGCCTG CAATTTTACT TGTGTGGAAC AATCTGGGCA TCGACAGAGC
a - u g l l l CCTGGTGTCA ACATTGCCTG CAATTTTACT TGTGTGGAAG AATCTGGGCA TCCACAGAAC
a - i a p l TATACTTTCA CCATGACCTG CAATTTCACT TGTGTGGAAC AATCTGGGCA TCGACAGAGC
a - u k c l 2 TTTCCTGTCA CCATTCCCTG CAATTTTACT TGTGTGGAAC AATCTGGGCA TCGACAGAGC
c - k l - 4 3 - b e r CCTGTTTCCA CACTTACCTG CAATTTTACT TGTGTGGGAC AATCTGGGCC TTCACACAGC
a - u g d l 2 ACTGTTGCCA ACATTACCTG CAATTTTACT TGTGTGGAAC AATCTGGGCA TCGACAGAGC
C o n s e n s u s ------- T ------ -----T ----------- CAATT-------T TGT-TG------- --TC TG G ----- T --A -A -A -C
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ATTTGGATTC AACGGTATCC ACCACCTGTC TTACAAACCT TGTGTGCACA
300
GCCATCAACC
d 2 - z k s 3 ATTTGGATTC AATGGTATAC AGAACCTGTC TTACAAACCT TGTGTGCACA GCCATCAAAC
b - u g d l ATTTGGATTG AATGGTATAC AACACCTGTC TTACAAACCT TGTGTGCACA GCCATCAAAC
b -u g d 2 6 ATTTGGATTG AATGGTATAC AACACCTGTC TTACAAACCT TGTGTGCACA GCCATCAAAC
b - u g d l 9 ATTTGGATTG AATGGTATAC AACACCTGTC TTACAAACCT TGTGTGCACA GCCATCAAAC
b - u g d 7 ATTTGGATTG AATGGTATAC AACACCTGTC TTACAAACCT TGTGTGCACA GCCATCAAAC
b -u g d 2 ATTTGGATTG AATGGCATAC AACACCTGTC TTACAAACCT TGTGTGCACA GCCATCAAAC
b -u g d 2 1 ATTTGGATTG AATGGTATCC AACACCTGTC TTACAAACCT TGTGTGCACA GCCATCAAAC
b -u g d lO ATTTGGATTC AATGGTATAC ACAACCTGTC TTACAAACCT TGTGTGCACA GCCATCAAAC
b -u k m a 2 4 ATTTGGATTG AATGGTATAC ACAACCTGTC TTACAAACCT TGTGTGCACA GCCATCAAAC
b - u g d 2 9 ATTTGGATTG AATGGTATAC ACAACCTGTC TTACAAACCT TGTGTACACA GCCATCAAAC
b - u g 5 2 ATTTGGATTG AATGGTATAC ACAACCTGTC TTACAAACCT TGTGTGCACA GCCATCAAAC
b -g 4 1 3 ATTTGGATTG AATGGTATAC ACAACCTGTC TTACAAACCT TGTGTGCACA GCCATCAAAC
b - g 4 8 2 ATTTGGATTG AATGGTATAC ACAACCTGTC TTACAAACCT CGTGTGCACA GCCATCAAAC
b - u g d l 3 ATTTGGATTG AATGGTATTC ACAACCTGTC TTACAAACCT TGTGTGCACA GCCATCAAAC
b -u g d 3 ATTTGGATTG AATGGTATTC ACAACCTGTC TTACAAACCT TGTGTGCACA GCCATCAAAC
b - u g d l 5 ATTTGGATTG AATGGTATTC ACAACCTGTC TTACAAACCT TGTGTGCACA GCCATCAAAC
b - g 7 1 ATTTGGATTG AATGGTATAC ACAACCTGTC TTACAAACCT TGTGTGCACA GCCATCAAAC
b - g 9 1 ATTTGGATTG AATGGTATAC AGAACCTGTC TTACAAACCT TGTGTGCACA GCCATCAAAC
c - g k l 7 CTTTGGATGG CATGGTATGC ACCACCTGTC TTACAAACCT TGTGTGGACA ACCAGCAAAC
c - i a p 3 CTTTGGATGG CATGGTATGC ACCACCTGTC TTACAAACCT TGTGTGGACA ACCAGCAAAC
c - e r l a CTTTGGATTA CATGGTATCC ACAACCTGTC TTACAAACCT TGTGTGGACA ACCATCAAAC
c - i c a m l CTTTGGATTA CATGGTATCG AGAACCTGTC TTACAAACCT TGTGTGGACA ACCATCAAAC
c - u k n ia l CTTTGGATTA CATGGTATCC ACAACCTGTC TTACAAACCT TGTGTGGACA ACCATCAAAC
c - i a p 2 CTTTGGATTA CATGGTATGC ACAACCTGTC TTACAAACCT TCTGTGGACA ACCATCAAAC
c - b b g l CTTTGGATTA CATGGTATCC ACAACCTGTC TTACAAACCT TGTGTGGACA ACCATCAAAC
c -u k m a 8 CTTTGGATTA CATGGTATCC ACAACCTGTC TTACAAACCT TGTGTGGACA ACCATCAAAC
c - b c 2 CTTTGGATTA CATGGTATCC ACAACCTGTC TTACAAACCT TGTGTGGACA ACCATCAAAC
c -u k m a 3 CTTTGGATTA CATGGTATCC ACAACCTGTC TTACAAACCT TGTGTGGACA ACCATCAAAC
c - i v e l CTTTGGATTA CATGGTATCC ACAACCTGTC TTACAAACCT TGTGTGGACA ACCATCAAAC
c -u k b 2 2 CTTTGGATTA CATGGTATCC ACAACCTGTC TTACAAACCT TGTGTGGACA ATCATCAAAC
c - g k l 8 CTTTGGATTA CATGGTATGC ACAACCTGTC TTACAAACCT TCTGTGGACA ACCATCAAAC
c - k l - 8 - d e m TTTTGGATTA CATGGCATGC ACAACCTGTC TTACAAACCT TGTGTGCACA ACCATCAAAC
c - u g d 2 3 CTTTGGATTA CATGGCATGC ACAACCTGTC TTACAAACCT TGTGTGCGCA ACCATCAAAC
a - u g d l 6 ATTTGGATTA CATGGAATGC ACAACCTGTC TTACAAACCT TGTGTGCACA GCCATCAAAC
a - u g d l 8 ATTTGGATTA CATGGAATGC ACAACCTGTC TTACAAACCT TGTGTGCACA GCCATCAAAC
a -u g d 2 4 ATTTGGATTA CATGGAATGC ACAACCTGTC TTACAAACCT TGTGTGCACA GCCATCAAAC
a - u g 3 7 4 ATTTGGATTA CATGGAATGC ACAACCTGTC TTACAAACCT TGTGTGCACA GCCATCAAAC
a - u g d 4 ATTTGGATTA CATGGAATGC ACAACCTGTC TTACAAACCT TGTGTGCACA GCCATCAAAC
a - b c b l l ATTTGGATTA CATGGCATGC ACAACCTGTC TTACAAACCT TGTGTGCACA GCCATCTAAC
a - u k a l 3 ATTTGGATTA CATGGCATGC ACAACCTGTC TTACAAACCT TGTGTGCACA GCCATCAAAC
a - u k a 2 1 ATTTGGATTA CATGGCATGC ACAACCTGTC TTACAAACCT TGTGTGCACA GCCATCAAAC
a -u k m a 4 ATTTGGATTA CATGGCATGC ACAACCTGTC TTACAAACCT TGTGTGCACA GCCATCAAAC
a - b c l ATTTGGATTA CATGGCGTGC ACAACCTGTC TTACAAACCT TGTGTGCACA GCCATCAAAC
a -e m a 7 ATTTGGATTA CATGGCATGC ACAACCTGTC TTACAAACCT TGTGTGCACA GCCATCAAAC
a - b c b l r ATTTGGATTA CATGGCATGC ACAACCTGTC TTACAAACCT TGTGTGCACA GCCATCAAAC
a - u k b l 2 ATTTGGATTA CATGGCATGC ACAACCTGTC TTACAAACCT TGTGTGCACA GCCATCAAAC
a - u g l l l ATTTGGATTA CATGGCATGC ACAACCTGTC TTACAAACCT TGTGTGCACA GCCATCAAAC
a - i a p l ATTTGGATTT CATGGCATAC ACAACCTGTC TTACAAACCT TGTGTGCACA GCCATCAAAC
a - u k c l 2 ATTTGGGTTA CATGGCATGC ACAACCTGTC TTACAAACCT TGTGTGCACA GCCATCAAAC
c - k l - 4 3 - b e r ATTTGGATCA CATGGTATGC AAAACCTGTC TTACAAACCT TGTGTGCACA GCCATCAAAC
a - u g d l 2 ATTTGGATTA CATGGAATGC ACAACCTGTC TTACAAACCT TGTGTGCACA GCCATCAAAC
C o n s e n s u s -T T T G G -T -- -A -G G --T -- A--ACCTGTC TTACAAACCT --T G T -----CA - -C A -C -A -C
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ACAGTTACTT GTGGTCAGCG TGTTAGTTTG CATTGTTCTA CCTCTGCAAA
360
TACTGTTACC
d 2 - z k s 3 ACAGTTACTT GTGGTCAGCG TGTTACTTTG CATTGCTCTA CCTCTGCAAG TACTGTTTTT
b - u g d l ACAGTGACTT GTGGTCAGCG TGTTACTTTG TATTGTCATA CCTCTTCAAA TAATGGTACC
b -u g d 2 6 ACAGTGACTT GTGGTCAGCG TGTTACTTTG TATTGTTATA CCTCTTCAAA TAATGGTACC
b - u g d l 9 ACAGTGACTT GTGGTCAGCG TGTTACTTTG TATTGTCATA CCTCTTCAAA TAATGGTACC
b - u g d 7 ACAGTGACTT GTGGTCAGCG TGTTACTTTG TATTGTCATA CCTCTTCAAA TAATGGTACC
b - u g d 2 ACAGTGACTT GTGGTCAGCG TGTTACTTTG TATTGTCATA CCTCTTCAAA TAATGGTACC
b -u g d 2 1 ACAGTGACTT GTGGTCAGCG TGTTACTTTG TATTGTCATA CCTCTTCAAA TAATGGTACC
b -u g d lO ACAGTGTCTT GTGGTCAGCC TGTTACTTTG TATTGTGATA CCTCTTCAAA TAATGTTACC
b -u k m a 2 4 ACAGTGTCTT GTGGTCAGCC TGTTACTTTG TATTGTGATA CCTCTTCAAA TAATGTTACC
b -u g d 2 9 ACAGTGTCTT GTGGTCAGCC TGTTACTTTG TATTGTGATA CCTCTTCAAA TAATGTTACC
b -u g 5 2 ACAGTGTCTT GTGGTCAGCC TGTTACTTTG TATTGTGATA CCTCTTCAAA TAATGTTACC
b -g 4 1 3 ACAGTGACTT GCGGTCAGCG TGTTACTTTG TATTGTCATA CCTCTTCAAA TAATGTTACC
b -g 4 8 2 ACAGTGACTT GCGGTCAGCG TGTTACTTCG TATTGTCATA CCTCTTCAAA TAATGTTAAC
b - u g d l 3 ACAGTGACTT GCGGTCAGCG TGTTACTTTG TATTGTCATA CCTCTTCAGA TAATGTTACC
b -u g d 3 ACAGTGACTT GCGGTCAGCG TGTTACTTTG TATTGTCATA CCTCTTCAGA TAATGTTACC
b - u g d l 5 ACAGTGACTT GCGGTCAGCG TGTTACTTTG TATTGTCATA CCTCTTCAGA TAATGTTACC
b - g 7 1 ACAGTGACTT GCGGTCAGCG TGTTACTTTG TATTGTCATA CCTCTTCAAA TAATGTTACC
b - g 9 1 ACAGTGACTT GCGGTCAGCG TGTTACTTTG TATTGTAATA CCTCTTCAAA TAATGTTACC
c - g k l 7 ACAGTCACTT GTGGTCAGCA TGTTACTTTG TATTGTTCTA CCTCTGGAAA TAATGTTACC
c - i a p 3 ACAGTCACTT GTGGTCAGCA TGTTACTTTG TATTGTTCTA CCTCTGGAAA TAATGTTACC
c - e r l a ACAGTCACTT GTGGTCAGCA TGTTACTTTG TATTGTTCTA CCTCTGGAAA TAATGTTACC
c - i c a m l ACAGTCACTT GTGGTCAGCA TGTTACTTTG TATTGTTCTA CCTCTGGAAA TAATGTTACC
c - u k m a l ACAGTCACTT GTGGTCAGCA TGTTACTTTG TATTGTTCTA CCTCTGGAAA TAATGTTACC
c - i a p 2 ACAGTCACTT GTGGTCAGCA TGTTACTTTG TATTGTTCTA CCTCTGGAAA TAATGTTACC
c - b b g l ACAGTCACTT GTGGTCAGCA TGTTACTTTG TATTGTTCTA CCTCTGGAAA TAATGTTACC
c -u k m a 8 ACAGTCACTT GTGGTCAGCA TGTTACTTTG TATTGTTCTA CCTCTGGAAA TAATGTTACC
c - b c 2 ACAGTCACTT GTGGTCAGCA TGTTACTTTG TATTGTTCTA CCTCTGGAAA TAATGTTACC
c -u k m a 3 ACAGTCACTT GTGGTCAGCA TGTTACTTTG TATTGTTCTA CCTCTGGAAA TAATGTTACC
c - i v e l ACAGTCACTT GTGGTCAGCA TGTTACTTTG TATTGTTCTA CCTCTGGAAA TAATGTTACC
c -u k b 2 2 ACAGTCACTT GTGGTCAGCA TGTTACTTTG TATTGTTCTA CCTCTGGAAA TAATGTTACC
c - g k l 8 ACAGTCACTT GTGGTCAGCA TGTTACTTTG TATTGTTCTA CCTCTGGAAA TAATGTTACC
c - k l - 8 - d e m ACAGTCACTT GTGCTCAGCA TGTTACTTTG TATTGTTCTA CCTCTGGAAA TAATGTTACC
c - u g d 2 3 ACAGTCACTT GTGGTCAGCA TGTTACTTTG TATTGTTCTA CCTCTGGAAA TAATGTTACC
a - u g d l 6 ACAGTCACTT GTGGTCAGCA TGTTACTTTG TATTGTTCTA CCTCTGGAAA TAATGTTACC
a - u g d l 8 ACAGTCACTT GTGGTCAGCA TGTTACTTTG TATTGTTCTA CCTCTGGAAA TAATGTTACC
a -u g d 2 4 ACAGTCACTT GTGGTCAGCA TGTTACTTTG TATTGTTCTA CCTCTGGAAA TAATGTTACC
a -u g 3 7 4 ACAGTCGCTT GTGGTCAGCA GGTTACTTTG TATTGTTCTA CCTCTGGAAA TAATGTTACC
a - u g d 4 ACAATCACTT GTGGTCAGCA TGTTACTTTG TATTGTTCTA CCTCTGGAAA TAATGTTACC
a - b c b l l ACAGTCACTT GTGGTCAGCA TGTTACTTTG TATTGTTCTA CCTCTGGAAA TAATGTTACC
a - u k a l 3 ACAGTCACTT GTGGTCAGCA TGTTACTTTG TATTGTTCTA CCTCTGGAAA TAATGTTACC
a - u k a 2 1 ACAGTCACTT GTGGTCAGCA TGTTACTTTG TATTGTTCTA CCTCTGGAAA TAATGTTACC
a -u k m a 4 ACAGTCACTT GTGGTCAGCA TGTTACTTTG TATTGTTCTA CCTCTGGAAA TAATGTTACC
a - b c l ACAGTCACTT GTGGTCAGCA TGTTACTTTG TATTGTTCTA CCTCTGGAAA TAATGTTACC
a -e m a 7 ACAGTCACTT GTGGTCAGCA TGTTACTTTG TATTGTTCTA CCTCTGGAAA TAATGTTACC
a - b c b l r ACAGTCACTT GTGGTCAGCA TGTTACTTTG TATTGTTCTA CCTCTGGAAA TAATGTTACC
a - u k b l 2 ACAGTCACTT GTGGTCAGCA TGTTACTTTG TATTGTTCTA CCTCTGGAAA TAATGTTACC
a - u g l l l ACAGTCACTT GTGGTCACCA TGTTACTTTG TATTGTTCTA CCTCTGGAAA TAATGTTACC
a - i a p l ACAGTCACTT GTGGTCAGCA TGTTACTTTG TATTGTTCTA CCTCTGGAAA TAATGTTACC
a - u k c l 2 ACAGTCACTT GTGGTCAGCA TGTTACTTTG TATTGTTCTA CCTCTGGAAA TAATGTTACC
c - k l - 4 3 - b e r ACAGTCACTT GTGGTCAGCA TGTTCCTTTG TATTGTTCTA CCTCTGGAAA TAATGTTACC
a - u g d l 2 ACAGTCGCTT GTGGTCAGCA GGTTACTTTG TATTGTTCTA CCTCTGGAAA TAATGTTACC
C o n s e n s u s A C A -T--C TT G -G -TC A -C - -G T T --T T -G -ATTG-----TA C C T C T --A -- T A -T G -T -----
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ATTTGGCGTC TACAAAACGA AGGACATCAA CCCGTGTCAC AAACTTACTA
420
CTATAATTTT
d 2 - z k s 3 ATTTGGCGTC TACACAGGGG AGGAAATCAA ACCGTGTCAC AAACTAACTA CTATAATTTT
b - u g d l ATTTGGCGTC TACAAAACGG ACACAATCAA ACCGTGTCAC AAACTAAATA CTATAATTTT
b -u g d 2 6 ATTTGGCGTC TACAAAACGG ACACAATCAA ACCGTGTCAC AAACTAAATA CTATAATTTT
b - u g d l 9 ATTTGGCGTC TACAAAAGGG ACACAATCAA ACCGTGTCAC AAACTAAATA CTATAATTTT
b - u g d 7 ATTTGGCGTC TACAAAACGG ACACAATCAA ACCGTGTCAC AAACTAAATA CTATAATTTT
b -u g d 2 ATTTGGCGTC TACAAAACGG ACACAATCAA ACCGTGTCAC AAACTAAATA CTATAATTTT
b -u g d 2 1 ATTTGGCGTC TACAAAACGG ACACAATCAA ACCGTGTCAC AAACTAAATA CTATAATTTT
b -u g d lO ATTTGGCGTC TACAAAACGG ACACAATCAA ACCGTGTCAC AAACTAAATA CTATAATTTT
b -u k m a 2 4 ATTTGGCGTC TACAAAACGG ACACAATCAA ACCGTGTCAC AAACTAAATA CTATAATTTT
b -u g d 2 9 ATTTGGCGTC TACAAACCGG ACACAATCAA ACCGTGTCAC AAACTAAATA CTATAATTTT
b -u g 5 2 ATTTGGCGTC TACAAAACGG ACACAATCAA ACCGTGTCAC AAACTAGATA CTATAATTTT
b -g 4 1 3 ATTTGGCGTC TACAAAACGG ACACAATCAA ACCGTGTCAC AAACTAAATA CTATAATTTT
b -g 4 8 2 ATTTGGCGTC TACAAAACGG ACACAATCAA ACCGTGTCAC AAACTAAATA CTATAATTTT
b - u g d l 3 ATTTGGCGTC TACAAAACGG ACACAATCAA ACCGTGTCAC AAACTAAATA CTATAATTTT
b -u g d 3 ATTTGGCGTC TACAAAACGG ACACAATCAA ACCGTGTCAC AAACTAAATA CTATAATTTT
b - u g d l 5 ATTTGGCGTC TACAAAACGG ACACAATCAA ACCGTGTCAC AAACTAAATA CTATAATTTT
b - g 7 1 ATTTGGCGTC TACAAAACGG ACACAATCAA ACCGTGTCAC AAACTAAATA CTATAATTTT
b - g 9 1 ATTTGGCGTC TACAAAACGG ACACAATCAA ACCGTGTCAC AAACTAAATA CTATAATTTT
c - g k l 7 GTTTGGCATC TACCAAACGG ACGAAATGAA ACCGTGTCAC AAACTAAATA CTATAATTTT
c - i a p 3 GTTTGGCATC TACCAAACGG ACGAAATGAA ACCGTGTCAC AAACTAAATA CTATAATTTT
c - e r l a GTTTGGCATC TACCAAACGG ACGAAATGAA ACCGTGTCAC AAACTAAATA CTATAATTTT
c - i c a m l GTTTGGCATC TACCAAACGG ACGAAATGAA ACCGTGTCAC AAACTAAATA CTATAATTTT
c - u k m a l GTTTGGCATC TACCAAACGG ACGAAATGAA ACCGTGTCAC AAACTAAATA CTATAATTTT
c - i a p 2 GTTTGGCATC TACCAAACGG ACGAAATGAA ACCGTGTCAC AAACTAAATA CTATAATTTT
c - b b g l GTTTGGCATC TACCAAACGG ACGAAATGAA ACCGTGTCAC AAACTAAATA CTATAATTTT
c -u k m a 8 GTTTGGCATC TACCAAACGG ACGAAATGAA ACCGTGTCAC AAACTAAATA CTATAATTTT
c - b c 2 GTTTGGCATC TACCAAACGG ACGAAATGAA ACCGTGTCAC AAACTAAATA CTATAATTTT
c -u k m a 3 GTTTGGCATC TACCAAACGG ACGAAATGAA ACCGTGTCAC AAACTAAATA CTATAATTTT
c - i v e l GTTTGGCATC TACCAAACGG ACGAAATGAA ACCGTGTCAC AAACTAAATA CTATAATTTT
c - u k b 2 2 GTTTGGCATC TACCAAACGG ACGAAATGAA ACCGTGTCAC AAACTAAATA CTATAATTTT
c - g k l 8 GTTTGGCATC TACCAAACGG ACAAAATGAA ACCGTGTCAC AAACTAAATA CTATAATTTT
c - k l - 8 - d e r a GTTTGGCATC TACCAAACGG ACGAAATGAA ACCGTGTCAC AAACTAAATA CTATAATTTT
c - u g d 2 3 GTTTGGCATC TACCAAACGG ACGAAATGAA ACCGTGTCAC AAACTAAATA CTATAATTTT
a - u g d l 6 GTTTGGCATC TACCAAACGG ACGAAATGAA ACCGTGTCAC AAACTAAATA CTATAATTTT
a - u g d l 8 GTTTGGCATC TACCAAACGG ACGAAATGAA ACCGTGTCAC AAACTAAATA CTATAATTTT
a -u g d 2 4 GTTTGGCATC TACCAAACGG ACGAAATGAA ACCGTGTCAC AAACTAAATA CTATAATTTT
a -u g 3 7 4 GTTTGGCATC TACCAAACGG ACGAAATGAA ACCGTGTCAC AAACTAAATA CTATAATTTT
a - u g d 4 GTTTGGCATC TACCAAACGG ACGAAATGAA ACCGTGTCAC AAACTAAATA CTATAATTTT
a - b c b l l GTTTGGCATC TACCAAACGG ACGAAATGAA ACCGTGTCAC AAACTAAATA CTATAATTTT
a - u k a l 3 GTTTGGCATC TACCAAACGG ACGAAATGAA ACCGTGTCAC AAACTAAATA CTATAATTTT
a - u k a 2 1 GTTTGGCATC TACCAAACGG ACGAAATGAA ACCGTGTCAC AAACTAAATA CTATAATTTT
a -u k m a 4 GTTTGGCATC TACCAAACGG ACGAAATGAA ACCGTGTCAC AAACTAAATA CTATAATTTT
a - b c l GTTTGGCATC TACCAAACGG ACGAAATGAA ACCGTGTCAC AAACTAAATA CTATAATTTT
a -e m a 7 GTTTGGCATC TACCAAACGG ACGAAATGAA ACCGTGTCAC AAACTAAATA CTATAATTTT
a - b c b l r GTTTGGCATC TACCAAACGG ACGAAATGAA ACCGTGTCAC AAACTAAATA CTATAATTTT
a - u k b l 2 GTTTGGCATC TACCAAACGG ACGAAATGAA ACCGTGTCAC AAACTAAATA CTATAATTTT
a - u g l l l GTTTGGCATC TACCAAACGG ACTAAATGAA ACCGTGTCAC AAACTAAATA CTATAATTTT
a - i a p l GTTTGGCATC TACCAAACGG ACGAAATGAA ACCGTGTCAC AAACTAAATA CTATAATTTT
a - u k c l 2 GTTTGGCATC TACCAAACGG ACGAAATGAA ACCGTGTCAC AAACTAAATA CTATAATTTT
c - k l - 4 3 - b e r ATTTGGCATC TACAAAACGG ACGAAATCAA ACCGTGTCAC AAACTAACTA CTATAATTTT
a - u g d l 2 GTTTGGCATC TACCAAACGG ACGAAATGAA ACCGTGTCAC AAACTAAATA CTATAATTTT
C o n s e n s u s -TTTGGC-TC T A C --A --G - A-------AT-AA - CCGTGTCAC AAACT-----TA CTATAATTTT
d l - t k s l O
421
ACGCTGATGA ACCAAACTCA GGGATGTTAT ACTTGTTCTA ACGGGCTGTC
480
GTCTCGCATG
d 2 - z k s 3 ACGCTGATGA ACCAAACTAA CGGCTGTTAT GCTTGTTCTA GCGGGCTGTC GTCTCGCCTG
b - u g d l ACGATGATGA ACCAAACTCA GGGGTGTTAT CTTTGTTCTG ACGGGCTGTC GTCTCGCCTG
b -u g d 2 6 ACGATGATGA ACCAAACTCA GGGGTGTTAT CTTTGTTCTG ACGGGCTGTC GTCTCGCCTG
b - u g d l 9 ACGATGATGA ACCAAACTGA GGGGTGTTAT CTTTGTTCTG ACGGGCTGTC GTCTCGCCTG
b - u g d 7 ACGATGATGA ACCAAACTCA GGGGTGTTAT TTTTGTTTTG ACGGGCTGTC GTCTCGCCTG
b -u g d 2 ACGATGATGA ACCAAACTCA GGGGTGTTAT ATTTGTTGTG ACGGGCTGTC GTCTCACCTG
b -u g d 2 1 ACGATGATGA ACCAAACTCA GGGGTGTTAT ATTTGTTGTG ACGGGCTGTC GTCTCGCCTG
b -u g d lO ACGATGATGA ACCAAACTCA GGGGTGTTAT ACTTGTTCTA ACGGGCTGTC GTCTCGCCTG
b -u k m a 2 4 ACGATGATGA ACCAAACTCA GGGGTGTTAT ACTTGTTCTA ACGGGCTGTC GTCTCGCCTG
b -u g d 2 9 ACGATGATGA ACCAAACTCA GGGGTGTTAT GCTTGTTCTA ACGGGCTGTC GTCTCGCCTG
b -u g 5 2 ACGATGATGA ACCAAACTCG GGGGTGTTAT Gt t t g TTCTG ACGGGCTGTC GTCTCGCCTG
b -g 4 1 3 ACGATGATGA ACCAAACTCA GGGGTGTTAT ACTTGTTCTA ACGGGCTGTC GTCTCGCCTG
b -g 4 8 2 ACGATGATGA ACCAAACTCA GGGGTGTTAT ACTTGTTCTA ACGGGCTGTC GTCTCGCCTG
b - u g d l 3 ACGATGATGG ACCAAACTCA GGGGTGTTAT ACTTGTTCTA ACGGGCTGTC GTCTCGCCTG
b -u g d 3 ACGATGATGG ACCAAACTCA GGGGTGTTAT ACTTGTTCTA ACGGGCTGTC GTCTCGCCTG
b - u g d l 5 ACGATGATGA ACCAAACTCA GGGGTGTTAT ACTTGTTCTA ACGGGCTGTC GTCTCGCCTG
b - g 7 1 ACGATGATGA ACCAAACTCA GGGGTGTTAT ACTTGTTCTA ACGGGCTGTC GTCTCGCCTG
b - g 9 1 ACGATGATGA ACCAAACTCA GGGGTGTTAT ACTTGTTCTA ACGGGCTGTC GTCTCGCCTG
c - g k l 7 ACGCTGATGA ACCAAACTGA GGGGTGTTAT GCTTGTTCTA ACGGGCTGTC GTCTGGCCTG
c - i a p 3 ACGCTGATGA ACCAAACTGA GGGGTGTTAT GCTTGTTCTA ACGGGCTGTC GTCTGGCCTG
c - e r l a ACGCTGATGA ACCAAACTGA GGGGTGTTAT GCTTGTTCTA ACGGGCTGTC GTCTCGCCTG
c - i c a m l ACGCTGATGA ACCAAACTGA GGGGTGTTAT GCTTGTTCTA ACGGGCTGTC GTCTCGCCTG
c - u k tn a l ACGCTGATGA ACCAAACTGA GGGGTGTTAT GCTTGTTCTA ACGGGCTGTC GTCTCGCCTG
c - i a p 2 ACGCTGATGA ACCAAACTGA GGGGTGTTAT GCTTGTTCTA ACGGGCTGTC GTCTCGCCTG
c - b b g l ACGCTGATGG ACCAAACGGA GGGGTGTTAT GCTTGTTCTG ACGGGCTGTC GTCTCGCCTG
c -u k m a 8 ACGCTGATGG ACCAAACGGA GGGGTGTTAT GCTTGTTCTG ACGGGCTGTC GTCTCGCCTG
c - b c 2 ACGCTGATGG ACCAAAGTGA GGGGTGTTAT GCTTGTTCTG ACGGGCTGTC GTCTCGCCTG
c -u k m a 3 ACGCTGATGG ACCAAACGGA GGGGTGTTAT GCTTGTTCTG ACGGGCTGTC GTCTCGCCTG
c - i v e l ACGCTGATGG ACCAAACGGA GGGGTGTTAT GCTTGTTCTG ACGGGCTGTC GTCTCGCCTG
c - u k b 2 2 ACGCTGATGG ACCAAACGGA GGGGTGTTAT GCTTGTTCTG ACGGGCTGTC GTCTCGCCTG
c - g k l 8 ACGCTCATGA ACCAAACTGA GGGGTGTTAT GCTTGTTCTA ACGGGCTGTC GTCTCGCCTG
c - k l - 8 - d e m ACGCTGATGA ACCAAACTGA GGGGTGTTAT GCTTGTTCTA ACGGCCTGTC GTCTCGCCTG
c - u g d 2 3 ACGCTGATGA ACCAAACTGA GGGGTGTTAT GGTTGTTCTA ACGGCCTGTC GTCTCGCCTG
a - u g d l 6 ACGCTGATGA ACCAAACTGA GGGGTGTTAT ACTTGTTCTA ACGGGCTGTC GTCTCGCCTG
a - u g d l 8 ACGCTGATGA ACCAAACTGA GGGGTGTTAT ACTTGTTCTA ACGGGCTGTC GTCTCGCCTG
a - u g d 2 4 ACGCTGATGA ACCAAACTGA GGGGTGTTAT ACTTGTTCTA ACGGGCTGTC GTCTCGCCTG
a - u g 3 7 4 ACGCTGATGA ACCAAACTGA GGGGTGTTAT ACTTGTTCTA ACGGGCTGTC GTCTCGCCTG
a - u g d 4 ACGCTGATGA ACCAAACTGA GGGGTGTTAT ACTTGTTCTA ACGGGCTGTC GTCTCGCCTG
a - b c b l l ACGCTGATGA ACCAAACTGA GGGGTGTTAT ACTTGTTCTA ACGGGCTGTC GTCTCGCCTG
a - u k a l 3 ACGCTGATGA ACCAAACTGA GGGGTGTTAT ACTTGTTCTA ACGGGCTGTC GTCTCGCCTG
a - u k a 2 1 ACGCTGATGA ACCAAACTGA GGGGTGTTAT ACTTGTTCTA ACGGGCTGTC GTCTCGCCTG
a -u k m a 4 ACGCTGATGA ACCAAACTGA GGGGTGTTAT ACTTGTTCTA ACGGGCTGTC GTCTCGCCTG
a - b c l ACGCTGATGA GCCAAACTGA GGGGTGTTAT ACTTGTTCTA ACGGGCTGTC GTCTCGCCTG
a -e m a 7 ACGCTGATGA ACCAAACTGA GGGGTGTTAT ACTTGTTCTA ACGGGCTGTC GTCTCGCCTG
a - b c b l r ACGCTGATGA ACCAAACTGA GGGGTGTTAT ACTTGTTCTA ACGGGCTGTC GTCTCGCCTG
a - u k b l 2 ACGCTGATGA ACCAAACTGA GGGGTGTTAT ACTTGTTCTA ACGGGCTGTC GTCTCGCCTG
a - u g l l l ACGCCGATGA ACCAAACTGA AGGGTGTTAT ACTTGTTCTA ACGGGCTGTC GTCTCGCCTG
a - i a p l ACGCTGATGA ACCAAACTGA GGGGTGTTAT ACTTGTTCTA ACGGGCTGTC GTCTCGCCTG
a - u k c l 2 ACGCTGATGA ACCAAACTGA GGGGTGTTAT ACTTGTTCTA ACGGGCTGTC GTCTCGCCTG
c - k l - 4 3 - b e r ACGGTGATGA ACCAAACTGA GGGGTGTTAT GCTTGTTCTA ACGGGCTGTC GTCTCGCCTG
a - u g d l 2 ACGCTGATGA ACCAAACTGA GGGGTGTTAT ACTTGTTCTA ACGGGCTGTC GTCTCGCCTG
C o n s e n s u s ACG-----ATG- -CCAAA------- -GG-TGTTAT - -T T G T T -T - -CGG-CTGTC G TC T--C -TG
d l - t k s l O
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TCAAATCGTA TATGTTTTTG GGCGCCTTGT GCCAATATAA CTCCAGAAAC
540
TGATACTGTA
d 2 - z k s 3 TCAAATCTTA TATGTTTTTG GGCGCATTGT GCCAATATAT CTCTAGAAAC TTCTACTGTA
b - u g d l TCAAATCGTA TATGTTTTTG GGCGTCTTGT ATCAATATAA CTCCAGAAAC TCCTACTGTC
b -u g d 2 6 TCAAATCGTA TATGTTTTTG GGCGTCTTGT ATCAATATAA CTCCAGAAAC TCCTACTGTC
b - u g d l 9 TCAAATCGTA TATGTTTTTG GGCGTCTTGT ATCAATATAA CTCCAGAAAC TCCTACTGTC
b - u g d 7 TCAAATCGTA TATGTTTTTG GGCGTCTTGT ATCAATATAA CTCCAGAAAC TCCTACTGTC
b -u g d 2 TCAAATCGTA TATGTTTTTG GGCGTCTTGT ATCAATATAA CTCCAGAAAC TCCTACTGTC
b -u g d 2 1 TCAAATCGTA TATGTTTTTG GGCGTCTTGT ATCAATATAA CTCCAGAAAC TCCTACTGTC
b -u g d lO TCAAATCGTA TATGTTTTTG GGCGTCTTGT ATCAATATAA CTCCAGAAAC TCCTACTGTC
b -u k m a 2 4 TCAAATCGTA TATGTTTTTG GGCGTCTTGT ATCAATATAA CTCCAGAAAC TCCTACTGTC
b -u g d 2 9 TCAAATCGTA TATGTTTTTG GGCGTCTTGT ATCAATGTAA CTCCAGAAAC TCCTACTGTC
b -u g 5 2 TCAAATCGTA TATGTTTTTG GGCGTCTTGT ATCAATATAA CTCCAGAAAC TCCTACTGTC
b -g 4 1 3 TCAAATCGTA TATGTTTTTG GGCGTCTTGT ATCAATATAA CTCCAGAAAC TCCTACTGTC
b -g 4 8 2 TCAAATCGTA TATGTTTTTG GGCGTCTTGT ATCAATATAA CTCCAGAAAC TCCTACTGTC
b - u g d l 3 TCAAATCGTA TATGTTTTTG GGCGTCTTGT ATTAATATAA CTCCAGAAAC TCCTACTGTC
b -u g d 3 TCAAATCGTA TATGTTTTTG GGCGTCTTGT ATTAATATAA CTCCAGAAAC TCCTACTGTC
b - u g d l 5 TCAAATCGTA TATGTTTTTG GGCGTCTTGT ATTAATATAA CTCCAGAAAC TCCTACTGTC
b - g 7 1 TCAAATCGTA TATGTTTTTG GGCGTCTTGT ATCAATATAA CTCCAGAAAC TCCTACTGTC
b - g 9 1 TCAAATCGTA TATGTTTTTG GGCGTCTTGT ATCAATCTAA CTCCTGAAAC TCCTACTCTC
c - g k l 7 TCAAATCGTC TCTGTTTTTG GGCGCGTTGT GCCAATATAA CTCCAGAAAC TCATACTGTA
c - i a p 3 TCAAATCGTC TATGTTTTTG GGCGCGTTGT GCCAATATAA CTCCAGAAAC TCATACTGTA
c - e r l a TCAAATCGTC TATGTTTTTC GGCGCGTTGT GCCAATCTAA CTCCAGAAAC TCATACTGTA
c - i c a m l TCAAATCGTC TATGTTTTTC GGCGCGTTGT GCCAATCTAA CTCCAGAAAC TCATACTGTA
c - u k m a l TCAAATCGTC TATGTTTTTC GGCGCGTTGT GCCAATATAA CTCCAGAAAC TCATACTGTA
c - i a p 2 TCAAATCGTC TATGTTTTTC GGCGCGTTGT GCCAATAGAA CTCCAGAAAC TCATACTGTA
c - b b g l TCAAATCGTC TATGTTTTTG GGCGCGTTGT GCCAATATAA CTCCAGAAAC TCATACTGTA
c -u k m a 8 TCAAATCGTC TATGTTTTTG GGCGCGTTGT GCCAATATAA CTCCAGAAAC TCATACTGTA
c - b c 2 TCAAATCCTC TATGTTTTTC GGCGCGTTGT GCCAATATAA CTCTAGAAAC TGATACTGTA
c -u k m a 3 TCAAATCGTC TATGTTTTTC GGCGCGTTGT GCCAATATAA CTCTAGAAAC TAATACTGTA
c - i v e l TCAAATCGTC TATGTTTTTC GGCGCGTTGT GCCAATATAA CTCTAGAAAC TCATACTGTA
c - u k b 2 2 TCAAATCGTC TATGTTTTTC GGCGCGTTGT GCCAATATAA CTCTAGAAAC TCATACTGTA
c - g k l 8 TCAAATCGTC TATGTTTTTC GGCGCGTTGT GCCAATATAA CTCCAGAAAC TCATACTGTA
c - k l - 8 - d e m TCAAATCGTA TATGTTTTTG GGCGCGTTGT GCCAATATAA CTCCAGAAAC TCATACTGTA
c -u g d 2 3 TCAAATCGTA TATGTTTTTG GGCGCGTTGT GCCAATATAA CTCCAGAAAC TCATACTGTA
a - u g d l 6 TCAAATCGTA TATGTTTTTG GGCGCGTTGT GCCAATATAA CTCCAGAAAC TCATACTGTA
a - u g d l 8 TCAAATCGTA TATGTTTTTG GGCGCGTTGT GCCAATATAA CTCCAGAAAC TCATACTGTA
a -u g d 2 4 TCAAATCGTA TATGTTTTTG GGCGCGTTGT GCCAATATAA CTCCAGAAAC TCATACTGTA
a - u g 3 7 4 TCAAATCGTA TATGTTTTTG GGCGCGTTGT GCCAATATAA CTCCAGAAAC TCATACTGTA
a - u g d 4 TCAAATCGTA TATGTTTTTG GGCGCGTTGT GCCAATATAA CTCCAGAAAC TCATACTGTA
a - b c b l l TCAAATCGTA TATGTTTTTG GGCGCGTTGT GCCAATATAA CTCCAGAAAC TCATACTGTA
a - u k a l 3 TCAAATCGTA TATGTTTTTG GGCTCGTTGT GCCAATCTAA CTCCAGAAAC TCATACTGTA
a - u k a 2 1 TCAAATCGTA TATGTTTTTG GGCTCGTTGT GCCAATATAA CTCCAGAAAC TCATACTGTA
a -u k m a 4 TCAAATCGTA TATGTTTTTG GGCTCGTTGT GCCAATATAA CTCCAGAAAC TCATACTGTA
a - b c l TCAAATCGTA TATGTTTTTG GGCGCGTTGT GCCAATATAA CTCCAGAAAC TCATACTGTA
a -e m a 7 TCAAATCGTA TATGTTTTTG GGCGCGTTGT GACAATATAA CTCCAGAAAC TCATACTGTA
a - b c b l r TCAAATCGTA TATGTTTTTG GGCGCGTTGT GCCAATATAA CTCCAGAAAC TCATACTGTA
a - u k b l 2 TCAAATCGTA TATGTTTTTG GGCGCGTTGT GCCAATATAA CTCCAGAAAC TCATACTGTA
a - u g l l l TCAAATCGTA TATGTTTTTG GGCGCGTTGT GCCAATATAA CTCCAGAAAC TCATACTGTA
a - i a p l TCAAATCGTA TATGTTTTTG GGCGCGTTGT GCCAATATAA CTCCAGAAAC TCATACTGTA
a - u k c l 2 TCAAATCGTA TATGTTTTTG GGCGCGTTGT GCCAATATAA CTCCAGAAAC TCAGACTGTA
c - k l - 4 3 - b e r TCAAATCCTA TATGTTTTTG GCCGCGTTGT GCCAATATAA CTCCAGAAAC TCATACTGTA
a - u g d l 2 TCAAATCGTA TATGTTTTTG GGCGCGTTGT GCCAATATAA CTCCAGAAAC TCATACTGTA
C o n s e n s u s TCAAATC-T- T-TGTTTTT- G -C -----TTGT -----A A T --A - CTC--GAAAC T -----A CT-T-




CTTTAAAACT CATACTGTAT CTGTCAGGAG TACTACAGGC
d 2 - z k s 3 TCTGTCAGCA GTACTACAGG CTTTAA.................................................................................................
b - u g d l TCCGCCAGCA GTACTACGGC CTTTAA.................................................................................................
b -u g d 2 6 TCCGCCAGCA GTACTACGGC CTTTAA.................................................................................................
b - u g d l 9 TCCGCCAGCA GTACTACGGC CTTTAA.................................................................................................
b - u g d 7 TCCGCCAGCA GTACTACGGC CTTTAA.................................................................................................
b -u g d 2 TCCGCCAGCA GTACTACGGC CATTAA..................................................................................................
b -u g d 2 1 TCCGCCAGCA GTACTACGGC CATTAA.................................................................................................
b -u g d lO TCCGCCAGCA GTACTATGGC CGTTAA.................................................................................................
b -u k m a 2 4 TCCGCCAGCA GTACTATGGC CGTTAA.................................................................................................
b -u g d 2 9 TCCGCCAGCA GTCCTATGGC CGTTAA.................................................................................................
b -u g 5 2 TCCGCCAGCA GTACTACGGC CTTTAA.................................................................................................
b -g 4 1 3 TCCTCCAGCA GTACTACGGC CTTTGA..................................................................................................
b - g 4 8 2 TCCTCCAGCA GTACTACGGC CTTTAA..................................................................................................
b - u g d l 3 TCCGCCAGCA GTACTACGGC CTTTAA..................................................................................................
b -u g d 3 TCCGCCAGCA GTACTACGGC CTTTAA..................................................................................................
b - u g d l 5 TCCGCCAGCA GTACTACGGC CTTTAA..................................................................................................
b - g 7 1 TCCGCCAGCA GTACTACGGC CTTTAA..................................................................................................
b - g 9 1 TCCGCCAGCA GTACTACGGC CTTTAA..................................................................................................
c - g k l 7 TCTGTCAGCA GTACTACAGG c t t t a g ..............................................................................
c - i a p 3 TCTGTCAGCA GTACTACAGG CTTTAG..................................................................................................
c - e r l a TCTGTCAGCA GTACTACAGG CTTTAG..................................................................................................
c - i c a m l TCTGTCAGCA GTACTACAGG CTTTAC..................................................................................................
c - u k m a l TCTGTCAGCA GTACTACAGG CTTTAG.................................................................................................
c - i a p 2 TCTGTCAGCA GTACTACAGG CTTTAG.................................................................................................
c - b b g l TCTGTCAGCA GTACTACAGG CTTTAG.................................................................................................
c -u k m a 8 TCTGTCAGCA GTACTACAGG CTTTAG..................................................................................................
c - b c 2 TCTGTCAGCA GTACTACAGG CTTTAG.................................................................................................
c -u k m a 3 TCTGTCAGCA GTACTACAGG CTTTAG.................................................................................................
c - i v e l TCTGTCAGCA GTACTACAGG CTTTAG..................................................................................................
c - u k b 2 2 TCTGTCAGCA GTACTACAGG CTTTAG........................... .. ..................... .. ...........................................
c - g k l 8 TCTGTCAGCA GTACTACAGG CTTTAG.................................................................................................
c - k l - 8 - d e m TCTGTCAGCA GTACTACAGG CTTTGG.................................................................................................
c - u g d 2 3 TCTGTCAGCA GTACTACAGG CTTTGG.................................................................................................
a - u g d l 6 TCTGTCAGCA GTACTACAGG CTTTAG..................................................................................................
a - u g d l 8 TCTGTCAGCA GTACTACAGG CTTTAG..................................................................................................
a -u g d 2 4 TCTGTCAGCA GTACTACAGG CTTTAG..................................................................................................
a - u g 3 7 4 TCTGTCAGCA GTACTACAGG CTTTAG..................................................................................................
a - u g d 4 TCTGTCAGCA GTACTACAGG CTTTAG..................................................................................................
a - b c b l l TCTGTCAGCA GTACTACAGG CTTTAG..................................................................................................
a - u k a l 3 TCTGTCAGCA GTACTACAGG CTTTAG..................................................................................................
a - u k a 2 1 TCTGTCAGCA GTACTACAGG CTTTAG.................................................................................................
a -u k rn a 4 TCTGTCAGCA GTACTACAGG CTTTAG.................................................................................................
a - b c l TCTGTCAGCA GTACTACAGG CTTTAG.................................................................................................
a -e m a 7 TCTGTCAGCA GTACTACAGG CTTTAG.................................................................................................
a - b c b l r TCTGTCAGCA GTACTACAGG CTTTAG..................................................................................................
a - u k b l 2 TCTGTCAGCA GTACTACAGG CTTTAG.................................................................................................
a - u g l l l TCTGTCAGCA GTACTACAGG CTTTAG.................................................................................................
a - i a p l TCTGTTAGCA GTACTACAGG CTTTAG..................................................................................................
a - u k c l 2 TCTGTCAGCA GTACTACAGG CTTTAG..................................................................................................
c - k l - 4 3 - b e r TCTGTCAGTA GTACTACAGG CTTTAG..................................................................................................
a - u g d l 2 TCTGTCAGCA GTACTA____
C o n s e n s u s TC-------AG-A GT-CTA-------
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d l - t k s l O TTTACAACAT TCAGTACTAA TAGATTAGTG AACATAATCC CTGCAACCAC ACATGCTGTA
d 2 - z k s 3 ...........AACAT TCAGTACTAA TAGATTAGTG AACATAATCC CTGCAACCAC ACATGCTGTA
b - u g d l ...........AATGT CAAGAACTAA TGGATTACTG AAAATAATCC CTGCAACCAC ACATGCTGCA
b -u g d 2 6 ...........AATGT CAAGAACTAA TGGATTACTG AAAATAATCC CTGCAACCAC ACATGCTGCA
b - u g d l 9 ...........AATGT CAAGAACTAA TGGATTACTG AAAATAATCC CTGCAACCAC ACATGCTGCA
b - u g d 7 ...........AATGT CAAGAACTAA TGGATTACTG AAAATAATCC CTGCAACCAC ACATGCTGCA
b -u g d 2 ...........AATGT CAAGAACTAA TGGATTACTG AAAATAATCC CTGCAACCAC ACATGCTGCA
b -u g d 2 1 ...........AATGT CAAGAACTAA TGGATTACTG AAAATAATCC CTGCAACCAC ACATGCTGCA
b -u g d lO ...........ACTAT TAAGAACTAA TGGATTACTG AAAATAATCC CTGCAACCAC ACATGCTGCA
b -u k m a 2 4 ...........AGTAT TAAGAACTAA TGGATTACTG AAAATAATCC CTGCAACCAC ACATGCTGCA
b - u g d 2 9 ...........AGTAT TAAGAACTAA TGGATTACTG AAAATAATCC CTGCAACCAC ACATGCTGCA
b -u g 5 2 ...........AATGT CAAGAACTAA TGGATTACTG AAAATAATCC CTGCAACCAC ACATGCTGCA
b -g 4 1 3 ...........AACAT TAAGAACTAA TGGATTACTG AAAATAATCC CTGCAACCAC ACATGCTGCA
b - g 4 8 2 ...........AACAT TAAGAACTAA TGGATTACTG AAAATAATCC CTGCAACCAC ACATGCTGCA
b - u g d l 3 ...........AACAT TAAGAACTAA TGGATTACTG AAAATAATCC CTGCAACCAC ACATGCTGCA
b -u g d 3 ...........AACAT TAACAACTAA TGGATTACTG AAAATAATCC CTGCAACCAC ACATGCTGCA
b - u g d l 5 ...........AACAT TAACAACTAA TGGATTACTG AAAATAATCC CTGCAACCAC ACATGCTGCA
b - g 7 1 ...........AAAAT TAAGAAATAA TGGATTACTG AAAATAATCC CTGCAACCAC ACATGCTGCA
b - g 9 1 ...........AACAT TAAGAACTAA TGGATTACTG AAAATAATCC CTGCAACCAC ACATGCTGCA
c - g k l 7 ...........AACAT TCAGTACTCA TAG................ ................... CC ATACAACCAC ACATGCTGTA
c - i a p 3 ...........AACAT TCAGTACTCA TAG................ ................... CC ATACAACCAC ACATGCTGTA
c - e r l a ...........AACAT TCAGTACTAA TAG................ ................... AC GTGGAACCAC ACTTGATGTA
c - i c a m l ...........AACAT TCAGTACTAA TAG................ ................... AC GTGGAACCAC ACTTGATGTA
c - u k m a l ...........AACAT TCAGTACTAA TAG................ ................... AC ATGCAGCCAC ACATGATATA
c - i a p 2 ...........AACAT TCAGTACTAA TAG................ ................... CC ATACAACCGC ACATAATGTA
c - b b g l ...........AACAT TCAGTACTAA TAG................ ................... CC ATGCAACCAA ACATGATGTA
c -u k m a 8 ...........AACAT TCAGTACTAA TAG................ ................... CC ATGCAACCAA ACATGATGTA
c - b c 2 ...........AACAT TCAGTACTAA TAG................ ................... CG CTGCAACCAC ACATGATGTA
c -u k m a 3 ...........AACAT TCAGTACTAA TAG................ ................... CG ATGCAACCAC ACATGATATA
c - i v e l ...........AACAT TCAGTACTAA TAG................ ................... CC ATGCAACCAC ACATGATGAA
c - u k b 2 2 ........... AACAT TCAGTACTAA TAG................ ................... CC ATGCAACCAC ACATGATGTA
c - g k l 8 ........... AACAT T ...................... . TGCAACCGC ACCTACTCTA
c - k l - 8 - d e m ...........AACAT TCAGTACTCA TAGATTAGTG AACAGAATCC ATGCAACCAC ACATGATGTA
c - u g d 2 3 ...........AACAT TGAGTACTCA TAGCTTAGTG AACAGAATCC ATGCAACCAC ACATGATGTA
a - u g d l 6 ...........AACAG TCAGTACTAA TAGCTTAGTG AACATAATCC ATGCAACCAA CCATGATGTA
a - u g d l 8 ...........AACAG TCAGTACTAA TAGCTTAGTG AACATAATCC ATGCAACCAA CCATGATGTA
a -u g d 2 4 ...........AACAG TCAGTACTAA TAGCTTAGTG AACATAATCC ATGCAACCAC ACATGATGTA
a - u g 3 7 4 ...........AACAT TCAGTACTAA TAGCTTAGTG AACATAATCC ATGCAACCAC ACATGATGTA
a - u g d 4 ........... AAATT TAAGTACTCA TAGCTTAGTG AACATAATCC ATGCAACCAC ACATCATGTA
a - b c b l l ...........AACAT TCAGTACTAA TAGCTTAGTG AACATAATCC ATGCAACCAC ACATAAAGTA
a - u k a l 3 ...........AACAT TCAGTACTAA TAGGTTAGTG AACATAATCC ATGCAACCAC ACATGATGTA
a - u k a 2 1 ...........AACAT TCAGTACTAA TAGGTTAGTG AACATAATCC ATGCAACCAC ACATGATGTA
a -u k m a 4 ...........AACAT TCAGTACTAA TAGGTTAGTG AACATAATCC ATGCAACCAC ACATGATGTA
a - b c l ...........AACAT TGAGTACTAA TAGCTTAGTG AAGATAATCC ATGCAACCAC ACGTGATGTA
a -e m a 7 ........... AACAT TGAGTACTAA TAGCTTAGTG AACATAATCC ATGCAACCAC ACATGATGTA
a - b c b l r ...........AACAT TCAGTACTAA TAGCTTAGTG AACATAATCC ATGCAACCAC ACATGATGTA
a - u k b l 2 ........... AACAT TCAGTACTAA TAGCTTAGTG AACATAATCC ATGCAACCAC ACATGATGTA
a - u g l l l ........... AACAT TCAGTACTAA TAGCTTAGTG AACATAATCC ATGCAACCAC ACATAATGTA
a - i a p l ........... AACAT TCAGTACTAA TAGCTTAGTG AACATAATCC ATGCAACCAC ACATGATGCA
a - u k c l 2 ...........AACAT TCAGTACTAA TAGCTTAGTG AACATAATCC ATG................. ...........ATGTA
c - k l - 4 3 - b e r ........... AACAT TCAGTACTAA TAGCATAGTG AACATAACCC ATGCAACCAC ACGTGCTGTA
a - u g d l 2 . . . . TAATCC ATGCAACCAC ACATGATGTA
C o n s e n s u s - T --------------- -----------------A
d l - t k s l O
661
GTTGTAGTGG AAAAAGTAAA ATCTCTACAT CCACATATTG AAGTGCCTTT
720
TCTTGTATTT
d 2 - z k s 3 GTTGTAGTGG AAGAACTAAA ATCTAGAAAT CCATATATTA AAGTGCATTT TCTTATATTA
b - u g d l GTTGCAGTGG AAGAAGTAAA ATCTACAAAT CCACATATTC AAGTGCCTTT TCTTGTATTT
b -u g d 2 6 GTTGCAGTGG AAGAAGTAAA ATCTACAAAT CCACATATTC AAGTGCCTTT TCTTGTATTT
b - u g d l 9 GTTGCAGTGG AAGAAGTAAA ATCTACAAAT CCACATATTC AAGTGCCTTT TCTTGTATTT
b - u g d 7 GTTGCAGTGG AAGAAGTAAA ATCTACAAAT CCACATATTC AAGTGCCTTT TCTTGTATTT
b -u g d 2 GTTGCAGTGG AAGAAGTAAA ATCTACAAAT CCACATATTC AAGTGCCTTT TCTTGTATTT
b -u g d 2 1 GTTGCAGTGG AAGAAGTAAA ATCTACAAAT CCACATATTC AAGTGCCTTT TCTTGTATTT
b -u g d lO GTTGCAGTGG AAGAAGTAAA ATCTACAAAT ACACATATTC AAGTGCCTTT TCTTGTATTT
b -u k m a 2 4 GTTGCAGTGG AAGAAGTAAA ATCTACAAAT ACACATATTC AAGTGCCTTT TCTTGTATTT
b -u g d 2 9 GTTGCAGTGG AAGAAGTAAA ATCTACAAAT ACACATATTC AAGTGCCTTT TCTTGTATTT
b - u g 5 2 GTTGCAGTGG AAGAAGTAAA ATCTACAAAT CCACATATTC AAGTGCCTTT TCTTGTATTT
b -g 4 1 3 GTTGCAGTGG AAGAAGTAAA ATCTACAAAT CCACATATTC AAGTGCCTTT TCTTGTATTT
b -g 4 8 2 GTTGCAGTGG AAGAAGTAAA ATCTACAAAT CCACATATTC AAGTGCCTTT TCTTGTATTT
b - u g d l 3 GTTGCAGTGG AAGAAGTAAA ATCTACAAAT CCACATATTC AAGTGCCTTT TCTTGTATTT
b -u g d 3 GTTGCAGTGG AAGAAGTAAA ATCTACAAAT CCACATATTC AAGTGCCTTT TCTTGTATTT
b - u g d l 5 GTTGCAGTGG AAGAAGTAAA ATCTACAAAT CCACATATTC AAGTGCCTTT TCTTGTATTT
b - g 7 1 GTTGCAGTGG AAGAAGTAAA ATCTACAAAT CCACATATTC AAGTGCCTTT TCTTGTATTT
b - g 9 1 GTTGCAGTGG AAGAAGTAAA ATCTACAAAT CCACATATTC AAGTGCCTTT TCTTGTATTT
c - g k l 7 GTTGTAGTGA AAGAAGCAAA ATTTACAAAT CCACATATTG AAGTGCCTTT TCTTGTATTT
c - i a p 3 GTTGTAGTGA AAGAAGCAAA ATTTACAAAT CCACATATTG AAGTGCCTTT TCTTGTATTT
c - e r l a CTTGTAATGA AAGAAGCAAA ATCTACAAAT CTACATATTC AAGTGCATTT TCTTGTATTT
c - i c a m l CTTGTAATGA AAGAAGCAAA ATCTACAAAT CTACATATTC AAGTGCATTT TCTTGTATTT
c - u k m a l CTTGTAATGA AAGAAGCAAA ATCTACAAAT CTACATATTC AAGTGCATTT TCTTGTATTT
c - i a p 2 CTTGTAATGA AAGAAGCAAA ATCTACAAAT CTACATATTC AAGTGCATTC TCTTGTATTT
c - b b g l GTTGTAGTAA AAGAAGCAAA ATTTACAAAT CCACATATTG AAGTGCCTTT TCTTGTATTT
c -u k m a 8 GTTGTAGTGA AAGAAGCAAA ATTTACAAAT CCACATATTG AAGTGCCTTT TCTTGTATTT
c - b c 2 CTTGTAATGA AAGAAGCCAA ATCTACAAAT CTACATATTC AAGTGCATTT TATTGTATTT
c -u k in a 3 CTTGTAATGA AAGAAGCCAA ATCTACAAAT CTACATATTC AAGTGCATTT TCTTGTATTT
c - i v e l CTTGTAATGA AAGAAGCCAA ATCTACAAAT CTACATATTC AAGTGCATTT TCTTGTATTT
c -u k b 2 2 CTTGTAATGA AAGAAGCCAA ATCTACAAAT CTACCTATTC AAGTGCATTT TTTTGTATTT
c - g k l 8 TTTGTAATGA AAGAAGTAAA ATCTACATAT CTATATATTC AAGAGCATTT GCTTGTATTT
c - k l - 8 - d e m GTTGTAGTGA AAGAAGCAAA ATCTACAAAT CCACATATTG AAGTGCCTTT TCTTGTATTT
c -u g d 2 3 GTTGTAGTGA AAGAAGCAAA ATCTACAAAT CCACATATTG AAGTGCCTTT TCTTGTATTT
a - u g d l 6 GTTGTAGTGA AAGAAGCAAA ATCTACAAAT CCACATATTG AAGTGCCTTT TCTTGTATTT
a - u g d l 8 GTTGTAGTGA AAGAAGCAAA ATCTACAAAT CCACATATTG AAGTGCCTTT TCTTGTATTT
a -u g d 2 4 GTTGTAGTGA AAGAAGCAAA ATCTACAAAT CCACATATTG AAGTGCCTTT TCTTGTATTT
a -u g 3 7 4 GTTGTAGTGA AAGAAGCAAA ATCTACAAAT CCACATATTG AAGTGCCTTT TCTTGTATTT
a - u g d 4 GTTGTAGTGA AAGAAGCAAA ATCTACAAAT CCACATATTG AAGTGCCTTT TCTTGTATTT
a - b c b l l GTTGTAGTGA AAGAAGCAAA ATCTACAAAT TCACATATTG AAGTGCATTT TCTTGTATTT
a - u k a l 3 GTTGTACTGA AAGAAGCAAA ATCTACACGT TTTCATATTG AACTGCATTT TCTTGTATTT
a - u k a 2 1 GTTGTACTGA AAGAAGCAAA ATCTACACGT TTTCATATTG AACTGCATTT TCTTGTATTT
a -u k m a 4 GTTGTACTGA AAGAAGCAAA ATCTATACGT TTTCATATTG AACTGCATTT TCTTGTATTT
a - b c l GTTGTAGTGA AAGAAGCAAA ATCTACACAT TTTCATATTG AAGTGCATTT TCTTGTATTT
a -e m a 7 GTTGTAGTGA AAGAAGCAAA ATCTACACAT TTTCATATTG AACTGCATTT TCTTGTATTT
a - b c b l r GTTGTAGTGA AAGAAGCAAA ATCTACACAT TTTCATATTG AACTGCATTT TCTTGTATTT
a - u k b l 2 GTTGCAGTGA AAGAAGCAAA ATCTACACAT TTTCATATTG AACTGCATTT TCTTGTATTT
a - u g l l l GTTGTAGTGA AAGAAGCAAA ATCTACACAT TTTCATATTG AACTGCATTT TCTTGTATTT
a - i a p l GTTGTAGTGA AAGAAGCAAA ATCTACACGT TTTCATATTG AAGTGCATTT TCTTGTATTT
a - u k c l 2 GTTGTAGTGA AAGAAGCAAA ATCTACACAT TTTCATATTG AACTGCATTT TCTTGTATTT
c - k l - 4 3 - b e r GTTGTAGTGA AAGAAGCAAA ATCTACAAAT CCACATATTG AAGTGCCTTT TCTTGTATTT
a - u g d l 2 GTTGTAGTGA AAGAAGCAAA ATCTACAAAT CCACATATTG AAGTGCCTTT TCTTGTATTT
C o n s e n s u s -T T G -A -T -- AA-AA-----AA A T - T - -A - -T ---------TATT- A A --G C -T T - - -TT -T A T T -
d l - t k s l O
721
ATGACACTCG TAGCTCTGAT AGGAACCATG TGTGGTATCT TAGGAACTAT
780
TATCTTTGCC
d 2 - z k s 3 ATGACGCTGG TAGCTCTGAT AGGAACCATG TGTGGTATCT TAGGAACTAT TATCTTTGCC
b - u g d l ATGACGCTCG TAGCTCTGAT AGGAACCATG TGTGGTATCT TAGGAACTCT TATCTTTACC
b -u g d 2 6 ATGACGCTCG TAGCTCTGAT AGGAACCATG TGTGGTATCT TAGGAACTCT TATCTTTACC
b - u g d l 9 ATGACGCTCG TAGCTCTGAT AGGAACCATG TGTGGTATCT TAGGAACTCT TATCTTTACC
b - u g d 7 ATGACGCTCG TAGCTCTGAT AGGAACCATG TGTGGTATCT TAGGAACTCT TATCTTTACC
b -u g d 2 ATGACGCTCG TAGCTCTGAT AGGAACCATG TGTGGTATCT TAGGAACTCT TATCTTTACC
b -u g d 2 1 ATGACGCTCG TAGCTCTGAT AGGAACCATG TGTGGTATCT TAGGAACTCT TATCTTTACC
b -u g d lO ATGACGCTCG TAGCTCTGAT AGGAACCATG TGTGGTATCT TAGGAACTCT TATCTTTACC
b -u k m a 2 4 ATGACGCTCG TAGCTCTGAT AGGAACCATG TGTGGTATCT TAGGAACTCT TATCTTTACC
b -u g d 2 9 ATGACGCTCG TAGCTCTGAT AGGAACCATG TGTGGTATCT TAGGAACTCT TATCTTTACC
b -u g 5 2 ATGACGCTCG TAGCTCTGAT AGGAACCATG TGTGGTATCT TAGGAACTCT TATCTTTACC
b -g 4 1 3 ATGACGCTCG TAGCTCTGAT AGGAACCATG TGTGGTATCT TAGGAACTGT TATCTTTACC
b -g 4 8 2 ATCACGCTCG TAGCTCTGAT AGGAACCATG TGTGGTATCT TAGGAGCTGT TATCTTTACC
b - u g d l 3 ATGACGCTCG TAGCTCTGAT AGGAACCATG TGTGGTATCT TAGGAACTGT TATCTTTACC
b -u g d 3 ATGACGCTCG TAGCTCTGAT AGGAACCATG TGTGGTATCT TAGGAACTGT TATCTTTACC
b - u g d l 5 ATGACGCTCG TAGCTCTGAT AGGAACCATG TGTGGTATCT TAGGAACTGT TATCTTTACC
b - g 7 1 ATGACGCTCG TAGCTCTGAT AGGAACCATG TGTGGTATCT TAGGAACTGT TATCTTTACC
b - g 9 1 ATGACGCTCG TAGCTCTCAT AGGAACCATG TGTGGTATCT TCGGAACTCT TATCTTTGCC
c - g k l 7 ATGACACTCG TAGCTCTGAT AGGAACCATG TGTGGTATCT TAGGAACTAT TATCTTTGCC
c - i a p 3 ATGACACTCG TAGCTCTGAT AGGAACCATG TGTGGTATCT TAGGAACTAT TATCTTTGCC
c - e r l a ATGACACTCG TAGCTCTGAT AGGAACCATG TGTGGTATCT TAGGAACTAT TATCTTTGCC
c - i c a m l ATGACACTCG TAGCTCTGAT AGGAACCATG TGTGGTATCT TAGGAACTAT TATCTTTGCC
c - u k m a l ATGACACTCG TAGCTCTGAT AGGAACCATG TGTGGTATCT TAGGAACTAT TATCTTTGCC
c - i a p 2 ATGACACTCG TAGCTCTGAT AGGAACCATG TGTGGTATCT TAGGAACTAT TATCTTTGCC
c - b b g l ATGACACTCG TAGCTCTAAT AGGAACCATG TGTGGTATCT TAGGAACTAT TATCTTTGCC
c-u k in a 8 ATGACACTCG TAGCTCTAAT AGGAACCATG TGTGGTATCT TAGGAACTAT TATCTTTGCC
c - b c 2 ATGACACTCG TAGCTCTGAT AGGAACCATG TGTGGTATCT TAGGAACTAT TATCTTTGCC
c -u k m a 3 ATGACACTCG TAGCTCTGAT AGGAACCATG TGTGGTATCT TAGGAACTAT TATCTTTGCC
c - i v e l ATGACACTCG TAGCTCTGAT AGGAACCATG TGTGGTATCT TAGGAACTAT TATCTTTGCC
c - u k b 2 2 ATGACACTCG TAGCTCTGAT AGGAACCATG TGTGGTATCT TAGGAACTAT TATCTTTGCC
c - g k l 8 ATGACACTCG TAGCTCTGAT AGGAACCATG TGTGGTATCT TAGGAACTAT TATCTTTGCC
c - k l - 8 - d e r a ATGACACTCG TAGCTCTGAT AGGAACCATG TGTGGTATCT TAGGAACTAT TATCTTTGCC
c - u g d 2 3 ATGACACTCG TAGCTCTGAT AGGAACCATG TGTGGTATCT TAGGAACTAT TATCTTTGCC
a - u g d l 6 ATGACACTCG TAGCTCTGAT AGGAACCATG TGTGGTATCT TAGGAACTAT TATCTTTGCC
a - u g d l 8 ATGACACTCG TAGCTCTGAT AGGAACCATG TGTGGTATCT TAGGAACTAT TATCTTTGCC
a -u g d 2 4 ATGACACTCG TAGCTCTGAT AGGAACCATG TGTGGTATCT TAGGAACTAT TATCTTTGCC
a -u g 3 7 4 ATGACACTCG TAGCTCTGAT AGGAACCATG TGTGGTATCT TAGGAACTAT TATCTTTGCC
a - u g d 4 ATGACACTCG TAGCTCTGAT AGGAACCATG TGTGGTATCT TAGGAACTAT TATCTTTGCC
a - b c b l l ATGACACTCG TAGCTCTGAT AGGAACCATG TGTGGTATCT TAGGAACTAT TATCTTTGCC
a - u k a l 3 ATGACACTCG TAGCTCTGAT AGGAACCATG TGTGGTATCG TAGGAACTAT TATCTTTTTC
a - u k a 2 1 ATGACACTCG TAGCTCTGAT AGGAACCATG TGTGGTATCG TAGGAACTAT TATCTTTTTC
a -u k m a 4 ATGACACTCG TAGCTCTGAT AGGAACCATG TGTGGTATCG TAGGAACTAT TATCTTTTTC
a - b c l ATGACACTCG TAGCTCTGAT AGGAACCATG TGTGGTATCT TAGGAACTAT TATCTTTGCC
a -e m a 7 ATGACACTCG TAGCTCTGAT AGGAACCGTG TGTGGTATCT TAGGAACTAT TATCTTTGCC
a - b c b l r ATGACACTCG TAGCTCTGAT AGGAACCATG TGTGGTATCT TAGGAACTAT TATCTTTGCC
a - u k b l 2 ATGACACTCG TAGCTCTGAT AGGAACCATG TGTGGTATCT TGGGAACTAT TATCTTTGCC
a - u g l l l ATGACACTCG TAGCTCTGAT AGGAACCATG TGTGGTATCT TAGGAACTAT TATCTTTGCC
a - i a p l ATGACACTCG TAGCTCTGAT AGGAACCATG TGTGGTATCT TAGGAACTAT TATCTTTGCC
a - u k c l 2 ATGACACTCG TAGCTCTGAT AGGAACCATG TGTGGTATCT TAGGAACTAT TATCTTTGCC
c - k l - 4 3 - b e r ATGACACTCG TAGCTCTGAT AGGAACCATG TGTGGTATCT TAGGAACTAT TATCTTTGCC
a - u g d l 2 ATGACACTCG TAGCTCTGAT AGGAACCATG TGTGGTATCT TAGGAACTAT TATCTTTGCC
C o n s e n s u s A T-AC-CT-G TAGCTCT-AT AGGAACC-TG TGTGGTATC- T-G G A -C T-T TATCTTT--C
d l - t k s l O
781
CATTGTCAAA AACAAAGTGA CTCAAACAAA ACAGTGCAAC AACAATTGCG
840
GGATTATTAT
d 2 - z k s 3 CGTTGTCAAA AACAAAGTGA CTCAAACAAA ACAGTGCCAC AACAATTGCG GGATTATTAT
b - u g d l CATTGTCAAA AAAAAAGTGA CTCAAGCAAA ACAGGGCAAC AACAATTGCG GGATTATTAT
b - u g d 2 6 CATTGTCAAA AAAAAAGTGA CTCAAGCAAA ACAGGGCAAC AACAATTGCG GGATTATTAT
b - u g d l 9 CATTGTCAAA AAAAAAGTGA CTCAAGCAAA ACAGGGCAAC AACAATTGCG GGATTATTAT
b -u g d 7 CATTGTCAAA AAAAAAGTGA CTCAAGCAAA ACAGGGCAAC AACAATTGCG GGATTATTAT
b -u g d 2 CATTGTCAAA AAAAAAGTGA CTCAAGCAAA ACAGGGCAAC AACAATTGCG GGATTATTAT
b -u g d 2 1 CATTGTCAAA AAAAAAGTGA CTCAAGCAAA ACAGGGCAAC AACAATTGCG GGATTATTAT
b -u g d lO CATTGTCAAA AAAAAAGTGA CTCAAGCAAA ACAGGGCAAC AACAATTGCG GGATTATTAT
b -u k m a 2 4 CATTGTCAAA AAAAAAGTGA CTCAAGCAAA ACAGGGCAAC AACAATTGCG GGATTATTAT
b -u g d 2 9 CATTGTCAAA AAAAAAGTGA CTCAAGCAAA ACAGGGCAAC AACAATTGCG GGATTATTAT
b -u g 5 2 CATTGTCAAA AAAAAAGTGA CTCAAGCAAA ACAGGGCAAC AACAATTGCG GGATTATTAT
b -g 4 1 3 CATTGTCAAA AAAAAAGTGA CTCAAGCAAA ACAGGGCAAC AACAATTGCG GGATTATTAT
b -g 4 8 2 CATTGTCAAA AAAAAAGTGA CTCAAGCAAA ACAGGGCAAC AACAATTGCG GGATTATTAT
b - u g d l 3 CATTGTCAAA AAAAAAGTGA CTCAAGCAAA ACAGGGCAAC AACAATTGCG GGGTTATTAT
b -u g d 3 CATTGTCAAA AAAAAAGTGA CTCAAGCAAA ACAGGGCAAC AACAATTGCG GGGTTATTAT
b - u g d l 5 CATTGTCAAA AAAAAAGTGA CTCAAGCAAA ACAGGGCAAC AACAATTGCG GGATTATTAT
b - g 7 1 CATTGTCAAA AAAAAAGTGA CTCAAGCAAA ACAGGGCAAC AACAATTGCC GGATTATTAT
b -g '9 1 CATTGTCAAA AACAAAGTGA CTCAAGCAAC ACAGGGCAAC AACAATTGCG GGATTATTAT
c - g k l 7 CATTGTCAAA AACAAAGTGA CTCAAACAAA ACAGTGCCAC AACAATTGCG GGATTATTAT
c - i a p 3 CATTGTCAAA AACAAAGTGA CTCAAACAAA ACAGTGCCAC AACAATTGCG GGATTATTAT
c - e r l a CATTGTCAAA AACAACGTGA CTCAAACAAA ACAGTGCCAC AACAATTGCA GGATTATTAT
c - i c a m l CATTGTCAAA AACAACGTGA CTCAAACAAA ACAGTGCCAC AACAATTGCA GGATTATTAT
c - u k m a l CATTGTCAAA AACAACGTGA CTCAAACAAA ACAGTGCCAC AACAATTGCA GGATTATTAT
c - i a p 2 CATTGTCAAA AACAACGTGA CTCAAACAAA ACAGTGCCAC AACAATTGCA GGATTATTAT
c - b b g l CATTGTCAAA AACAAAGTGA CTCAAACAAA ACAGTGCCAC AACAATTGCG GGATTATTAT
c -u k m a 8 CATTGTCAAA AACAAAGTGA CTCAAACAAA ACAGTGCCAC AACAATTGCG GGATTATTAT
c - b c 2 CATTGTCAAA AACAACGTGA CTCAAACAAA ACAGTGCCAC AACAATTGCA GGATTATTAT
c -u k m a 3 CATTGTCAAA AACAAAGTGA CTCAAACAAA ACAGTGCCAC AACAATTGCG GGATTATTAT
c - i v e l CATTGTCAAA AACAAAGTGA CTCAAACAAA ACAGTGCCAC AACAATTGCG GGATTATTAT
c - u k b 2 2 CATTGTCAAA AACAAAGTGA CTCAAACAAA ACAGTGCCAC AACAATTGCG GGATTATTAT
c - g k l 8 CATTGTCAAA AACAACGTGA CTCAAACAAA ACAGTGCCAC AACAATTGCA GGATTATTAT
c - k l - 8 - d e m CATTGTCAAA AACAAAGTGA CTCAAAAAAA ACAGTGCCAC AACAATTGCG GGATTATTAT
c -u g d 2 3 CATTGTCAAA AACAAAGTGA CTCAAACAAA ACAGTGCCAC AACAATTGCG GGATTATTAT
a - u g d l 6 CATTGTCAAA AACAACGTGA CTCAAACAAA ACAGTGCCAC AACAATTGCA GGATTATTAT
a - u g d l 8 CATTGTCAAA AACAACGTGA CTCAAACAAA ACAGTGCCAC AACAATTGCA GGATTATTAT
a -u g d 2 4 CATTGTCAAA AACAACGTGA CTCAAACAAA ACAGTGCCAC AACAATTGCA GGATTATTAT
a -u g 3 7 4 CATTGTCAAA AACAACGTGA CTCAAACAAA ACAGTGCCAC AACAATTGCA GGATTATTAT
a - u g d 4 CATTGTCAAA AACAACGTGA CTCAAACAAA ACAGTGCCAC AACAATTGCA GGATTATTAT
a - b c b l l CATTGTCAAA AACAACGTGA CTCAAACAAA ACAGTGCCAC AACAATTGCA GGATTATTAT
a - u k a l 3 CATTGTCAAA AACAACGTGA CTCAAACAAA ACAGTGCCAC AACAATTGCA GGATTATTAT
a - u k a 2 1 CATTGTCAAA AACAACGTGA CTCAAACAAA ACAGTGCCAC AACAATTGCA GGATTATTAT
a -u k m a 4 CATTGTCAAA AACAACGTGA CTCAAACAAA ACAGTGCCAC AACAATTGCA GGATTATTAT
a - b c l CATTGTCAAA AACAACGTGA CTCAAACAAA ACAGTGCCAC AACAATTGCA GGATTATTAT
a -e m a 7 CATTGTCAAA AACAACGTGA CTCAAACAAA ACAGTGCCAC AACAATTGCA GGATTATTAT
a - b c b l r CATTGTCAAA AACAACGTGA CTCAAACAAA ACAGTGCCAC AACAATTGCA GGATTATTAT
a - u k b l 2 CATTGTCAAA AACAACGTGA CTCAAACAAA ACAGTGCCAC AACAATTGCA GGATTATTAT
a - u g l l l CATTGTCGAA AACAACGTGA CTCAAACAAA CCAGTGCCAC AACAATTGCA GGATTATTAT
a - i a p l CATTGTCAAA AACAACGTGA CTCAAACAAA ACAGTGCCAC AACAATTGCA GGATTATTAT
a - u k c l 2 CATTGTCAAA AACAACGTGA CTCAAACAAA ACAGTGCCAC AACAATTGCA GGATTATCAT
c - k l - 4 3 - b e r CATTGTCAAA AACAAAGTGA CTCAAACAAA ACAGTGCCAC AACAATTGCG GGATTATTAT
a - u g d l 2 CATTGTCAAA AACAACGTGA CTCAAACAAA ACAGTGCCAC AACAATTGCA GGATTATTAT
C o n s e n s u s C-TTGTC-AA AA-AA-GTGA CTCAA--AA- -CAG-GC-AC AACAATTGC- GG-TTAT-AT
841 879
d l - t k s l O TCCCTACACG ATTTTAACAC GGAAGACTAT ACGCAACCA
d 2 - z k s 3 TCCCTACACG ATTTTATCAC GGAAGACTAT ATGCAACCA
b - u g d l TCCCTAGACT ATTTTCACAC GGAAGAGTAT ACGCAACCA
b - u g d 2 6 TCCCTAGACT ATTTTCACAC GGAAGAGTAT ACGCAACCA
b - u g d l 9 TCCCTAGACT ATTTTCACAC GGAAGAGTAT ACGCAACCA
b - u g d 7 TCCCTAGACT ATTTTCACAC GGAAGAGTAT ACGCAACCA
b -u g d 2 TCCCTAGACT ATTTTCACAC GGAAGAGTAT ACGCAACCA
b - u g d 2 1 TCCCTAGACT ATTTTCACAC GGAAGAGTAT ACGCAACCA
b -u g d lO TCCCTAGACT ATTTTCACAC GGAAGACTAT ACGCAACCA
b -u k m a 2 4 TCCCTAGACT ATTTTCACAC GGAAGACTAT ACGCAACCA
b -u g d 2 9 TCCCTAGACT ATTTTCACAC GGAAGACTAT ACGCAACCA
b -u g 5 2 TCCCTAGACT ATTTTCACAC GGAAGACTAT ACGCAACCA
b -g 4 1 3 TCCCTAGACT ATTTTCACAC GGAAGACTAT ACGCAACCA
b -g 4 8 2 TCCCTAGACT ATTTTCACAC GGAAGACTAT ACGCAACCA
b - u g d l 3 TCCCTAGACT ATTTTCACAC GGAAGAGTAT ACACAACCA
b -u g d 3 TCCCTAGACT ATTTTCACAC GGAAGAGTAT ACACAACCA
b - u g d l 5 TCCCTAGACT ATTTTCACAC GGAAGAGTAT ACACAACCA
b - g 7 1 TCCCTAGACT ATTTTCACAC GGAAGAGTAT ACACAACCA
b - g 9 1 TCCCTAGACT ATTTTCACAC GGAAGAGTAT ACGCAACCA
c - g k l 7 TCCCTACACG ATTTGTGCAC GGAAGACTAT ACGCAACCA
c - i a p 3 TCCCTACACG ATTTGTGCAC GGAAGACTAT ACGCAACCA
c - e r l a TCCCTACACG ATTTGTGCAC GGAAGACTAT ACGCAACCA
c - i c a m l TCCCTACACG ATTTGTGCAC GGAAGACTAT ACGCAACCA
c - u k m a l TCCCTACACG ATTTGTGCAC GGAAGACTAT ACGCAACCA
c - i a p 2 TCCCTACACG ATTTGTGCAC GGAAGACTAT ACGCAACCA
c - b b g l TCCCTACACG ATTTGTGCAC GGAAGACTAT ACGCAACCA
c -u k m a 8 TCCCTACACG ATTTGTGCAC GGAAGACTAT ACGCAACCA
c - b c 2 TCCCTACACG ATTTGTGCAC GGAAGACTAT ACGCAACCA
c -u k m a 3 TCCCTACACG ATTTGTGCAC GGAAGACTAT ACGCAACCA
c - i v e l TCCCTACACG ATTTGTGCAC GGAAGACTAT ACGCAACCA
c - u k b 2 2 TCCCTACACG ATTTGTGCAC GGAAGACTAT ACGCAACCA
c - g k l 8 TCCCTACACG ATTTGTGCAC GGAAGACTAT ACGCAACCA
c - k l - 8 - d e m TCCCTACACG ATTTCTGCAC GGAAGACTAT ACGCAACCA
c - u g d 2 3 TCCCTACACG At t t c TGCAC GGAAGACTAT ACGCAACCA
a - u g d l 6 TCCCTACACG ATTTGTGCAC GGAAGACTAT ACGCAACCA
a - u g d l 8 TCCCTACACG ATTTGTGCAC GGAAGACTAT ACGCAACCA
a - u g d 2 4 TCCCTACACG ATTTGTGCAC GGAAGACTAT ACGCAACCA
a - u g 3 7 4 TCCCTACACG ATTTGTGCAC GGAAGACTAT ACGCAACCA
a - u g d 4 TCCCTACACG ATTTGTGCAC GGAAGACTAT ACGCAACCA
a - b c b l l TCCCTACACG ATTTGTGCAC GGAAGACTAT ACGCAACCA
a - u k a l 3 TCCCTACACG ATTTGTGCAC GGAAGACTAT ACGCAACCA
a - u k a 2 1 TCCCTACACG ATTTGTGCAC GGAAGACTAT ACGCAACCA
a -u k m a 4 TCCCTACACG ATTTGTGCAC GGAAGACTAT ACGCAACCA
a - b c l TCCCTACACG ATTTGTGCAC GGAAGACTAT ACGCAACCA
a -e m a 7 TCCCTACACG ATTTGTGCAC GGAAGACTAT ACGCAACCA
a - b c b l r TCCCTACACG ATTTGTGCAC GGAAGACTAT ACGCAACCA
a - u k b l 2 TCCCTACACG ATTTGTGCAC GGAAGACTAT ACGCAACCA
a - u g l l l TCCCTACACG ATTTGTGCAC GGAAGACTAT ACGCAACCA
a - i a p l TCCCTACACG ATTTGTGCAC GGAAGACTAT ACGCAACCA
a - u k c l 2 TCCCTACACG ATTTGTGCAC GGAAGACTAT ACGCAACCA
c - k l - 4 3 - b e r TCCCTACACG ATTTGTGCAC GGAAGACTAT ACGCAACCA
a - u g d l 2 TCCCTACACG ATTTGTGCAC GGAAGACTAT ACGCAACCA
C o n s e n s u s TCCCTA-AC- ATTT-----CAC GGAAGA-TAT A - -CAACCA
Bb -u g d 2
1
LCSLWWFPK LLSLHLPSFP HLCPGVHFTP YTLTCPSNRS LPISWYCNGT
60
QLSRIRASTL
b -u g d 2 1 LCSLWWFPQ LLSLHLPSFP HLCPGVHFTS YTLTCPSNRS LPISWYCNGT QLWRIRENTL
b - u g d l LCCLWWFPK LLSLHLPSFP HLCPGVLFTP YTLTCPSNRS LPTSWYCNGT QLRRIRGSNL
b -u g d 2 6 LCSLWWFPK LLSLHLPSFP HLCPGVLFTP YTLTCPSNRS LPISWYCNGT QLRRIRESTL
b - u g d l 9 LCSLWWFPK LLSLHLPSFP HLCPGVLFTP YTLTCPSNRS LPISWYCNGT RLWRIRESNL
b - u g d 7 LCSLW CFPK LLSLHLPSFP HLCPGVLFTP YTLTCPSNRS LPISWYCNGT QLWRITDSTL
b -u g d lO VCSLLVCFPK LLSLHLPSFP HLCPGVISTP YTLTCPSNRS LPISWYCNGT QLHRITASNL
b -u k m a 2 4 LYGFLVCFPK LLSLHLPSFP HLCPGVISTP YTLTCPSNRS LPISWYCNGT RLHRLTASNL
b - u g d 2 9 VSSLLVCFPK LLSLHLPSFP PLCPGVISTP YTLTCPSNRF LPISWYCNGT RLHRITASNL
b -u g 5 2 VCSLAVCFPK LLSLHLPSFP HLCPGVISTP YTLTCPSTRS LSISWYCNGT RLHRITASNL
b -g 4 1 3 VCSLAVCFPK LLSLHLPSFP HLCPGVISTP YTLTCPSNRS LPISWYCNGT RLLRITASNP
b -g 4 8 2 VCSLAVCFPK LLSLHLPSFP HLCPGVLSTP YTLTCPSNRS LPISWYCNGT RLWRITASNL
b - u g d l 3 VCSLLVCFPK LLSLHLPSFP HLCPGWSTP YTLTCPSNRS LPISWYCNGT RLWRITASNL
b -u g d 3 VCSLLVCFPK LLSLHLPSFP HLCPGWSTP YTLTCPSNRS LPISWYCNGT RLWRITASNL
b - u g d l 5 VCSLLVCFPK LLSLHLPSFP HLCPGWSTP YTLTCPSNRS LPISWYCNGT RLWRITASNL
b - g 7 1 VCSLLVCFPQ LLSFNLPSFP HLCPGVISTP YTLTCPSNRS LPISWYCNGT RLWRITASNL
b - g 9 1 LCNLWCFPK LLSLHLPSFP HLCPGVISTP YTLTCPSNRS LPISWYCNGT QLLRITASNL
a - b c l VCSLAVCFRG LLSLSLLSSP NLCPGVISTP YTLTCLSNAS LPISWYCNNT RLLRLTERRV
a -e m a 7 VCSLAVCFRG LLSLSLLSSP NLCPGVISTP YNLTCLSNAS LPISWYCNNT RLLRLTERRV
a - u k a l 3 VCSLAVCFRG LLSLSLLSSP NLCPGVISTP YNLTCLSNAS LPISWYCNNT RLFRLTERTL
a - u k a 2 1 VCSLAVCFRG LLSLSLLSSP NLCPGVISTP YNLTCLSNAS LPISWYCNNT RLFRLTERTL
a -u k m a 4 VCSLAVCFRG LLSLSLLSSP NLCPGVISTP YNLTCLSNAS LPISWYCNNT RLLRLTERTL
a - b c b l r VCSLAVCFRG LLSLSLLSSP NLCPGVISTP YKLTCLSNAS LPISWYCNNT RLFRPTETTL
a - u k b l 2 VCSLAVCFRG LLSLSLLSSP NLCPGVISTP YTLTCLSNAS LPIFWYCNNT RLFRLTKTIF
a - u k c l 2 VCSLAVCFRG LLSLSLLSSP NLCPGVISTP YKLTCLSNAS LPISWYCNDT RLFRLTERTL
a - i a p l VCSLAVCFRG LLSLSLLSSP NLCPGVISTP YTLTCLSDTS LPISWYCNNT RLLRLTTKTL
a - u g l l l VCSLAVCFRG LLSLSLLSSP NLCPGVISTP YNLTCLSNAS LPISWYCNNT RLFRLTEKTL
c - k l - 8 - d e m VCSLAVCFRG LLSLYVQSSP NLCPGVISTP YTLTCPSDAT LPISWYCNDT RLFRLTQQTL
c - u g d 2 3 VCSLAVCFRG LLSLYVQSSP NLCPGVISTP YTLTCPSDAT LPISWYCNDT RLLRLTQQTF
a - u g d l 6 VCSLAVCFQG LLSLYLQSSP NLCPGVISTP YTLTCLSDAS LPISWYCNDT RLLRLTDQSF
a - u g d l 8 VCSLAVCFQG LLSLYLQSSP NLCPGVISTP YTLTCLSDAS LPISWYCNDT RLLRLTDQSF
a -u g d 2 4 VCSLAVCFQG LLSLYLQSSP NLCPGVISTP YTLTCLSDAS LPISWYCNDT RLLRLTDQSF
a - u g 3 7 4 VCSLAVCFRG LLSLYLQSSP NLCPGVISTP YTLTCLSDAS LPISWYCNDT RLWRLTDQSF
a - u g d 4 VCSLAVCFRG LLSLYLQSSP NLCPGVISTP YTLTCLSDAS LPISWYCNDT RLWRLTDQSF
a - u g d l 2 VCSLAVCFRG LLSLYLQSSP NLCPGVISTP YTLTCLSDAS LPISWYCNDT RLWRLTDQSF
a - b c b l l VCSLAVCFRG LLSLYVLSSP NLCPGVISTP YTLTCLSDSS LPISWYCNDT RLWRLTKPTL
c - g k l 7 VCSLAVCFRG LLSLYLQSSP NMCPGVISTP YTLTCPSGTS LPTSWYCNDT RLFRLTQDTF
c - i a p 3 VCSLAVCFRG LLSLYLQSSP NMCPGVISTP YTLTCPSNTS LPTSWYCNDT RLFRLTQDTF
c - b b g l VCSLAVCFRG LLSLSLQSSP NLCPGVISTP YTLTCPSNTS LPTSWYCNDT RLLRLTQQTF
c -u k m a 8 VCSLAVCFRG LLSLSLQSSP NLCPGVISTP YTLTCPSNTS LPTSWYCNDT RLLRLTQQTF
c - b c 2 VCSLAVCFRG LLSLSLQSSP NLCPGVISTP YTLTCPSNTS LPTSWYCNDT RLLRLTQQTF
c -u k m a 3 VCSLAVCFRG LLSLSLQSSP NLCPGVISTP YTLTCPSNTS LPTSWYCNDT RLLRLTQQTI
c - i v e l VGSLAVCFQG LLSLSLQSSP NLCPGVILTP YTLTCPSNTS LPTSWYCNDT RLFRLTQQTL
c - u k b 2 2 VCSLAVCFRG LLSLSLQSSP NLCPRVISTP YTLTCPSNTS LPTSWYCNDT RLFRLTQQTL
c - e r l a VCSLAVCFRG LLSLSLQSSP NLCPGVISTP YTLTCPSNTS LPTSWYCNDT RLLRLTQQTF
c - i c a m l VCSLAVCFRG LLSLSLQSSP NLCPGVISTP YTLTCPSNTS LPTSWYCNDT RLLRLTQQTF
c - u k m a l VCSLAVCFRG LLSLSLQSSP NLCPGVISTP YTLTCPSNTS LPTSWYCNDT RLFRLTQQTW
c - i a p 2 VCSLAVCFRG LLSLSLQSSP NLCPGVISTT YTLTCPSNTS LPTSWYCNDT RLFRLTQQTF
c - g k l 8 VCSLAVCFRG LLSLSLQSSP NLCPGVISTP YTLTCPSNTS LPTSWYCNDT RLLRVTQGTL
c - k l - 4 3 - b e r VCSLAVCFPG LLSLYVQSSP HLCPGVISTP YTLTCPSDAS LPISWYCNGT QLLRLTQRSV
d l - t k s l O VCSLAVCFPG LLSLHLSVSP QFCPAVLSTS YTLTCLSDAS LPISWYCNGT RLLRITGATL
d 2 - z k s 3 VCNLAVCFPG LLSLHLPAFP PLCPGVLSTN YTLTCLSDAS LPISWYCNGT LLMRYHRTTL
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b - u g d 2 1 TVSSLTGNFT CMTASGPTYS IWIEWYPTPV LQTLCAQPSN TVTCGQRVTL YCHTSSNNGT
b - u g d l TVSLLTCNFT CMTASGPTHS IWIEWYTTPV LQTLCAQPSN TVTCGQRVTL YCHTSSNNGT
b - u g d 2 6 TVSFLTCNFT CMTASGPTHS IWIEWYTTPV LQTLCAQPSN TVTCGQRVTL YCYTSSNNGT
b - u g d l 9 TVASLTGNFT CMTASGPTHS IWIEWYTTPV LQTLCAQPSN TVTCGQRVTL YCHTSSNNGT
b - u g d 7 TVSSLTGNFT CMTASGPTHS IWIEWYTTPV LQTLCAQPSN TVTCGQRVTL YCHTSSNNGT
b -u g d lO TVSSLTCNFT CMTTSGPTHS IWIQWYTQPV LQTLCAQPSN TVSCGQPVTL YCDTSSNNVT
b -u k m a 2 4 TVSSLTCNFT CMTTSGPTHS IWIEWYTQPV LQTLCAQPSN TV S CGQPVTL YCDTSSNNVT
b - u g d 2  9 TVSSLTCNFT CMTTSGPTHS IWIEWYTQPV LQTLCTQPSN TVSCGQPVTL YCDTSSNNVT
b -u g 5 2 TVSSLTCNFT CMTTSGPTHS IWIEWYTQPV LQTLCAQPSN TVSCGQPVTL YCDTSSNNVT
b -g 4 1 3 TVCSLTCNFT CMTASGPTHS IWIEWYTQPV LQTLCAQPSN TVTCGQRVTL YCHTSSNNVT
b -g 4 8 2 TVSRLTCNFT CMTRSGPTHS IWIEWYTQPV LQTSCAQPSN TVTCGQRVTS YCHTSSNNVN
b - u g d l 3 TVLSVTCNFT CMTTSGPTHS IWIEWYSQPV LQTLCAQPSN TVTCGQRVTL YCHTSSDNVT
b -u g d 3 TVLSVTCNFT CMTTSGPTHS IWIEWYSQPV LQTLCAQPSN TVTCGQRVTL YCHTSSDNVT
b - u g d l 5 TVLSVTCNFT CMTTSGPTHS IWIEWYSQPV LQTLCAQPSN TVTCGQRVTL YCHTSSDNVT
b - g 7 1 TVSSLSCNFT CMTTSGPTHS IWIEWYTQPV LQTLCAQPSN TVTCGQRVTL YCHTSSNNVT
b - g 9 1 TVSAMTCNFT CMTTSGPTHS IWIEWYTEPV LQTLCAQPSN TVTCGQRVTL YCNTSSNNVT
a - b c l ILDTIACNFT CVEQSGHRQS IWITWRAQPV LQTLCAQPSN TVTCGQHVTL YCSTSGNNVT
a -e m a 7 ILVTIACNFT CVEQSGHRQS IWITWHAQPV LQTLCAQPSN TVTCGQHVTL YCSTSGNNVT
a - u k a l 3 FSVTIACNFT CVEQSGHRQS IWITWHAQPV LQTLCAQPSN TVTCGQHVTL YCSTSGNNVT
a - u k a 2 1 FSVTIACNFT CVEQSGHRQS IWITWHAQPV LQTLCAQPSN TVTCGQHVTL YCSTSGNNVT
a -u k m a 4 FSVTIACNFT CVEQSGHRQS IWITWHAQPV LQTLCAQPSN TVTCGQHVTL YCSTSGNNVT
a - b c b l r FPVTIACNFT CVEQSGHRQS IWITWHAQPV LQTLCAQPSN TVTCGQHVTL YCSTSGNNVT
a - u k b l 2 STVTIACNFT CVEQSGHRQS IWITWHAQPV LQTLCAQPSN TVTCGQHVTL YCSTSGNNVT
a - u k c l 2 FPVTIPCNFT CVEQSGHRQS IWVTWHAQPV LQTLCAQPSN TVTCGQHVTL YCSTSGNNVT
a - i a p l YTFTMTCNFT CVEQSGHRQS IWISWHTQPV LQTLCAQPSN TVTCGQHVTL YCSTSGNNVT
a - u g l l l PGVNIACNFT CVEESGHPQN IWITWHAQPV LQTLCAQPSN TVTCGHHVTL YCSTSGNNVT
c - k l - 8 - d e m TFTNLTCNFT CVGQSGHRHS FWITWHAQPV LQTLCAQPSN TVTCAQHVTL YCSTSGNNVT
c - u g d 2 3 TFANLTCNFT CVGQSGYRHS VWITWHAQPV LQTLCAQPSN TVTCGQHVTL YCSTSGNNVT
a - u g d l 6 TVATITCNFT CVEQSGHRQS IWITWNAQPV LQTLCAQPSN TVTCGQHVTL YCSTSGNNVT
a - u g d l 8 TVATITCNFT CVEQSGHRQS IWITWNAQPV LQTLCAQPSN TVTCGQHVTL YCSTSGNNVT
a - u g d 2 4 TVATITCNFT CVEQSGHRQS IWITWNAQPV LQTLCAQPSN TVTCGQHVTL YCSTSGNNVT
a -u g 3 7 4 TVATITCNFT CVEQSGHRQS IWITWNAQPV LQTLCAQPSN TVACGQQVTL YCSTSGNNVT
a - u g d 4 TVATITCNFT CVEQSGHRQS IWITWNAQPV LQTLCAQPSN TITCGQHVTL YCSTSGNNVT
a - u g d l 2 TVANITCNFT CVEQSGHRQS IWITWNAQPV LQTLCAQPSN TVACGQQVTL YCSTSGNNVT
a - b c b l l T ID IIT C N FT CVEQSGHRQS IWITWHAQPV LQTLCAQPSN TVTCGQHVTL YCSTSGNNVT
c - g k l 7 TWNFMCNFS CVGQSGHRHS LWMAWYAPPV LQTLCGQPAN TVTCGQHVTL YCSTSGNNVT
c - i a p 3 TWNLMCNFS CVGQSGHRHS LWMAWYAP PV LQTLCGQPAN TVTCGQHVTL YCSTSGNNVT
c - b b g l TW TLICN FS CVEQSGHRHS LWITWYPQPV LQTLCGQPSN TVTCGQHVTL YCSTSGNNVT
c -u k tn a 8 TW TLICN FS CVGQSGHRHS LWITWYPQPV LQTLCGQPSN TVTCGQHVTL YCSTSGNNVT
c - b c 2 TW ALICNFS CVGQSGHRHS LWITWYPQPV LQTLCGQPSN TVTCGQHVTL YCSTSGNNVT
c -u k m a 3 TW TLICN FS CVGQSGHRHS LWITWYPQPV LQTLCGQPSN TVTCGQHVTL YCSTSGNNVT
c - i v e l TW TLICN FS CVGQSGHRHS LWITWYPQPV LQTLCGQPSN TVTCGQHVTL YCSTSGNNVT
c - u k b 2 2 TW DLICNFS CVGQSGHRHS LWITWYPQPV LQTLCGQSSN TVTCGQHVTL YCSTSGNNVT
c - e r l a TVDTLICNFS CVGQSGHRHS LWITWYPQPV LQTLCGQPSN TVTCGQHVTL YCSTSGNNVT
c - i c a m l TW ALICNFS CVGQSGHRHS LWITWYREPV LQTLCGQPSN TVTCGQHVTL YCSTSGNNVT
c - u k m a l TVHTLICNFS CVGQSGHRHS LWITWYPQPV LQTLCGQPSN TVTCGQHVTL YCSTSGNNVT
c - i a p 2 TVNTLICNFT CVGQSGHRHS LWITWYAQPV LQTFCGQPSN TVTCGQHVTL YCSTSGNNVT
c - g k l 8 TVDTLICNFS CVGQSGHRYS LWITWYAQPV LQTFCGQPSN TVTCGQHVTL YCSTSGNNVT
c - k l - 4 3 - b e r PVSTLTCNFT CVGQSGPSHS IWITWYAKPV LQTLCAQPSN TVTCGQHVPL YCSTSGNNVT
d l - t k s l O TIPSLTGNFT CVDHSGLSHS IWIQRYPPPV LQTLCAQPST TVTCGQRVSL HCSTSANTVT
d 2 - z k s 3 TLMNLAANWT CVNQSGISHS IWIQWYTEPV LQTLCAQPSN TVTCGQRVTL HCSTSASTVF
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b - u g d 2 1 IWRLQNGHNQ TVSQTKYYNF TMMNQTQGCY ICCDGLSSRL SNRICFWASC INITPETPTV
b - u g d l IWRLQNGHNQ TVSQTKYYNF TMMNQTQGCY LCSDGLSSRL SNRICFWASC INITPETPTV
b - u g d 2 6 IWRLQNGHNQ TVSQTKYYNF TMMNQTQGCY LCSDGLSSRL SNRICFWASC INITPETPTV
b - u g d l 9 IWRLQKGHNQ TVSQTKYYNF TMMNQTEGCY LCSDGLSSRL SNRICFWASC INITPETPTV
b - u g d 7 IWRLQNGHNQ TVSQTKYYNF TMMNQTQGCY FCFDGLSSRL SNRICFWASC INITPETPTV
b - u g d lO IWRLQNGHNQ TVSQTKYYNF TMMNQTQGCY TCSNGLSSRL SNRICFWASC INITPETPTV
b -u k m a 2 4 IWRLQNGHNQ TVSQTKYYNF TMMNQTQGCY TCSNGLSSRL SNRICFWASC INITPETPTV
b - u g d 2 9 IWRLQTGHNQ TVSQTKYYNF TMMNQTQGCY ACSNGLSSRL SNRICFWASC INVTPETPTV
b - u g 5 2 IWRLQNGHNQ TVSQTRYYNF TMMNQTRGCY VCSDGLSSRL SNRICFWASC INITPETPTV
b - g 4 1 3 IWRLQNGHNQ TVSQTKYYNF TMMNQTQGCY TCSNGLSSRL SNRICFWASC INITPETPTV
b - g 4 8 2 IWRLQNGHNQ TVSQTKYYNF TMMNQTQGCY TCSNGLSSRL SNRICFWASC INITPETPTV
b - u g d l 3 IWRLQNGHNQ TVSQTKYYNF TMMDQTQGCY TCSNGLSSRL SNRICFWASC IN ITPETPTV
b - u g d 3 IWRLQNGHNQ TVSQTKYYNF TMMDQTQGCY TCSNGLSSRL SNRICFWASC INITPETPTV
b - u g d l 5 IWRLQNGHNQ TVSQTKYYNF TMMNQTQGCY TCSNGLSSRL SNRICFWASC IN ITPETPTV
b - g 7 1 IWRLQNGHNQ TVSQTKYYNF TMMNQTQGCY TCSNGLSSRL SNRICFWASC IN ITPETPTV
b - g 9 1 IWRLQNGHNQ TVSQTKYYNF TMMNQTQGCY TCSNGLSSRL SNRICFWASC INLTPETPTL
a - b c l VWHLPNGRNE TVSQTKYYNF TLMSQTEGCY TCSNGLSSRL SNRICFWARC ANITPETHTV
a -e m a 7 VWHLPNGRNE TVSQTKYYNF TLMNQTEGCY TCSNGLSSRL SNRICFWARC DNITPETHTV
a - u k a l 3 WHLPNGRNE TVSQTKYYNF TLMNQTEGCY TCSNGLSSRL SNRICFWARC ANLTPETHTV
a - u k a 2 1 VWHLPNGRNE TVSQTKYYNF TLMNQTEGCY TCSNGLSSRL SNRICFWARC ANITPETHTV
a -u k m a 4 VWHLPNGRNE TVSQTKYYNF TLMNQTEGCY TCSNGLSSRL SNRICFWARC ANITPETHTV
a - b c b l r VWHLPNGRNE TVSQTKYYNF TLMNQTEGCY TCSNGLSSRL SNRICFWARC ANITPETHTV
a - u k b l 2 VWHLPNGRNE TVSQTKYYNF TLMNQTEGCY TCSNGLSSRL SNRICFWARC ANITPETHTV
a - u k c l 2 VWHLPNGRNE TVSQTKYYNF TLMNQTEGCY TCSNGLSSRL SNRICFWARC ANITPETQTV
a - i a p l VWHLPNGRNE TVSQTKYYNF TLMNQTEGCY TCSNGLSSRL SNRICFWARC ANITPETHTV
a - u g l l l VWHLPNGLNE TVSQTKYYNF TPMNQTEGCY TCSNGLSSRL SNRICFWARC ANITPETHTV
c - k l - 8 - d e m VWHLPNGRNE TVSQTKYYNF TLMNQTEGCY ACSNGLSSRL SNRICFWARC ANITPETHTV
c -u g d 2 3 VWHLPNGRNE TVSQTKYYNF TLMNQTEGCY GCSNGLSSRL SNRICFWARC ANITPETHTV
a - u g d l 6 VWHLPNGRNE TVSQTKYYNF TLMNQTEGCY TCSNGLSSRL SNRICFWARC ANITPETHTV
a - u g d l 8 VWHLPNGRNE TVSQTKYYNF TLMNQTEGCY TCSNGLSSRL SNRICFWARC ANITPETHTV
a -u g d 2 4 VWHLPNGRNE TVSQTKYYNF TLMNQTEGCY TCSNGLSSRL SNRICFWARC ANITPETHTV
a -u g 3 7 4 VWHLPNGRNE TVSQTKYYNF TLMNQTEGCY TCSNGLSSRL SNRICFWARC ANITPETHTV
a - u g d 4 VWHLPNGRNE TVSQTKYYNF TLMNQTEGCY TCSNGLSSRL SNRICFWARC ANITPETHTV
a - u g d l 2 VWHLPNGRNE TVSQTKYYNF TLMNQTEGCY TCSNGLSSRL SNRICFWARC ANITPETHTV
a - b c b l l VWHLPNGRNE TVSQTKYYNF TLMNQTEGCY TCSNGLSSRL SNRICFWARC ANITPETHTV
c - g k l 7 VWHLPNGRNE TVSQTKYYNF TLMNQTEGCY ACSNGLSSGL SNRLCFWARC ANITPETHTV
c - i a p 3 VWHLPNGRNE TVSQTKYYNF TLMNQTEGCY ACSNGLSSGL SNRLCFWARC ANITPETHTV
c - b b g l VWHLPNGRNE TVSQTKYYNF TLMDQTEGCY ACSDGLSSRL SNRLCFWARC ANITPETHTV
c -u k m a 8 VWHLPNGRNE TVSQTKYYNF TLMDQTEGCY ACSDGLSSRL SNRLCFWARC ANITPETHTV
c - b c 2 VWHLPNGRNE TVSQTKYYNF TLMDQSEGCY ACSDGLSSRL SNPLCFSARC ANITLETDTV
c -u k m a 3 VWHLPNGRNE TVSQTKYYNF TLMDQTEGCY ACSDGLSSRL SNRLCFSARC ANITLETNTV
c - i v e l VWHLPNGRNE TVSQTKYYNF TLMDQTEGCY ACSDGLSSRL SNRLCFSARC ANITLETHTV
c - u k b 2 2 VWHLPNGRNE TVSQTKYYNF TLMDQTEGCY ACSDGLSSRL SNRLCFSARC ANITLETHTV
c - e r l a VWHLPNGRNE TVSQTKYYNF TLMNQTEGCY ACSNGLSSRL SNRLCFSARC ANLTPETHTV
c - i c a m l VWHLPNGRNE TVSQTKYYNF TLMNQTEGCY ACSNGLSSRL SNRLCFSARC ANLTPETHTV
c - u k m a l VWHLPNGRNE TVSQTKYYNF TLMNQTEGCY ACSNGLSSRL SNRLCFSARC ANITPETHTV
c - i a p 2 VWHLPNGRNE TVSQTKYYNF TLMNQTEGCY ACSNGLSSRL SNRLCFSARC ANRTPETHTV
c - g k l 8 VWHLPNGQNE TVSQTKYYNF TLMNQTEGCY ACSNGLSSRL SNRLCFSARC ANITPETHTV
c - k l - 4 3 - b e r IWHLQNGRNQ TVSQTNYYNF TVMNQTEGCY ACSNGLSSRL SNPICFWPRC ANITPETHTV
d l - t k s l O IWRLQNEGHQ PVSQTYYYNF TLMNQTQGCY TCSNGLSSRM SNRICFWAPC ANITPETDTV
d 2 - z k s 3 IWRLHRGGNQ TVSQTNYYNF TLMNQTNGCY ACSSGLSSRL SNLICFWAHC ANISLETSTV
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b - u g d 2 1 SASSTTAIK .............................. . . MSRTNGLL KIIPATTHAA VAVEEVKSTN PHIQVPFLVF
b - u g d l SASSTTAFK.............................. . .MSRTNGLL KIIPATTHAA VAVEEVKSTN PHIQVPFLVF
b - u g d 2 6 SASSTTAFK.............................. . . MSRTNGLL KIIPATTHAA VAVEEVKSTN PHIQVPFLVF
b - u g d l 9 SASSTTAFK.............................. . . MSRTNGLL KIIPATTHAA VAVEEVKSTN PHIQVPFLVF
b -u g d 7 SASSTTAFK.............................. . . MSRTNGLL KIIPATTHAA VAVEEVKSTN PHIQVPFLVF
b -u g d lO SASSTMAVK.............................. . . LLRTNGLL KIIPATTHAA VAVEEVKSTN THIQVPFLVF
b -u k m a2 4 SASSTMAVK.............................. . . VLRTNGLL KIIPATTHAA VAVEEVKSTN THIQVPFLVF
b -u g d 2 9 SASSPMAVK.............................. . . VLRTNGLL KIIPATTHAA VAVEEVKSTN THIQVPFLVF
b -u g 5 2 SASSTTAFK.............................. . . MSRTNGLL KIIPATTHAA VAVEEVKSTN PHIQVPFLVF
b -g 4 1 3 SSSSTTA FE.............................. . . TLRTNGLL KIIPATTHAA VAVEEVKSTN PHIQVPFLVF
b -g 4 8 2 SSSSTTAFK.............................. . . TLRTNGLL KIIPATTHAA VAVEEVKSTN PHIQVPFLVF
b - u g d l 3 SASSTTAFK.............................. . . TLTTNGLL KIIPATTHAA VAVEEVKSTN PHIQVPFLVF
b -u g d 3 SASSTTAFK.............................. . . TLTTNGLL KIIPATTHAA VAVEEVKSTN PHIQVPFLVF
b - u g d l 5 SASSTTAFK.............................. . . TLTTNGLL KIIPATTHAA VAVEEVKSTN PHIQVPFLVF
b - g 7 1 SASSTTAFK.............................. . . KLRNNGLL KI IPATTHAA VAVEEVKSTN PHIQVPFLVF
b - g 9 1 SASSTTAFK.............................. . . TLRTNGLL KIIPATTHAA VAVEEVKSTN PHIQVPFLVF
a - b c l SVSSTTGFR.............................. . . TLSTNSLV KIIHATTRDV VWKEAKSTH FHIEVHFLVF
a -e m a 7 SVSSTTGFR.............................. . . TLSTNSLV NIIHATTHDV VWKEAKSTH FHIELHFLVF
a - u k a l 3 SVSSTTGFR.............................. . . TFSTNRLV NIIHATTHDV WLKEAKSTR FHIELHFLVF
a - u k a 2 1 SVSSTTGFR.............................. . . TFSTNRLV NIIHATTHDV WLKEAKSTR FHIELHFLVF
a -u k m a 4 SVSSTTGFR.............................. . . TFSTNRLV NIIHATTHDV W LKEAKSIR FHIELHFLVF
a - b c b l r SVSSTTGFR.............................. . . TFSTNSLV NIIHATTHDV VWKEAKSTH FHIELHFLVF
a - u k b l 2 SVSSTTGFR.............................. . . TFSTNSLV NIIHATTHDV VAVKEAKS TH FHIELHFLVF
a - u k c l 2 SVSSTTGFR.............................. . .TFSTNSLV N i l ____ HDV VWKEAKSTH FHIELHFLVF
a - i a p l SVSSTTGFR.............................. . . TFSTNSLV NIIHATTHDA VWKEAKSTR FHIEVHFLVF
a - u g l l l SVSSTTGFR.............................. . . TFSTNSLV NIIHATTHNV VWKEAKSTH FHIELHFLVF
c - k l - 8 - d e m SVSSTTGFG.............................. . . TFSTHRLV NRIHATTHDV VWKEAKSTN PHIEVPFLVF
c -u g d 2 3 SVSSTTGFG.............................. . . TLSTHSLV NRIHATTHDV VWKEAKSTN PHIEVPFLVF
a - u g d l 6 SVSSTTGFR.............................. . . TVSTNSLV NIIHATNHDV VWKEAKSTN PHIEVPFLVF
a - u g d l 8 SVSSTTGFR.............................. . . TVSTNSLV NIIHATNHDV VWKEAKSTN PHIEVPFLVF
a - u g d 2 4 SVSSTTGFR.............................. . . TVSTNSLV NIIHATTHDV VWKEAKSTN PHIEVPFLVF
a - u g 3 7 4 SVSSTTGFR.............................. . . TFSTNSLV NIIHATTHDV VWKEAKSTN PHIEVPFLVF
a -u g d 4 SVSSTTGFR.............................. . . NLSTHSLV NIIHATTHHV VWKEAKSTN PHIEVPFLVF
a - u g d l 2 SV SST......................................... . IIHATTHDV VWKEAKSTN PHIEVPFLVF
a - b c b l l SVSSTTGFR.............................. . . TFSTNSLV NIIHATTHKV VWKEAKSTN SHIEVHFLVF
c - g k l 7 SVSSTTGFR.............................. . . TFSTH S. . . . . HTTTHAV VWKEAKFTN PHIEVPFLVF
c - i a p 3 SVSSTTGFR.............................. . . TFSTH S. . . . . HTTTHAV VWKEAKFTN PHIEVPFLVF
c - b b g l SVSSTTGFR.............................. . . TFSTN S. . . . . HATKHDV VWKEAKFTN PHIEVPFLVF
c -u k m a 8 SVSSTTGFR.............................. . . TFSTN S. . . . . HATKHDV VWKEAKFTN PHIEVPFLVF
c - b c 2 SVSSTTGFR.............................. . . TFSTN S. . . . . AATTHDV LVMKEAKSTN LHIQVHFIVF
c -u k m a3 SVSSTTGFR.............................. . .T F S T N S .. . . . DATTHDI LVMKEAKSTN LHIQVHFLVF
c - i v e l SVSSTTGFR.............................. . . TFSTN S. . . . . HATTHDE LVMKEAKSTN LHIQVHFLVF
c - u k b 2 2 SVSSTTGFR.............................. . . TFSTN S. . . . . HATTHDV LVMKEAKSTN LPIQVHFFVF
c - e r l a SVSSTTGFR.............................. . . TFSTNR. . . . . RGTTLDV LVMKEAKSTN LHIQVHFLVF
c - i c a m l SVSSTTGFT.............................. . . TFSTNR. . . . . RGTTLDV LVMKEAKSTN LHIQVHFLVF
c - u k m a l SVSSTTGFR.............................. . . TFSTNR. . . . . HAATHDI LVMKEAKSTN LHIQVHFLVF
c - i a p 2 SVSSTTGFR.............................. . . TFSTN S. . . . . HTTAHNV LVMKEAKSTN LHIQVHSLVF
c - g k l 8 SVSSTTGFR.............................. . . T F .............. . . . . ATAPTL FVMKEVKSTY LYIQEHLLVF
c - k l - 4 3 - b e r SVSSTTGFR.............................. . .TFSTN SIV NITHATTRAV VWKEAKSTN PHIEVPFLVF
d l - t k s l O SVRSTTGFKT HTVSVRSTTG FTTFSTNRLV NIIPATTHAV VWEKVKSLH PHIEVPFLVF
d 2 - z k s 3 SVSSTTGFK.............................. . . TFSTNRLV NIIPATTHAV VWEELKSRN PYIKVHFLIL
C o n s e n s u s S - - S ----------- ---------------------- ----------- K----- - - I -------------
b -u g d 2
241
MTLVALIGTM CGILGTLIFT HCQKKSDSSK TGQQQLRDYY SLDYFHTEEY
293
TQP
b -u g d 2 1 MTLVALIGTM CGILGTLIFT HCQKKSDSSK TGQQQLRDYY SLDYFHTEEY TQP
b - u g d l MTLVALIGTM CGILGTLIFT HCQKKSDSSK TGQQQLRDYY SLDYFHTEEY TQP
b -u g d 2 6 MTLVALIGTM CGILGTLIFT HCQKKSDSSK TGQQQLRDYY SLDYFHTEEY TQP
b - u g d l 9 MTLVALIGTM CGILGTLIFT HCQKKSDSSK TGQQQLRDYY SLDYFHTEEY TQP
b - u g d 7 MTLVALIGTM CGILGTLIFT HCQKKSDSSK TGQQQLRDYY SLDYFHTEEY TQP
b -u g d lO MTLVALIGTM CGILGTLIFT HCQKKSDSSK TGQQQLRDYY SLDYFHTEDY TQP
b -u k m a 2 4 MTLVALIGTM CGILGTLIFT HCQKKSDSSK TGQQQLRDYY SLDYFHTEDY TQP
b -u g d 2  9 MTLVALIGTM CGILGTLIFT HCQKKSDSSK TGQQQLRDYY SLDYFHTEDY TQP
b - u g 5 2 MTLVALIGTM CGILGTLIFT HCQKKSDSSK TGQQQLRDYY SLDYFHTEDY TQP
b -g 4 1 3 MTLVALIGTM CGILGTVIFT HCQKKSDSSK TGQQQLRDYY SLDYFHTEDY TQP
b -g 4 8 2 ITLVALIGTM CGILGAVIFT HCQKKSDSSK TGQQQLRDYY SLDYFHTEDY TQP
b - u g d l 3 MTLVALIGTM CGILGTVIFT HCQKKSDSSK TGQQQLRGYY SLDYFHTEEY TQP
b -u g d 3 MTLVALIGTM CGILGTVIFT HCQKKSDSSK TGQQQLRGYY SLDYFHTEEY TQP
b - u g d l 5 MTLVALIGTM CGILGTVIFT HCQKKSDSSK TGQQQLRDYY SLDYFHTEEY TQP
b - g 7 1 MTLVALIGTM CGILGTVIFT HCQKKSDSSK TGQQQLPDYY SLDYFHTEEY TQP
b - g 9 1 MTLVALIGTM CGIFGTLIFA HCQKQSDSSN TGQQQLRDYY SLDYFHTEEY TQP
a - b c l MTLVALIGTM C G ILG TIIFA HCQKQRDSNK TVPQQLQDYY SLHDLCTEDY TQP
a -e m a 7 MTLVALIGTV C G ILG TIIFA HCQKQRDSNK TVPQQLQDYY SLHDLCTEDY TQP
a - u k a l 3 MTLVALIGTM C G IV G TIIFF HCQKQRDSNK TVPQQLQDYY SLHDLCTEDY TQP
a - u k a 2 1 MTLVALIGTM C G IV G TIIFF HCQKQRDSNK TVPQQLQDYY SLHDLCTEDY TQP
a -u k m a 4 MTLVALIGTM C G IV G TIIFF HCQKQRDSNK TVPQQLQDYY SLHDLCTEDY TQP
a - b c b l r MTLVALIGTM C G ILG TIIFA HCQKQRDSNK TVPQQLQDYY SLHDLCTEDY TQP
a - u k b l 2 MTLVALIGTM C G ILG TIIFA HCQKQRDSNK TVPQQLQDYY SLHDLCTEDY TQP
a - u k c l 2 MTLVALIGTM C G ILG TIIFA HCQKQRDSNK TVPQQLQDYH SLHDLCTEDY TQP
a - i a p l MTLVALIGTM C G ILG TIIFA HCQKQRDSNK TVPQQLQDYY SLHDLCTEDY TQP
a - u g l l l MTLVALIGTM C G ILG TIIFA HCRKQRDSNK PVPQQLQDYY SLHDLCTEDY TQP
c - k l - 8 - d e m MTLVALIGTM C G ILG TIIFA HCQKQSDSKK TVPQQLRDYY SLHDFCTEDY TQP
c -u g d 2 3 MTLVALIGTM C G ILG TIIFA HCQKQSDSNK TVPQQLRDYY SLHDFCTEDY TQP
a - u g d l 6 MTLVALIGTM C G ILG TIIFA HCQKQRDSNK TVPQQLQDYY SLHDLCTEDY TQP
a - u g d l 8 MTLVALIGTM C G ILG TIIFA HCQKQRDSNK TVPQQLQDYY SLHDLCTEDY TQP
a - u g d 2 4 MTLVALIGTM C G ILG TIIFA HCQKQRDSNK TVPQQLQDYY SLHDLCTEDY TQP
a - u g 3 7 4 MTLVALIGTM C G ILG TIIFA HCQKQRDSNK TVPQQLQDYY SLHDLCTEDY TQP
a -u g d 4 MTLVALIGTM C G ILG T IIFA HCQKQRDSNK TVPQQLQDYY SLHDLCTEDY TQP
a - u g d l 2 MTLVALIGTM C G ILG T IIFA HCQKQRDSNK TVPQQLQDYY SLHDLCTEDY TQP
a - b c b l l MTLVALIGTM C G ILG TIIFA HCQKQRDSNK TVPQQLQDYY SLHDLCTEDY TQP
c - g k l 7 MTLVALIGTM C G ILG T IIFA HCQKQSDSNK TVPQQLRDYY SLHDLCTEDY TQP
c - i a p 3 MTLVALIGTM C G ILG T IIFA HCQKQSDSNK TVPQQLRDYY SLHDLCTEDY TQP
c - b b g l MTLVALIGTM C G ILG TIIFA HCQKQSDSNK TVPQQLRDYY SLHDLCTEDY TQP
c -u k m a 8 MTLVALIGTM C G ILG TIIFA HCQKQSDSNK TVPQQLRDYY SLHDLCTEDY TQP
c - b c 2 MTLVALIGTM C G ILG TIIFA HCQKQRDSNK TVPQQLQDYY SLHDLCTEDY TQP
c -u k m a 3 MTLVALIGTM C G ILG TIIFA HCQKQSDSNK TVPQQLRDYY SLHDLCTEDY TQP
c - i v e l MTLVALIGTM C G ILG TIIFA HCQKQSDSNK TVPQQLRDYY SLHDLCTEDY TQP
c - u k b 2 2 MTLVALIGTM C G ILG TIIFA HCQKQSDSNK TVPQQLRDYY SLHDLCTEDY TQP
c - e r l a MTLVALIGTM C G ILG TIIFA HCQKQRDSNK TVPQQLQDYY SLHDLCTEDY TQP
c - i c a m l MTLVALIGTM C G ILG TIIFA HCQKQRDSNK TVPQQLQDYY SLHDLCTEDY TQP
c - u k m a l MTLVALIGTM C G ILG TIIFA HCQKQRDSNK TVPQQLQDYY SLHDLCTEDY TQP
c - i a p 2 MTLVALIGTM C G ILG TIIFA HCQKQRDSNK TVPQQLQDYY SLHDLCTEDY TQP
c - g k l 8 MTLVALIGTM C G ILG TIIFA HCQKQRDSNK TVPQQLQDYY SLHDLCTEDY TQP
c - k l - 4 3 - b e r MTLVALIGTM C G ILG TIIFA HCQKQSDSNK TVPQQLRDYY SLHDLCTEDY TQP
d l - t k s l O MTLVALIGTM C G ILG TIIFA HCQKQSDSNK TVQQQLRDYY SLHDFNTEDY TQP
d 2 - z k s 3 MTLVALIGTM C G ILG TIIFA RCQKQSDSNK TVPQQLRDYY SLHDFITEDY MQP
C o n s e n s u s -TLVALIGT- C G I - G - - I F - -C - K - - D S - - -----Q Q L --Y - SL -------TE-Y -Q P
Fig. 4.6. HHV-8 K I phylogenetic tree.
A neighbour joining tree comprising 52 almost complete KI DNA sequences 
(840 bp, codons 6-285), 17 from this study (highlighted by black dots) and 35 
from previous studies (Cook et al., 1999; Zong et al., 1999; Lacoste et al., 
2000a). It was rooted at the midpoint between the sum o f the longest branches 
(Ugd2 and ZKS3). Four subtypes (A-D), A5 variants and the three B clusters (BI, 
BII and Bill) to which the Ugandan B subtype strains belong are indicated. 
Selected bootstrap values are included. The bar at the bottom o f the tree shows 
the divergence scale (substitutions/site). The tree was constructed by Duncan 


























































The majority (11) of the Ugandan samples cluster with the B subtype, five 
(Ugd4, Ugdl2, Ugdl6, Ugdl8 and Ugd24) with the A subtype and one (Ugd23) 
with the C subtype. The Ugandan B subtype strains fall into three clusters that 
have been designated as BI, BII and B ill (Fig. 4.6) for ease o f reference. All the 
Ugandan A strains cluster closely with the previously identified A5 variant, 
Ug374 (Cook et al., 1999). Ugd23 clusters closely with Kl-8/Dem (Lacoste et 
al., 2000a), and both branch early in the C lineage. The relatively low bootstrap 
value (76) for this node implies that inclusion of these strains in the C subtype is 
tentative.
Visual inspection of the KI protein sequence alignment (Fig. 4.5B) reveals that 
both Ugd23 and Kl-8/Dem do not have the characteristic 5-aa deletion of 
subtype C strains. Instead, they have a sequence that differs from that in subtype 
A strains by only one amino acid residue. In addition to unique differences (three 
each), characteristics of the A and C subtypes are present throughout their 
sequences. These data argue against recombination between an A and C subtype 
to generate these strains. The Ugd23 and Kl-8/Dem KI protein sequences differ 
by nine amino acid residues.
4.6 VARIABILITY WITHIN THE UGANDAN KI SEQUENCES
DNA and amino acid alignments comprising the 17 Ugandan KI sequences were 
made (Fig. 4.7). The results show that all strains have 289 amino acids in the 
complete KI protein, except Ugdl2, which has a unique deletion of 13 residues 
(aa 191-203). This deletion has not been reported in any other strain.
In order to identify the least and most widely diverged sequences within each 
subtype, distances between pairs o f KI nucleotide and amino acid sequences 
were determined. The values are shown in Table 4.3. The range of pairwise
Fig. 4.7. Alignments of K I DNA and amino acid sequences of 17 HHV-8 
strains.
The alignments include almost complete KI DNA (A) or amino acid (B) 
sequences o f strains analysed in this study. Prefixes on sequence names denote 
KI subtypes. The alignments run in the orientation o f the genomic sequence, 
nucleotide 1 and 855 corresponding to 120 and 974, respectively in the BC-1 
genome. Fifteen base pairs were omitted at the 5'-end of the DNA sequences, 
while 5 amino acids at the N-terminus of the protein sequences were omitted; 
thus positions 1 and 284 are equivalent to aa 6 and 289 (end o f the predicted 
protein), respectively. The two hypervariable regions (VR1, VR2) are indicated. 
Amino acids that replaced two cysteine residues in some o f the Ugandan strains 
are highlighted in red. Key amino acids in the predicted ITAM are highlighted by 
asterisks. TM, transmembrane domain; CYT, cytoplasmic domain.
b - u g d l  
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b -u g d 2  
b -u g d 2 1  
b - u g d l 3 
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b - u g d l  
b -u g d 2 6  
b - u g d l 9 
b - u g d 7  
b -u g d 2  
b -u g d 2 1  
b - u g d l 3  
b -u g d 3  
b - u g d l 5 
b -u g d lO  
b - u g d 2 9  
a - u g d l 6  
a - u g d l 8  
a - u g d 2 4  
a - u g d 4  
c -u g d 2 3  















































































































T - A - - - A - - C
b - u g d l  
b - u g d 2 6  
b - u g d l 9 
b - u g d 7  
b -u g d 2  
b -u g d 2 1  
b - u g d l 3 
b -u g d 3  
b - u g d l 5  
b -u g d lO  
b -u g d 2 9  
a - u g d l 6  
a - u g d l 8  
a -u g d 2 4  
a -u g d 4  
c -u g d 2 3  















































































































b - u g d l  
b - u g d 2 6  
b - u g d l 9  
b - u g d 7  
b - u g d 2  
b - u g d 2 1  
b - u g d l 3 
b - u g d 3  
b - u g d l 5  
b - u g d lO  
b - u g d 2 9  
a - u g d l 6  
a - u g d l 8  
a - u g d 2 4  
a - u g d 4  
c -u g d 2 3  
a - u g d l 2  














































































































T --A -A -A G C
b - u g d l  
b - u g d 2 6  
b - u g d l 9 
b - u g d 7  
b - u g d 2  
b - u g d 2 1  
b - u g d l 3 
b -u g d 3  
b - u g d l 5 
b - u g d lO  
b - u g d 2 9  
a - u g d l 6  
a - u g d l 8  
a - u g d 2 4  
a - u g d 4  
c - u g d 2 3  
a - u g d l 2  















































































































b - u g d l  
b - u g d 2 6  
b - u g d l 9 
b - u g d 7  
b - u g d 2  
b - u g d 2 1  
b - u g d l 3 
b - u g d 3  
b - u g d l 5 
b - u g d lO  
b - u g d 2 9  
a - u g d l 6  
a - u g d l 8  
a - u g d 2 4  
a - u g d 4  
c - u g d 2 3  
















































































































b - u g d l
361
ATTTGGCGTC
b - u g d 2 6 ATTTGGCGTC
b - u g d l 9 ATTTGGCGTC
b -u g d 7 ATTTGGCGTC
b -u g d 2 ATTTGGCGTC
b -u g d 2 1 ATTTGGCGTC
b - u g d l 3 ATTTGGCGTC
b -u g d 3 ATTTGGCGTC
b - u g d l 5 ATTTGGCGTC
b -u g d lO ATTTGGCGTC
b -u g d 2 9 ATTTGGCGTC
a - u g d l 6 GTTTGGCATC
a - u g d l 8 GTTTGGCATC
a - u g d 2 4 GTTTGGCATC
a -u g d 4 GTTTGGCATC
c -u g d 2 3 GTTTGGCATC
a - u g d l 2 GTTTGGCATC
C ons -TTTGGC-TC
b - u g d l
421
ACGATGATGA
b - u g d 2 6 ACGATGATGA
b - u g d l 9 ACGATGATGA
b -u g d 7 ACGATGATGA
b -u g d 2 ACGATGATGA
b - u g d 2 1 ACGATGATGA
b - u g d l 3 ACGATGATGG
b -u g d 3 ACGATGATGG
b - u g d l 5 ACGATGATGA
b -u g d lO ACGATGATGA
b -u g d 2 9 ACGATGATGA
a - u g d l 6 ACGCTGATGA
a - u g d l 8 ACGCTGATGA
a -u g d 2 4 ACGCTGATGA
a -u g d 4 ACGCTGATGA
c -u g d 2 3 ACGCTGATGA
a - u g d l 2 ACGCTGATGA
C ons ACG-TGATG-
b - u g d l
481
TCAAATCGTA
b - u g d 2 6 TCAAATCGTA
b - u g d l 9 TCAAATCGTA
b -u g d 7 TCAAATCGTA
b -u g d 2 TCAAATCGTA
b - u g d 2 1 TCAAATCGTA
b - u g d l 3 TCAAATCGTA
b -u g d 3 TCAAATCGTA
b - u g d l 5 TCAAATCGTA
b -u g d lO TCAAATCGTA
b -u g d 2  9 TCAAATCGTA
a - u g d l 6 TCAAATCGTA
a - u g d l 8 TCAAATCGTA
a - u g d 2 4 TCAAATCGTA
a -u g d 4 TCAAATCGTA
c -u g d 2 3 TCAAATCGTA







































































































































































b - u g d l  
b - u g d 2 6  
b - u g d l 9 
b - u g d 7  
b - u g d 2  
b - u g d 2 1  
b - u g d l 3 
b - u g d 3  
b - u g d l 5 
b - u g d lO  
b - u g d 2 9  
a - u g d l 6  
a - u g d l 8  
a - u g d 2 4  
a - u g d 4  
c - u g d 2 3  
a - u g d l 2  
C o n s
b - u g d l  
b - u g d 2 6  
b - u g d l 9 
b - u g d 7  
b - u g d 2  
b - u g d 2 1  
b - u g d l 3 
b - u g d 3  
b - u g d l 5 
b -u g d lO  
b - u g d 2 9  
a - u g d l 6  
a - u g d l 8  
a - u g d 2 4  
a - u g d 4  
c -u g d 2 3  
a - u g d l 2  
C ons
b - u g d l  
b - u g d 2 6  
b - u g d l 9 
b - u g d 7  
b - u g d 2  
b - u g d 2 1  
b - u g d l 3 
b - u g d 3  
b - u g d l 5 
b - u g d lO  
b - u g d 2 9  
a - u g d l 6  
a - u g d l 8  
a - u g d 2 4  
a - u g d 4  
c -u g d 2 3  
a - u g d l 2  







































































































































































b - u g d l  
b -u g d 2 6  
b - u g d l 9 
b - u g d 7  
b -u g d 2  
b -u g d 2 1  
b - u g d l 3 
b -u g d 3  
b - u g d l 5 
b -u g d lO  
b -u g d 2  9 
a - u g d l 6  
a - u g d l 8  
a - u g d 2 4  
a -u g d 4  
c -u g d 2 3  
a - u g d l 2  
C o n s
b - u g d l  
b - u g d 2 6  
b - u g d l 9 
b - u g d 7  
b -u g d 2  
b -u g d 2 1  
b - u g d l 3 
b -u g d 3  
b - u g d l 5 
b - u g d l 0 
b -u g d 2 9  
a - u g d l 6  
a - u g d l 8  
a - u g d 2 4  
a - u g d 4  
c - u g d 2 3  
a - u g d l 2  
C ons
b - u g d l  
b -u g d 2 6  
b - u g d l 9  
b - u g d 7  
b -u g d 2  
b -u g d 2 1  
b - u g d l 3 
b -u g d 3  
b - u g d l 5 
b -u g d lO  
b - u g d 2 9  
a - u g d l 6  
a - u g d l 8  
a -u g d 2 4  
a - u g d 4  
c -u g d 2 3  



























































CAACAATTGC GGGATTATTA TTCCCTAGAC 
CAACAATTGC GGGATTATTA TTCCCTAGAC 
CAACAATTGC GGGATTATTA TTCCCTAGAC 
CAACAATTGC GGGATTATTA TTCCCTAGAC 
CAACAATTGC GGGATTATTA TTCCCTAGAC 
CAACAATTGC GGGATTATTA TTCCCTAGAC 
CAACAATTGC GGGGTTATTA TTCCCTAGAC 
CAACAATTGC GGGGTTATTA TTCCCTAGAC 
CAACAATTGC GGGATTATTA TTCCCTAGAC 
CAACAATTGC GGGATTATTA TTCCCTAGAC 
CAACAATTGC GGGATTATTA TTCCCTAGAC 
CAACAATTGC AGGATTATTA TTCCCTACAC 
CAACAATTGC AGGATTATTA TTCCCTACAC 
CAACAATTGC AGGATTATTA TTCCCTACAC 
CAACAATTGC AGGATTATTA TTCCCTACAC 
CAACAATTGC GGGATTATTA TTCCCTACAC 
CAACAATTGC AGGATTATTA TTCCCTACAC 
CAACAATTGC -GG-TTATTA TTCCCTA-AC
840
TATTTTCACA CGGAAGAGTA TACGCAACCA 
TATTTTCACA CGGAAGAGTA TACGCAACCA 
TATTTTCACA CGGAAGAGTA TACGCAACCA 
TATTTTCACA CGGAAGAGTA TACGCAACCA 
TATTTTCACA CGGAAGAGTA TACGCAACCA 
TATTTTCACA CGGAAGAGTA TACGCAACCA 
TATTTTCACA CGGAAGAGTA TACACAACCA 
TATTTTCACA CGGAAGAGTA TACACAACCA 
TATTTTCACA CGGAAGAGTA TACACAACCA 
TATTTTCACA CGGAAGACTA TACGCAACCA 
TATTTTCACA CGGAAGACTA TACGCAACCA 
GATTTGTGCA CGGAAGACTA TACGCAACCA 
GATTTGTGCA CGGAAGACTA TACGCAACCA 
GATTTGTGCA CGGAAGACTA TACGCAACCA 
GATTTGTGCA CGGAAGACTA TACGCAACCA 
GATTTCTGCA CGGAAGACTA TACGCAACCA 
GATTTGTGCA CGGAAGACTA TACGCAACCA 




















Ba - u g d l 6  
a - u g d l 8  
a - u g d 2 4  
a -u g d 4  
a - u g d l 2  
c - u g d 2 3  
b -u g d 2  
b -u g d 2 1  
b - u g d l  
b - u g d 2 6  
b - u g d l 9 
b -u g d 7  
b - u g d l 3  
b - u g d 3  
b - u g d l 5 
b - u g d lO  
b -u g d 2 9  














































































































-L - R -----------
a - u g d l 6  
a - u g d l 8  
a - u g d 2 4  
a -u g d 4  
a - u g d l 2  
c - u g d 2 3  
b -u g d 2  
b -u g d 2 1  
b - u g d l  
b - u g d 2 6  
b - u g d l 9 
b -u g d 7  
b - u g d l 3  
b - u g d 3  
b - u g d l 5  
b - u g d lO  

















































































































Y C-TS— N -T
a - u g d l 6  
a - u g d l 8  
a - u g d 2 4  
a - u g d 4  
a - u g d l 2  
c -u g d 2 3  
b -u g d 2  
b -u g d 2 1  
b - u g d l  
b - u g d 2 6  
b - u g d l 9 
b -u g d 7  
b - u g d l 3  
b - u g d 3  
b - u g d l 5  
b -u g d lO  















































































































-N -T P E T -T V
a - u g d l 6  
a - u g d l 8  
a -u g d 2 4  
a - u g d 4  
a - u g d l 2  
c - u g d 2 3  
b - u g d 2  
b -u g d 2 1  
b - u g d l  
b - u g d 2 6  
b - u g d l 9 
b -u g d 7  
b - u g d l 3  
b - u g d 3  
b - u g d l 5  
b - u g d lO  




















































































































a - u g d l 6  
a - u g d l 8  
a - u g d 2 4  
a -u g d 4  
a - u g d l 2  
c -u g d 2 3  
b -u g d 2  
b -u g d 2 1  
b - u g d l  
b - u g d 2 6  
b - u g d l 9 
b -u g d 7  
b - u g d l 3 
b - u g d 3  
b - u g d l 5  
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divergences (expressed as the percentage of substitutions per nucleotide or amino 
acid residue) within and between KI subtypes were then calculated and are 
shown in Table 4.4. The sequences exhibit among themselves from 0% (Ugdl6 
vs. Ugdl8 and Ugd3 vs. Ugdl3) to 14.2% (Ugd2 vs. Ugd23) nucleotide 
divergence and from 0% (Ugdl6 vs. Ugdl8 and Ugd3 vs. Ugdl3) to 30.5% 
(Ugd2 vs. Ugdl6) amino acid divergence. Divergence within A5, BI, BII, and 
B ill groups is minimal in both the nucleotide (0-0.9%, 0.9-2.1%, 1.2% and 0- 
0.2%, respectively) and amino acid (0-2.2%, 2.1-5.6%, 3.9%, and 0-0.7%, 
respectively) sequences. Divergence between the B subdivisions is 2.7-5.1% in 
nucleotide sequence and 6.7-13.7% in amino acid sequence. A high divergence 
of up to 14.2% and 30.5% in nucleotide and amino acid sequences, respectively, 
is noted between subtype B and A5 and C (Ugd23) variants. Divergence between 
A5 and C variants is much less, up to 3.4% and 8.1% in nucleotide and amino 
acid sequences, respectively, indicating that Ugd23 is closely related to the A5 
variants. Indeed, pairwise divergences in DNA sequences of the 52 strains 
indicates that A5 strains and Ugd23 are more widely diverged from other A 
strains (up to 5% and 6.3%, respectively) than they are from each other. 
Furthermore, Ugd23 DNA sequence differs from other C subtype sequences by 
up to 6%. DNA sequence divergence among the B variants for the 52-sequence 
set is the same as that in the 17-sequence set o f Ugandan strains only.
Visual inspection of the predominantly B subtype alignment comprising KI 
amino acid sequences o f the 17 Ugandan samples (Fig. 4.7B) indicates that the 
VR1 and VR2 regions are present, located between aa 53-94 and aa 190-219, 
respectively. The VR2 in this alignment is shorter than that in the alignment 
comprising the 52 sequences (aa 149-230; Fig. 4.5B). Peak variability within 
VR1 and VR2 is between aa 60-70 and aa 190-203, respectively. The alignment 
also shows a high level of variability across the entire gene, except for the 
transmembrane region (aa 230-253) which is highly conserved. Although the
Table 4.4. Range of pairwise divergence values8 within and between KI subtypes





























a Values are expressed as the percentage of substitutions per nucleotide (top value in 
cell) or amino acid residue (bottom value). 
b Not done, only one C isolate was identified.
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short cytoplasmic domain (37 residues) is also variable, the predicted ITAM 
motif (DX10DYYSLX7YTQP) is highly conserved. Cysteine residues noted 
previously to be conserved (Zong et al., 1999) are also conserved in this 
alignment, except two (aa 12 and aa 72) that were replaced with W or G, 
respectively (Fig. 4.7B).
4.7 ASSOCIATION OF K I SUBTYPES W ITH  DISEASE AND TRIBE
The 17 KI subtypes were distributed by HIV status, clinical presentation and 
tribe of the patients. Table 4.5A shows the association between subtypes and 
HIV status. Four of the 5 A5 subtypes came from HIV-negative individuals, and 
one from a HIV-positive patient. The B subtype was nearly equally distributed 
between the two groups, while the single C variant came from an HIV-positive 
individual. All the three subtypes were associated with nodular KS lesions and 
involvement of the extremities. The clinically aggressive non-AIDS-associated 
case (Ugdl2) (Table 4.2) was associated with an A5 variant.
The 12 tribes represented were categorized into five groups according to the 
region in Uganda where the tribes occur predominantly (the total number of 
patients in each category is shown in parentheses): Central Uganda (7)-Ganda; 
Eastern Uganda (3)-Nyori/Jopadhola/Samia; Rwanda (3)- 
Nyarwanda/Mufumbira; South-West Uganda (3)-
Nyankole/Mutoro/Konjo/Nyoro; Northern Uganda (l)-Lugbara/Luo/Langi. 
These groups broadly correspond to ethnic background. The results, presented in 
Table 4.5B, show that while the B subtype is present in all tribal groups, three of 
the five A5 variants came from patients o f the Ganda tribe (Central Uganda) and 
two from patients belonging to the South-West Uganda group. The single C 
variant came from a Mufumbira, a tribe ethnically related to that o f the people in 
Rwanda.
Table 4.5.
A. KI subtypes and HIV status
Subtype A5 B C TOTAL
HIV status
HIV-1 positive 1 6 1 8
HIV-1 negative 4 5 0 9
TOTAL 5 11 1 17
B. KI subtypes and tribe
Subtype A5 B C TOTAL
Tribal group a
Central Uganda 3 4 0 7
Eastern Uganda 0 3 0 3
Rwanda 0 2 1 3
South-West Uganda 2 1 0 3
Northern Uganda 0 1 0 1
TOTAL 5 11 1 17
a The tribal groups include: Central Uganda-Ganda; Eastern Uganda- 
Nyori/Jopadhola/Samia; Rwanda-Nyarwanda/Mufumbira; South-West Uganda- 
Nyankole/Mutoro/Konjo/Nyoro; Northern Uganda-Lugbara/Luo/Langi.
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4.8 ASSOCIATION OF KI SUBTYPES WITH PLACE OF RESIDENCE
The KI subtypes were plotted on a map of Uganda according to the place of 
residence of the patient, as shown in Fig. 4.8. The B subtype is distributed 
throughout the region where patients came from (i.e. the southern part of the 
country). The few A5 variants are also distributed throughout this region, except 
for the Eastern part. The C variant came from Jinja, in the Eastern part of the 
country. A number of strains (8, two A5 and six B) cluster around the Kampala 
area.
4.9 CONCLUSION AND DISCUSSION
4.9.1 KI subtypes
Representatives o f three of the five subtypes o f KI gene were identified in 
biopsy samples from 17 Ugandan KS patients: five A5 variants, 11 subtype B 
strains and a single unusual subtype C variant. Subtype B was found to be more 
distant from A5 and C than A5 and C are from each other. These results are 
consistent with those of previous studies (Cook et al., 1999; Meng et al., 1999; 
Zong et al., 1999) and strengthen the evidence that subtype B predominates in 
Uganda. In contrast to the situation in Central and West Africa (Lacoste et al., 
2000a), the A5 variant does not appear to be as prevalent as the B subtype in 
Uganda.
4.9.2 Association of KI subtypes with disease, tribe and place of residence
As in most previous studies, no obvious association was noted between subtype 
B and HIV status, clinical picture, tribe or place of residence of the patient. 
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Fig. 4.8. Geographical distribution of K I subtypes in Uganda.
The subtypes were plotted according to the place of residence of the 
KS patient. Triangles, circles and square represent A5, B and C 
subtypes, respectively.
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from Mukono area (Ugdl, Ugd21 and Ugd26) belonged to one subtype B 
subdivision (BI; Table 4.2 and Fig. 4.6). It should be noted that the sample size 
in these analyses was too small (n=17) for meaningful statistical analysis to be 
performed. Thus, larger studies are required before definitive conclusions can be 
drawn.
The fact that no patients came from Northern Uganda was due to a war going on 
in that area during the time I collected samples, and not because KS is absent. A 
large proportion of patients (8) came from around Kampala because of easy 
access to UCI, and not because KS is more prevalent in this area.
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CHAPTER 5 
RESULTS AND DISCUSSION-III 
CHARACTERIZATION OF THE K15 GENE
5.1 INTRODUCTION
The HHV-8 K15 gene occurs as two highly diverged alleles, P and M (Choi et 
al., 2000; Glenn et al., 1999; Poole et al., 1999), which appear to be essentially 
unlinked to KI subtype (Poole et al., 1999). Divergence within each allele, 
however, appears to be minimal (Hayward, 1999). The M allele has been 
identified in samples from various parts of the world, including parts of Africa 
but not East Africa (Lacoste et al., 2000a,b; Meng et al., 2001; Poole et al., 
1999). It appears to be highly prevalent in West and Central Africa (Lacoste et 
al., 2000a) where 10 of 19 samples contained this allele. Poole et al. (1999) 
detected the M allele in 18 of 63 HHV-8 strains from various parts of the world 
(mostly USA). It was most commonly associated with the KI C subtype 
(especially from Taiwan); 13 of the 18 M-allele containing genomes had subtype 
C KI genes. Poole et al. (1999) reported that there was virtually no sequence 
variation at all within the M allele of these strains, although the data were not 
published. In this study, eight strains from Eastern Africa (five from Zambia, two 
from Tanzania and one from Zaire) had the P allele. The K15 allele in the two 
strains from Uganda (ST1 and ST2) was not determined. Indeed, no study has 
examined the K15 allele(s) present in HHV-8 strains from Uganda. The 
objectives of this study were to identify the K15 allele(s) present in Ugandan 
strains and to evaluate divergence within them.
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5.2 IDENTIFICATION OF K15 GENOTYPES IN UGANDAN SAMPLES
To identify the K15 alleles present in DNA samples from 30 KS patients Table 
4.2), specific fragments of the K15 gene were amplified using either K15 M- 
(K15-3A/K15-4A) or P- (K15-3C/K15-4C) specific primers. Details of the 
primers used are given in Table 2.3. Twenty-seven samples gave products with 
P- but not M-specific primers, indicating that they contain the P allele. One 
sample (UgdlO) gave a product with M- but not P-specific primers, indicating 
that it contains the M allele. Two samples (Ugd5 and Ugdl4) gave no product 
with either primer pair. Representative PCR products are shown in Fig. 5.1. All 
positive samples (except one) gave PCR products on the first attempt. The 
exception, Ugd30, required several attempts involving changes in PCR 
conditions. Eventually, a faint band was obtained when the annealing 
temperature was increased from 47.5 °C to 60 °C.
5.3 PCR AMPLIFICATION OF THE ENTIRE K15 GENE
The entire K15 gene of Ugandan samples representing the M (UgdlO; 2101 bp) 
and P (Ugd2, Ugd4, Ugdl2, Ugdl5, Ugdl6, Ugdl9, Ugd23 and Ugd29; up to 
2086) alleles was amplified. The eight samples with the P allele represented the 
three KI subtypes. Each PCR product also consisted of sequences (about 200 bp) 
flanking each side of the gene, with the downstream region extending to the 
beginning of ORF75. The sequence for the M allele was derived from two 
overlapping fragments (I and II) (Table 2.3). The PCR products are shown in 
Fig. 5.2A. Four primer sets were tried for amplification of the entire K15P gene, 
yielding varying levels o f specificity. Primer set K15-6C/K5-7C (Table 2.3) gave 
the best results: fewer non-specific bands and stronger specific bands. The 
specific bands were gel purified and are shown in Fig. 5.2B. For both alleles, the 
PCR products were cloned before sequencing.
Fig. 5.1. K15 genotypes in KS tum our DNA samples.
EtBr-stained 1.8% (w/v) agarose gels showing PCR products o f representative 
samples amplified with (A) K15 M- (K 15-3 A/4 A; 298 bp) or (B) K15 P- (K15- 
3C/4C; 285 bp) specific primers. Lanes: 1, 2, 4, 5, 7, 8, and 10, representative 
samples; 6, UgdlO; 3, water control; 9, negative DNA control; M, 100 bp DNA 
ladder.
Fig. 5.2. PCR amplification of the entire K15 gene.
EtBr-stained 1% (w/v) agarose gels showing PCR products o f (A) UgdlO 
(M allele) and (B) representative samples containing the P allele. (A) The 
two overlapping fragments, I (1374 bp) and II (1483 bp) used to amplify the 
entire K15 gene of UgdlO. (B) The products (2494 bp) containing the full 
length K15 gene of the samples with the P allele. The numbers at the top of 
the lanes denote sample names without the Ugd-prefix, e.g. 4 is Ugd4.
M, 1 kbp DNA ladder.
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5.4 DIVERGENCE WITHIN THE K15 GENE
5.4.1 Divergence within the K15 M allele
The sequence of UgdlO was compared with that o f BC-1, the only M allele 
sequence published. The DNA alignment (including K15 gene plus flanking 
sequences) is shown in Fig. 5.3, and the positions of nucleotide and amino acid 
changes (in the K15 gene alone) are shown in Fig. 5.4A.
The results show that the sequence of UgdlO is closely related to that of BC-1. 
The two sequences are equal in length, except that BC-1 lacks a T residue within 
exon 1 (position 370 in Fig. 5.3; this was previously identified as an error; Glenn 
et al., 1999; Poole et al., 1999) and has an additional G residue in intron 5 
(position 1416 in Figure 5.3). Both sequences exhibit major divergence from the 
P allele, commencing at the same position 21 bp downstream from the K15 stop 
codon (position 2331 in Fig. 5.3).
The K15 gene of UgdlO differs from that o f BC-1 at 25 positions (Fig. 5.4A). 
This is equivalent to a divergence of 1.2%. In coding regions, six substitutions 
are synonymous and nine are non-synonymous; ten substitutions are within 
introns. One substitution was identified in the upstream flanking region and none 
in the downstream region (Fig. 5.3).
5.4.2 Divergence within the K15 P allele
The K15 P sequences were analysed together with the corresponding regions of 
GK18 and BCBL-R (Table 2.1). The DNA sequence alignment of the K15 gene 
plus flanking regions is shown in Fig. 5.5. K15 P sequences exhibit major
Fig. 5.3. DNA alignment of K15 M allele sequences.
The alignment includes the entire K15 gene, and sequences (approx. 200 bp) 
flanking both sides, o f UgdlO and BC-1 oriented from left to right, i.e. opposite 
to the genomic orientation; nucleotides 1 and 2540 are equivalent to 136980 and 
134442, respectively, in the BC-1 genome. The BC-1 sequence was modified 
before alignment by replacing the missing T residue (position 370 marked with 
asterisk). The start and stop codons are highlighted in bold-blue. Sequences in 
exons are underlined with a dashed line enclosed within *<* and ‘>* signs. 
Positions o f nucleotide changes are shown in bold-red; the deletion is represented 
by a dot. The position (nucleotide 2331) where the M and P alleles become 
distinct is highlighted in bold-pink.
1 60
U gdlO CACCAGGATG CAGTGTTACA TTATCAGCTT TTTGCAGCTG TGCCATTTTA TAAGCCCTTC
BC-1 CACCAGGATG CAGTGTTACA TTATCAGCTT TTTGCAGCTG TGCCATTTTA TAAGCCCTTC
C ons CACCAGGATG CAGTGTTACA TTATCAGCTT TTTGCAGCTG TGCCATTTTA TAAGCCCTTC
61 120
U gdlO ATCCGGATTT TAGGTTTCCA AACAAAAATA GGATGTCTGG TTCTGTGCAA AACTAACTCA
BC-1 ATCCGGATTT TAGGTTTCCA AACAAAAATA GGATGTCTGG TTCTGTGCAA AACTAACTCA
C ons ATCCGGATTT TAGGTTTCCA AACAAAAATA GGATGTCTGG TTCTGTGCAA AACTAACTCA
121 180
U gdlO TCCAGCTATA TAATTCCTTG TCCAACTACA CTGAATTACA TATTTCTTTT GTCCACTTCA
BC-1 TCCAGCTATA TAATTCCTTG TCCAACTACA CTTAATTACA TATTTCTTTT GTCCACTTCA
C ons TCCAGCTATA TAATTCCTTG TCCAACTACA CT-AATTACA TATTTCTTTT GTCCACTTCA
181 start 240
U gdlO TTTTTGGGCC TTGGGCTTTT TGTCTACAAT GAATTACAAA AAATACCTGT GGGGTACTTG
BC-1 TTTTTGGGCC TTGGGCTTTT TGTCTACAAT GAATTACAAA AAATACCTGT GGGGTACTTG






U gdlO GTTTGCAGCA CTTATAACCT GTTGTGGGTG TTTGTCTATT ATGTTTTGTC TTTTAACTAT
BC-1 GTTTGCAGCA CTTATAACAT GTTGTGGGTG TTTGTCTATT ATGTTTTGTC TTTTAACTAT
C ons GTTTGCAGCA CTTATAAC-T GTTGTGGGTG TTTGTCTATT ATGTTTTGTC TTTTAACTAT
301 360
U gdlO AAATTTAGAA AACACCATAT TTTTGCTTAG TAACATAAGT GTTTACTACC AACTTTTTTG
BC-1 AAATTTACAA AACACCATAT TTTTGCTCAG TAACATAAGT GTTTACTACC AACTTTTTTG
C ons AAATTTA-AA AACACCATAT TTTTGCT-AG TAACATAAGT GTTTACTACC AACTTTTTTG
361 420
U gdlO TACAATAACA AACATATATG TGCAGTCAAA AAAACAACGT TTTCAAGCTT CCCCTCCACT
BC-1 TACAATAACA AACATATATG TGCAGTCAAA AAAACAACGT TTTCAAGCTT CCCCTCCCAT
C ons TACAATAACA 
________ ★ .
AACATATATG TGCAGTCAAA AAAACAACGT TTTCAAGCTT CCCCTCC--T
421 480
U gdlO TGGACCATCT ATAATTGTTG GTAAGTTACA TTTTTTAAAT GTTTAACTTA TTTCTTTCTA
BC-1 TGGACCATCT ATAATTGTTG GTAAGTTACA TTTTTTAAAT GTTTAACTTA TTTCTTTCTA
C ons TGGACCATCT ATAATTGTTG GTAAGTTACA TTTTTTAAAT GTTTAACTTA TTTCTTTCTA
481 540
U gdlO AGTATACATT GTTTAAATGT CTCATGTATT TGTCTTTTGT TTTAGGATGT ATTGCCTTTG
BC-1 AGTATACATT GTTTAAATGT CTCGTGTATT TGTCTTTTGT TTTAGGATGT ATTGCCTTTG
C ons AGTATACATT GTTTAAATGT CTC-TGTATT TGTCTTTTGT TTTAGGATGT




U gdlO CCAGTTGGAG TTTCTCTACT CAAAGTACTT TGAGTACTGT TTGTGTTTGT ATTATAAGTT
B C-1 CCAGTTGGAG TTTCTCTACT CAAAGTACTT TGAGTACTGT TTGTGTTTGT ATTATAAGTT
C ons CCAGTTGGAG TTTCTCTACT CAAAGTACTT TGAGTACTGT TTGTGTTTGT ATTATAAGTT
601 660
U gdlO TATTGTCTAT AATTACTGGT AAGTTTTACT AAAGGTTTTT TATTAAATAA ACATTATGTA
B C-1 TATTGTCTAT AATTACTGGT AAGTTTTACT AAAGGTTTTT TATTAAATAA AAATTATGTA




U gdlO TCTAATATTT CCATTTTTTA AAAAAAACGT AATTCCCCTG TATGTGTTTT TCAGCCATTC
BC-1 TCTAATATTT CCAATTTTTT AAAAAAACGT AATTCCCCTG TATGTGTTTT TCAGCCATTC





U gdlO TATCACTTGG TGGAACATTA AGAGTCGTTA AATGCACTAT TGACAGCGGA TTACTGTGCA
BC-1 TATCACTTGG TGGAACATTA AGAGTCGTTA AATGCACTAT TGATAGCGGA TTACTGTGCA
C ons TATCACTTGG TGGAACATTA AGAGTCGTTA AATGCACTAT TGA-AGCGGA TTACTGTGCA
781 840
U gdlO TTGCTATGGT GTTGGTACTT ATATTCTCAA TGGGATTGCA GATTTACAAC AACTGGACAC
B C-1 TTGTTATGGT GTTGGTACTT ATATTCTCAA TGGGATTGCA GATTTACAAC AACTGGACAC
C ons TTG-TATGGT GTTGGTACTT ATATTCTCAA TGGGATTGCA GATTTACAAC AACTGGACAC
841 900
U gdlO ATTGCCAGTT TTTTTTGCCA TTATGGACAT TGTTGCTTGT TTTTTTTATA CATATCTTTG
B C-1 ATTGCCAGTT TTTTTTGCCA TTATGGACAT TGTTGCTTGT TTTTTTTATA CATATCTTTG
C ons ATTGCCAGTT TTTTTTGCCA TTATGGACAT TGTTGCTTGT TTTTTTTATA CATATCTTTG
901 960
U gdlO CAACAAATAA TGGGCCTTGT CTCAAGCTCG CTGCATGTGT GTTTGCAATA TGTGGTGGTA
B C-1 CAACAGATAA TGGGCCTTGT CTCAAGCTCG CTGCATGTGT GTTTGCAATA TGTGGTGGTA
C ons CAACA-ATAA TGGGCCTTGT CTCAAGCTCG CTGCATGTGT GTTTGCAATA TGTGGTGGTA
961 1020
U gdlO AGTCTGGTTT TTACTGCTAT GCAATTATGT CTGCTTGCAC CTAAGCATTG CAACCAACAA
BC-1 AGTCTGGTTT TTACTGCTAT GCAATTATGT CTGCTTGCAC CTAAGCATTG CAACCAACAA
C ons AGTCTGGTTT TTACTGCTAT GCAATTATGT CTGCTTGCAC CTAAGCATTG CAACCAACAA
1021 1080
U gdlO TATTATTTAT TTTTTACTAC AGGTATACTC AAGGCAACAC CGGCCTTTTT TTGCGTTTCC
BC-1 TATTATTTAT TTTTTACTAC AGGTATACTC AAGGCAACAC CGGCCTTTTT TTGCGTTTCC





U gdlO CATTCATGCC TTTCTGTAAT CACCGCAGGA TGCATAAGCT GCATACATAT TGGTATATAA
BC-1 CATTCATGCC TTTCTGTAAT CATCGCAGGA TGCATAAGCT GCATACATAT TGGTATATGA
C ons CATTCATGCC TTTCTGTAAT CA-CGCAGGA TGCATAAGCT GCATACATAT TGGTATAT-A
1141 1200
U gdlO CTACTGTGAA GTTTACATTA TCTTAACTAA ACATTACCAA TACTATTATA ACATTTTGTA
BC-1 CTACTGTGAA GTTTACATTA TCTTAACTAA ACATTACCAA TACTATTATA ACATTTTGTA
C ons CTACTGTGAA GTTTACATTA TCTTAACTAA ACATTACCAA TACTATTATA ACATTTTGTA
1201 1 260
U gdlO ATGAATAACT TTATTACAGG TATGACCGGC TTGTTTATAA CAATGAAACG ACATTGGATT
B C-1 A'TGAATAACT TTATTACAGG TATGACCGGC TTGTTTATAA CAATGAAACG ACATTGGATT




U gdlO GGATCAACTA AGGGGCTTAT GTCATTTTTA CTTTTACAAG GAGGAGTGTT GGTTACACTA
BC-1 GGATCAACTA AGGGGCTTAT GTCATTTTTA CTTTTACAAG GAGGAGTGTT GGTTACACTA
C ons GGATCAACTA AGGGGCTTAT GTCATTTTTA CTTTTACAAG GAGGAGTGTT GGTTACACTA
1321 1380
U gdlO ACCACAACAA TAGGGATACT GTTTATAAAG CGCGAACAAG ACACCAATAA CGAAGGTATG
BC-1 ACCACAACAA TAGGGATACT GTTTATAAAG CGCGAACAAG ACACCAATAA CGAAGGTATG
C ons ACCACAACAA TAGGGATACT GTTTATAAAG CGCGAACAAG ACACCAATAA CGAAGGTATG
13 8 1 1440
U gdlO TTTTTAGCAG TATAGTGGTT TACATTACAT TTTTT. GACA TACTTATTGG GTGTCATAAA
BC-1 TTTTTACCAG TATAGTGGTT TACATTACAT TTTTTCCACA TACTTATTGG GTGTCATAAA
C ons TTTTTA-CAG TATAGTGGTT TACATTACAT TTTTT--ACA TACTTATTGG GTGTCATAAA
1441 1500
U gdlO TTATTACTGT CCATGTTTTT TATTTACAGG GAGTATAACA TTACTAGCAG GCTGTGGCTT
B C-1 TTATTACTGT CCATATTTTT TATTTACAGG GAGTATAACA TTACTAGCAG GCTGTGGCTT




U gdlO TTTATTATAT TGTTTCTTCT GCTGGCAAAG CTTTCACAAA GCTTCACTCT CTGGTGGCTT
BC-1 TTTATTATAT TGTTTCTTCT GCTGGCAAAG CTTTCACAAA GCTTCACTCT CTGGTGGCTT
C ons TTTATTATAT TGTTTCTTCT GCTGGCAAAG CTTTCACAAA GCTTCACTCT CTGGTGGCTT
1561 1620
U gdlO CCTGTTTCTA TTTTTGGGTA AGGATTTTTT GTACCTGGGT AGCAGCTCCC TGGTCATAAA
BC-1 CCTGTTTCTA TTTTTGGGTA AGGATTTTTT GTACCTGGGT AGCAGCTCCC TGGTCATAAA
C ons CCTGTTTCTA TTTTTGGGTA AGGATTTTTT GTACCTGGGT AGCAGCTCCC TGGTCATAAA
1621 1680
U gdlO GCAAACCGAA ACATAACTTT GGTTTATTTC CTTAGCATGG ACATGTGCTG GATGCTGTGT
BC-1 GCAAACCGAA ACATAACTTT GGTTTATTTC CTTAGCATGG ACATGTGCTG GATGCTGTGT




U gdlO TAAGTTAGTC CTGCTCTACA CTGACGGTTG GACTACAGGT GTCACTTCAG GACTGATTTG
BC-1 TAAGTTAGTC CTGCTCTACA CTGACGGTTG GACTACAGGT GTTACTTCAG GACTGATTTG
C ons TAAGTTAGTC CTGCTCTACA CTGACGGTTG GACTACAGGT GT-ACTTCAG GACTGATTTG
1741 1800
U gdlO TGTAATTGTG ATATTAAGTG AGTTGTGTTT TTATTTATGA TTGAAACACC AGCGCCACAT
BC-1 TGTAATTGTG ATATTAAGTG AGTTGTGTTT TTATTTATAA TTGGAACACC AGCGCCACAT
C ons TGTAATTGTG ATATTAAGTG 
____ _ _ _ \
AGTTGTGTTT TTATTTAT-A TTG-AACACC AGCGCCACAT
1801 1860
U gdlO AAAAACAGAG ATTAACGATT TTATTTTTTC TTATTAGGTA CTGGCCAAGC CGTACTGGTG
BC-1 AAAAACAGAG ATTAACGATT TTATTTTTTC TTATTAGGTA CTGGCCAAGC CGTACTGGTG






UgdlO GGTTATCTCT ACCGAGAGAG CAGACTTGTG TCGTTCAACA ATGTAACAAC AAGATTACCA
BC-1 GGTTATCTCT ACCGAgAGAG CAGACTTGTG TCGTTCAACA ATGTAACAAC AAGATTACCA
C ons GGTTATCTCT ACCGAGAGAG CAGACTTGTG TCGTTCAACA ATGTAACAAC AAGATTACCA
1921 1980
U gdlO ATATATACAC CCCACGACAC ACCACATGCT CATGCAGGCA GGATATGTCC CGATGTTAAT
BC-1 ATATATACAC CACACGACAC ACCACATGCT CATGCAGGCA GGATATGTCC CGATGTTAAT
C ons ATATATACAC C-CACGACAC ACCACATGCT CATGCAGGCA GGATATGTCC CGATGTTAAT
1981 2 0 4 0
U gdlO CATTTAGCTC GCCGTTTACC ACCTCTACCA TCTAGAAATC TTATACACTC GCGTATTTTA
BC-1 CATTTAGCTC GCCGTTTACC ACCTCTACCA TCTAGAAATG TTATACACTC GCGTATTTTA
C ons CATTTAGCTC GCCGTTTACC ACCTCTACCA TCTAGAAAT- TTATACACTC GCGTATTTTA
20 4 1 2 1 0 0
U gdlO AGTTCCACAA CAGACATGGC ATTATCTCCA ATAAGGGTTT GCAACACAGA AGTAACGACC
BC-1 AGTTCCACAA CAGACATGGC ATTATCTCCA GTAAGGGTTT GCAACACAGA AGTAACGACC
C ons AGTTCCACAA CAGACATGGC ATTATCTCCA -TAAGGGTTT GCAACACAGA AGTAACGACC
2101 2 1 6 0
U gdlO CAACTTGAAA TGCAGCAACT ACATAACGAA CACACAGTCA CCTATGCTAG ATTCTTGGGC
BC-1 CAACTTGAAA TGCAGCAACT ACATAGCGAA CGCACAGTCA CCTATGCTAG ATTCTTGGGC
C ons CAACTTGAAA TGCAGCAACT ACATA-CGAA C-CACAGTCA CCTATGCTAG ATTCTTGGGC
21 6 1 2 2 2 0
U gdlO GACAACACGC CTCCACCAAC GCGTGCGTCC GCTTGTATTA ACCAATCAGG TATCTCTAAT
BC-1 GACAACACGC CTCCACCAAC GCGTGCGTCC GCTTGTATTA ACCAATCAGG TATCTCTAAT
C ons GACAACACGC CTCCACCAAC GCGTGCGTCC GCTTGTATTA ACCAATCAGG TATCTCTAAT
22 2 1 2 2 8 0
U gdlO GTGAGCAACT GTGGTGTAAG GAGTCTGGAT CCGCCACCAT TTCAGCCTGC AGATGAAGTG
B C-1 GTGAGCAACT GTGGTGTAAG GAGTCTGGAT CCGCCACCAT TTCAGCCTGC AGATGAAGTG
C ons GTGAGCAACT GTGGTGTAAG GAGTCTGGAT CCGCCACCAT TTCAGCCTGC AGATGAAGTG
22 8 1 s t o p 2340
U gdlO TATGAGGAAG TTTTGTTTCC CACGGACTAA CCTAGGACCA CAGCATTTTT CCATCGATAG
B C-1 TATGAGGAAG TTTTGTTTCC CACGGACTAA CCTAGGACCA CAGCATTTTT CCATCGATAG
C ons TATGAGGAAG TTTTGTTTCC CACGGACTAA CCTAGGACCA CAGCATTTTT CCATCGATAG
-------------------> < 21 bo >
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Fig. 5.4. Nucleotide changes within (A) HHV-8 K15 M and (B) K15 P alleles.
Sequences o f Ugandan strains (bold) were analysed together with those of BC-1, 
BCBL-R and GK18 (Table 2). K1 subtypes are indicated. The results are 
presented in the context o f variation from the BC-1 (A) or BCBL-R (B) 
sequences, hyphens denoting identity. The alignments in each case consist o f the 
entire K15 gene oriented from left to right (opposite to the genomic orientation; 
nucleotides 1 and 2102 in K15 M are equivalent to 136772 and 134672, 
respectively, in the BC-1 genome). The BC-1 sequence was modified before 
alignment by replacing the missing T residue at 136610 (see text). Nucleotides 1 
and 2086 in K15 P are equivalent to 3652 and 1578, respectively, in the BCBL-R 
sequence and to 21490 and 19415, respectively, in the GK18 sequence. The 
position in the final alignment is indicated in the ‘nucleotide’ row. The 
‘exon/intron’ row shows the number of the exon (E l-8) or intron (11-7) in which 
each substitution or deletion is located. Amino acid differences are depicted in 
the ‘residue’ row, asterisks and exclamation marks indicating synonymous 
substitutions in exons and non-coding substitutions in introns, respectively. 
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Fig. 5.5. DNA alignment of K15 P allele sequences.
The alignment includes the entire K15 gene, and sequences (approx. 200 bp) 
flanking both sides, of strains with the P allele. Sequences o f Ugandan strains 
were analysed together with those of BCBL-R and GK18. The alignment is 
oriented from left to right, i.e. opposite to the genomic orientation. Nucleotides 1 
and 2505 are equivalent to 3862 and 1369, respectively, in the BCBL-R sequence 
and to 21700 and 19161, respectively, in the GK18 sequence. The start and stop 
codons are highlighted in bold-blue. Sequences in exons are underlined with a 
dashed line enclosed within ‘<* and *>’ signs. Positions o f nucleotide changes are 
shown in bold-red, with deletions represented by dots. The position (nucleotide 
2321) where the M and P alleles become distinct is highlighted in bold-pink.
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ATTATTGGTA AGTAGACTTT CATACTGGCT 









ATTATTGGTA AG---------------  — TACTGGCT
481
TTTTTTCATT GTAGTATAAA CATTGCAAGC 
TTTTTTCATT GTAGTATAAA CATTGCAAGC 
TTTTTTCATT GTAGTATAAA CATTGCAAGC 
TTTTTTCATT GTAGTATAAA CATTGCAAGC 
TTTTTTCATT GTAGTATAAA CATTGCAAGC 
TTTTTTCATT GTAGTATAAA CATTGCAAGC 
TTTTTTCATT GTAGTATAAA CATTGCAAGC 
TTTTTTCATT GTAGTATAAA CATTGCAAGC 
TTTTTTCATT GTAGTATAAA CATTGCAAGC 
TTTTTTCATT GTAGTATAAA CATTGCAAGC 
TTTTTTCATT GTAGTATAAA CATTGCAAGC
480
ACCAGGAATT CCTGGTAAGT AGCTTTTCCT 
ACCAGGAATT CCTGGTAAGT AGCTTTTCCT 
ACCAGGAATT CCTGGTAAGT AGCTTTTCCT 
ACCAGGAATT CCTGGTAAGT AGCTTTTCCT 
ACCAGGAATT CCTGGTAAGT AGCTTTTCCT 
ACCAGGAATT CCTGGTAAGT AGCTTTTCCT 
ACCAGGAATT CCTGGTAAGT AGCTTTTCCT 
ACCAGGAATT CCTGGTAAGT AGCTTTTCCT 
ACCAGGAATT CCTGGTAAGT AGCTTTTCCT 
ACCAGGAATT CCTGGTAAGT AGCTTTTCCT 
ACCAGGAATT CCTGGTAAGT AGCTTTTCCT
540
TGCCACTTGT ATATTCACAT ACATTTGTTT 
TGCCACTTGT ATATTCACAT ACATTTGTTT 
TGCCACTTGT ATATTCACAT ACATTTGTTT 
TGACACTTGT ATATTCACAT ACATTTGTTT 
TGACACTTGT ATATTCACAT ACATTTGTTT 
TGACACTTGT ATATTCACAT ACATTTGTTT 
TGACACTTGT ATATTCACAT ACATTTGTTT 
TGACACTTGT ATATTCACAT ACATTTGTTT 
TGACACTTGT ATATTCACAT ACATTTGTTT 
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2 2 8 1  s t o p  23 4 0
ATTTCCCAGG AACTAGCCCT CCACGACCAC AGACTTTTTG ACATCGATAC CTTTTTTTGA
ATTTCCCAGG AACTAGCCCT CCACGACCAC AGACTTTTTG ACATCGATAC CTTTTTTTGA
ATTTCCCAGG AACTAGCCCT CCACGACCAC AGACTTTTTG ACATCGATAC CTTTTTTTGA
ATTTCCCAGG AACTAGCCCT CCACGACCAC AGACTTTTTG ACATCGATAC CTTTTTTTGA
ATTTCCCAGG AACTAGCCCT CCACGACCAC AGACTTTTTG ACATCGATAC CTTTTTTTGA
ATTTCCCAGG AACTAGCCCT CCACGACCAC AGACTTTTTG ACATCGATAC CTTTTTTTGA
ATTTCCCAGG AACTAGCCCT CCACGACCAC AGACTTTTTG ACATCGATAC CTTTTTTTGA
ATTTCCCAGG AACTAGCCCT CCACGACCAC AGACTTTTTG ACATCGATAC CTTTTTTTGA
ATTTCCCAGG AACTAGCCCT CCACGACCAC AGACTTTTTG ACATCGATAC CTTTTTTTGA
ATTTCCCAGG AACTAGCCCT CCACGACCAC AGACTTTTTG ACATCGATAC CTTTTTTTGA
ATTTCCCAGG AACTAGCCCT CCACGACCAC AGACTTTTTG ACATCGATAC CTTTTTTTGA
-----------------------------------------------------------------X ---------------------- 25  b p ------------------- >
2 3 4 1  24 0 0
GTATTTGAGG TTAGTGACAT GGCTACATGT AACTGTGGAT TCCACGAAAG CGAAAACAAA
GTATTTGAGG TTAGTGACAT GGCTACATGT AACTGTGGAT TCCACGAAAG CGAAAACAAA
GTATTTGAGG TTAGTGACAT GGCTACATGT AACTGTGGAT TCCACGAAAG CGAAAACAAA
GTATTTGAGG TTAGTGACAT GGCTACATGT AACTGTGGAT TCGACGAAAG CGAAAACAAA
GTATTTGAGG TTAGTGACAT GGCTACATGT AACTGTGGAT TCGACGAAAG CGAAAACAAA
GTATTTGAGG TTAGTGACAT GGCTACATGT AACTGTGGAT TCCACGAAAG CGAAAACAAA
GTATTTGAGG TTAGTGACAT GGCTACATGT AACTGTGGAT TCCACGAAAG CGAAAACAAA
GTATTTGAGG TTAGTGACAT GGCTACATGT AACTGTGGAT TCCACGAAAG CGAAAACAAA
GTATTTGAGG TTAGTGACAT GGCTACATGT AACTGTGGAT TCCACGAAAG CGAAAACAAA
GTATTTGAGG TTAGTGACAT GGCTACATGT AACTGTGGAT TCCACGAAAG CGAAAACAAA
GTATTTGAGG TTAGTGACAT GGCTACATGT AACTGTGGAT TC-ACGAAAG CGAAAACAAA
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divergence from the M allele commencing 25 bp downstream from the K15 stop 
codon (position 2321 in Fig. 5.5). Sites o f nucleotide and amino acid changes (in 
K15 alone) are shown in Fig. 5.4B.
A total of 34 substitutions (Fig. 5.4B) were identified in the gene collection in 
addition to a 3-bp deletion (nt 226-228; Fig. 5.5) in the first exon of Ugd29 and a 
10-bp insertion (nt 433-442; Fig. 5.5) in the first intron o f Ugd2, Ugdl2 and 
U gdl9. In coding regions, nine substitutions are synonymous and 16 are non- 
synonymous; nine substitutions are within introns (Fig. 5.4B). A cluster of four 
sites plus the 3 bp deletion in Ugd29 are present within the first six codons (Fig. 
5.5). Two substitutions are located in the downstream flanking region and none 
in the upstream region (Fig. 5.5).
Overall, the nucleotide changes divide the P strains into two distinct groups: 
Ugd2, U gdl2 and Ugdl9; and Ugd4, Ugdl5, Ugdl6, Ugd23, Ugd29, BCBL-R 
and GK18. All ten sequences (including BCBL-R and GK18) are different from 
each other (see below chapter 6; Fig. 6.3D). Pairwise sequence comparisons 
(shown Table 5.1) show an overall nucleotide divergence among the sequences 
ranging from 0.05% (between U gdl5 and Ugd23) to 0.9% (between BCBL- 
R/GK18/Ugdl6 and Ugd2/Ugdl2/Ugdl9). Divergence within each of the two 
main groups (Ugd2/12/19 and the other group) is minimal, 0.2% and 0.05-0.4%, 
respectively. The divergence between the two groups is 0.8-0.9%. Thus, the most 
widely diverged P sequences differ by 0.9%.
5.4.3 Conclusion
The results indicate that the sequences of the M allele in UgdlO and BC-1 differ 
by a value (1.2%) that is similar to that (0.9%) for the two most widely diverged 



























































































































































5.5 CONCLUSION AND DISCUSSION
5.5.1 K15 genotypes in Uganda
The majority of HHV-8-positive samples from Uganda contains the P allele, as 
was predicted by Poole et al. (1999) from data on Eastern Africa samples. This 
allele is associated with all the K1 subtypes (A5, B and C) identified in the 
Ugandan samples in this study. The M allele was identified in a single sample 
(UgdlO, which has a K1 B subtype) originating from a 70-yr old male patient 
with endemic KS from Western Uganda, a region where endemic KS was 
common in older men prior to the HIV epidemic (Ziegler and Katongole- 
Mbidde, 1996). To my knowledge, this is the first time the K15 M allele has 
been reported in Eastern Africa samples. Therefore, this allele appears to be rarer 
in Eastern Africa than in Central and West Africa as found by Lacoste et al. 
(2000a).
Two samples, Ugd5 and Ugdl4, gave no product with either M- or P-specific 
primers, suggesting that they might contain a non-P, non-M allele, or that they 
are deleted in the region amplified. However, it is also possible that sub-optimal 
PCR conditions were responsible for this result, e.g. sub-optimal levels of the 
template resulting from low DNA concentration (as may be the case with Ugd5) 
or low HHV-8 DNA copy numbers (as may be the case with U gdl4).
5.5.2 Divergence within the K15 gene
The data on the sequences of the M and P alleles indicate that each of these 
alleles has been evolving in at least two forms. The level of divergence (1.2%) 
detected in the sequences with the M allele (UgdlO and BC-1) was surprising in 
view of the reports by Poole et al. (1999) and Hayward (1999). They claimed
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that the M sequences in the strains they analysed were virtually identical to that 
in BC-1. This observation also rules out the possibility that the variation in the 
BC-1 sequence is an artifact o f adaptation to growth in vitro. The maximum 
divergence within the P allele sequences (0.9%) is similar to that between the 
two M allele sequences.
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CHAPTER 6 
RESULTS AND DISCUSSION-IV 
CHARACTERIZATION OF OTHER LOCI
6.1 INTRODUCTION
Poole et al. (1999) analysed sequence variation of more than 60 strains at gene 
loci ORF26, T0.7/K12 and ORF75. Subtypes were defined based on nucleotide 
patterns. Sequence variation at these loci was much less than that in K l, but there 
was a general correlation between the groups defined at these loci and the K l 
groups. Nevertheless, sequences of some strains belonging to certain K l 
subtypes could not be distinguished. In ORF26, some K l B strains had 
sequences indistinguishable from those of K l C strains (a pattern designated 
B/C), also K l D strains had sequences indistinguishable from those of Kl 
subtype A strains (D/A pattern). Similarly, some K l A strains had sequences 
indistinguishable from those of K l C strains at T0.7/K12 (A/C), while K l 
subtype A and C strains had indistinguishable ORF75 sequences (also referred to 
as A/C). Furthermore, in ORF75, eight of 14 K l B strains analysed also had the 
A/C nucleotide pattern. In genomes with the K15 M allele, Poole et al. (1999) 
noted a nucleotide pattern (designated M) that was associated with the presence 
of the K15 M allele and extended into ORF75 and, in some cases, T0.7/K12.
Alagiozoglou et al. (2000) analysed the phylogenetic relationships of HHV-8 
strains in South Africa using the ORF75 gene. These investigators found that, in 
addition to the previously identified A (later renamed A/C by Poole et al., 1999), 
B and C (also later renamed M by Poole et al., 1999) subtypes, a novel subtype 
(designated N) is circulating in South Africa. The old nomenclature for ORF75 
groups used by Alagiozoglou et al. (2000) was derived from previous work by
67
Zong et al. (1997). The revised nomenclature (Poole et al., 1999) is used in this 
study.
Evidence for recombination was noted in 20-30% of the genomes studied by 
Poole et al. (1999). Approximately half (five of 12) o f African strains displayed 
mosaic genomes that probably reflect a history of recombination within and 
among subtypes. All five strains (including ST1 from Uganda) had the A/C 
pattern at ORF75. Furthermore, five of the 12 African strains (including ST1) 
had the B/C pattern in ORF26. ST2 (the only other Ugandan strain in this study) 
had subtype B patterns in ORF26 and ORF75, and this genome was interpreted 
as being subtype B throughout. However, the patterns o f ST1 and ST2 were not 
determined in T0.7/K12 (and K15, as seen in section 5.1 above). A strain from 
Tanzania (OKS3; Table 2.1) with an A5 K1 gene had what was described as 
being a mosaic genome, with a subtype B pattern in ORF26 and T0.7/K12, an 
A/C pattern in ORF75 and a K15 P allele. On the other hand, 431KAP (Table 
2.1) from Zaire had subtype B patterns at K l, ORF26, T0.7/K12 and ORF75 and 
was linked to a K15 P allele. This strain was described as being subtype B 
throughout.
Evidence for recombination has also been observed in EBV. Three intertypic 
recombinants with type 1 sequences at the EBNA2 locus and type 2 sequences at 
some or all of the EBNA-3A, -3B, -3C loci were identified among 34 EBV 
isolates from non-immunocompromised Chinese donors (Midgley et al., 2000).
Apart from the two Ugandan HHV-8 strains (ST1 and ST2) whose genomes have 
been characterised at two other gene loci (in addition to K l), no other Ugandan 
strain has been characterised at multiple loci. The objective o f this study was to 
analyse sequence variation in strains from Uganda at five additional loci (K3,
68
ORF26, K9, T0.7/K12 and ORF75). The overall genotypes o f these strains were 
then evaluated, shedding further light on the evolution of HHV-8.
6.2 PCR AMPLIFICATION
PCR products were generated from loci K3, ORF26, K9, T0.7/K12 and ORF75 
of the nine strains (Ugd2, Ugd4, UgdlO, Ugdl2, Ugdl5, Ugdl6, Ugdl9, Ugd23 
and Ugd29) whose K15 genes had been sequenced. The loci selected were 
spaced out at roughly equal intervals across the genome (K3 at 0.14 map units 
(MU), ORF26 at 0.35 MU, K9 at 0.61 MU, T0.7/K12 at 0.85 MU and ORF75 at 
0.97MU), and also included loci examined in previous studies (Alagiozoglou et 
al., 2000; Poole et al., 1999). The coordinates are given in Table 2.2. The portion 
of ORF75 immediately adjacent to K15 was chosen for analysis with the view 
that this might shed more light on the evolution of the K15 gene region. For 
ORF26, PCR products were also generated from all the other Ugandan samples. 
PCR products were also generated for K9, T0.7/K12 and ORF75 loci o f Ugd30. 
The primers used and sizes o f the products are shown in Table 2.3. ORF26 
products used in this study were those amplified by KS4/KS5.
Representative PCR products are shown in Fig. 6.1. All the loci gave strong 
signals for all samples, and this allowed direct sequencing of the PCR products. 
The segments consisted entirely of coding sequences, except for T0.7/K12, 
which consisted of a portion of the K12 gene (aa 13-60 [end]) plus the non­
coding sequences downstream from the K12 stop codon.
Fig. 6.1. K3, ORF26, K9, T0.7/K12, ORF75 PCR products.
EtBr-stained 1% (w/v) agarose gels showing PCR products of K3 (635 
bp), ORF26 (571 bp), K9 (594 bp), T0.7/K12 (648 bp), ORF75 (749 
bp) in lanes 1-5, respectively. The products were amplified using 
primers shown in Table 2.3. M, 123 bp DNA ladder.
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6.3 NETWORK ANALYSIS
6.3.1 Genotypes at each loci
The Ugandan sequences were aligned together with reference strains, BC-1 (for 
all loci), and BCBL-R and GK18 (for ORF75). The alignments are shown in Fig. 
6.2. Networks were then drawn to determine the relationships of the strains at 
each locus. Those for K3 and ORF26 were similar, and therefore were combined 
(Fig. 6.3A). That for K9 (with only one substitution) was combined with that for 
T0.7/K12 (Fig. 6.3B). The K15 M allele group (UgdlO and BC-1) represents a 
third group not shown at the K15 locus because it is very distant from the P 
allele.
The groups defined for each locus (together with those for K l) are shown in 
Table 6.1. Ugd2, Ugdl2 and Ugdl9 co-segregate at all loci (excluding K l), as do 
Ugd4, Ugdl5, Ugdl6, Ugd23, Ugd29 (with the exception of Ugd23 at K3- 
ORF26 locus). UgdlO groups with Ugd4/15/16/29 at locus K3-ORF26, but 
shows links to BC-1 in K9-T0.7/K12, ORF75 and K15.
6.3.2 Evidence for recombination in Ugandan strains
Evaluation of the groups defined by the network analysis together with the 
phylogenetic groups in K l indicates that some strains group differently at 
different loci. Firstly, in K l, the three strains (Ugd4, Ugdl2, and Ugdl6) that 
have A5 K l genes are closer to BC-1 than to other Ugandan strains with B Kl 
genes. These, however, cluster with other Ugandan strains, and not with BC-1, in 
K3-ORF26, K9-T0.7/K12, ORF75 and K15, providing evidence for 
recombination between K l and K3. Secondly, UgdlO, which does not cluster 
with BC-1 in K l and K3-ORF26, appears to be linked to this strain in K9-
Fig. 6.2.Alignments of (A) K3, (B) ORF26, (C) K9, (D) T0.7/K12 and (E) 
ORF75 DNA sequences of Ugandan and reference strains.
The alignments are in reverse orientation to the genomic sequence except for K3 
and ORF26. The coordinates for each loci are given in Table 2.2. Positions o f 
nucleotide changes are shown in bold-red, with the deletion in D represented by 
dots. Locations o f mutated codons are highlighted by open boxes. Asterisks 
denote synonymous substitutions and amino acid changes are shown for non- 
synonymous substitutions. The start (E) and stop (D) codons are highlighted in 
bold-blue.
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U gdlO  
Ugd4 
U g d l 6 
U gd29 
U g d l2  
U g d l9  
Ugd2 








































































U gdlO  
Ugd4 
U g d l 6 
Ugd2 9 
U g d l2  
U g d l9  
Ugd2 








































































U gdlO  
Ugd4 
U g d l 6 
Ugd2 9 
U g d l2  
U g d l 9 
Ugd2 








































































U gdlO  
Ugd4 
U g d l6  
Ugd2 9 
U g d l2  
U g d l 9 
Ugd2 




























































* 420  













U g d l6
U gd29
U g d l2
U g d l9
Ugd2










































































U g d l6
U gd29
U g d l2
U g d l9
Ugd2




















































U g d l2




U g d l5








































































U g d l2  
U g d l9  
Ugd2 
U gd23 
U gdlO  
U g d l5  









































































U g d l2  
U g d l9  
Ugd2 
U gd23 
U gdlO  
U g d l5  









































































U g d l2




U g d l5









































































U g d l2




U g d l5










































































301 I / L * 360
U g d l2 GAATCCAACG g a t t t g a c Iat  cIg t g t t c c c c a t g g t c g t g Ic cgIc a g c a a c t GGGGCACGCT
U g d l 9 GAATCCAACG GATTTGACAT CGTGTTCCCC ATGGTCGTGC CGCAGCAACT GGGGCACGCT
Ugd2 GAATCCAACG GATTTGACAT CGTGTTCCCC ATGGTCGTGC CGCAGCAACT GGGGCACGCT
U gd23 GAATCCAACG GATTTGACAT CGTGTTCCCC ATGGTCGTGC CTCAGCAACT GGGGCACGCT
U gdlO GAATCCAACG GATTTGACCT CGTGTTCCCC ATGGTCGTGC CGCAGCAACT GGGGCACGCT
U g d l5 GAATCCAACG GATTTGACCT CGTGTTCCCC ATGGTCGTGC CGCAGCAACT GGGGCACGCT
U g d l6 GAATCCAACG GATTTGACCT CGTGTTCCCC ATGGTCGTGC CGCAGCAACT GGGGCACGCT
Ugd2 9 GAATCCAACG GATTTGACCT CGTGTTCCCC ATGGTCGTGC CGCAGCAACT GGGGCACGCT
Ugd4 GAATCCAACG GATTTGACCT CGTGTTCCCC ATGGTCGTGC CGCAGCAACT GGGGCACGCT
BC-1 GAATCCAACG GATTTGACCT CGTGTTCCCC ATGGTCGTGC CGCAGCAACT GGGGCACGCT
C ons GAATCCAACG GATTTGAC-T CGTGTTCCCC ATGGTCGTGC C-CAGCAACT GGGGCACGCT
G/M
361 ★ 420
U g d l2 ATTCTGCAGC ag |c t g )t t g g t GTACCACATC TACTCCAAAA TATCGGCCGG g g c c c c g Iggt]
U g d l 9 ATTCTGCAGC AGCTGTTGGT GTACCACATC TACTCCAAAA TATCGGCCGG GGCCCCGGGT
Ugd2 ATTCTGCAGC AGCTGTTGGT GTACCACATC TACTCCAAAA TATCGGCCGG GGCCCCGGGT
U gd23 ATTCTGCAGC AGCTGTTGGT GTACCACATC TACTCCAAAA TATCGGCCGG GGCCCCGGGT
U gdlO ATTCTGCAGC AGTTGTTGGT GTACCACATC TACTCCAAAA TATCGGCCGG GGCCCCGGAT
U g d l5 ATTCTGCAGC AGTTGTTGGT GTACCACATC TACTCCAAAA TATCGGCCGG GGCCCCGGAT
U g d l 6 ATTCTGCAGC AGTTGTTGGT GTACCACATC TACTCCAAAA TATCGGCCGG GGCCCCGGAT
U gd29 ATTCTGCAGC AGTTGTTGGT GTACCACATC TACTCCAAAA TATCGGCCGG GGCCCCGGAT
Ugd4 ATTCTGCAGC AGTTGTTGGT GTACCACATC TACTCCAAAA TATCGGCCGG GGCCCCGGAT
BC-1 ATTCTGCAGC AGCTGTTGGT GTACCACATC TACTCCAAAA TATCGGCCGG GGCCCCGGAT
C ons ATTCTGCAGC AG-TGTTGGT GTACCACATC TACTCCAAAA TATCGGCCGG GGCCCCGG-T
421 * 480
U g d l2 g a tIg t c Ia a ta TGGCGGAACT TGATCTATAT ACCACCAATG TGTCATTTAT GGGGCGCACA
U g d l 9 GATGTCAATA TGGCGGAACT TGATCTATAT ACCACCAATG TGTCATTTAT GGGGCGCACA
Ugd2 GATGTCAATA TGGCGGAACT TGATCTATAT ACCACCAATG TGTCATTTAT GGGGCGCACA
U gd23 GATGTCAATA TGGCGGAACT TGATCTATAT ACCACCAATG TGTCATTTAT GGGGCGCACA
U gdlO GATGTCAATA TGGCGGAACT TGATCTATAT ACCACCAATG TGTCATTTAT GGGGCGCACA
U g d l5 GATGTCAATA TGGCGGAACT TGATCTATAT ACCACCAATG TGTCATTTAT GGGGCGCACA
U g d l6 GATGTCAATA TGGCGGAACT TGATCTATAT ACCACCAATG TGTCATTTAT GGGGCGCACA
U gd29 GATGTCAATA TGGCGGAACT TGATCTATAT ACCACCAATG TGTCATTTAT GGGGCGCACA
Ugd4 GATGTCAATA TGGCGGAACT TGATCTATAT ACCACCAATG TGTCATTTAT GGGGCGCACA
B C-1 GATGTAAATA TGGCGGAACT TGATCTATAT ACCACCAATG TGTCATTTAT GGGGCGCACA
C ons GATGT-AATA TGGCGGAACT TGATCTATAT ACCACCAATG TGTCATTTAT GGGGCGCACA
481 495
U g d l2 TATCGTCTGG ACGTA
U g d l9 TATCGTCTGG ACGTA
Ugd2 TATCGTCTGG ACGTA
U gd23 TATCGTCTGG ACGTA
U gdlO TATCGTCTGG ACGTA
U g d l5 TATCGTCTGG ACGTA
U g d l 6 TATCGTCTGG ACGTA
Ugd2 9 TATCGTCTGG ACGTA
Ugd4 TATCGTCTGG ACGTA
B C-1 TATCGTCTGG ACGTA




U g d l2
U g d l5











































































U gdlO  
U g d l2  
U g d l5  












































































U gdlO  
U g d l2  
U g d l5  













































































U g d l2
U g d l5












































































U gdlO  
U g d l2  
U g d l5  













































































U g d l2
U g d l5








U gdlO  
U g d l2  
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1 p / L, * 60 
u g d l  9 g t c Ic c g Ig a tg  t g t t a c t a a a  t g g g tg g c g c  tggaggIc t t Ig g g g c g a ta c c  a c c a c t c g t t
Ugd2 GTCCCGGATG TGTTACTAAA TGGGTGGCGC TGGAGGCTCG GGGCGATACC ACCACTCGTT
U g d l2 GTCCCGGATG TGTTACTAAA TGGGTGGCGC TGGAGGCTTG GGGCGATACC ACCACTCGTT
U g d l6 GTCCCGGATG TGTTACTAAA TGGGTGGCGC TGGAGGCTTG GGGCGATACC ACCACTCGTT
U gd29 GTCCCGGATG TGTTACTAAA TGGGTGGCGC TGGAGGCTTG GGGCGATACC ACCACTCGTT
U gd23 GTCCCGGATG TGTTACTAAA TGGGTGGCGC TGGAGGCTTG GGGCGATACC ACCACTCGTT
Ugd4 GTCCTGGATG TGTTACTAAA TGGGTGGCGC TGGAGGCTTG GGGCGATACC ACCACTCGTT
BC-1 GTCCCGGATG TGTTACTAAA TGGGTGGCGC TGGAGGCTTG GGGCGATACC ACCACTCGTT
U gdlO  GTCCCGGATG TGTTACTAAA TGGGTGGCGC TGGAGGCTTG GGGCGATACC ACCACTCGTT
U g d l5 GTCCCGGATG TGTTACTAAA TGGGTGGCGC TGGAGGCTTG GGGCGATACC ACCACTCGTT
C ons GTCC-GGATG TGTTACTAAA TGGGTGGCGC TGGAGGCT-G GGGCGATACC ACCACTCGTT
U g d l9
Ugd2
U g d l2






U g d l5
C ons
61 L /V
























































A / P  * 120












U g d l9 ACACGAGTTG CAACGGGCGC GCACTGAAGC TAGCGTG. . . CCCTCCCGAA GAGTGTCAGT
Ugd2 ACACGAGTTG CAACGGGCGC GCACTGAAGC TAGCGTG. . . CCCTCCCGAA GAGTGTCAGT
U g d l2 ACACGAGTTG CAACGGGCGC GCACTGAAGC TAGCGTG. . . CCCTCCCGAA GAGTGTCAGT
U g d l6 ACACGAGTTG CAACGGGCGC GCACTGAAGC TAGCGTG. . . CCCTCCCGAG GAGTGTCAGT
Ugd2 9 ACACGAGTTG CAACGGGCGC GCACTGAAGC TAGCGTG. - . CCCTCTCGAG GAGTGTCAGT
U gd23 ACACGAGTTG CAACGGGCGC GCACTGAAGC TAGCGTG. . . CCCTCCCGAG GAGTGTCAGT
Ugd4 ACACGAGTTG CAACGGGCGC GCACTGAAGC TAGCGTG. . . CCCTCCCGAG GAGTGTCAGT
BC-1 ACACGAGTTG CAACGGGCGC GCACTGAAGC TAGCGTG. . . CCCTCCCAAA GAGTGTCAGT
U gdlO ACACGAGTTG CAACGGGCGC GCACTGAAGC TAGCGTG. . . CCCTCCCGAA GAGTGTCAGT
U g d l5 ACACGAGTTG CAACGGGCGC GCACTGAAGC TAGCGTGCCC CCCCCCCGAG GAGTGTCAGT
C ons ACACGAGTTG CAACGGGCGC GCACTGAAGC TAGCGTG----- C C C -C -C -A - GAGTGTCAGT
181 240
U g d l9 AAAATAAAAT ACAAAAACAC AATCACGGTT GCACCAAGCA CAACATCAAA CACATACAAT
Ugd2 AAAATAAAAT ACAAAAACAC AATCACGGTT GCACCAAGCA CAACATCAAA CACATACAAT
U g d l2 AAAATAAAAT ACAAAAACAC AATCACGGTT GCACCAAGCA CAACATCAAA CACATACAAT
U g d l6 AAAATAAAAT ACAAAAACAC AATCACGGTT GCACCAAGCA CAACATCAAA CACATACAAT
U gd29 AAAATAAAAT ACAAAAACAC AATCACGGTT GCACCAAGCA CAACATCAAA CACATACAAT
U gd23 AAAATAAAAT ACAAAAACAC AATCACGGTT GCACCAAGCA CAACATCAAA CACATACAAT
Ugd4 AAAATAAAAT ACAAAAACAC AATCACGGTT GCACCAAGCA CAACATCAAA CACATACAAT
B C-1 AAAATAAAAT ACAAAAACAC AATCACGGTT GCACCAAGCA CAACATTAAA CACATACAAT
U gdlO  AAAATAAAAT ACAAAAACAC AATCACGGTT GCACCAAGCA CAACATCAAA CACATACAAT
U g d l5 AAAATAAAAT ACAAAAACAC AATCACGGTT GCACCAAGCA CAACATCAAA CACATACAAT
C ons AAAATAAAAT ACAAAAACAC AATCACGGTT GCACCAAGCA CAACAT--AAA CACATACAAT
241  300
U g d l9 GCTGAAGAGT AGGAGTATCG AGGGCATATC CGTGGCTCAT AACACAGTCA CAGTTCAGAA
Ugd2 GCTGAAGAGT AGGAGTATCG AGGGCATATC CGTGGCTCAT AACACAGTCA CAGTTCAGAA
U g d l2 GCTGAAGAGT AGGAGTATCG AGGGCATATC CGTGGCTCAT AACACAGTCA CAGTTCAGAA
U g d l6 GCTGAAGAGC AGGCGTATCG AGGGCATACC CGTGGCTCAT AACACAGTCA CAGTTCAGAA
U gd29 GCTGAAGAGC AGGCGTATCG AGGGCATACC CGTGGCTCAT AACACAGTCA CAGTTCAGAA
U gd23 GCTGAAGAGC AGGCGTATCG AGGGCATACC CGTGGCTCAT AACACAGTCA CAGTTCAGAA
Ugd4 GCTGAAGAGC AGGCGTATCG AGGGCATACC CGTGGCTCAT AACACAGTCA CAGTTCAGAA
BC-1 GCTGAAGAGC AGGCGTATCG AGGGCATACC CGTGGCTCAT AACACAGTCA CAGTTCAGAT
U gdlO  CCTGAAGAGC AGGCGTATCG AGGGCATACC CGTGGCTCAT AACACAGTCA CAGTTCAGAA
U g d l5 GCTGAAGAGC AGGCGTATCG AGGGCATACC CGTGGCTCAT AACACAGTCA CAGTTCAGAA
C ons -CTGAAGAG- AGG-GTATCG AGGGCATA-C CGTGGCTCAT AACACAGTCA CAGTTCAGA-
U g d l9  
Ugd2 
U g d l2  





U gdlO  
U g d l5  





































































U g d l 9 
Ugd2 
U g d l2  





U gdlO  
U g d l5  





































































U g d l 9 
Ugd2 
U g d l2  





U gdlO  






































































U g d l9  
Ugd2 
U g d l2  





U gdlO  






































































U g d l9  
Ugd2 
U g d l2  





U gdlO  

















U g d l5  




U g d l2  
U g d l 9 
Ugd2 





















































































U g d l5  




U g d l2  
U g d l9  
Ugd2 
U gdlO  
BC-1 
C ons
61 * S /N

















































































U g d l5
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U g d l5
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U g d l5  




U g d l2  
U g d l9  
Ugd2 
U gdlO  
B C-1 
C o n s
BCBL-R 
GK18 
U g d l5  




U g d l2  
U g d l9  
Ugd2 
U gdlO  
B C-1 
C o n s
BCBL-R 
GK18 
U g d l5  
U g d l6  
U gd2 3 
U gd2 9 
Ugd4 
U g d l2  
U g d l 9 
Ugd2 
U gdlO  
B C-1 
C o n s
BCBL-R 
GK18 
U g d l5  




U g d l2  
U g d l 9 
Ugd2 
U gdlO  
BC-1 
C ons
241 A / P / v  G /E 300
c a t g t c a t c a  g g c g g t c t |c c  g|cc a c g g |ggg | AGCGAGCGTG TTGTATCCTT TGGCTACGGG
CATGTCATCA GGCGGTCTCC GCCACGGGGG AGCGAGCGTG TTGTATCCTT TGGCTACGGG
CATGTCATCA GGCGGTCTCC GCCACGGGGG AGCGAGCGTG TTGTATCCTT TGGCTACGGG
CATGTCATCA GGCGGTCTCC GCCACGGGGG AGCGAGCGTG TTGTATCCTT TGGCTACGGG
CATGTCATCA GGCGGTCTCC GCCACGGGGG AGCGAGCGTG TTGTATCCTT TGGCTACGGG
CATGTCATCA GGCGGTCTCC GCCACGGGGG AGCGAGCGTG TTGTATCCTT TGGCTACGGG
CATGTCATCA GGCGGTCTCC GCCACGGGGG AGCGAGCGTG TTGTATCCTT TGGCTACGGG
CATGTCATCA GGCGGTCTGC GCCACGGGGG AGCGAGCGTG TTGTATCCTT TGGCTACGGG
CATGTCATCA GGCGGTCTGC GCCACGGGGG AGCGAGCGTG TTGTATCCTT TGGCTACGGG
CATGTCATCA GGCGGTCTGC GCCACGGGGG AGCGAGCGTG TTGTATCCTT TGGCTACGGG
CATGTCATCA GGCGGTCTGC GCCACGGGAG AGCGAGCGTG TTGTATCCTT TGGCTACGGG
CATGTCATCA GGCGGTCTGT GCCACGGGGG AGCGAGCGTG TTGTATCCTT TGGCTACGGG
CATGTCATCA GGCGGTCT-- GCCACGGG-G AGCGAGCGTG TTGTATCCTT TGGCTACGGG
301 I /M  N/H * * * A /G  * *
c c a a a c |a t a a  ac |ca c |agg |cc  cacaaca |ctg | |t c a |a cag ag c  t t |g g a g t t t t
CCAAACATAA ACCACAGGCC CACAACACTG TCAACAGAGC TTGGAGTTTT 
CCAAACATAA ACCACAGGCC CACAACACTG TCAACAGAGC TTGGAGTTTT 
CCAAACATAA ACCACAGGCC CACAACACTG TCAACAGAGC TTGGAGTTTT 
CCAAACATAA ACCACAGGCC CACAACACTG TCAACAGAGC TTGGAGTTTT 
CCAAACATAA ACCACAGGCC CACAACACTG TCAACAGAGC TTGGAGTTTT 
CCAAACATAA ACCACAGGCC CACAACACTG TCAACAGAGC TTGGAGTTTT 
CCAAACATAA ACCACAGGCC CACAACACTG TCAACAGAGC TTGCAGTTTT 
CCAAACATAA ACCACAGGCC CACAACACTG TCAACAGAGC TTGCAGTTTT 
CCAAACATAA ACCACAGGCC CACAACACTG TCAACAGAGC TTGCAGTTTT 
CCAAACATAA ACCACAGGCC CACAACACTG TCCACAGAGC TTGCAGTGTT 
CCAAACATGC ACCACCGGCC CACAACATTG TCAACAGAGC TTGCAGTTCT 
CCAAACAT-- ACCAC-GGCC CACAACA-TG TC-ACAGAGC TTG -A G T--T
R/Q  360







































































































































BCBL-R CTGGTACCGT ACGAGGGGTT GGAAGTGCCC GAGGGTCCCC AGCCCGTGGC TAGGCCACAC
GK18 CTGGTACCGT ACGAGGGGTT GGAAGTGCCC GAGGGTCCCC AGCCCGTGGC TAGGCCACAC
U g d l5 CTGGTACCGT ACGAGGGGTT GGAAGTGCCC GAGGGTCCCC AGCCCGTGGC TAGGCCACAC
U g d l6 CTGGTACCGT ACGAGGGGTT GGAAGTGCCC GAGGGTCCCC AGCCCGTGGC TAGGCCACAC
U gd23 CTGGTACCGT ACGAGGGGTT GGAAGTGCCC GAGGGTCCCC AGCCCGTGGC TAGGCCACAC
U gd29 CTGGTACCGT ACGAGGGGTT GGAAGTGCCC GAGGGTCCCC AGCCCGTGGC TAGGCCACAC
Ugd4 CTGGTACCGT ACGAGGGGTT GGAAGTGCCC GAGGGTCCCC AGCCCGTGGC TAGGCCACAC
U g d l2 CTGGTACCGT ACGAGGGGTT GGAAGTGCCC GAGGGTCCCC AGCCCGTGGC TAGGCCACAC
U g d l 9 CTGGTACCGT ACGAGGGGTT GGAAGTGCCC GAGGGTCCCC AGCCCGTGGC TAGGCCACAC
Ugd2 CTGGTACCGT ACGAGGGGTT GGAAGTGCCC GAGGGTCCCC AGCCCGTGGC TAGGCCACAC
U gdlO CTGGTACCGT ACGAGGGGTT GGAAGTGCCC GAGGGTCCCC AGCCCGTGGC TAGGCCACAC
BC-1 CTGGTACCGT ACGAGGGGTT GGAAGTGCCC GAGGGTCCCC AGCCCGTGGC TAGGCCACAC
C ons CTGGTACCGT ACGAGGGGTT GGAAGTGCCC GAGGGTCCCC AGCCCGTGGC TAGGCCACAC
541 578
BCBL-R ATTGAAGATG ATGTCATTAT GCAGGCTGTT ATGATATC
GK18 ATTGAAGATG ATGTCATTAT GCAGGCTGTT ATGATATC
U g d l5 ATTGAAGATG ATGTCATTAT GCAGGCTGTT ATGATATC
U g d l6 ATTGAAGATG ATGTCATTAT GCAGGCTGTT ATGATATC
Ugd23 ATTGAAGATG ATGTCATTAT GCAGGCTGTT ATGATATC
U gd29 ATTGAAGATG ATGTCATTAT GCAGGCTGTT ATGATATC
Ugd4 ATTGAAGATG ATGTCATTAT GCAGGCTGTT ATGATATC
U g d l2 ATTGAAGATG ATGTCATTAT GCAGGCTGTT ATGATATC
U g d l9 ATTGAAGATG ATGTCATTAT GCAGGCTGTT ATGATATC
Ugd2 ATTGAAGATG ATGTCATTAT GCAGGCTGTT ATGATATC
U gdlO ATTGAAGATG ATGTCATTAT GCAGGCTGTT ATGATATC
BC-1 ATTGAAGATG ATGTCATTAT GCAGGCTGTT ATGATATC
C ons ATTGAAGATG ATGTCATTAT GCAGGCTGTT ATGATATC
Fig. 6.3. Networks displaying relationships among DNA sequences in (A) 
K3-ORF26, (B) K9-T0.7/K12, (C) ORF75 and (D) K15 P loci.
Alignments were made consisting o f sequences o f the Ugandan strains and those 
of BC-1, BCBL-R and GK18. The length of the alignments and the number of 
substitution sites used to construct the networks are indicated. All substitution 
sites were used with the exception o f one independently mutated site in T0.7/K12 
(see text). Samples are represented by circles, whose sizes are proportional to the 
number o f samples. Each subdivision represents a single substitution site; the 
asterisk indicates the single site in K9. Deletions are not represented. Rory 
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Kl 0 3 A-(BC-1, Ugd4, Ugdl2, Ugdl6)
B-(Ugd2, UgdlO, Ugdl5, Ugdl9, Ugd29) 
C-(Ugd23)
K3-ORF26 0.35 4 (BC-1)
(Ugd2, Ugdl 2, Ugdl 9)
(Ugd4, UgdlO, Ugdl5, Ugdl6 , Ugd29) 
(Ugd23)
K9-T0.7/K12 0.85 3 (BC-1, UgdlO)
(Ugd2, Ugdl2, Ugdl 9)
(Ugd4, Ugdl5, Ugdl6 , Ugd23, Ugd29)
ORF75 0.97 3 (BC-1, UgdlO)
(Ugd2, Ugdl2, Ugdl9)
(Ugd4, Ugdl5, Ugdl6 , Ugd23, Ugd29, GK18, BCBL-R)
K15 1.0 3 Same as for ORF75
a Strains that belong to the same group are enclosed in parentheses.
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T0.7/K12, ORF75 and K15, suggesting recombination between ORF26 and K9- 
T0.7/K12. Thirdly, the K l C variant (Ugd23) has a distinct sequence at K3- 
ORF26, but clusters with other Ugandan strains at the three remaining loci, 
suggesting recombination between ORF26 and K9-T0.7/K12.
There is no evidence for recombination in strains Ugd2, U gd l5, U gdl9 and 
Ugd29, as they co-segregate at all seven loci, Ugd2/19 in one group and 
U gdl5/29 in another group. Moreover, all strains co-segregate in K9-T0.7/K12, 
ORF75 and K15, thus providing no evidence for recombination within this 
region. Also, no evidence for recombination was noted within the loci examined.
Thus, network analysis, which is independent o f previous categorisations of 
nucleotide pattern, indicates that five of the nine Ugandan strains (Ugd4, UgdlO, 
U gdl2, U gdl6 and Ugd23) are recombinants. It provides evidence for 
recombination between K l and K3 and between ORF26 and T0.7/K12 in certain 
strains, but not between the three loci towards the right end of the genome.
6.4 VARIABILITY WITHIN THE LOCI
Variability among the Ugandan sequences at each locus was examined. Ten 
substitutions (nine synonymous and one non-synonymous) were identified in K3 
(Fig. 6.2A), while six (three synonymous and three non-synonymous) were 
identified in ORF26 (Fig. 6.2B). Deletions were present in neither gene 
collection. Pairwise comparisons for K3 and ORF26 combined show a 
divergence among the sequences ranging from 0% (in identical sequences e.g. 
Ugd2/12/19; Fig. 6.3A) to 1% (between Ugd4/10 and Ugd2/12/19).
One synonymous substitution was identified in K9.
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In T0.7/K12, all the sequences are different from each other (Fig. 6.3B). A total 
of 25 substitutions (24 shown in Fig. 6.3B) plus a unique 3-bp insertion in 
U gd l5 (Fig. 6.2D and 6.4B; see below) were identified. Seven (of which four are 
non-synonymous and three synonymous) are in the K12 gene and the rest are in 
the non-coding region (Fig. 6.2D). The synonymous substitution (position 90 in 
Fig. 6.2D) is not represented in the network (Fig. 6.3B) because it could not be 
resolved into a single mutation event. At this position, sequences UgdlO, U gdl2, 
U gdl6 and Ugd29 possess an A residue whereas all the other sequences possess 
a G residue. It is difficult to envisage a recombination event that could produce 
this polymorphism. Thus, the site most likely resulted from multiple independent 
mutations. This is the first time this observation has been made in T0.7/K12. All 
sequences published previously have a G residue at this position (Fig. 6.4B 
below).
Divergence in T0.7/K12 (shown in Table 6.2) ranges from 0.2% (Ugd4 vs. 
U gdl6) to 2.4% (BC-1 vs. U gdl2). That within the P-linked and within the two 
M-linked strains is 0.2-2.0% and 1.6%, respectively. Divergence between the M- 
and P-linked strains ranges from 1.5% (between UgdlO and Ugd23) to 2.4% 
(between BC-1 and U gdl2).
Sixteeen substitutions (eight synonymous and eight non-synonymous) were 
identified in ORF75 (Fig. 6.2E and 6.3C). No deletions were present. UgdlO and 
BC-1 each have eight and three unique mutations, respectively. Two groups of 
strains linked to the P allele are also evident at this locus, and the strains in each 
group are identical (Fig. 6.3C). Divergence between these two groups is minimal 
(0.5%; Table 6.2). The M-linked strains, on the other hand, show a considerably 
higher divergence (1.9%), almost four-fold compared to K15 P strains. 
Divergence between UgdlO and the K15 P strains (0.9-1.4%) is less than that 
between UgdlO and BC-1 (1.9%), indicating that UgdlO is more closely related
Table 6.2. Pairwise divergence values8 within and between groups in T0.7/K12, 
ORF75 and UPS75’
T0.7/K12 ORF75 UPS75’
Size (bp) 548 578 209
Within Ugd2/12/19 (P) 0.2-0.4 0 0-0.5
Within Ugd4/15/16/23/29 (P) 0.4-1.1 0 0-0.5
Between Ugd2/12/19 (P) and 
Ugd4/15/16/23/29 (P)
1.1-2.0 0.5 0.5-1.4
Between UgdlO (M) and 
BC-1 (M)
1.6 1.9 0
Between UgdlO (M) and 
Ugd2/12/19 (P)
1.8-2.2 0.9 13.9-14.4
Between UgdlO (M) and 
Ugd4/15/16/23/29 (P)
1.5-2.0 1.4 14.4-15.0
Between BC-1 (M) and 
Ugd2/12/19 (P)
2.0-2.4 1.7 13.9-14.4
Between BC-1 (M) and 
Ugd4/15/16/23/29 (P)
1.6-2.2 2.2 14.4-15.0
Expressed as the percentage of substitutions per nucleotide. Ranges are given.
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to the K15 P strains, in particular Ugd2/12/19 (from which it diverges by 0.9%), 
than to BC-1.
6.5 ANALYSIS OF ORF26, T0.7/K12 AND ORF75 SEQUENCES WITH 
PUBLISHED DATA
All the Ugandan sequences (30 for ORF26 and 10 each for T0.7/K12 and 
ORF75) were compared with sequences obtained from GenBank or published 
literature (Alagiozoglou et al., 2000; Poole et al., 1999; Zong et al., 1997). 
Where possible, all the groups identified previously were represented. This 
analysis enabled the Ugandan sequences to be categorised according to the 
genotypes established by Poole et al. (1999).
Sequences for ORF26, T0.7/K12, and some for ORF75 were generated from the 
listings of polymorphic sites and other information given by the authors (Poole et 
al., 1999; Zong et al., 1997). The alignments are shown in Fig. 6.4 (A, B, C). 
ORF75 sequences from South Africa were available from GenBank 
(Alagiozoglou et al., 2000). This alignment is shown in Fig. 6.4D. Two separate 
analyses were performed for ORF75, one comprising sequences generated from 
data by Zong et al. (1997) (Fig. 6.4C) and one comprising South African 
sequences (Fig. 6.4D). In the former case, ORF75 was analysed in conjunction 
with the 209 bp region (designated UPS75’) which extends upstream from 
ORF75 to the point where the M and P alleles become distinct (Fig. 6.4C; Fig.
5.3 and 5.5).
The summarized data showing only substitution sites for sequences in this study 
and representative published sequences are shown in Fig. 6.5.
Fig. 6.4. Alignments of (A) ORF26, (B) T0.7/K12, (C) ORF75-UPS75’ and 
(D) ORF75 DNA sequences of Ugandan and published strains.
Sequences of Ugandan strains (bold-only the first lines) were compared with 
published sequences (Alagiozoglou et al., 2000; Glenn et al., 1999; Poole et al., 
1999; Zong et al., 1997). BCBL-R sequence is identical to that of BC-1 in (A), as 
is Ugdl2 and Ugdl5 to Ugd2/19 and Ugd4/16/23/29/BCBL-R/GK18, 
respectively, in (D). The groups to which sequences were (previous studies) or 
are (this study) assigned are indicated to the right o f the first 6 blocks of each 
alignment. (A, C) are in the same orientation as the genomic sequence, and (B, 
D) are in the opposite orientation. Coordinates in the BC-1 genome for each loci: 
A, 47193-47490; B, 118065-117518; C, 133864-134650; D, 134441-133866. 
Positions of nucleotide changes are shown in bold-red, with the deletion (in B) 




GGATCCCTCT GACAACCTTC AGATAAAAAA CGTATATGCC CCCTTTTTTC
60
AGTGGGACAG
E r l a GGATCCCTCT GACAACCTTC AGATAAAAAA CGTATATGCC CCCTTTTTTC AGTGGGACAG
BCBL1 GGATCCCTCT GACAACCTTC AGATAAAAAA CGTATATGCC CCCTTTTTTC AGTGGGACAG
BC2 GGATCCCTCT GACAACCTTC AGATAAAAAA CGTATATGCC CCCTTTTTTC AGTGGGACAG
Ugd23 GGATCCCTCT GACAACCTTC AGATAAAAAA CGTATATGCC CCCTTTTTTC AGTGGGACAG
431KAP GGATCCCTCT GACAACCTTC AGATAAAAAA CGTATATGCC CCCTTTTTTC AGTGGGACAG
Ugd30 GGATCCCTCT GACAACCTTC AGATAAAAAA CGTATATGCC CCCTTTTTTC AGTGGGACAG
S T 2 -3 GGATCCCTCT GACAACCTTC AGATAAAAAA CGTATATGCC CCCTTTTTTC AGTGGGACAG
Ugdl GGATCCCTCT GACAACCTTC AGATAAAAAA CGTATATGCC CCCTTTTTTC AGTGGGACAG
Ugdl 2 GGATCCCTCT GACAACCTTC AGATAAAAAA CGTATATGCC CCCTTTTTTC AGTGGGACAG
Ugdl 9 GGATCCCTCT GACAACCTTC AGATAAAAAA CGTATATGCC CCCTTTTTTC AGTGGGACAG
Ugd2 GGATCCCTCT GACAACCTTC AGATAAAAAA CGTATATGCC CCCTTTTTTC AGTGGGACAG
Ugd21 GGATCCCTCT GACAACCTTC AGATAAAAAA CGTATATGCC CCCTTTTTTC AGTGGGACAG
Ugd26 GGATCCCTCT GACAACCTTC AGATAAAAAA CGTATATGCC CCCTTTTTTC AGTGGGACAG
Ugd7 GGATCCCTCT GACAACCTTC AGATAAAAAA CGTATATGCC CCCTTTTTTC AGTGGGACAG
Ugd8 GGATCCCTCT GACAACCTTC AGATAAAAAA CGTATATGCC CCCTTTTTTC AGTGGGACAG
Ugd9 GGATCCCTCT GACAACCTTC AGATAAAAAA CGTATATGCC CCCTTTTTTC AGTGGGACAG
OKS 3 GGATCCCTCT GACAACCTTC AGATAAAAAA CGTATATGCC CCCTTTTTTC AGTGGGACAG
UgdlO GGATCCCTCT GACAACCTTC AGATAAAAAA CGTATATGCC CCCTTTTTTC AGTGGGACAG
Ugdll GGATCCCTCT GACAACCTTC AGATAAAAAA CGTATATGCC CCCTTTTTTC AGTGGGACAG
Ugdl 4 GGATCCCTCT GACAACCTTC AGATAAAAAA CGTATATGCC CCCTTTTTTC AGTGGGACAG
Ugdl 5 GGATCCCTCT GACAACCTTC AGATAAAAAA CGTATATGCC CCCTTTTTTC AGTGGGACAG
Ugdl 6 GGATCCCTCT GACAACCTTC AGATAAAAAA CGTATATGCC CCCTTTTTTC AGTGGGACAG
Ugdl 7 GGATCCCTCT GACAACCTTC AGATAAAAAA CGTATATGCC CCCTTTTTTC AGTGGGACAG
Ugdl 8 GGATCCCTCT GACAACCTTC AGATAAAAAA CGTATATGCC CCCTTTTTTC AGTGGGACAG
Ugd20 GGATCCCTCT GACAACCTTC AGATAAAAAA CGTATATGCC CCCTTTTTTC AGTGGGACAG
Ugd22 GGATCCCTCT GACAACCTTC AGATAAAAAA CGTATATGCC CCCTTTTTTC AGTGGGACAG
Ugd24 GGATCCCTCT GACAACCTTC AGATAAAAAA CGTATATGCC CCCTTTTTTC AGTGGGACAG
Ugd27 GGATCCCTCT GACAACCTTC AGATAAAAAA CGTATATGCC CCCTTTTTTC AGTGGGACAG
Ugd28 GGATCCCTCT GACAACCTTC AGATAAAAAA CGTATATGCC CCCTTTTTTC AGTGGGACAG
Ugd29 GGATCCCTCT GACAACCTTC AGATAAAAAA CGTATATGCC CCCTTTTTTC AGTGGGACAG
Ugd3 GGATCCCTCT GACAACCTTC AGATAAAAAA CGTATATGCC CCCTTTTTTC AGTGGGACAG
Ugd4 GGATCCCTCT GACAACCTTC AGATAAAAAA CGTATATGCC CCCTTTTTTC AGTGGGACAG
Ugd5 GGATCCCTCT GACAACCTTC AGATAAAAAA CGTATATGCC CCCTTTTTTC AGTGGGACAG
Ugd6 GGATCCCTCT GACAACCTTC AGATAAAAAA CGTATATGCC CCCTTTTTTC AGTGGGACAG
ASM72 GGATCCCTCT GACAACCTTC AGATAAAAAA CGTATATGCC CCCTTTTTTC AGTGGGACAG
TKS1 GGATCCCTCT GACAACCTTC AGATAAAAAA CGTATATGCC CCATTTTTTC AGTGGGACAG
Ugdl 3 GGATCCCTCT GACAACCTTC AGATAAAAAA CGTATATGCC CCCTTTTTTC AGTGGGACAG
Ugd25 GGATCCCTCT GACAACCTTC AGATAAAAAA CGTATATGCC CCCTTTTTTC AGTGGGACAG
ZKS6 GGATCCCTCT GACAACCTTC AGATAAAAAA CGTATATGCC CCCTTTTTTC AGTGGGACAG
C ons GGATCCCTCT GACAACCTTC AGATAAAAAA CGTATATGCC CC-TTTTTTC AGTGGGACAG
BCBL-R
61
CAACACCCAG CTAGCAGTGC TACCCCCATT TTTTAGCCGA AAGGATTCCA
120
CCATTGTGCT
E r l a CAACACCCAG CTAGCAGTGC TACCCCCATT TTTTAGCCGA AAGGATTCCA CCATTGTGCT
BCBL1 CAACACCCAG CTAGCAGTGC TACCCCCATT TTTTAGCCGA AAGGATTCCA CCATTGTGCT
BC2 CAACACCCAG CTAGCAGTGC TACCCCCACT TTTTAGCCGA AAGGATTCCA CCATTGTGCT
U gd23 CAACACCCAG CTAGCAGTGC TACCCCCACT TTTTAGCCGA AAGGATTCCA CCATTGTGCT
431KAP CAACACCCAG CTAGCAGTGC TACCCCCACT TTTTAGCCGA AAGGATTCCA CCATTGTGCT
U gd30 CAACACCCAG CTAGCAGTGC TACCCCCACT TTTTAGCCGA AAGGATTCCA CCATTGTGCT
S T 2 -3 CAACACCCAG CTAGCAGTGC TACCCCCACT TTTTAGCCGA AAGGATTCCA CCATTGTGCT
U g d l CAACACCCAG CTAGCAGTGC TACCCCCACT TTTTAGCCGA AAGGATTCCA CCATTGTGCT
U g d l2 CAACACCCAG CTAGCAGTGC TACCCCCACT TTTTAGCCGA AAGGATTCCA CCATTGTGCT
U g d l9 CAACACCCAG CTAGCAGTGC TACCCCCACT TTTTAGCCGA AAGGATTCCA CCATTGTGCT
Ugd2 CAACACCCAG CTAGCAGTGC TACCCCCACT TTTTAGCCGA AAGGATTCCA CCATTGTGCT
U gd21 CAACACCCAG CTAGCAGTGC TACCCCCACT TTTTAGCCGA AAGGATTCCA CCATTGTGCT
U gd26 CAACACCCAG CTAGCAGTGC TACCCCCACT TTTTAGCCGA AAGGATTCCA CCATTGTGCT
Ugd7 CAACACCCAG CTAGCAGTGC TACCCCCACT TTTTAGCCGA AAGGATTCCA CCATTGTGCT
Ugd8 CAACACCCAG CTAGCAGTGC TACCCCCACT TTTTAGCCGA AAGGATTCCA CCATTGTGCT
Ugd9 CAACACCCAG CTAGCAGTGC TACCCCCACT TTTTAGCCGA AAGGATTCCA CCATTGTGCT
OKS 3 CAACACCCAG CTAGCAGTGC TACCCCCACT TTTTAGCCGA AAGGATTCCA CCATTGTGCT
U gdlO CAACACCCAG CTAGCAGTGC TACCCCCACT TTTTAGCCGA AAGGATTCCA CCATTGTGCT
U g d l l CAACACCCAG CTAGCAGTGC TACCCCCACT TTTTAGCCGA AAGGATTCCA CCATTGTGCT
U g d l4 CAACACCCAG CTAGCAGTGC TACCCCCACT TTTTAGCCGA AAGGATTCCA CCATTGTGCT
U g d l5 CAACACCCAG CTAGCAGTGC TACCCCCACT TTTTAGCCGA AAGGATTCCA CCATTGTGCT
U g d l6 CAACACCCAG CTAGCAGTGC TACCCCCACT TTTTAGCCGA AAGGATTCCA CCATTGTGCT
U g d l7 CAACACCCAG CTAGCAGTGC TACCCCCACT TTTTAGCCGA AAGGATTCCA CCATTGTGCT
U g d l8 CAACACCCAG CTAGCAGTGC TACCCCCACT TTTTAGCCGA AAGGATTCCA CCATTGTGCT
U gd20 CAACACCCAG CTAGCAGTGC TACCCCCACT TTTTAGCCGA AAGGATTCCA CCATTGTGCT
U gd22 CAACACCCAG CTAGCAGTGC TACCCCCACT TTTTAGCCGA AAGGATTCCA CCATTGTGCT
Ugd24 CAACACCCAG CTAGCAGTGC TACCCCCACT TTTTAGCCGA AAGGATTCCA CCATTGTGCT
Ugd27 CAACACCCAG CTAGCAGTGC TACCCCCACT TTTTAGCCGA AAGGATTCCA CCATTGTGCT
U gd28 CAACACCCAG CTAGCAGTGC TACCCCCACT TTTTAGCCGA AAGGATTCCA CCATTGTGCT
Ugd2 9 CAACACCCAG CTAGCAGTGC TACCCCCACT TTTTAGCCGA AAGGATTCCA CCATTGTGCT
Ugd3 CAACACCCAG CTAGCAGTGC TACCCCCACT TTTTAGCCGA AAGGATTCCA CCATTGTGCT
Ugd4 CAACACCCAG CTAGCAGTGC TACCCCCACT TTTTAGCCGA AAGGATTCCA CCATTGTGCT
Ugd5 CAACACCCAG CTAGCAGTGC TACCCCCACT TTTTAGCCGA AAGGATTCCA CCATTGTGCT
Ugd6 CAACACCCAG CTAGCAGTGC TACCCCCACT TTTTAGCCGA AAGGATTCCA CCATTGTGCT
ASM72 CAACACCCAG CTAGCAGTGC TACCCCCACT TTTTAGCCGA AAGGATTCCA CCATTGTGCT
TKS1 CAACACCCAG CTAGCAGTGC TACCCCCACT TTTTAGCCGA AAGGATTCCA CCATTGTGCT
U g d l3 CAACACCCAG CTAGCAGTGC TACCCCCACT TTTTAGCCGA AAGGATTCCA CCATTGTGCT
U gd25 CAACACCCAG CTAGCAGTGC TACCCCCACT TTTTAGCCGA AAAGATTCCA CCATTGTGCT
ZKS6 CAACACCCAG CTAGCAGTGC TACCCCCACT TTTTAGCCGA AAGGATTCCA CCATTGTGCT
C ons CAACACCCAG CTAGCAGTGC TACCCCCA-T TTTTAGCCGA AA-GATTCCA CCATTGTGCT
121 180
BCBL-R CGAATCCAAC GGATTTGACC TCGTGTTCCC CATGGTCGTG CCGCAGCAAC TGGGGCACGC
E r l a CGAATCCAAC GGATTTGACC TCGTGTTCCC CATGGTCGTG CCGCAGCAAC TGGGGCACGC
BCBL1 CGAATCCAAC GGATTTGACC TCGTGTTCCC CATGGTCGTG CCGCAGCAAC TGGGGCACGC
BC2 CGAATCCAAC GGATTTGACA TCGTGTTCCC CATGGTCGTG CCTCAGCAAC TGGGGCACGC
U gd23 CGAATCCAAC GGATTTGACA TCGTGTTCCC CATGGTCGTG CCTCAGCAAC TGGGGCACGC
431KAP CGAATCCAAC GGATTTGACC TCGTGTTCCC CATGGTCGTG CCGCAGCAAC TGGGGCACGC
U gd30 CGAATCCAAC GGATTTGACC TCGTGTTCCC CATGGTCGTG CCGCAGCAAC TGGGGCACGC
S T 2 -3 CGAATCCAAC GGATTTGACA TCGTGTTCCC CATGGTCGTG CCGCAGCAAC TGGGGCACGC
U g d l CGAATCCAAC GGATTTGACA TCGTGTTCCC CATGGTCGTG CCGCAGCAAC TGGGGCACGC
U g d l2 CGAATCCAAC GGATTTGACA TCGTGTTCCC CATGGTCGTG CCGCAGCAAC TGGGGCACGC
U g d l9 CGAATCCAAC GGATTTGACA TCGTGTTCCC CATGGTCGTG CCGCAGCAAC TGGGGCACGC
Ugd2 CGAATCCAAC GGATTTGACA TCGTGTTCCC CATGGTCGTG CCGCAGCAAC TGGGGCACGC
Ugd21 CGAATCCAAC GGATTTGACA TCGTGTTCCC CATGGTCGTG CCGCAGCAAC TGGGGCACGC
Ugd2 6 CGAATCCAAC GGATTTGACA TCGTGTTCCC CATGGTCGTG CCGCAGCAAC TGGGGCACGC
Ugd7 CGAATCCAAC GGATTTGACA TCGTGTTCCC CATGGTCGTG CCGCAGCAAC TGGGGCACGC
Ugd8 CGAATCCAAC GGATTTGACA TCGTGTTCCC CATGGTCGTG CCGCAGCAAC TGGGGCACGC
Ugd9 CGAATCCAAC GGATTTGACA TCGTGTTCCC CATGGTCGTG CCGCAGCAAC TGGGGCACGC
OKS 3 CGAATCCAAC GGATTTGACC TCGTGTTCCC CATGGTCGTG CCGCAGCAAC TGGGGCACGC
U gdlO CGAATCCAAC GGATTTGACC TCGTGTTCCC CATGGTCGTG CCGCAGCAAC TGGGGCACGC
U g d l l CGAATCCAAC GGATTTGACC TCGTGTTCCC CATGGTCGTG CCGCAGCAAC TGGGGCACGC
U g d l4 CGAATCCAAC GGATTTGACC TCGTGTTCCC CATGGTCGTG CCGCAGCAAC TGGGGCACGC
U g d l5 CGAATCCAAC GGATTTGACC TCGTGTTCCC CATGGTCGTG CCGCAGCAAC TGGGGCACGC
U g d l 6 CGAATCCAAC GGATTTGACC TCGTGTTCCC CATGGTCGTG CCGCAGCAAC TGGGGCACGC
U g d l7 CGAATCCAAC GGATTTGACC TCGTGTTCCC CATGGTCGTG CCGCAGCAAC TGGGGCACGC
U g d l8 CGAATCCAAC GGATTTGACC TCGTGTTCCC CATGGTCGTG CCGCAGCAAC TGGGGCACGC
U gd20 CGAATCCAAC GGATTTGACC TCGTGTTCCC CATGGTCGTG CCGCAGCAAC TGGGGCACGC
Ugd22 CGAATCCAAC GGATTTGACC TCGTGTTCCC CATGGTCGTG CCGCAGCAAC TGGGGCACGC
Ugd24 CGAATCCAAC GGATTTGACC TCGTGTTCCC CATGGTCGTG CCGCAGCAAC TGGGGCACGC
Ugd27 CGAATCCAAC GGATTTGACC TCGTGTTCCC CATGGTCGTG CCGCAGCAAC TGGGGCACGC
Ugd28 CGAATCCAAC GGATTTGACC TCGTGTTCCC CATGGTCGTG CCGCAGCAAC TGGGGCACGC
Ugd2 9 CGAATCCAAC GGATTTGACC TCGTGTTCCC CATGGTCGTG CCGCAGCAAC TGGGGCACGC
Ugd3 CGAATCCAAC GGATTTGACC TCGTGTTCCC CATGGTCGTG CCGCAGCAAC TGGGGCACGC
Ugd4 CGAATCCAAC GGATTTGACC TCGTGTTCCC CATGGTCGTG CCGCAGCAAC TGGGGCACGC
Ugd5 CGAATCCAAC GGATTTGACC TCGTGTTCCC CATGGTCGTG CCGCAGCAAC TGGGGCACGC
Ugd6 CGAATCCAAC GGATTTGACC TCGTGTTCCC CATGGTCGTG CCGCAGCAAC TGGGGCACGC
ASM72 CGAATCCAAC GGATTTGACC TCGTGTTCCC CATGGTCGTG CCGCAGCAAC TGGGGCACGC
TKS1 CGAATCCAAC GGATTTGACC TCGTGTTCCC CATGGTCGTG CCGCAGCAAC TGGGGCACGC
U g d l3 CGAATCCAAC GGATTTGACC TCGTGTTCCC CATGGTCGTG CCGCAGCAAC TGGGGCACGC
U gd25 CGAATCCAAC GGATTTGACC TCGTGTTCCC CATGGTCGTG CCGCAGCAAC TGGGGCACGC
ZKS6 CGAATCCAAC GGATTTGACC TCGTGTTCCC CATGGTCGTG CCGCAGCAAC TGGGGCACGC
C ons CGAATCCAAC GGATTTGAC- TCGTGTTCCC CATGGTCGTG CC-CAGCAAC TGGGGCACGC
BCBL-R
181
TATTCTGCAG CAGCTGTTGG TGTACCACAT CTACTCCAAA ATATCGGCCG
240
GGGCCCCGGA
E r l a TATTCTGCAG CAGCTGTTGG TGTACCACAT CTACTCCAAA ATATCGGCCG GGGCCCCGGA
BCBL1 TATTCTGCAG CAGCTGTTGG TGTACCACAT ATACTCCAAA ATATCGGCCG GGGCCCCGGA
BC2 TATTCTGCAG CAGCTGTTGG TGTACCACAT CTACTCCAAA ATATCGGCCG GGGCCCCGGG
U gd23 TATTCTGCAG CAGCTGTTGG TGTACCACAT CTACTCCAAA ATATCGGCCG GGGCCCCGGG
431KAP TATTCTGCAG CAGCTGTTGG TGTACCACAT CTACTCCAAA ATATCGGCCG GGGCCCCGGG
U gd30 TATTCTGCAG CAGCTGTTGG TGTACCACAT CTACTCCAAA ATATCGGCCG GGGCCCCGGG
S T 2 -3 TATTCTGCAG CAGCTGTTGG TGTACCACAT CTACTCCAAA ATATCGGCCG GGGCCCCGGG
U g d l TATTCTGCAG CAGCTGTTGG TGTACCACAT CTACTCCAAA ATATCGGCCG GGGCCCCGGG
U g d l2 TATTCTGCAG CAGCTGTTGG TGTACCACAT CTACTCCAAA ATATCGGCCG GGGCCCCGGG
U g d l9 TATTCTGCAG CAGCTGTTGG TGTACCACAT CTACTCCAAA ATATCGGCCG GGGCCCCGGG
Ugd2 TATTCTGCAG CAGCTGTTGG TGTACCACAT CTACTCCAAA ATATCGGCCG GGGCCCCGGG
Ugd21 TATTCTGCAG CAGCTGTTGG TGTACCACAT CTACTCCAAA ATATCGGCCG GGGCCCCGGG
Ugd2 6 TATTCTGCAG CAGCTGTTGG TGTACCACAT CTACTCCAAA ATATCGGCCG GGGCCCCGGG
Ugd7 TATTCTGCAG CAGCTGTTGG TGTACCACAT CTACTCCAAA ATATCGGCCG GGGCCCCGGG
Ugd8 TATTCTGCAG CAGCTGTTGG TGTACCACAT CTACTCCAAA ATATCGGCCG GGGCCCCGGG
Ugd9 TATTCTGCAG CAGCTGTTGG TGTACCACAT CTACTCCAAA ATATCGGCCG GGGCCCCGGG
0KS3 TATTCTGCAG CAGTTGTTGG TGTACCACAT CTACTCCAAA ATATCGGCCG GGGCCCCGGA
UgdlO TATTCTGCAG CAGTTGTTGG TGTACCACAT CTACTCCAAA ATATCGGCCG GGGCCCCGGA
U g d l l TATTCTGCAG CAGTTGTTGG TGTACCACAT CTACTCCAAA ATATCGGCCG GGGCCCCGGA
U gd l4 TATTCTGCAG CAGTTGTTGG TGTACCACAT CTACTCCAAA ATATCGGCCG GGGCCCCGGA
U g d l5 TATTCTGCAG CAGTTGTTGG TGTACCACAT CTACTCCAAA ATATCGGCCG GGGCCCCGGA
U g d l6 TATTCTGCAG CAGTTGTTGG TGTACCACAT CTACTCCAAA ATATCGGCCG GGGCCCCGGA
U g d l7 TATTCTGCAG CAGTTGTTGG TGTACCACAT CTACTCCAAA ATATCGGCCG GGGCCCCGGA
U g d l8 TATTCTGCAG CAGTTGTTGG TGTACCACAT CTACTCCAAA ATATCGGCCG GGGCCCCGGA
U gd20 TATTCTGCAG CAGTTGTTGG TGTACCACAT CTACTCCAAA ATATCGGCCG GGGCCCCGGA
Ugd22 TATTCTGCAG CAGTTGTTGG TGTACCACAT CTACTCCAAA ATATCGGCCG GGGCCCCGGA
Ugd24 TATTCTGCAG CAGTTGTTGG TGTACCACAT CTACTCCAAA ATATCGGCCG GGGCCCCGGA
Ugd27 TATTCTGCAG CAGTTGTTGG TGTACCACAT CTACTCCAAA ATATCGGCCG GGGCCCCGGA
Ugd28 TATTCTGCAG CAGTTGTTGG TGTACCACAT CTACTCCAAA ATATCGGCCG GGGCCCCGGA
U gd29 TATTCTGCAG CAGTTGTTGG TGTACCACAT CTACTCCAAA ATATCGGCCG GGGCCCCGGA
Ugd3 TATTCTGCAG CAGTTGTTGG TGTACCACAT CTACTCCAAA ATATCGGCCG GGGCCCCGGA
Ugd4 TATTCTGCAG CAGTTGTTGG TGTACCACAT CTACTCCAAA ATATCGGCCG GGGCCCCGGA
Ugd5 TATTCTGCAG CAGTTGTTGG TGTACCACAT CTACTCCAAA ATATCGGCCG GGGCCCCGGA
Ugd6 TATTCTGCAG CAGTTGTTGG TGTACCACAT CTACTCCAAA ATATCGGCCG GGGCCCCGGA
ASM72 TATTCTGCAG CAGTTGTTGG TATACCACAT CTACTCCAAA ATATCGGCCG GGGCCCCGGA
TKS1 TATTCTGCAG CAGTTGTTGG TGTACCACAT CTACTCCAAA ATATCGGCCG GGGCCCCGGA
U g d l3 TATTCTGCAG CAGTTGTTGG TGTACCACAT CTACTCCAAA ATATCGGCCG GGGCCCCGGA
U gd25 TATTCTGCAG CAGTTGTTGG TGTACCACAT CTACTCCAAA ATATCGGCCG GGGCCCCGGA
ZKS6 TATTCTGCAG CAGTTGTTGG TGTACCACAT CTACTCCAAA ATATCGGCCT GGGCCCCGGA
C ons TATTCTGCAG CAG-TGTTGG T-TACCACAT -TACTCCAAA ATATCGGCC- GGGCCCCGG-
BCBL-R
241
TGATGTAAAT ATGGCGGAAC TTGATCTATA TACCACCAAT GTGTCATTTA
298
TGGGGCGC
E r l a TGATGTAAAT ATGGCGGAAC TTGATCTATA TACCACCAAT GTGTCATTTA TGGGGCGC
BCBL1 TGATGTAAAT ATGGCGGAAC TTGATCTATA TACCACCAAT GTGTCATTTA TGGGGCGC
BC2 TGATGTCAAT ATGGCGGAAC TTGATCTATA TACCACCAAT GTGTCATTTA TGGGGCGC
U gd23 TGATGTCAAT ATGGCGGAAC TTGATCTATA TACCACCAAT GTGTCATTTA TGGGGCGC
431KAP TGATGTCAAT ATGGCGGAAC TTGATCTATA TACCACCAAT GTGTCATTTA TGGGGCGC
U gd30 TGATGTCAAT ATGGCGGAAC TTGATCTATA TACCACCAAT GTGTCATTTA TGGGGCGC
S T 2 -3 TGATGTCAAT ATGGCGGAAC TTGATCTATA TACCACCAAT GTGTCATTTA TGGGGCGC
U g d l TGATGTCAAT ATGGCGGAAC TTGATCTATA TACCACCAAT GTGTCATTTA TGGGGCGC
U g d l2 TGATGTCAAT ATGGCGGAAC TTGATCTATA TACCACCAAT GTGTCATTTA TGGGGCGC
U g d l9 TGATGTCAAT ATGGCGGAAC TTGATCTATA TACCACCAAT GTGTCATTTA TGGGGCGC
Ugd2 TGATGTCAAT ATGGCGGAAC TTGATCTATA TACCACCAAT GTGTCATTTA TGGGGCGC
U gd21 TGATGTCAAT ATGGCGGAAC TTGATCTATA TACCACCAAT GTGTCATTTA TGGGGCGC
U gd26 TGATGTCAAT ATGGCGGAAC TTGATCTATA TACCACCAAT GTGTCATTTA TGGGGCGC
Ugd7 TGATGTCAAT ATGGCGGAAC TTGATCTATA TACCACCAAT GTGTCATTTA TGGGGCGC
Ugd8 TGATGTCAAT ATGGCGGAAC TTGATCTATA TACCACCAAT GTGTCATTTA TGGGGCGC
Ugd9 TGATGTCAAT ATGGCGGAAC TTGATCTATA TACCACCAAT GTGTCATTTA TGGGGCGC
OKS 3 TGATGTCAAT ATGGCGGAAC TTGATCTATA TACCACCAAT GTGTCATTTA TGGGGCGC
U gdlO TGATGTCAAT ATGGCGGAAC TTGATCTATA TACCACCAAT GTGTCATTTA TGGGGCGC
U g d l l TGATGTCAAT ATGGCGGAAC TTGATCTATA TACCACCAAT GTGTCATTTA TGGGGCGC
U g d l4 TGATGTCAAT ATGGCGGAAC TTGATCTATA TACCACCAAT GTGTCATTTA TGGGGCGC
U g d l5 TGATGTCAAT ATGGCGGAAC TTGATCTATA TACCACCAAT GTGTCATTTA TGGGGCGC
U g d l6 TGATGTCAAT ATGGCGGAAC TTGATCTATA TACCACCAAT GTGTCATTTA TGGGGCGC
U g d l7 TGATGTCAAT ATGGCGGAAC TTGATCTATA TACCACCAAT GTGTCATTTA TGGGGCGC
U g d l8 TGATGTCAAT ATGGCGGAAC TTGATCTATA TACCACCAAT GTGTCATTTA TGGGGCGC
U gd20 TGATGTCAAT ATGGCGGAAC TTGATCTATA TACCACCAAT GTGTCATTTA TGGGGCGC
U gd22 TGATGTCAAT ATGGCGGAAC TTGATCTATA TACCACCAAT GTGTCATTTA TGGGGCGC
Ugd24 TGATGTCAAT ATGGCGGAAC TTGATCTATA TACCACCAAT GTGTCATTTA TGGGGCGC
Ugd27 TGATGTCAAT ATGGCGGAAC TTGATCTATA TACCACCAAT GTGTCATTTA TGGGGCGC
U gd28 TGATGTCAAT ATGGCGGAAC TTGATCTATA TACCACCAAT GTGTCATTTA TGGGGCGC
U gd29 TGATGTCAAT ATGGCGGAAC TTGATCTATA TACCACCAAT GTGTCATTTA TGGGGCGC
Ugd3 TGATGTCAAT ATGGCGGAAC TTGATCTATA TACCACCAAT GTGTCATTTA TGGGGCGC
Ugd4 TGATGTCAAT ATGGCGGAAC TTGATCTATA TACCACCAAT GTGTCATTTA TGGGGCGC
Ugd5 TGATGTCAAT ATGGCGGAAC TTGATCTATA TACCACCAAT GTGTCATTTA TGGGGCGC
Ugd6 TGATGTCAAT ATGGCGGAAC TTGATCTATA TACCACCAAT GTGTCATTTA TGGGGCGC
ASM72 TGATGTCAAT ATGGCGGAAC TTGATCTATA TACCACCAAT GTGTCATTTA TGGGGCGC
TKS1 TGATGTCAAT ATGGCGGAAC TTGATCTATA TACCACCAAT GTGTCATTTA TGGGGCGC
U g d l3 TGATGTCAGT ATGGCGGAAC TTGATCTATA TACCACCAAT GTGTCATTTA TGGGGCGC
U gd25 TGATGTCAAT ATGGCGGAAC TTGATCTATA TACCACCAAT GTGTCATTTA TGGGGCGC
ZKS6 TGATGTCAAT ATGGCGGAAC TTGATCTATA TACCACCAAT GTGTCATTTA TGGGGCGC
C ons TGATGT-A-T ATGGCGGAAC TTGATCTATA TACCACCAAT GTGTCATTTA TGGGGCGC
B - T0.7/K12
1
4 31KAP GTCCCGGATG 
OKS3 GTCCCGGATG 
U g d l 6 GTCCCGGATG 
U g d 4  GTCCTGGATG 
U g d 2 3  GTCCCGGATG 
ZKS6 GTCCCGGATG 
U g d 3 0  GTCCCGGATC 




U g d lO  GTCCCGGATG 
OKS4 GTCCCGGATG 
U g d l 9 GTCCCGGATG 
RKS1 GTCCCGGATG 
RKS3 GTCCCGGATG 
U g d 2  GTCCCGGATG 
U g d l 2 GTCCCGGATG 
OKS7 GTCCCGGATG 
BCBL-R GTCCCGGATG 
E r l a  GTCCCGGATG 


































































































U gdlO  
OKS4 




U g d l2  
OKS 7 
BCBL-R 






















































































































































































U gdlO  
OKS 4 




U g d l2  
OKS 7 
BCBL-R 
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U g d l2  
OKS7 
BCBL-R 
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TAGCGTG. . .  
TAGCGTG. . .  
TAGCGTG. . .  
TAGCGTG. . .  
TAGCGTG. . .  
TAGCGTG. . .  
TAGCGTG. . .  
TAGCGTG. . .  
TAGCGTG.. .  
TAGCGTG. . .  
TAGCGTG. . .  
TAGCGTG. . .  
TAGCGTG. . .  
TAGCGTG. . .  
TAGCGTG. . .  
TAGCGTG. . .  
TAGCGTG. . .  
TAGCGTG. . .  
TAGCGTG. . .  





























































































































U gdlO  
OKS4 




U g d l2  
OKS 7 
BCBL-R 


















U gdlO  
OKS 4 




U g d l2  
OKS7 
BCBL-R 


























































































































































































































































































































































U gdlO  
OKS 4 




U g d l2  
OKS7 
BCBL-R 


















U gdlO  
OKS 4 




U g d l2  
OKS7 
BCBL-R 































































































































































































































































431KAP ATGGCAAAAA ACACTCCCCC ACAATGTATT GACCTTGTTT GTTAATGAAA GTGTGGCACT
OKS 3 ATGGCAAAAA ACACTCCCCC ACAATGTATT GACCTTGTTT GTTAATGAAA GTGTGGCATT
U g d l6 ATGGCAAAAA ACACTCCCCC ACAATGTATT GACCTTGTTT GTTAATGAAA GTGTGGCATT
Ugd4 ATGGCAAAAA ACACTCCCCC ACAATGTATT GACCTTGTTT GTTAATGAAA GTGTGGCATT
Ugd23 ATGGCAAAAA ACACTCCCCC ACAATGTATT GACCTTGTTT GTTAATGAAA GTGTGGCACT
ZKS6 ATGGCAAAAA ACACTCCCCC ACAATGTATT GACCTTGTTT GTTAATGAAA GTGTGGCACT
U gd30 ATGGCAAAAA ACACTCCCCC ACAATGTATT GACCTTGTTT GTTAATGAAA GTGTGGCACT
U gd29 ATGGCAAAAA ACACTCCCCC ACAATGTATT GACCTTGTTT GTTAATGAAA GTGTGGCACT
TKS10 ATGGCAAAAA ACACTCCCCC ACAATATATT GACCTTGTTT GTTAATGAAA t t g t g g c a c t
ZKS3 ATGGCAAAAA ACACTCCCCC ACAATATATT GACCTTGTTT GTTAATGAAA t t g t g g c a c t
SKS1 ATGGCAAAAA ACACTCCCCC ACAATGTATT GACCTTGTTT GTTAATGAAA TTGTGGCACT
U gdlO ATGGCAAAAA ACCCTCCCCC ACAATGTATT GACCTTGTTT GTTAATGAAA TTGTGGCACT
OKS 4 ATGGCAAAAA ACACTCCCCC ACAATGTATT GACCTTGTTT GTTAATGAAA TTGTGGCACT
U g d l9 ATGGCAAAAA ACACTCCCCC ACAATGTATT GACCTTGTTT GTTAATGAAA TTGTGGCACT
RKS1 ATGGCAAAAA ACACTCCCCC ACAATGTATT GACCTTGTTT GTTAATGAAA TTGTGGCACT
RKS3 ATGGCAAAAA ACACTCCCCC ACAATGTATT GACCTTGTTT GTTAATGAAA TTGTGGCACT
Ugd2 ATGGCAAAAA ACACTCCCCC ACAATGTATT GACCTTGTTT GTTAATGAAA TTGTGGCACT
U g d l2 ATGGCAAAAA ACACTCCCCC ACAATGTATT GACCTTGTTT GTTAATGAAA TTGTGGCACT
OKS7 ATGGCAAAAA ACACTCCCCC ACAATGTATT GACCTTGTTT GTTAATGAAA TTGTGGCACT
BCBL-R ATGGCAAAAA ACACTCCCTC AGAATGTATT GACCTTGTTT GTTAATGAAA TTGTGGCACT
E r l a ATGGCAAAAA ACACTCCCTC AGAATGTATT GACCTTGTTT GTTAATGAAA TTGTGGCACT
BC-1 ATGGCAAAAA ACACTCCCTC ACAATGTATT GACCTTGTTT GTTAATGAAA TTGTGGCACT
3K S16 ATGGCAAAAA ACACTCCCTC ACAATGTATT GACCTTGTTT GTTAATGAAA TTGTGGCACT
BCBL1 ATGGCAAAAA ACACTCCCTC ACAATGTATT GACCTTGTTT GTTAATGAAA TTGTGGCACT
ASM72 ATGGCAAAAA ACACTCCCTC ACAATGTATT GACCTTGTTT GTTAATGAAA TTGTGGCACT
U g d l5 ATGGCAAAAA ACACTCCCCC ACAATGTATT GACCTTGTTT GTTAATGAAA GTGTGGCACT
C ons ATGGCAAAAA AC-CTCCC-C A-AAT-TATT GACCTTGTTT GTTAATGAAA -TGTGGCA-T
541 551
431KAP GACTTCGGCA G
OKS 3 GACTTCGGCA G




U gd30 GACTTCGGCA G





OKS 4 GACTTCGGCA G




U g d l2 GACTTCGGCA G
OKS 7 GACTTCGGCA G
BCBL-R GACTTCGGCA G





U g d l5 GACTTCGGCA G
C ons GACTTCGGCA G
C - ORF75-UPS75’
431KAP 
U g d l  2 
Ugd2 




U g d l  5 
U gd23 
U gd29 








































































































U g d l2
Ugd2




U g d l5
U gd23
U gd29









































































































U g d l2  
Ugd2 




U g d l5  
U gd23 
U gd29 












































































































U g d l2  
Ugd2 




U g d l5  
U gd23 
U gd29 









































































































U g d l2  
Ugd2 




U g d l5  
U gd23 
U gd29 








































































































4 3 1 K1AP 
U g d l 2 
Ugd2 




U g d l5  
U gd23 
U gd29 











































































































U g d l2 AGCACAGCGA
Ugd2 AGCACAGCGA




U g d l5 AGCACAGCGA
U gd23 AGCACAGCGA
Ugd2 9 AGCACAGCGA









U g d l2 GGAGGTCTTC
Ugd2 GGAGGTCTTC




U g d l5 GGAGGTCTTC
U gd23 GGAGGTCTTC
U gd29 GGAGGTCTTC









U g d l2 GTGAGTGTGC
Ugd2 GTGAGTGTGC




U g d l5 GTGAGTGTGC
U gd23 GTGAGTGTGC
U gd29 GTGAGTGTGC




























































































































































U g d l2 TCACTCTCCA
Ugd2 TCACTCTCCA




U g d l5 TCACTCTCCA
U gd23 TCACTCTCCA
Ugd2 9 TCACTCTCCA









U g d l2 GGGGACACCC
Ugd2 GGGGACACCC




U g d l5 GGGGACACCC
U gd23 GGGGACACCC
Ugd2 9 GGGGACACCC









U g d l2 AAACTGAGAA
Ugd2 AAACTGAGAA




U g d l5 AAACTGAGAA
U gd23 AAACTGAGAA
U gd29 AAACTGAGAA
U g d l6 AAACTGAGAA
Ugd4 AAACTGAGAA
C282 AAACTGAGAA
























































































































































U g d l2  
Ugd2 




U g d l5  
U gd23 
U gd29 




U gdlO  
C ons
431KAP 
U g d l2  
Ugd2 
































































m e n 2 1 z a ATGGCCTACG ACGTCACTGG GTTGTGGTTG GAGAGTGATC
r s 8 2 0 z a ATGGCCTACG ACGTCACTGG GTTGTGGTTG GAGAGTGATC
d s 8 9 5 z a ATGGCCTACG ACGTCACTGG GTTGTGGTTG GAGAGTGATC
k s 3 3 z a ATGGCCTACG ACGTCACTGG GTTGTGGTTG GAGAGTGATC
k s 9 8 z a ATGGCCTACG ACGTCACTGG GTTGTGGTTG GAGAGTGATC
k s 7 8 z a ATGGCCTACG ACGTCACTGG GTTGTGGTTG GAGAGTAATC
B C-1 ATGGCCTACG ACGTCACTGG GCTGTGGTTG GAGAGTGATC
d s 8 1 4 z a ATGGCCTACG ACGTCACTGG GCTGTGGTTG GAGAGTGATC
k s 7 0 z a ATGGCCTACG ACGTCACTGG GCTGTGGTTG GAGAGTGATC
k s 9 1 z a ATGGCCTACG ACGTCACTGG GCTGTGGTTG GAGAGTGATC
U gdlO ATGGCCTACG ACGTCACTGG GCTGTGGTTG GAGAGTGATC
k s 8 4 z a ATGGCCTACG ACGTCACTGG GCTGTGGTTG GAGAGTGATC
U g d l  2 ATGGCCTACG ACGTCACTGG GCTGTGGTTG GAGAGTGATC
k s 6 5 z a ATGGCCTACG ACGTCACTGG GCTGTGGTTG GAGAGTGATC
k s 8 5 z a ATGGCCTACG ACGTCACTGG GCTGTGGTTG GAGAGTGATC
m e n 4 3 z a ATGGCCTACG ACGTCACTGG GCTGTGGTTG GAGAGTGATC
l n 7 z a ATGGCCTACG ACGTCACTGG GCTGTGGTTG GAGAGTGATC
p b 7 z a ATGGCCTACG ACGTCACTGG GCTGTGGTTG GAGAGTGATC
k s 3 1 z a ATGGCCTACG ACGTCACTGG GCTGTGGTTG GAGAGTGATC
k s 6 4 z a ATGGCCTACG ACGTCACTGG GCTGTGGTTG GAGAGTGATC
k s 8 1 z a ATGGCCTACG ACGTCACTGG GCTGTGGTTG GAGAGTGATC
k s 8 3 z a ATGGCCTACG ACGTCACTGG GCTGTGGTTG GAGAGTGATC
k s 8 8 z a ATGGCCTACG ACGTCACTGG GCTGTGGTTG GAGAGTGATC
t s 7 9 9 z a ATGGCCTACG ACGTCACTGG GCTGTGGTTG GAGAGTGATC
k s4  9 z a ATGGCCTACG ACGTCACTGG GCTGTGGTTG GAGAGTGATC
t s 5 2 2 z a ATGGCCTACG ACGTCACTGG GCTGTGGTTG GAGAGTGATC
k s l 3 z a ATGGCCTACG ACGTCACTGG GCTGTGGTTG GAGAGTGATC
k s 3 5 z a ATGGCCTACG ACGTCACTGG GCTGTGGTTG GAGAGTGATC
k s3 7  z a ATGGCCTACG ACGTCACTGG GCTGTGGTTG GAGAGTGATC
k s 6 1 z a ATGGCCTACG ACGTCACTGG GCTGTGGTTG GAGAGTGATC
k s7  6 z a ATGGCCTACG ACGTCACTGG GCTGTGGTTG GAGAGTGATC
U g d l  5 ATGGCCTACG ACGTCACTGG GCTGTGGTTG GAGAGTGATC
Ugd30 ATGGCCTACG ACGTCACTGG GCTGTGGTTG GAGAGTGATC
k s l 8 z a ATGGCCTACG ACGTCACTGG GCTGTGGTTG GAGAGTGATC
r s 9 0 1 z a ATGGCCTACG ACGTCACTGG GCTGTGGTTG GAGAGTGATC
r s 9 0 4 z a ATGGCCTACG ACGTCACTGG GCTGTGGTTG GAGAGTGATC
t s 6 5 2 z a ATGGCCTACG ACGTCACTGG GCTGTGGTTG GAGAGTGATC
k s 2 3 z a ATGGCCTACG ACGTCACTGG GCTGTGGTTG GAGAGTGATC
k s 8 0 z a ATGGCCTACG ACGTCACTGG GCTGTGGTTG GAGAGTGATC
k s 8 2 z a ATGGCCTACG ACGTCACTGG GCTGTGGTTG GAGAGTGATC
p p l6 3 z a ATGGCCTACG ACGTCACAGG GCTGTGGTTG GAGAGTGATC
k s l 2 z a ATGGCCTACG ACGTCACTGG GCTGTGGTTG GAGAGTGATC
p p l5 8 z a ATGGCCTACG ACGTCACTGG GCTGTGGTTG GAGAGTGATC



















































m e n 2 1 z a
61
TTTGTCAACT TCTATACTGG CCGAACGGGC ACACTCACTC TCGTACCCGG
120
TGGCACCGGA
r s 8 2 0 z a TTTGTCAACT TCTATACTGG CCGAACGGGC ACACTCACTC TCGTACCCGG TGGCACCGGA
d s 8 9 5 z a TTTGTCAACT TCTATACTGG CCGAACGGGC ACACTCACTC TCGTACCCGG TGGCACCGGA
k s 3 3 z a TTTGTCAACT TCTATACTGG CCGAACGGGC ACACTCACTC TCGTACCCGG TGGCACCGGA
k s 9 8 z a TTTGTCAACT TCTATACTGG CCGAACGGGC ACACTCACTC TCGTACCCGG TGGCACCGGA
k s 7 8 z a TTTGTCAACT TCTATACTGG CCGAACGGGC ACACTCACTC TCGTACCCGG TGGCACCGGA
BC-1 TTTGTGAACT TTTATACAAG CCGTACGGGC ACACTCACTC TCGTACCCGG TGGCACCGGA
d s 8 1 4 z a TTTGTGAACT TTTATACAAG CCGTACGGGC ACACTCACTC TCGTACCCGG TGGCACCGGA
k s 7 0 z a TTTGTGAACT TTTATACAAG CCGTACGGGC ACACTCACTC TCGTACCCGG TGGCACCGGA
k s 9 1 z a TTTGTGAACT TTTATACAAG CCGTACGGGC ACACTCACTC TCGTACCCGG TGGCACCGGA
U gdlO TTTGTGAACT TTTATACAAG CCGTACGGGC ACACTCACTC TCGTACCCGG TGGCACCGGA
k s8 4  z a TTTGTGAACT TTTATACAAG CCGTACGGGC ACACTCACTC TCGTACCCGG TGGCACCGGA
U g d l2 TTTGTCAGCT TTTATACAAG CCGTACGGGC ACACTCACTC TCGTACCCGG TGGCACCGGA
k s 6 5 z a TTTGTCAGCT TTTATACAAG CCGTACGGGC ACACTCACTC TCGTACCCGG TGGCACCGGA
k s 8 5 z a TTTGTCAGCT TTTATACAAG CCGTACGGGC ACACTCACTC TCGTACCCGG TGGCACCGGA
men4 3 z a TTTGTCAGCT TTTATACAAG CCGTACGGGC ACACTCACTC TCGTACCCGG TGGCACCGGA
ln 7  za TTTGTCAGCT TTTATACAAG CCGTACGGGC ACACTCACTC TCGTACCCGG TGGCACCGGA
pb7  za TTTGTCAGCT TTTATACAAG CCGTACGGGC ACACTCACTC TCGTACCCGG TGGCACCGGA
k s 3 1 z a TTTGTCAGCT TTTATACAAG CCGTACGGGC ACACTCACTC TCGTACCCGG TGGCACCGGA
k s 6 4 z a TTTGTCAGCT TTTATACAAG CCGTACGGGC ACACTCACTC TCGTACCCGG TGGCACCGGA
k s 8 1 z a TTTGTCAGCT TTTATACAAG CCGTACGGGC ACACTCACTC TCGTACCCGG TGGCACCGGA
k s 8 3 z a TTTGTCAGCT TTTATACAAG CCGTACGGGC ACACCCACTC TCGTACCCGG TGGCACCGGA
k s 8 8 z a TTTGTCAGCT TTTATACAAG CCGTACGGGC ACACTCACTC TCGTACCCGG TGGCACCGGA
t s 7  9 9 z a TTTGTCAGCT TTTATACAAG CCGTACGGGC ACACTCACTC TCGTACCCGG TGGCACCGGA
k s4  9 z a TTTGTCAGCT TTTATACAAG CCGTACGGGC ACACTCACTC TCGTACCCGG TGGCACCGGA
t s 5 2 2 z a TTTGTCAGCT TTTATACAAG CCGTACGGGC ACACTCACTC TCGTACCCGG TGGCACCGGA
k s l 3 z a TTTGTCAGCT TTTATACAAG CCGTACGGGC ACACTCACTC TCGTACCCGG TGGCACCGGA
k s 3 5 z a TTTGTCAGCT TTTATACAAG CCGTACGGGC ACACTCACTC TCGTACCCGG TGGCACCGGA
k s3 7  za TTTGTCAGCT TTTATACAAG CCGTACGGGC ACACTCACTC TCGTACCCGG TGGCACCGGA
k s 6 1 z a TTTGTCAGCT TTTATACAAG CCGTACGGGC ACACTCACTC TCGTACCCGG TGGCACCGGA
k s7  6 z a TTTGTCAGCT TTTATACAAG CCGTACGGGC ACACTCACTC TCGTACCCGG TGGCACCGGA
U g d l5 TTTGTCAGCT TTTATACAAG CCGTACGGGC ACACTCACTC TCGTACCCGG TGGCACCGGA
U gd30 TTTGTCAGCT TTTATACAAG CCGTACGGGC ACACTCACTC TCGTACCCGG TGGCACCGGA
k s l 8 z a TTTGTCAGCT TTTATACAAG CCGTACGGGC ACACTCACTC TCGTACCCGG TGGCACCGGA
r s 9 0 1 z a TTTGTCAGCT TTTATACAAG CCGTACGGGC ACACTCACTC TCGTACCCGG TGGCACCGGA
r s 9 0 4 z a TTTGTCAGCT TTTATACAAG CCGTACGGGC ACACTCACTC TCGTACCCGG TGGCACCGGA
ts 6 5 2 z a TTTGTCAGCT TTTATACAAG CCGTACGGGC ACACTCACTC TCGTACCCGG TGGCACCGGA
k s 2 3 z a TTTGTCAGCT TTTATACAAG CCGTACGGGC ACACTCACTC TCGTACCCGG TGGCACCGGA
k s 8 0 z a TTTGTCAGCT TTTATACAAG CCGTACGGGC ACACTCACTC TCGTACCCGG TGGCACCGGA
k s 8 2 z a TTTGTCAGCT TTTATACAAG CCGTACGGGC ACACTCACTC TCGTACCCGG TGGCACCGGA
p p l6 3 z a TTTGTCAGCT TTTATACAAT CCGTACGGGC ACACTCACTC TCGTACCCGG TGGCACCGGA
k s l 2 z a TTTGTCAGCT TTTATACAAG CCGTACGGGC ACACTCACTC TCGTACCCGG TGGCACCGGA
p p l5 8 z a TTTGTCAGCT TTTATACAAG CCGTACGGGC ACACTCACTC TCGTACCCGG CGGCACCGGA
C ons TTTGT-A-CT T-TATAC----- CCG-ACGGGC ACAC-CACTC TCGTACCCGG -GGCACCGGA
m e n 2 1 z a
121
GGCTACTATT TGCTATGGAT AACTTTCCGA AGACCTCCCA CCTCGAGGGA
180
GGAGCGAGAG
r s 8 2 0 z a GGCTACTATT TGCTATGGAT AACTTTCCGA AGACCTCCCA CCTCGAGGGA GGAGCGAGAG
d s 8 9 5 z a GGCTACTATT TGCTATGGAT AACTTTCCGA AGACCTCCCA CCTCGAGGGA GGAGCGAGAG
k s 3 3 z a GGCTACTATT TGCTATGGAT AACTTTCCGA AGACCTCCCA CCTCGAGGGA GGAGCGAGAG
k s 9 8 z a GGCTACTATT TGCTATGGAT AACTTTCCGA AGACCTCCCA CCTCGAGGGA GGAGCGAGAG
k s 7 8 z a GGCTACTATT TGCTATGGAT AACTTTCCGA AGACCTCCCA CCTCGAGGGA GGAGCGAGAG
BC-1 GGCTACTATC TGCTATGGAT AACTTTCCGA AGACCTCCCA CTTCGAGGGA GGAGCGAGAG
d s 8 1 4 z a GGCTACTATC TGCTATGGAT AACTTTCCGA AGACCTCCCA CTTCGAGGGA GGAGCGAGAG
k s 7 0 z a GGCTACTATC TGCTATGGAT AACTTTCCGA AGACCTCCCA CTTCGAGGGA G GAG C GAGAG
k s 9 1 z a GGCTACTATC TGCTATGGAT AACTTTCCGA AGACCTCCCA CTTCGAGGGA GGAGCGAGAG
U gdlO GGCTACTATC TGCTATGGAT AACTTTCCGA AGACCTCCCA CTTCGAGGGA GGAGCGAGAG
k s 8 4 z a GGCTACTATC TGCTATGGAT AACTTTCCGA AGACCTCCCA CTTCGAGGGA GGAGCGAGAG
U g d l2 GGCTACTATC TGCTATGGAT AACTTTCCGA AGACCTCCCA CTTCGAGGGA GGAGCGAGAG
k s 6 5 z a GGCTACTATC TGCTATGGAT AACTTTCCGA AGACCTCCCA CTTCGAGGGA GGAGCGAGAG
k s 8 5 z a GGCTACTATC TGCTATGGAT AACTTTCCGA AGACCTCCCA CTTCGAGGGA GGAGCGAGAG
men4 3 z a GGCTACTATC TGCTATGGAT AACTTTCCGA AGACCTCCCA CTTCGAGGGA GGAGCGAGAG
ln 7  za GGCTACTATC TGCTATGGAT AACTTTCCGA AGACCTCCCA CTTCGAGGGA GGAGCGAGAG
pb7  za GGCTACTATC TGCTATGGAT AACTTTCCGA AGACCTCCCA CTTCGAGGGA GGAGCGAGAG
k s 3 1 z a GGCTACTATC TGCTATGGAT AACTTTCCGA AGACCTCCCA CTTCGAGGGA GGAGCGAGAG
k s 6 4 z a GGCTACTATC TGCTATGGAT AACTTTCCGA AGACCTCCCA CTTCGAGGGA GGAGCGAGAG
k s 8 1 z a GGCTACTATC TGCTATGGAT AACTTTCCGA AGACCTCCCA CTTCGAGGGA GGAGCGAGAG
k s 8 3 z a GGCTACTATC TGCTATGGAT AACTTTCCGA AGACCTCCCA CTTCGAGGGA GGAGCGAGAG
k s 8 8 z a GGCTACTATC TGCTATGGAT AACTTTCCGA AGACCTCCCA CTTCGAGGGA GGAGCGAGAG
t s 7 9 9 z a GGCTACTATC TGCTATGGAT AACCTTCCGA AGACCTCCCA CTTCGAGGGA GGGGCGAGAG
k s 4 9 z a GGCTACTATC TGCTATGGAT AACTTTCCGA AGACCTCCCA CTTCGAGGGA GGAGCGAGAG
t s 5 2 2 z a GGCTACTATC TGCTATGGAT AACTTTCCGG AGACCTCCCA CTTCGAGGGA GGAGCGAGAG
k s l 3 z a GGATACTATC TGCTATGGAT AACTTTCCGA AGACCTCCCA CTTCGAGGGA GGAGCGAGAG
k s 3 5 z a GGATACTATC TGCTATGGAT AACTTTCCGA AGACCTCCCA CTTCGAGGGA GGAGCGAGAG
k s 3 7 z a GGATACTATC TGCTATGGAT AACTTTCCGA AGACCTCCCA CTTCGAGGGA GGAGCGAGAG
k s 6 1 z a GGATACTATC TGCTATGGAT AACTTTCCGA AGACCTCCCA CTTCGAGGGA GGAGCGAGAG
k s7  6 z a GGCTACTATC TGCTATGGAT AACTTTCCGA AGACCTCCCA CTTCGAGGGA GGAGCGAGAG
U g d l5 GGCTACTATC TGCTATGGAT AACTTTCCGA AGACCTCCCA CTTCGAGGGA GGAGCGAGAG
U gd30 GGCTACTATC TGCTATGGAT AACTTTCCGA AGACCTCCCA CTTCGAGGGA G GAG C GAGAG
k s l 8 z a GGCTACTATC TGCTATGGAT AACTTTCCGA AGACCTCCCA CTTCGAGGGA GGAGCGAGAG
r s 9 0 1 z a GGCTACTATC TGCTATGGAT AACTTTCCGA AGACCTCCCA CTTCGAGGGA GGAGCGAGAG
r s 9 0 4  za GGCTACTATC TGCTATGGAT AACTTTCCGA AGACCTCCCA CTTCGAGGGA GGAGCGAGAG
t s 6 5 2 z a GGCTACTATC TGCTATGGAT AACTTTCCGA AGACCTCCCA CTTCGAGGGA GGAGCGAGAG
k s 2 3 z a GGCTACTATC TGCTATGGAT AACTTTCCGA AGACCTCCCA CTTCGAGGGA GGAGCGAGAG
k s 8 0 z a GGCTACTATC TGCTATGGAT AACTTTCCGA AGACCTCCCA CTTCGAGGGA GGAGCGAGAG
k s 8 2 z a GGCTACTATC TGCTATGGAT AACTTTCCGA AGACCTCCCA CTTCGAGGGA GGAGCGAGAG
p p l6 3 z a GGCTACTATC TGCTATGGAT AACTTTCCGA AGACCTCCCA CTTCGAGGGA GGAGCGAGAG
k s l 2 z a GGCTACTATC TGCTACGGAT AACTTTCCGA AGACCTCCCA CTTCGAGGGA GGAGCGAGAG
p p l5 8 z a GGCTACTATC TGCTATGGAT AACTTTCCGA AGACCTCCCA CTTCGAGGGA GGAGCGAGAG
C ons GG-TACTAT- TGCTA-GGAT AAC-TTCCG- AGACCTCCCA C-TCGAGGGA GG-GCGAGAG
m e n 2 1 z a
181
AGACGAGATG TGGAAGTGCA GACGGTGCTC GCTGTGCTGT CACCGCTCCT
240
TGGATATCCC
r s 8 2 0 z a AGACGAGATG TGGAAGTGCA GACGGTGCTC GCTGTGCTGT CACCGCTCCT TGGATATCCC
d s 8 9 5 z a AGACGAGATG TGGAAGTGCA GACGGTGCTC GCTGTGCTGT CACCGCTCCT TGGATATCCC
k s 3 3 z a AGACGAGATG TGGAAGTGCA GGCGGTGCTC GCTGTGCTGT CACCGCTCCT TGGATATCCC
k s 9 8 z a AGACGAGATG TGGAAGTGCA GACGGTGCTC GCTGTGCTGT CACCGCTCCT TGGATATCCC
k s 7 8 z a AGACGAGATG TGGAAGTGCA GACGGTGCTC GCTGTGCTGT CACCGCTCCT TGGATATCCC
BC-1 AGACGGGATG TGGAAATACA GACGGTGCTC GCTGTGCTGT CACCGCTCCT TGGATATCCC
d s 8 1 4 z a AGACGGGATG TGGAAATACA GACGGTGCTC GCTGTGCTGT CACCGCTCCT TGGATATCCC
k s 7 0 z a AGACGGGATG TGGAAATACA GACGGTGCTC GCTGTGCTGT CACCGCTCCT TGGATATCCC
k s 9 1 z a AGACGGGATG TGGAAATACA GACGGTGCTC GCTGTGCTGT CACCGCTCCT TGGATATCCC
U gdlO AGACGGGATG TGGAAATACA GACGGTGCTC GCTGTGCTGT CACCGCTCCT TGGATATCCC
k s 8 4 z a AGACGGGATG TGGAAATACA GACGGTGCTC GCTGTGCTGT CACCGCTCCT TGGATATCCC
U g d l2 AGACGGGATG TGGAAATACA GACGGTGCTC GCTGTGCTGT CACCGCTCCT TGGATATCCC
k s 6 5 z a AGACGGGATG TGGAAATACA GACGGTGCTC GCTGTGCTGT CACCGCTCCT TGGATATCCC
k s 8 5 z a AGACGGGATG TGGAAATACA GACGGTGCTC GCTGTGCTGT CACCGCTCCT TGGATATCCC
men4 3 z a AGACGGGATG TGGAAATACA GACGGTGCTC GCTGTGCTGT CACCGCTCCT TGGATATCCC
l n 7 z a AGACGGGATG TGGAAATACA GACGGTGCTC GCTGTGCTGT CACCGCTCCT TGGATATCCC
p b 7 z a AGACGGGATG TGGAAATACA GACGGTGCTC GCTGTGCTGT CACCGCTCCT TGGATATCCC
k s 3 1 z a AGACGGGATG TGGAAATACA GACGGTGCTC GCTGTGCTGT CACCGCTCCT TGGATATCCC
k s 6 4 z a AGACGGGATG TGGAAATACA GACGGTGCTC GCTGTGCTGT CACCGCTCCT TGGATATCCC
k s 8 1 z a AGACGGGATG TGGAAATACA GACGGTGCTC GCTGTGCTGT CACCGCTCCT TGGATATCCC
k s 8 3 z a AGACGGGATG TGGAAATACA GACGGTGCTC GCTGTGCTGT CACCGCTCCT TGGATATCCC
k s 8 8 z a AGACGGGATG TGGAAATACA GACGGTGCTC GCTGTGCTGT CACCGCTCCT TGGATATCCC
t s 7  9 9 z a AGACGGGATG TGGAAATACA GACGGTGCTC GCTGTGCTGT CACCGCTCCT TGGATATCCC
k s4  9 z a AGACGGGATG TGGAAATACA GACGGTGCTC GCTGTGCTGT TACCGCTCCT TGGATATCCC
t s 5 2 2 z a AGACGGGATG TGGAAATACA GACGGTGCTC GCTGTGCTGT CACCGCTCCT TGGATTTCCC
k s l 3 z a AGACGGGATG TGGAAATGCA GACGGTGCTC GCTGTGCTGT CACCACTCCT TGGATATCCC
k s 3 5 z a AGACGGGATG TGGAAATACA GACGGTGCTC GCTGTGCTGT CACCACTCCT TGGATATCCC
k s 3 7 z a AGACGGGATG TGGAAATACA GACGGTGCTC GCTGTGCTGT CACCACTCCT TGGATATCCC
k s S l z a AGACGGGATG TGGAAATACA GACGGTGCTC GCTGTGCTGT CACCACTCCT TGGATATCCC
k s7  6 z a AGACGGGATG TGGAAATACA GACGGTGCTC GCTGTGCTGT CACCACTCCT TGGATATCCC
U g d l5 AGACGGGATG TGGAAATACA GACGGTGCTC GCTGTGCTGT CACCGCTCCT TGGATATCCC
U gd30 AGACGGGATG TGGAAATACA GACGGTGCTC GCTGTGCTGT CACCGCTCCT TGGATATCCC
k s l 8 z a AGACGGGATG TGGAAATACA GACGGTGCTC GCTGTGCTGT CACCGCTCCT TGGATATCCC
r s 9 0 1 z a AGACGGGATG TGGAAATACA GACGGTGCTC GCTGTGCTGT CACCGCTCCT TGGATATCCC
r s 9 0 4 z a AGACGGGATG TGGAAATACA GACGGTGCTC GCTGTGCTGT CACCGCTCCT TGGATATCCC
ts 6 5 2 z a AGACGGGATG TGGAAATACA GACGGTGCTC GCTGTGCTGT CACCGCTCCT TGGATATCCC
k s 2 3 z a AGACGGGATG TGGAAATACA GACGGTGCTC GCTGTGCTGT CACCGCTCCT TGGATATCCC
k s 8 0 z a AGACGGGATG TGGAAATACA GACGGTGCTC GCTGTGCTGT CACCGCTCCT TGGATATCCC
k s 8 2 z a AGACGGGATG TGGAAATACA GACGGCGCTC GCTGTGTTGT CACCGCTCCT TGGATATCCC
p p l6 3 z a AGACGGGATG TGGAAATACA GACGGTGCTC GCTGTGCTGT CACCGCTCCT TGGATATCCC
k s l 2 z a AGACGGGATG TGGAAATACA GACGGTGCTC GCTGTGCTGT CACCGCTCCT TGGATATCCC
p p l5 8 z a AGACGGGATG TGGAAATACA GACGGTGCTC GCTGTGCTGT CGCCGCTCCT TGGATATCCC
C ons AGACG-GATG TGGAA-T-CA G-CGG-GCTC GCTGTG-TGT — CC-CTCCT TGGAT-TCCC
m e n 2 1 z a
241
CATGTGATCA GGCGGTCCGC GCCACGGGGG AGCGAGCATG TTGTATCCTT
300
TGGGTACGGG
r s 8 2 0 z a CATGTGATCA GGCGGTCCGC GCCACGGGGG AGCGAGCATG TTGTATCCTT TGGGTACGGG
d s 8 9 5 z a CATGTGATCA GGCGGTCCGC GCCACGGGGG AGCGAGCATG TTGTATCCTT TGGGTACGGG
k s 3 3 z a CATGTGATCA GGCGGTCCGC GCCACGGGGG AGCGAGCATG TTGTATCCTT TGGGTACGGG
k s 9 8 z a CATGTGATCA GGCGGTCCGC GCCACGGGGG AGCGAGCATG TTGTATCCTT TGGGTACGGG
k s 7 8 z a CATGTGATCA GGCGGTCCGC GCCACGGGGG AGCGAGCATG TTGTATCCTT TGGGTACGGG
BC-1 CATGTCATCA GGCGGTCTGT GCCACGGGGG AGCGAGCGTG TTGTATCCTT TGGCTACGGG
d s 8 1 4 z a CATGTCATCA GGCGGTCTGT GCCACGGGGG AGCGAGCGTG TTGTATCCTT TGGCTACGGG
k s 7 0 z a CATGTCATCA GGCGGTCTGT GCCACGGGGG AGCGAGCGTG TTGTATCCTT TGGCTACGGG
k s 9 1 z a CATGTCATCA GGCGGTCTGT GCCACGGGGG AGCGAGCGTG TTGTATCCTT TGGCTACGGG
U gdlO CATGTCATCA GGCGGTCTGC GCCACGGGAG AGCGAGCGTG TTGTATCCTT TGGCTACGGG
k s 8 4 z a CATGTCATCA GGCGGTCTGC GCCACGGGGG AGCGAGCGTG TTGTATCCTT TGGCTACGGG
U g d l2 CATGTCATCA GGCGGTCTGC GCCACGGGGG AGCGAGCGTG TTGTATCCTT TGGCTACGGG
k s 6 5 z a CATGTCATCA GGCGGTCTGC GCCACGGGGG AGCGAGCGTG TTGTATCCTT TGGCTACGGG
k s 8 5 z a CATGTCATCA GGCGGTCTGC GCCACGGGGG AGCGAGCGTG TTGTATCCTT TGGCTACGGG
m e n 4 3 z a CATGTCATCA GGCGGTCTGC GCCACGGGGG AGCGAGCGTG TTGTATCCTT TGGCTACGGG
ln 7 z a CATGTCATCA GGCGGTCTGC GCCACGGGGG AACGAGCGTG TTGTATCCTT TGGCTACGGG
p b 7 z a CATGTCATCA GGCGGTCTGC GCCACGGGGG AACGAGCGTG TTGTATCCTT TGGCTACGGG
k s 3 1 z a CATGTCATCA GGCGGTCTGC GCCACGGGGG AACGAGCGTG TTGTATCCTT TGGCTACGGG
k s 6 4 z a CATGTCATCA GGCGGTCTGC GCCACGGGGG AACGAGCGTG TTGTATCCTT TGGCTACGGG
k s 8 1 z a CATGTCATCA GGCGGTCTGC GCCACGGGGG AACGAGCGTG TTGTATCCTT TGGCTACGGG
k s 8 3 z a CATGTCATCA GGCGGTCTGC GCCACGGGGG AACGAGCGTG TTGTATCCTT TGGCTACGGG
k s 8 8 z a CATGTCATCA GGCGGTCTGC GCCACGGGGG AACGAGCGTG TTGTATCCTT TGGCTACGGG
t s 7  9 9 z a CATGTCATCA GGCGGTCTGC GCCACGGGGG AACGAGCGTG TTGTATCCTT TGGCTACGGG
k s4  9 z a CATGTCATCA GGCGGTCTGC GCCACGGGGG AGCGAGCGTG TTGTATCTTT TGGCTACGGG
t s 5 2 2 z a CATGTCATCA GGCGGTCTGC GCCACGGGGG AACGAACGTG TTGTATCCTT TGGCTACGGG
k s l 3 z a CATGTCATCA GGCGGTCTAC GCCACGGGGG AGCGAGCGTG TTGTATCCTT TGGCTACGGG
k s 3 5 z a CATGTCATCA GGCGGTCTAC GCCACGGGGG AGCGAGCGTG TTGTATCCTT TGGCTACGGG
k s 3 7 z a CATGTCATCA GGCGGTCTAC GCCACGGGGG AGCGAGCGTG TTGTATCCTT TGGCTACGGG
k s  6 1 za CATGTCATCA GGCGGTCTGC GCCACGGGGG AGCGAGCGTG TTGTATCCTT TGGCTACGGG
k s7  6 z a CATGTCATCA GGCGGTCTGC GCCACGGGGG AGCGAGCGTG TTGTATCCTT TGGCTACGGG
U g d l5 CATGTCATCA GGCGGTCTCC GCCACGGGGG AGCGAGCGTG TTGTATCCTT TGGCTACGGG
U gd30 CATGTCATCA GGCGGTCTCC GCCACGGGGG AGCGAGCGTG TTGTATCCTT TGGCTACGGG
k s l 8 z a CATGTCATCA GGCGGTCTCC GCCACGGGGG AGCGAGCGTG TTGTATCCTT TGGCTACGGG
r s 9 0 1 z a CATGTCATCA GGCGGTCTCC GCCACGGGGG AGCGAGCGTG TTGTATCCTT TGGCTACGGG
r s 9 0 4 z a CATGTCATCA GGCGGTCTCC GCCACGGGGG AGCGAGCGTG TTGTATCCTT TGGCTACGGG
ts 6 5 2 z a CATGTCATCA GGCGGTCTCC GCCACGGGGG AGCGAGCGTG TTGTATCCTT TGGCTACGGG
k s 2 3 z a CATGTCATCA GGCGGTCTGC GCCACGGGGG AACGAGCGTG TTGTATCCTT TGGCTACGGG
k s 8 0 z a CATGTCATCA GGCGGTCTCC GCCACGGGGG AGCGAGCGTG TTGTATCCTT TGGCTACGGG
k s 8 2 z a CATGTCATCA GGCGGTCTCC GCCACGGGGG AGCGAGCGTG TTGTATCCTT TGGCTACGGG
p p l6 3 z a CATGTCATCA GGCGGTCTCC GCCACGGGGG AGCGAGCGTG TTGTATCCTT TGGCTACGGG
k s l 2 z a CATGTCATCA GGCGGTCTGC GACACGGGGG AGCGAGCGTG TTGTATCCTT TGGCTACGGG
p p l 5 8 z a CATGCCATCA GGCGGTCTCC GCCACGGGGG AGCGAGCGTG TTGTATCCTT TGGCTACGGG
C ons CATG--ATCA GGCGGTC----- G-CACGGG-G A-CGA-C-TG TTGTATC-TT TGG-TACGGG
ra en 2 1 za
301
CCAGACAGGG ACCGCAGGCC TACGACACTG TCAACAGAGC TTGCAGTTCT
360
GCTGCGAGAA
r s 8 2 0 z a C CAGACAGGG ACCGCAGGCC TACGACACTG TCAACAGAGC TTGCAGTTCT GCTGCGAGAA
d s 8 9 5 z a CCAGACAGGG ACCGCAGGCC TACGACACTG TCAACAGAGC TCGCAGTTCT GCTGCGAGAA
k s 3 3 z a CCAGACAGGG ACCGCAGGCC TACGACACTG TCAACAGAGC TTGCAGTTCT GCTGCGAGAA
k s 9 8 z a CCAGACAGGG ACCGCAGGCC TACGACACTG TCAACAGAGC TTGCAGTTCT GCTGCGAGAA
k s 7 8 z a CCAGACAGGG ACCGCAGGCC TACGACACTG TCAACAGAGC TTGCAGTTCT GCTGCGAGAA
BC-1 CCAAACATGC ACCACCGGCC CACAACATTG TCAACAGAGC TTGCAGTTCT GCTGCAAGAG
d s 8 1 4 z a CCAAACATGC ACCACCGGCC CACAACATT G TCAACAGAGC TTGCAGTTCT GCTGCAAGAG
k s 7 0 z a CCAAACGTGC ACCACAGGCC CACAACATTA TCAACAGAGC TTGCAGTTCT GCTGCAAGAG
k s 9 1 z a CCAAACCTTC ACCACAGGCC CACAACATTA TCAACAGAGC TTCGAGTTCT GCTGCAAGAG
U gdlO CCAAACATAA ACCACAGGCC CACAACACTG TCCACAGAGC TTGCAGTGTT GCTGCGAGAG
k s8 4  z a CCAAACATAA ACCACAGGCC CACAACACTG TCAACAGAGC TTGGAGTTTT GCTGCGAGAG
U g d l2 CCAAACATAA ACCACAGGCC CACAACACTG TCAACAGAGC TTGCAGTTTT GCTGCGAGAG
k s 6 5 z a CCAAACATAA ACCACAGGCC CACAACACTG TCAACAGAGC TTGCAGTTTT GCTGCGAGAG
k s 8 5 z a CCAAACATAA ACCACAGGCC CACAACACTG TCAACAGAGC TTGCAGTTTT GCTGCGAGAG
m en 4 3 za CCAAACATAA ACCACAGGCC CACAACACTG TCAACAGAGC TTGCAGTTTT GCTGCGAGAG
l n 7 z a CCAAACATAA ACCACAGGCC CACAACACTG TCAACAGAGC TTGCAGTTTT GCTGCGAGAG
pb7  za CCAAACATAA ACCACAGGCC CACAACACTG TCAACAGAGC TTGCAGTTTT GCTGCGAGAG
k s 3 1 z a CCAAACATAA ACCACGGGCC CACAACACTG TCAACAGAGC TTGCAGTTTT GCTGCGAGAG
k s6 4  z a CCAAACATAA ACCACAGGCC CACAACACTG TCAACAGAGC TTGCAGTTTT GCTGCGAGAG
k s 8 1 z a CCAAACATAA ACCACAGGCC CACAACACTG TCAACAGAGC TCGCAGTTTT GCTGCGAGAG
k s 8 3 z a CCAAACATAA ACCACAGGCC CACAACACTG TCAACAGAGC TTGCAGTTTT GCTGCGAGAG
k s 8 8 z a CCAAACATAA ACCACAGGCC CACAACACTG TCAACAGAGC TTGCAGTTTT GCTGCGAGAG
t s 7 9 9 z a CCAAACATAA ACCACAGGCC CACAACACTG TCAACAGAGC TTGCAGTTTT GCTGCGAGAG
k s4  9 z a CCAAACATAA ACCACAGGCC CACAACACTG TCAACAGAGC TTGCAGTTTT GCTGCGAGAG
t s 5 2 2 z a CCAAACATAA ACCACAGGCC CACAACACTG TCAACAGAGC TTGCAGTTTT GCTGCGAGAG
k s l 3 z a CCAAACATAA ACCACAGGCC CACAACACTG TCAACAGAGC TTGCAGTTTT GCTGCGAGAG
k s 3 5 z a CCAAACATAA ACCACAGGCC CACAACACTG TCAACAGAGC TTGCAGTTTT GCTGCGAGAG
k s3 7  za CCAAACATAA ACCACAGGCC CACAACACTG TCAACAGAGC TTGCAGTTTT GCTGCGAGAG
k s 6 1 z a CCAAACATAA ACCACAGGCC CACAACACTG TCAACAGAGC TTGCAGTTTT GCTGCGAGAG
k s7  6 z a CCAAACATAA ACCACAGGCC CACAACACTG TCAACAGAGC TTGCAGTTTT GCTGCGAGAG
U g d l5 CCAAACATAA ACCACAGGCC CACAACACTG TCAACAGAGC TTGGAGTTTT GCTGCGAGAG
U gd30 CCAAACATAA ACCACAGGCC CACAACACTG TCAACAGAGC TTGGAGTTTT GCTGCGAGAG
k s l 8 z a CCAAACATAA ACCACAGGCC CACAACACTG TCAACAGAGC TTGGAGTTTT GCTGCGAGAG
r s 9 0 1 z a CCAAACATAA ACCACAGGCC CACAACACTG TCAACAGAGC TTGGAGTTTT GCTGCGAGAG
r s 9 0 4 z a CCAAACATAA ACCACAGGCC CACAACACTG TCAACAGAGC TTGGAGTTTT GCTGCGAGAG
ts 6 5 2 z a CCAAACATAA ACCACAGGCC CACAACACTG TCAACAGAGC TTGGAGTTTT GCTGCGAGAG
k s 2 3 z a CCAAACATAA ACCACAGGCC CACAACACTG TCAACAGAGC TTGGAGTTTT GCTGCGAGAG
k s 8 0 z a CCAAACATAA ACCACAGGCC CACAACACTG TCAACAGAGC TTGGAGTTTT GCTGCGAGAG
k s 8 2 z a CCAAACATAA ACCACAGGCC CACAACACTG TCAACAGAGC TTGGAGTTTT GCTGCGAGAG
p p l6 3 z a CCAAACATAA ACCACAGGCC CACAACACTG TCAACAGAGC TTGGAGTTTT GCTGCGAGAG
k s l 2 z a CCAAACATAA ACCACAGGCC CACAACATTG TCAACAGAGC TTGGAGTTTT GCTGCGAGAG
p p l5 8 z a CCAAACATAA ACCACAGGCC CACAACACTG TCAACAGAGC TTGGAGTTTT GCTGCGAGAG
C ons CCA-AC------- ACC-C-GGCC -A C -A C A -T - TC-ACAGAGC T -----A G T --T GCTGC-AGA-
m e n 2 1 z a
361
CTAGGACTGC AGGAGTGGGC TAGAGTGGAA GTGGGTAGGC ACCTGGTATC
420
AAAAAT CACA
r s 8 2 0 z a CTAGGACTGC AGGAGTGGGC TAGAGTGGAA GTGGGTAGGC ACCTGGTATC AAAAAT CACA
d s 8 9 5 z a CTAGGACTGC AGGAGTGGGC TAGAGTGGAA GTGGGTAGGC ACCTGGTATC AAAAATCACA
k s 3 3 z a CTAGGACTGC AGGAGTGGGC TAGAGTGGAA GTGGGTAGGC ACCTGGTATC AAAAATCACA
k s 9 8 z a CTAGGACTGC AGGAGTGGGC TAGAGTGGAA GTGGGTAGGC ACCTGGTATC AAAAATCACA
k s 7 8 z a CTAGGACTGC AGGAGTGGGC TAGAGTGGAA GTGGGTAGGC ACCTGGTATC AAAAATCACA
BC-1 CTAGGATTGC AGGAGTGGGC TAGAGTGGAA GTGGGCAGGC ACCTGGTGTC CAAAATCACA
d s 8 1 4 z a CTAGGATTGC AGGAGTGGGC TAGAGTGGAA GTGGGCAGGC ACCTGGTGTC CAAAATCACA
k s 7 0 z a CTAGGATTGC AGGAGTGGGC TAGAGTGGAA GTGGGCAGGC ACCTGGTGTC CAAAATCACA
k s 9 1 z a CTAGGATTGC AGGAGTGGGC TAGAGTGGAA GTGGGCAGGC ACCTGGTGTC CAAAATCACA
U gdlO CTAGGACTGC AGGAGTGGGC TAGAGTGGAA GTGGGCAGGC ACCTGGTGTC CAAAATCACA
k s 8 4 z a CTAGGACTGC AGGAGTGGGC TAGAGTGGAA GTGGGCAGGC ACCTGGTGTC CAAAATCACA
U g d l2 CTAGGACTGC AGGAGTGGGC TAGAGTGGAA GTGGGCAGGC ACCTGGTGTC CAAAATCACA
k s 6 5 z a CTAGGACTGC AGGAGTGGGC TAGAGTGGAA GTGGGCAGGC ACCTGGTGTC CAAAATCACA
k s 8 5 z a CTAGGACTGC AGGAGTGGGC TAGAGTGGAA GTGGGCAGGC ACCTGGTGTC CAAAATCACA
m e n 4 3 z a CTAGGACTGC AGGAGTGGGC TAGAGTGGAA GTGGGCAGGC ACCTGGTGTC CAAAATCACA
ln 7  za CTAGGACTGC AGGAGTGGGC TAGAGTGGAA GTGGGCAGGC ACCTGGTGTC CAAAATCACA
pb7  za CTAGGACTGC AGGAGTGGGC TAGAGTGGAA GTGGGCAGGC ACCTGGTGTC CAAAATCACA
k s 3 1 z a CTAGGACTGC AGGAGTGGGC TAGAGTGGAA GTGGGCAGGC ACCTGGTGTC CAAAATCACA
k s6 4  za CTAGGACTGC AGGAGTGGGC TAGAGTGGAA GTGGGCAGGC ACCTGGTGTC CAAAATCACA
k s 8 1 z a CTAGGACTGC AGGAGTGGGC TAGAGTGGAA GTGGGCAGGC ACCTGGTGTC CAAAATCACA
k s 8 3 z a CTAGGACTGC AGGAGTGGGC TAGAGTGGAA GTGGGCAGGC ACCTGGTGTC CAAAATCACA
k s 8 8 z a CTAGGACTGC AAGAGTGGGC TAGAGTGGCA GTGGGCAGGC ACCTGGTGTC CAAAATCACA
t s 7  9 9 z a CTAGGACTGC AGGAGTGGGC TAGAGTGGAA GTGGGCAGGC ACCTGGTGTC CAAAATCACA
k s4  9 z a CTAGGACTGC AGGAGTGGGC TAGAGTGGAA GTGGGCAGGC ACCTGGTGTC CAAAATCACA
t s 5 2 2 z a CTAGGACTGC AGGAGTGGGC TAGAGTGGAA GTGGGCAGGC ACCTGGTGTC CAAAATCACA
k s l 3 z a CTAGGACTGC AGGAGTGGGC TAGAGTGGAA GTGGGCAGGC ACCTGGTGTC CAAAATCACA
k s 3 5 z a CTAGGACTGC AGGAGTGGGC TAGAGTGGAA GTGGGCAGGC ACCTGGTGTC CAAAATCACA
k s 3 7 z a CTAGGACTGC AGGAGTGGGC TAGAGTGGAA GTGGGCAGGC ACCTGGTGTC CAAAATCACA
k s 6 1 z a CTAGGACTGC AGGAGTGGGC TAGAGTGGAA GTGGGCAGGC ACCTGGTGTC CAAAATCACA
k s7  6 z a CTAGGACTGC AGGAGTGGGC TAGAGTGGAA GTGGGCAGGC ACCTGGTGTC CAAAATCACA
U g d l5 CTAGGACTGC AGGAGTGGGC TAGAGTGGAA GTGGGCAGGC ACCTGGTGTC CAAAATCACA
U gd30 CTAGGACTGC AGGAGTGGGC TAGAGTGGAA GTGGGCAGGC ACCTGGTGTC CAAAATCACA
k s l 8 z a CTAGGACTGC AGGAGTGGGC TAGAGTGGAA GTGGGCAGGC ACCTGGTGTC CAAAATCACA
r s 9 0 1 z a CTAGGACTGC AGGAGTGGGC TAGAGTGGAA GTGGGCAGGC ACCTGGTGTC CAAAATCACA
r s 9 0 4 z a CTAGGACTGC AGGAGTGGGC TAGAGTGGAA GTGGGCAGGC ACCTGGTGTC CAAAATCACA
t s 6 5 2 z a CTAGGACTGC AGGAGTGGGC TAGAGTGGAA GTGGGCAGGC ACCTGGTGTC CAAAATCACA
k s 2 3 z a CTAGGACTGC AGGAGTGGGC TAGAGTGGAA GTGGGCAGGC ACCTGGTGTC CAAAATCACA
k s 8 0 z a CTAGGATTGC AGGAGTGGGC TAGAGTGGAA GTGGGCAGGC ACCTGGTGTC CAAAATCACA
k s 8 2 z a CTAGGACTGC AGGAGTGGGC TAGAGTGGAA GTGGGCAGGC ACCTGGTGTC CAAAATCACA
p p l 6 3 z a CTAGGACTGC AGGAGTGGGC TAGAGTGGAA GTGGGCAGGC ACCTGGTGTC CAAAATCACA
k s l 2 z a CTAGGACTGC AGGAGTGGGC TAGAGTGGAA GTGGGCAGGC ACCTGGTGTC CAAAATCACA
p p l 5 8 z a CTAGGGCTGC AGGAGTGGGC TAGAGTGGAA GTGGGCAGGC ACCTGGTGTC CAAAATCACA
C ons CTAGG--TGC A-GAGTGGGC TAGAGTGG-A GTGGG-AGGC ACCTGGT-TC -AAAATCACA
m e n 2 1 z a
421
CAGACTCTGC TAGAACCACA CCCACCTCAG TTTATAAGGG CATTTACACA
480
AAATACCGAC
r s 8 2 0 z a CAGACTCTGC TAGAACCACA CCCACCTCAG TTTATAAGGG CATTTACACA AAATACCGAC
d s 8 9 5 z a CAGACTCTGC TAGAACCACA CCCACCTCAG TTTATAAGGG CATTTACACA AAATACCGAC
k s 3 3 z a CAGACTCTGC TAGAACCACA CCCACCTCAG TTTATAAGGG CATTTACACA AAATACCGAC
k s 9 8 z a CAGACCCTGC TAGAACCACA CCCACCTCAG TTTATAAGGG CATTTACACA AAATACCGAC
k s 7 8 z a CAGACTCTGC TAGAACCACA CCCACCTCAG TTTATAAGGG CATTTACACA AAATACCGAC
BC-1 CAGACCCTGC TAGAACCACA CCCACCTCAG TTTATCAGGG CATTTACACA AAATACCGAC
d s 8 1 4 z a CAGACCCTGC TAGAACCACA CCCACCTCAG TTTATCAGGG CATTTACACA AAATACCGAC
k s7  0 z a CAGACCCTGC TAGAACCACA CCCACCTCAG TTTATCAGGG CATTTACACA AAATACCGAC
k s 9 1 z a CAGACCCTGC TAGAACCACA CCCACCTCAG TTTATCAGGG CATTTACACA AAATACCGAC
U gdlO CAGACCCTGC TAGAACCACA CCCACCTCAG TTTATCAGGG CATTTACACA AAATACCGAC
k s 8 4 z a CAGACCCTGC TAGAACCACA CCCACCTCAG TTTATCAGGG CATTTACACA AAATACCGAC
U g d l2 CAGACCCTGC TAGAACCACA CCCACCTCAG TTTATCAGGG CATTTACACA AAATACCGAC
k s 6 5 z a CAGACCCTGC TAGAACCACA CCCACCTCAG TTTATCAGGG CATTTACACA AAATACCGAC
k s 8 5 z a CAGACCCTGC TAGAACCACA CCCACCTCAG TTTATCAGGG CATTTACACA AAATACCGAC
m e n 4 3 z a CAGACCCTGC TAGAACCACA CCCACCTCAG TTTATCAGGG CATTTACACA AAATACCGAC
ln 7  z a CAGACCCTGC TAGAACCACA CCCACCTCAG TTTATCAGGG CATTTACACA AAATACCGAC
pb7 z a CAGACCCTGC TAGAACCACA CCCACCTCAG TTTATCAGGG CATTTACACA AAATACCGAC
k s 3 1 z a CAGACCCTGC TAGAACCACA CCCACCTCAG TTTATCAGGG CATTTACACA AAATACCGAC
k s 6 4 z a CAGACCCTGC TAGAACCACA CCCACCTCAG TTTATCAGGG CATTTACACA AAATACCGAC
k s 8 1 z a CAGACCCTGC TAGAACCACA CCCACCTCAG TTTATCAGGG CATTTACACA AAATACCGAC
k s 8 3 z a CAGACCTTGC TAGAACCACA CCCACCTCAG TTTATCAGGG CATTTACACA AAATACCGAC
k s 8 8 z a CAGACCCTGC TAGAACCACA CCCACCTCAG TTTATCAGGG CATTTACACA AAATACCGAC
t s 7 9 9 z a CAGACCCTGC TAGAACCACA CCCACCTCAG TTTATCAGGG CATTTACACA AAATACCGAC
k s4  9 z a CAGACCCTGC TAGAACCACA CCCACCTCAG TTTATCAGGG CATTTACACA AAATACCGAC
ts 5 2 2 z a CAGACCCTGC TAGAACCACA CCCACCTCAG TTTATCAGGG CATTTACACA AAATACCGAC
k s l 3 z a CAGACCCTGC TAGAACCACA CCCACCTCAG TTTATCAGGG CATTTACACA AAATACCGAC
k s 3 5 z a CAGACCCTGC TAGAACCACA CCCACCTCAG TTTATCAGGG CATTTACACA AAATACCGAC
k s 3 7 z a CAGACCCTGC TAGAACCACA CCCACCTCAG TTTATCAGGG CATTTACACA AAATACCGAC
k s S l z a CAGACCCTGC TAGAACCACA CCCACCTCAG TTTATCAGGG CATTTACACA AAATACCGAC
k s7  6 z a CAGACCCTGC TAGAACCACA CCCACCTCAG TTTATCGGGG CATTTACACA AAATACCGAC
U g d l5 CAGACCCTGC TAGAACCACA CCCACCTCAG TTTATCAGGG CATTTACACA AAATACTGAC
U gd30 CAGACCCTGC TAGAACCACA CCCACCTCAG TTTATCAGGG CATTTACACA AAATACTGAC
k s l 8 z a CAGACCCTGC TAGAACCACA CCCACCTCAG TTTATCAGGG CATTTACACA AAATACTGAC
r s 9 0 1 z a CAGACCCTGC TAGAACCACA CCCACCTCAG TTTATCAGGG CATTTACACA AAATACTGAC
r s 9 0 4 z a CAGACCCTGC TAGAACCACA CCCACCTCAG TTTATCAGGG CATTTACACA AAATACTGAC
t s 6 5 2 z a CAGACCCTGC TAGAACCACA CCCACCTCAG TTTATCAGGG CATTTACACA AAATACTGAC
k s 2 3 z a CAGACCCTGC TAGAACCACA CCCACCTCAG TTTATCAGGG CATTTACACA AAATACTGAC
k s 8 0 z a CAGACCCTGC TAGAACCACA CCCACCTCAG TTTATCAGGG CATTTACACA AAATACTGAC
k s 8 2 z a CAGACCCTGC TAGAACCACA CCCACCTCAG TTTATCAGGG CATTTACACA AAATACTGAC
p p l6 3 z a CAGACCCTGC TAGAACCACA CCCACCTCAG TTTATCAGGG CATTTACACA AAATACTGAC
k s l 2 z a CAGACCCTGC TAGAACCACA CCCACCTCAG TTTATCAGGG CATTTACACA AAATACTGAC
p p l5 8 z a CAGACCCTGC TAGAACCACA CCCACCTCAG TTTATCAGGG CATTTACACA AAATACTGAC
C ons CAGAC--TGC TAGAACCACA CCCACCTCAG TTTAT— GGG CATTTACACA AAATAC-GAC
m e n 2 1 z a
481
CTGGTACCGT ACGAGGGGTT GGACGCGCCC GAGGGTCCCC CGCCCGTGGC
540
TAGGCCACAC
r s 8 2 0 z a CTGGTACCGT ACGAGGGGTT GGACGCGCCC GAGGGTCCCC CGCCCGTGGC TAGGCCACAC
d s 8  9 5 z a CTGGTACCGT ACGAGGGGTT GGACGCGCCC GAGGGTCCCC CGCCCGTGGC TAGGCCACAC
k s 3 3 z a CTGGTACCGT ACGAGGGGTT GGACGCGCCC GAGGGTCCCC CGCCCGTGGC TAGGCCACAC
k s 9 8 z a CTGGTACCGT ACGAGGGGTT GGACGCGCCC GAGGGTCCCC CGCCCGTGGC TAGGCCACAC
k s7  8 z a CTGGTACCGT ACGAGGGGTT GGACGCGCCC GAGGGTCCCC CGCCCGTGGC TAGGCCACAC
B C-1 CTGGTACCGT ACGAGGGGTT GGAAGTGCCC GAGGGTCCCC AGCCCGTGGC TAGGCCACAC
d s 8 1 4 z a CTGGTACCGT ACGAGGGGTT GGAAGTGCCC GAGGGTCCCC AGCCCGTGGC TAGGCCACAC
k s7  0 z a CTGGTACCGT ACGAGGGGTT GGAAGTGCCC GAGGGTCCCC AGCCCCTGGC TAGGCCACAC
k s 9 1 z a CTGGTACCGT ACGAGGGGTT GGAAGTGCCC GAGGGTCCCC AGCCCGTGGC TAGGCCACAC
U gdlO CTGGTACCGT ACGAGGGGTT GGAAGTGCCC GAGGGTCCCC AGCCCGTGGC TAGGCCACAC
k s 8 4 z a CTGGTACCGT ACGAGGGGTT GGAAGTGCCC GAGGGTCCCC AGCCCGTGGC TAGGCCACAC
U g d l2 CTGGTACCGT ACGAGGGGTT GGAAGTGCCC GAGGGTCCCC AGCCCGTGGC TAGGCCACAC
k s 6 5 z a CTGGTACCGT ACGAGGGGTT GGAAGTGCCC GAGGGTCCCC AGCCCGTGGC TAGGCCACAC
k s 8 5 z a CTGGTACCGT ACGAGGGGTT GGAAGTGCCC GAGGGTCCCC AGCCCGTGGC TAGGCCACAC
m e n 4 3 z a CTGGTACCGT ACGAGGGGTT GGAAGTGCCC GAGGGTCCCC AGCCCGTGGC TAGGCCACAC
ln 7 z a CTGGTACCGT ACGAGGGGTT GGAAGTGCCC GAGGGTCCCC AGCCCGTGGC TAGGCCACAC
p b 7 z a CTGGTACCGT ACGAGGGGTT GGAAGTGCCC GAGGGTCCCC AGCCCGTGGC TAGGCCACAC
k s 3 1 z a CTGGTACCGT ACGAGGGGTT GGAAGTGCCC GAGGGTCCCC AGCCCGTGGC TAGGCCACAC
k s  64 z a CTGGTACCGT ACGAGGGGTT GGAAGTGCCC GAGGGTCCCC AGCCCGTGGC TAGGCCACAC
k s 8 1 z a CTGGTACCGT ACGAGGGGTT GGAAGTGCCC GAGGGTCCCC AGCCCGTGGC TAGGCCACAC
k s 8 3 z a CTGGTACCGT ACGAGGGGTT GGAAGTGCCC GAGGGTCCCC AGCCCGTGGC TAGGCCACAC
k s 8 8 z a CTGGTACCGT ACGAGGGGTT GGAAGTGCCC GAGGGTCCCC AGCCCGTGGC TAGGCCACAC
t s 7  9 9 z a CTGGTACCGT ACGAGGGGTT GGAAGTGCCC GAGGGTCCCC AGCCCGTGGC TAGGCCACAC
k s4  9 z a CTGGTACCGT ACGAGGGGTT GGAAGTGCCC GAGGGTCCCC AGCCCGTGGC TAGGCCACAC
t s 5 2 2 z a CTGGTACCGT ACGAGGGGTT GGAAGTGCCC GAGGGTCCCC AGCCCGTGGC TAGGCCACAC
k s l 3 z a CTGGTACCGT ACGAGGGGTT GGAAGTGCCC GAGGGTCCCC AGCCCGTGGC TAGGCCACAC
k s 3 5 z a CTGGTACCGT ACGAGGGGTT GGAAGTGCCC GAGGGTCCCC AGCCCGTGGC TAGGCCACAC
k s 3 7 z a CTGGTACCGT ACGAGGGGTT GGAAGTGCCC GAGGGTCCCC AGCCCGTGGC TAGGCCACAC
k s 6 1 z a CTGGTACCGT ACGAGGGGTT GGAAGTGCCC GAGGGTCCCC AGCCCGTGGC TAGGCCACAC
k s7  6 z a CTAGTACCGT ACGAGGGGTT GGAAGTGCCC GAGGGTCCCC AGCCCGTGGC TAGGCCACAC
U g d l5 CTGGTACCGT ACGAGGGGTT GGAAGTGCCC GAGGGTCCCC AGCCCGTGGC TAGGCCACAC
U gd30 CTGGTACCGT ACGAGGGGTT GGAAGTGCCC GAGGGTCCCC AGCCCGTGGC TAGGCCACAC
k s l 8 z a CTGGTACCGT ACGAGGGGTT GGAAGTGCCC GAGGGTCCCC AGCCCGTGGC TAGGCCACAC
r s 9 0 1 z a CTGGTACCGT ACGAGGGGTT GGAAGTGCCC GAGGGTCCCC AGCCCGTGGC TAGGCCACAC
r s 9 0 4 z a CTGGTACCGT ACGAGGGGTT GGAAGTGCCC GAGGGTCCCC AGCCCGTGGC TAGGCCACAC
ts 6 5 2 z a CTGGTACCGT ACGAGGGGTT GGAAGTGCCC GAGGGTCCCC AGCCCGTGGC TAGGCCACAC
k s 2 3 z a CTGGTACCGT ACGAGGGGTT GGAAGTGCCC GAGGGTCCCC AGCCCGTGGC TAGGCCACAC
k s 8 0 z a CTGGTACCGT ACGAGGGGTT GGAAGTGCCC GAGGGTCCCC AGCTCGTGGC TAGGCCACAC
k s 8 2 z a CTGGTACCGT ACGAGGGGTT GGAAGTGCCC GAGGGTCCCC AGCCCGTGGC TAGGCCACAC
p p l 6 3 z a CTGGTACCGT ACGAGGGGTT GGAAGTGCCC GAGGGTCCCC AGCCCGTGGC TAGGCCACAC
k s l 2 z a CTGGTACCGT ACGAGGGGTT GGAAGTGCCC GAGGGTCCCC AGCCCGTGGC TAGGCCACAC
p p l 5 8 z a CTGGTACCGT ACGAGGGGTT GGAAGTGCCC GAGGGTCCCC AGCCCGTGGC TAGGCCACAC
C ons CT-GTACCGT ACGAGGGGTT GGA-G-GCCC GAGGGTCCCC -GC-C-TGGC TAGGCCACAC





r s 8 2 0 z a ATTGAAGATG ATGTCATTAT GCAGGCTGTT ATGATG
d s 8 9 5 z a ATTGAAGATG ATGTCATTAT GCAGGCTGTT ATGATG
k s 3 3 z a ATTGAAGATG ATGTCATTAT GCAGGCTGTT ATGATG
k s 9 8 z a ATTGAAGATG ATGTCATTAT GCAGGCTGTT ATGATG
k s 7 8 z a ATTGAAGATG ATGTCATTAT GCAGGCTGTT ACGATG
B C-1 ATTGAAGATG ATGTCATTAT GCAGGCTGTT ATGATA
d s 8 1 4 z a ATTGAAGATG ATGTCATTAT GCAGGCTGTT ATGATA
k s 7 0 z a ATTGAAGATG ATGTCATTAT GCAGGCTGTT ATGATA
k s 9 1 z a ATTGAAGATG ATGTCATTAT GCAGGCTGTT ATGATA
U gdlO ATTGAAGATG ATGTCATTAT GCAGGCTGTT ATGATA
k s 8 4 z a ATTGAAGATG ATGTCATTAT GCAGGCTGTT ATGATA
U g d l2 ATTGAAGATG ATGTCATTAT GCAGGCTGTT ATGATA
k s 6 5 z a ATTGAAGATG ATGTCATTAT GCAGGCTGTT ATGATA
k s 8 5 z a ATTGAAGATG ATGTCATTAT GCAGGCTGTT ATGATA
m en 4 3 za ATTGAAGATG ATGTCATTAT GCAGGCTGTT ATGATA
l n 7 z a ATTGAAGATG ATGTCATTAT GCAGGCTGTT ATGATA
p b 7 z a ATTGAAGATG ATGTCATTAT GCAGGCTGTT ATGATA
k s 3 1 z a ATTGAAGATG ATGTCATTAT GCAGGCTGTT ATGATA
k s6 4  z a ATTGAAGATG ATGTCATTAT GCAGGCTGTT GTGATA
k s 8 1 z a ATTGAAGATG ATGTCATTAT GCAGGCTGTT ATGATA
k s 8 3 z a ATTGAAGATG ATGTCATTAT GCAGGCTGTT ATGATA
k s 8 8 z a ATTGAAGATG ATGTCATTAT GCAGGCTGTT ATGATA
t s 7 9 9 z a ATTGAAGATG ATGTCATTAT GCAGGCTGTT ATGATA
k s4  9 z a ATTGAAGATG ATGKCATTAT GCAGGCTGTT ATGATA
ts 5 2 2 z a ATTGAAGATG ATGTCATTAT GCAGGCTGTT ATGATA
k s l 3 z a ATTGAAGATG ATGTCATTAT GCAGGCTGTT ATGATA
k s 3 5 z a ATTGAAGATG ATGTCATTAT GCAGGCTGTT ATGATA
k s3 7  za ATTGAAGATG ATGTCATTAT GCAGGCTGTT ATGATA
k s 6 1 z a ATTGAAGATG ATGTCATTAT GCAGGCTGTT ATGATA
k s7  6 z a ATTGAAGATG ATGTCATTAT GCAGGCTGTT ATGATA
U g d l5 ATTGAAGATG ATGTCATTAT GCAGGCTGTT ATGATA
U gd30 ATTGAAGATG ATGTCATTAT GCAGGCTGTT ATGATA
k s l 8 z a ATTGAAGATG ATGTCATTAT GCAGGCTGTT ATGATA
r s 9 0 1 z a ATTGAAGATG ATGTCATTAT GCAGGCTGTT ATGATA
rs 9 0 4  za ATTGAAGATG ATGTCATTAT GCAGGCTGTT ATGATA
ts 6 5 2 z a ATTGAAGATG ATGTCATTAT GCAGGCTGTT ATGATA
k s 2 3 z a ATTGAAGATG ATGTCATTAT GCAGGCTGTT ATGATA
k s 8 0 z a ATTGAAGATG ATGTCATTAT GCAGGCTGTT ATGATA
k s 8 2 z a ATTGAAGATG ATGTCATTAT GCAGGCTGTT ATGATA
p p l6 3 z a ATTGAAGATG ATGTCATTAT GCAGGCTGTT ATGATA
k s l 2 z a ATTGAAGATG ATGTCATTAT GCAGGCTGTT ATGATA
p p l.5 8 z a ATTGAAGATG ATGTCATTAT GCAGGCTGTT ATGATA
C ons ATTGAAGATG ATG-CATTAT GCAGGCTGTT --G A T -
Fig. 6.5. Nucleotide changes within (A) ORF26, (B) T0.7/K12 and (C) 
ORF75-UPS75’ loci.
Sequences of Ugandan strains (bold) were compared with published sequences 
(Fig. 6.4) and results of this analysis are summarized in this figure, showing the 
groups to which the Ugandan strains belong. Only representative published 
sequences for the groups to which the Ugandan sequences belong are also 
shown. Group designations are those defined by Poole et al. (1999). K1 subtypes 
are indicated. The results are presented in the context o f variation from BCBL-R 
sequences; hyphens and dots denote identical and deleted residues, respectively. 
ORF26 and ORF75/UPS75’ are in the same orientation as the genomic sequence, 
and T0.7/K12 is in the opposite orientation. The number at the top of each site 
indicates position in the alignment. PG, groups published previously; DG, groups 
determined in this study; nk, unknown.
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BCBL-R A1 T G C G C G A A A A
BC-1 A2 A
BC2 C3 C - A T - - G C - C3
Ugd23 C C - A T - - G C - C3
ST2-3 B C - A - - - G C - B2
Ugdl B C - A - - - G C - B2
Ugdl2 A5 C - A - - - G C - B2
Ugdl9 B C - A - - - G C - B2
Ugd2 B C - A - - - G C - B2
Ugd21 B C - A - - - G C - B2
Ugd26 B C - A - - - G C - B2
Ugd7 B C - A - - - G C - B2
Ugd8 n k C - A - - - G C - B2
Ugd9 n k C - A - - - G C - B2
431KAP B C G C - B1
Ugd30 n k C G C - B1
OKS3 A5 C - - - T - - C - B3/C2
UgdlO B C - - - T - - C - B3/C2
Ugdll n k C - - - T - - C - B3/C2
Ugdl4 n k C - - - T - - C - B3/C2
Ugdl5 B C - - - T - - C - B3/C2
Ugdl6 A5 C - - - T - - C - B3/C2
Ugdl7 n k C - - - T - - C - B3/C2
Ugdl8 A5 C - - - T - - C - B3/C2
Ugd20 nk C - - - T - - C - B3/C2
Ugd22 n k c - - - T - - C - B3/C2
Ugd24 A5 c - - - T - - c - B3/C2
Ugd27 n k c - - - T - - c - B3/C2
Ugd28 n k c - - - T - - c - B3/C2
Ugd29 B c - - - T - - c - B3/C2
Ugd3 B c - - - T - - c - B3/C2
Ugd4 A5 c - - - T - - c - B3/C2
Ugd5 n k c - - - T - - c - B3/C2
Ugd6 n k c - - - T - - c G B3/C2
Ugdl3 B c - - - T - - c - B3/C2
Ugd25 n k c A - - T - - c - B3/C2
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Fig. 6.5A shows that all the Ugandan sequences clustered into patterns described 
previously in ORF26. The majority (19) have the B3/C2 pattern (like OKS3; 
Table 2.1), nine have the B2 pattern (like ST-3; Table 2.1), one (Ugd30) has the 
B1 pattern (like 431KAP; Table 2.1) and one (Ugd23) has the C3 pattern (like 
BC2, Table 2.1). Notably, none of the 30 Ugandan sequences grouped with the A 
subtypes.
Also in T0.7/K12, the Ugandan strains (with the exception o f UgdlO) fall into 
nucleotide patterns reported previously (Fig. 6.5B). Six (Ugd4/15/16/23/29/30) 
cluster with strains o f the B1 nucleotide pattern (e.g. 431KAP) and three 
(Ugd2/12/19) with strains of the B2 pattern (e.g. OKS3). The M pattern in 
T0.7/K12 is represented by ASM72 (Table 2.1). BC-1 belongs to pattern A2 at 
this locus. The pattern of UgdlO is distinct, but it shares characteristics with both 
B and M patterns at positions 168, 197, 227, 477 and 502 (Fig. 6.4B). This 
pattern has therefore been denoted M \ As in ORF26, none of the Ugandan 
sequences clustered with sequences o f the A (e.g. BC-1) or A/C (e.g. BCBL-R) 
patterns.
In ORF75 (Fig. 6.5C), the five sequences (Ugd4/15/16/23/29) that have a B1 
pattern in T0.7/K12 are identical, but, surprisingly, cluster with sequences that 
have the pattern A/C (e.g. BCBL-R). The three Ugandan sequences 
(Ugd2/12/19) that have a B2 pattern at T0.7/K12 are also identical and cluster 
with sequences that have pattern B (e.g. 431KAP). The M pattern in ORF75 is 
represented by BC-1, but this sequence is identical to that o f ASM72. UgdlO 
shows a distinct pattern in ORF75 as well, and also shares characteristics with 
both the B and M patterns (positions 102, 235 and 320; Fig. 6.5C). This pattern 
has also been designated as M \ Interestingly, the ORF75 sequence of UgdlO is 
closely related to that o f KS84ZA (Fig. 6.4D and 6.5C; Table 2.1), a sequence 
categorised among the A/C group previously (Alagiozoglou et al., 2000). The M
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sequences in samples from South Africa (DS814ZA, KS70ZA and KS91ZA; 
Table 2.1) are more closely related to BC-1 than to UgdlO (Fig. 6.4D and 6.5C). 
It is clear from Fig 6.4D that the N subtype from South Africa (Alagiozoglou et 
al., 2000) is distinct from all other sequences in the alignment.
Analysis of the 209 bp region upstream from ORF75 (UPS75’) revealed 32 
substitution sites (Fig. 6.5C). Surprisingly, in this region UgdlO is identical to 
BC-1. The sequences linked to the P allele show variation ranging from 0% (in 
identical sequences) to 1.4% (Ugd4/16 vs. Ugdl9; Fig. 6.5C and Table 6.2). 
However, the M-linked strains differ from the P-linked strains by up to 15%.
In summary, comparison of the Ugandan sequences with those published 
previously revealed that in ORF75 Ugd4/15/16/23/29/30 have the same pattern 
as BCBL-R and all other sequences that have the same sequence as BCBL-R, 
while Ugd2/12/19 belong to a different group with 431KAP (Table 2.1) and B 
pattern sequences from South Africa (Fig. 6.4C, D). The fact that UgdlO shares 
characteristics with the B and M groups in T0.7/K12 and ORF75 suggests that it 
is evolutionarily related to these two groups.
6.5.1 Overall genotypes of the Ugandan strains
Analysis o f the patterns identified in ORF26, T0.7/K12 and ORF75 together with 
those o f K1 and K15 resulted in the overall genotypes summarised in Table 6.3. 
The two K15 P groups have been designated as B and A/C because of the 
continuity of their respective patterns into the B and A/C patterns of the 
immediately adj acent portion of ORF75.
The grouping of Ugandan sequences based on nucleotide patterns also reveals 
evidence for recombination between K1 and ORF26, and between ORF26 and
Table 6.3. Subtype designations at each locus and overall genotypes
Sample3 K1 ORF26 T0.7/K12 ORF75 UPS75’ K15 Overall6 Revised
Overall
Ugd4 A5 B3/C2 BI A/C A/C P(A/C) A5-B-A A5-BII
Ugdl6 A5 B3/C2 BI A/C A/C P(A/C) A5-B-A A5-BII
Ugdl2 A5 B2 B2 B B P(B) A5-B A5-BI
Ugd2 BI B2 B2 B B P(B) B BI
Ugdl9 BI B2 B2 B B P(B) B BI
431KAP BIF BI BI B B Pd B BII-BI
Ugd30 nk BI BI A/C nk pd nk-B-A/C nk-BII
Ugdl5 Bill B3/C2 BI A/C A/C P(A/C) B-A/C BIII-BII
Ugd29 BII B3/C2 BI A/C A/C P(A/C) B-A/C BII
Ugd23 C C3 BI A/C A/C P(A/C) C-B-C C-BII
BC2 C3 C3 A/C A/C A/C pd C C-BII
BCBL-R Al A A/C A/C A/C P(A/C) A A-BII
UgdlO BII B3/C2 M’ M’ M M(M’) B-M’ BII-M’
ASM72 Cl Cl M M nk Md C-M C-M
BC-1 A2 A A M M M(M) A-M A-M
a Ugandan samples are in bold, and selected sequences (Table 2.4) used in the 
comparative analysis are also shown. Subtypes are designated according to the 
nomenclature of Poole et al. (1999), except for K15 and the revised overall genotypes 
that were designated on the basis of observations made in this study. The use of 
slashes (e.g. B3/C2) indicates that subtypes could not be distinguished. 
b The most parsimonious solution is shown.
c 431KAP clustered with UKma24 (Lacoste et al., 2000a), therefore in this study it 
falls into BII with UKma24 (Fig. 4.6).
d K15 genotype based on PCR assay only, and not on DNA sequence (Poole et al., 
1999; this study for Ugd30). In determining the overall genotype, the K15 genotype 
was assumed to be the same as that for ORF75.
Abbreviation: nk, unknown.
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T0.7/K12 in these strains. Ugd2/19 and Ugdl5/29 co-segregate at all six loci, 
suggesting that their genomes have not been subjected to detectable 
recombination. Except in K l, Ugdl2 has the same type of genome as Ugd2/19, 
and Ugd4/16 the same type as Ugd 15/29. Ugd23 has the same type of genome as 
Ugd4/15/16/29, except in K l and ORF26. UgdlO has the same genotype as 
Ugd29 in K l and ORF26, but it is distinct in T0.7/K12 and ORF75, and is 
closely related to BC-1 in UPS75’-K15.
It is interesting to note that BCBL-R (which in ORF26, T0.7/K12 and ORF75 
has the same sequence as several strains with K l A or C genes) groups with 
Ugd4/15/16/23/29 in ORF75/UPS75’ and K15 but not at other loci (with the 
exception of K l). This suggests recombination between T0.7/K12 and ORF75, 
which was not evident from the network analysis (section 6.3 above). Therefore, 
BCBL-R and its counterparts probably have recombinant genomes. Thus, 
although the group designations (Table 6.3) suggest that Ugd4/15/16/23/29 may 
be recombinants between T0.7/K12 and ORF75, this may not be the case. 
Furthermore, 431KAP (the strain regarded as the prototype for subtype B strains; 
Poole et al., 1999) has the pattern of Ugd2/12/19 in ORF75 and the pattern of 
Ugd4/15/16/23/29 in T0.7/K12, suggesting recombination between members of 
the same subtype at a point between T0.7/K12 and ORF75.
These observations highlight the problems associated with fixing prototype 
strains on the basis of “ weight of numbers” , as was done in previous studies 
(Poole et al., 1999; Zong et al., 1999). To gain further insights into the 
relationships of these strains, a network analysis was performed.
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6.5.2 Network analysis of Ugandan sequences with selected published 
sequences
The networks (Fig. 6.3) for ORF26, T0.7/K12 and ORF75 were modified using 
data in Fig. 6.5 to include sequences of Ugd30 (which clustered with 431KAP in 
ORF26), 431KAP and BCBL-R. The modified networks are shown in Fig. 6.6.
Examination of the groups, together with those for K l and K15 (Table 6.1), 
reveals that BCBL-R (which belongs to subtype A in K l) clusters with BC-1 in 
K l, ORF26 and T0.7/K12 (Fig. 6.6A,B), but clusters with Ugd4/15/16/23/29 in 
ORF75 (Fig. 6.6C) and K15 (Fig. 6.3D), suggesting recombination between 
T0.7/K12 and ORF75 in the BCBL-R lineage. 431KAP (which belongs to 
subtype B K l) clusters with Ugd4/15/16/23/29 in T0.7/K12 (Fig. 6.6B) but with 
Ugd2/12/19 in ORF75 (Fig. 6.6C), suggesting recombination between T0.7/K12 
and ORF75 in this strain. Ugd30 clusters with 431KAP in ORF26 (Fig. 6.6A) 
and with Ugd4/15/16/23/29 in T0.7/K12 and ORF75 (Fig. 6.6B, C). 
Interestingly, BC-1 appears to maintain the same position throughout.
Thus, the overall genotypes may be revised as shown in the last column of Table
6.3. Ugd2/19 and Ugd29 (whose genomes show no evidence for recombination) 
are considered to represent two sublineages (BI and BII, respectively) within the 
B lineage. The designation has been based on the fact that K l phylogenetic 
analysis indicated that both Ugd2/19 and Ugd29 lineages belong to subtype B. 
Ugdl5 belongs to a distinct K l B cluster (Bill; see Figure 4.6).
6.6 CONCLUSION AND DISCUSSION
Ugd4, UgdlO, Ugdl2, Ugdl6, Ugd23 and BCBL-R have genomes that may 
reflect a history of recombination between subtypes, while Ugdl5 and 431KAP
Fig. 6.6. Modified networks for (A) ORF26, (B) T0.7/K12 and (C) ORF75.
The corresponding networks in Fig. 6.3 were modified based on the data shown 
in Fig. 6.4 to show the relationships between the Ugandan sequences (including 
Ugd30) and BCBL-R and 431KAP. The length of the alignments and the number 
of substitution sites used to construct the networks are indicated. The groups 
defined previously are indicated in parentheses. Rory Bowden drew the networks 
in Coreldraw. The network in (A) was drawn at twice the scale as those in (B)
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have genomes that may reflect a history of recombination between sublineages of 
the B subtype. Ugd2, Ugdl9 and Ugd29 appear to have subtype B characteristics 
throughout their genomes. The genome of BCBL-R was previously assumed to 
be non recombinant (Poole et al., 1999), but the analysis presented here indicates 
that this may not be the case. In agreement with the conclusion of Poole et al. 
(1999), the network analysis identified recombinants among the Ugandan strains 
and also showed that all the Ugandan strains have some features of subtype B 
genomes.
Importantly, the study indicates that network analysis (and phylogenetic analysis 
where it can be performed reliably e.g with the K1 gene) is a useful tool for 




This chapter gives an overall discussion of the results and their implications in 
the evolution of HHV-8. The study has made a contribution towards elucidating 
some of the virological factors involved in KS epidemiology in Uganda. HHV-8 
antibodies were detected in a high percentage of blood donors (74%) residing in 
Kampala. Furthermore, KS patients in Uganda are infected with HHV-8 strains 
belonging to three K1 subtypes (A5, B and C), and virtually all these strains are 
linked to the K15 P allele. A rare K1 B subtype strain containing a novel type of 
K15 M allele was identified in a single patient. Over half (5 of 9) o f the strains in 
Ugandan KS patients are recombinants between subtypes.
7.1. HHV-8 SEROPREVALENCE IN BLOOD DONORS
Previous serological studies do not support a widespread distribution of HHV-8 
in most normal populations. Seroprevalence rates have been reported to be high 
in African countries, including Uganda, The Gambia, Ivory Coast, Zambia and 
South Africa, compared to other areas of the world (Table 3.1 and reviewed by 
Chatlynne and Ablashi, 1999; Moore 2000; Schulz, 1998). In the current study, 
blood donors were tested for HHV-8 antibodies by combining two tests, an 
ELISA (against both lytic [ORF65] and latent [ORF73/LANA] antigens) and a 
LANA IF test. Together with WB analysis (to rule out non-specific ELISA 
reactions) the tests provide a method of HHV-8 antibody detection that is both 
highly sensitive and highly specific. This was an improvement on most previous 
studies, which used single tests (reviewed by Chatlynne and Ablashi, 1999; Jaffe 
and Pellett, 1999). A high seroprevalence rate (74%) was found in blood donors 
using this approach. This result provides additional evidence that HHV-8 
infection is more widespread in the normal populations o f Africa than elsewhere
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in the world. The reasons for the geographic differences in seroprevalence are 
unknown (Jaffe and Pellett, 1999). Studies o f HHV-8 seroprevalence in South 
Africa (Sitas et al., 1999; Sitas and Newton, 2001) suggest that seroprevalence 
rates decrease with increasing levels of education and are lower in whites than in 
blacks, suggesting that socioeconomic risk factors may be important 
determinants of HHV-8 transmission. However, a previous Ugandan study found 
that KS patients had more education and were more affluent than control patients 
(Ariyoshi et al., 1998).
HHV-8 seroprevalence rates among women and men blood donors were similar, 
as has been found by previous studies (Calabro et al., 1998; Mayama et al., 1998; 
Sitas et al., 1999). Since KS in Africa is about 8-10 times as common among 
men as among women (Cook-Mozaffari et al., 1998), there must be a reason in 
addition to HHV-8 infection to explain this difference.
The results of this and previous studies of HHV-8 seroprevalence in Ugandan 
populations should be regarded as being preliminary given the relatively small 
sample sizes involved (Table 3.1; Chatlynne and Ablashi, 1999). More detailed, 
large-scale population-based studies using currently available highly sensitive 
and highly specific serological assays are required in order to determine absolute 
prevalence rates and risk factors involved in the transmission of HHV-8. 
Furthermore, although levels of HHV-8 seroprevalence are similarly high in 
Uganda, Zambia, The Gambia and Ivory Coast, endemic KS is common only in 
Uganda and Zambia, indicating that a co-factor(s) might be necessary for the 
development of KS.
80
7.2 HHV-8 SUBTYPES IN KS PATIENTS 
7.2.1 Overall genotypes
The results of this and previous studies show that representatives of A5, B and C 
K1 subtypes circulate in Uganda, subtype B being predominant (Table 4.1; Fig.
4.6). The results o f the current study strengthen the evidence that the K1 B 
subtype predominates in Africa (Cook et al., 1999; Meng et al., 1999; Zong et 
al., 1999; Lacoste et al., 2000a). A recent compilation of 75 K1 sequences 
originating from African patients or from individuals o f African origin (but 
living elsewhere) indicated that A5 variants may be as prevalent and widespread 
in Africa as the B subtype (Lacoste et al., 2000a). A5 variants have been detected 
in samples from Zambia, Tanzania, Uganda, Cameroon, the Central African 
Republic and in Creoles, recent African immigrants to French Guiana (Kasolo et 
al., 1998; Cook et al., 1999, Meng et al., 1999; Zong et al., 1999; Lacoste et al., 
2000a.). My study adds to the number o f A5 variants identified from Ugandan 
samples. The single subtype C strain (Ugd23) identified in this study together 
with its counterpart (Kl-43/Ber) (Lacoste et al., 2000a) appear to belong only 
nominally to the C subtype (Fig. 4.6).
Previous reports examining variability in the K15 gene, including an extensive 
study of more than 60 strains, largely used PCR assays to distinguish the P and 
M alleles (Poole et al., 1999, Lacoste et al., 2000a,b; Meng et al., 2001). PCR 
screening of 30 Ugandan KS tumour samples confirmed that the majority 
contains the P allele, as predicted by Poole et al. (1999). The K15 M allele was 
identified in a single sample (UgdlO) containing a subtype B K1 gene. This is the 
first time a K15 M allele has been identified in Eastern Africa samples. These 
results contrast those in the study by Lacoste et al (2000a), which showed an 
equal proportion of P and M alleles in samples from Central/West Africa.
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Extension of the PCR study to sequence analysis o f the entire K15 gene in 
selected strains revealed that the M and P alleles occur in two main forms, the 
BC-1 (M) and UgdlO (M’) forms for the M allele, and the Ugd2/12/19 (BI or 
P[B]) and BCBL-R (BII or P[A/C]) forms for the P allele (see Table 6.3).
The overall predominance of the P allele in most parts o f the world, should it be 
confirmed by further genotyping and sequence analysis studies, may imply some 
form of selective advantage for the P allele over the M allele. The M allele, on 
the other hand, appears to survive and spread better in certain populations (e.g. 
Central/West Africa and Taiwan) than in others (e.g. Eastern Africa) (Lacoste et 
al., 2000a,b; Poole et al., 1999).
There is published evidence for recombination in about 20-30% of HHV-8 
strains (including five out o f 12 African strains) by the criterion of lack of co­
segregation at multiple genetic loci (Poole et al., 1999). In agreement, the 
network analysis identified at least five o f nine Ugandan strains as recombinants 
(Table 6.3). HHV-8 recombinants are thus common in nature. However, survival 
of the individual products of recombination is likely to be very rare, given the 
relatively low number of recombination events required to explain observed 
genome structures (Table 6.3), the lack of detectable recombination within 
individual loci, and the time thought to have elapsed since the subtypes diverged 
(of the order o f 105 years; Hayward, 1999). Intraspecies recombination is not 
unique to HHV-8 among the herpesviruses; it has also been observed in EBV, 
the human herpesvirus most closely related to HHV-8 (Midgley et al., 2000). 
Poole et al. (1999), in their study of more than 60 HHV-8 genomes, noted that 
for some viral strains, sequence divergence at the K15 gene between the P and M 
subtypes extends leftwards (at a greatly reduced degree) up to T0.7/K12. A 
similar observation was made in UgdlO (Table 6.3).
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7.2.2 Correlation of subtype with disease
As in most previous studies (Cook et al., 1999; Meng et al., 1999, 2001; Lacoste 
et al., 2000a; Zong et al., 1999), no obvious association was found between K1 
subtype and the clinical/epidemiological forms of KS. Similarly, no correlation 
was found with ethnicity or geographical location of the patient. Interestingly, 
however, all three P(BI) K15 subtypes (Ugd2/12/19) identified in this study 
originated from endemic KS patients (Table 4.2). Previous studies have 
examined correlation of HHV-8 subtypes with disease on the basis o f single gene 
segments, e.g. K1 or ORF26. However, it is likely to be more fruitful to take into 
account overall genotypes. It is also possible that co-factor(s) may be responsible 
for the different clinical and epidemiological forms of KS. These could be other 
infectious agents, host or environmental factors. Whereas HIV-1 appears to be an 
important co-factor in epidemic (AIDS-associated) KS, co-factors in endemic KS 
remain a mystery.
7.2.3. Classification and nomenclature of HHV-8 subtypes
This study, like most previous studies (Cook et al., 1999; Meng et al., 2001; 
Lacoste et al., 2000a), highlights the need to redefine and name HHV-8 subtypes 
objectively. K1 subtypes (except subtype E) currently have two main 
designations as shown in Table 1.3, and this can be confusing. Further 
subdivisions have also been proposed in previous studies (Table 1.3), but the 
criteria for these designations are not well defined and therefore not uniform. 
Furthermore, the resulting classifications are not always supported by 
phylogenetic analysis. The K1 subtype B designations used in this study (Fig.
4.6) are also provisional and subject to change with rigorous testing methods and 
as more strains are described. Further complications in K1 phylogenetic analysis 
arise from detection of strains in the A/C lineage belonging to neither subtype
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(e.g. Kl-43/Ber; Fig. 4.6; Lacoste et al., 2000a) or only nominally to the C 
subtype (e.g. Ugd23 and Kl-8/Dem; Fig. 4.6; Lacoste et al., 2000a). This 
problem reduces the usefulness o f the phylogenetic distinction between the A 
and C subtypes, and could be resolved either by abolishing the distinction, or by 
introducing additional subtypes to accommodate novel strains.
Analysis o f groups at internal loci by network analysis also underlines the need 
to redefine parental genotypes. Previously, parental strains were determined on 
the basis of “ weight of numbers” (Poole et al., 1999; Zong et al., 1999), but the 
analysis presented in chapter 6 indicates that this method might produce 
misleading results in some cases (e.g. BCBL-R and 431KAP which might be 
recombinants themselves; Fig. 6.6). Network analysis o f conserved regions of the 
genome together with K1 phylogenetic analysis (using computer programs) of 
large data sets (i.e. including a large set of samples covering a large part of the 
genome) would help provide an objective, and therefore more reliable, definition 
o f parental genotypes and recombinants.
7.3. EVOLUTION OF HHV-8
Whereas the hypervariability of K1 is likely to represent a rapid evolution of the 
modem form of HHV-8 (McGeoch and Davison, 1999b; Hayward, 1999), the 
very low level o f nucleotide variation found within either the P or M allele 
suggests that the K15 divergence originated from a recombination event with a 
HHV-8-like vims (Hayward, 1999; Poole et al., 1999). In a model focusing on 
the origin of the K15 alleles (depicted in Fig. 7.1), Hayward (1999) proposed that 
an ancestor of HHV-8 diverged into two forms, one o f which eventually led to 
extant P allele lineages and one of which obtained the M allele by recombination 
with a related Old World monkey, or perhaps great ape, vims. In order to 
accommodate the claim of Poole et al. (1999) that the M allele in 18 strains of
Fig. 7.1. Models for the origin of K15 divergence.
The new model is proposed in this study and the old model was proposed 
previously (Hayward, 1999; Poole et al., 1999). The time period for the 
divergence of the ancestral HHV-8 virus was not stated in the old model 
(reflected by arrows). Question marks indicate viruses that have not been 
identified or may be extinct. M and P represent M and P allele-containing strains, 
respectively; X, diverged P strain sequences; A, B, C and D denote K1 subtypes. 
An approximate time scale is shown in a non-linear fashion. I acknowledge 
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HHV-8 exhibited virtually no sequence variation, it was proposed that the M 
allele and adjacent sequences re-entered extant lineages relatively recently 
(approximately 35000 years ago) via a single recombination event with a K1 C 
subtype genome. The M allele was then passed to other subtypes, with further 
recombination events resulting in differences in the extent o f adjacent M-allele 
linked sequences.
The data presented here indicate that the M allele and adjacent regions have been 
evolving in at least two forms for a period equivalent to that during which extant 
subtypes have diversified. In the absence of evidence for either allele undergoing 
unusual evolutionary processes, this implies that introduction of the M allele into 
modem lineages did not occur via a single, recent event (as proposed in the 
model above). In principle, the M allele could have been introduced by a single, 
ancient recombination event into a lineage that gave rise to extant subtypes, or 
into modem lineages by two separate, possibly recent recombination events 
involving diverged donors of the M allele. Noting the high level o f divergence in 
UPS75’ between strains containing P and M alleles, the former scenario is more 
likely. Thus a new model can be proposed (Fig. 7.1). Two viral lineages diverged 
during primate evolution (of the order o f 107 years ago), continuing to evolve 
with their host species and eventually producing distinct viruses containing the 
M or P alleles. At the stage when the host was a hominid (106 years ago), the M 
allele was transferred to a P allele-containing genome. The M allele and adjacent 
UPS75’ region (now diverged from its equivalent in P-allele containing 
genomes) were then transferred into a P allele-containing lineage in an ancestral 
human (105 years ago). Further divergence, recombination and extinctions as 
envisaged by Hayward (1999), coupled with the vicissitudes o f human survival 
and migration, resulted in extant HHV-8 genotypes. It is conceivable that the 
original M allele-containing vims corresponds to the RRV lineage present in Old
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World monkeys and possibly in the great apes, but that this lineage has become 
extinct in humans, with only the K15 allele surviving in HHV-8 recombinants.
The identification of diverged versions o f the M allele might be taken as 
compromising the assumption that the P allele is indigenous to HHV-8 and that 
the M allele was captured. Identification of apparently non-recombinant 
Ugandan strains that contain the P allele (Ugd2, Ugdl9 and Ugd29) supports the 
view that the P allele was indeed indigenous, but it must be recognised that this 
argument depends upon correct definition of parental genotypes. Further insights 
into the fascinating but complex aspects o f HHV-8 evolution are expected to 
emerge from continuing examination of extant HHV-8 lineages and related 
primate viruses.
7.4. CONCLUSION
Analysis o f samples from Uganda for HHV-8 antibodies or HHV-8 strains has 
shed light on the virological factors involved in KS epidemiology in this country, 
as well as provided further glimpses into the evolution of HHV-8. The study has 
strengthened the notion that HHV-8 infection is widespread in Uganda, 
determined the characteristics of strains associated with KS disease, showed that 
the M allele (though very rare) exists in Eastern Africa, and that the P and M 
alleles have both been evolving in at least two forms for equivalent lengths of 
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